Commonwealth of Australia Gazette

No. GN 11, Wednesday, 29 March 1989
Published by the Australian Government Publishing Service, Canberra

GOVERNMENT NOTICES

CONTENTS

Variation of closing times 648

Special information 649

Legislation 650

Government departments 651

Special Gazettes Nos S 87, S 88, S 89, S 90, S 91, S 92, S 93, S 94, S 95, S 96, S 97, S 98, S 99, S 100 and S 101 are herewith

The date of publication of this Gazette is 29 March 1989.

LATE COPY/AUTHOR'S CORRECTIONS SURCHARGES

Late copy may be accepted on payment of a surcharge. Late copy is a notice submitted for publication in a nominated *Gazette* for which the copy deadline has closed but printing has not commenced. The **late copy** surcharge will be an **additional fifty per cent of the current rate.**

A surcharge will also apply for **author's corrections** made after the copy deadline. These corrections will be charged at **$2.00 per altered printed line.**

For further information contact Don Kime on (062) 95 4657.

10085/89 Cat. No. 89 5571 6

Variation of closing times

Commonwealth of Australia Gazette

Tuesday, 25 April 1989 is a public holiday in the Australian Capital Territory, thus affecting times for submission of copy, for several issues of the *Gazette*.

Notices for publication should be lodged at the Gazette Office unless otherwise specified by the following times for the issues concerned.

The Government Notice Gazette of 26 April 1989 will have the following closing time:

Wednesday, 19 April 1989 at 10.00 a.m.

The Government Notice Gazette of 3 May 1989 will have the following closing time:

Friday, 28 April 1989 at 10.00 a.m.

GENERAL INFORMATION

Government Notices issues, published each Wednesday, containing all legislation, proclamations, special information and government departments notices and are sold at $5.95 each or on subscription of $290.00 (50 issues), $150.00 (25 issues) or $75.00 (12 issues).

NOTICES FOR PUBLICATION and related correspondence should be addressed to:

Gazette Officer, Australian Government Publishing Service, GPO Box 4007, Canberra ACT 2601. Telephone (062) 95 4656

or lodged at AGPS, Government Printing Office Building, Wentworth Avenue, Kingston. Notices are accepted for publication in the next available issue, unless otherwise specified.

Except where a standard form is used, all notices for publication must have a covering instruction setting out requirements. A typewritten original or good copies are to be provided, wherever possible double-spaced, with a margin surrounding the typewritten matter. Copy is to be confined to one side of the paper, sheets are to be of uniform size (preferably A4), numbered consecutively and fastened securely together. Dates, proper names and signatures particularly are to be shown clearly.

Copy will be returned unpublished if not submitted in accordance with these requirements.

CLOSING TIMES. Notices for publication should be lodged at AGPS, Government Printing Office Building, unless otherwise specified, by the following times (except at holiday periods for which special advice of earlier closing times will be given).

Government Notices Gazette all copy: Friday at 10.00 a.m. in the week before publication.

ADVERTISING RATES for Government Notices are: $345.00 per typeset page $115.00 per camera-ready page $225.00 per altered magnetic tape page; and $150.00 per unaltered magnetic tape page.

For Special *Gazette* notices the rates are the same as for Government Notices plus $100.00 per issue.

For Periodic *Gazette* notices the rates are $260.00 per typeset page plus $200.00 per issue. Material supplied as camera-ready copy and magnetic tape (altered and unaltered) will be charged at the respective Government Notices rate.

SUBSCRIPTIONS are payable in advance and are accepted for a maximum period of one year. All subscriptions are on a firm basis and refunds for cancellations will not be given. Rates include surface postage in Australia and overseas. Other carriage rates are available on application.

AVAILABILITY. The *Gazette* may be purchased by mail from:

Mail Order Sales, Australian Government Publishing Service, GPO Box 84, Canberra ACT 2601

or over the counter from Commonwealth Government Bookshops at:

Adelaide:	55 Currie St, tel. (08) 237 6955
Brisbane:	294 Adelaide St, tel. (07) 229 6822
Canberra:	70 Alinga St, tel. (062) 47 7211
Hobart:	162 Macquarie St, tel. (002) 23 7151
Melbourne:	347 Swanston St, tel. (03) 663 3010
Perth:	200 St George's Tce, tel. (09) 322 4737
Sydney:	120 Clarence St, tel. (02) 29 1940

Commonwealth Acts and Statutory Rules, Australian Capital Territory Ordinances and Regulations, and other Commonwealth Government publications may also be purchased at these addresses.

ALL REMITTANCES should be made payable to: Collector of Public Moneys, Australia Government Publishing Service.

OTHER ISSUES OF THE GAZETTE

Public Service issues contain notices concerning administrative matters, including examinations, vacancies, transfers and promotions within the Australian Public Service and the Services of the Australian Postal Corporation, Australian Telecommunications Corporation, Commonwealth Teaching Service and Defence Force appointments etc. These issues are published weekly at 10.30 a.m. on Thursday, and sold at $8.95 each or on subscription of $395.00 (50 issues), $206.00 (25 issues) or $103.00 (12 issues).

Business issues, published each Tuesday, containing Notices under the Co-operative Companies and Securities Scheme, Bankruptcy Act and Private Notices and sold at $3.95 each or on subscription of $220.00 (50 issues), $116.00 (25 issues) or $58.00 (12 issues).

Special issues include notices which require urgent publication. All costs associated with producing Specials will be borne by the responsible department or authority. A limited number of Special *Gazettes* will be made available for sale from the Commonwealth Government Bookshop, Canberra, on the day of publication. General distribution of these notices will be by their inclusion in the next published issue of the Government Notices *Gazette* or Business *Gazette* as well as in the next published issue of the series of the *Gazette* in which the notice would normally have been published.

Tariff concessions issues contain notices of tariff concessions proposed, granted or revoked in accordance with the provisions of Part XVA of the *Customs Act 1901*. These issues are published each Wednesday and are sold at $1.95 or on subscription only at $115.00 for 50 issues including surface postage.

Periodic issues contain lengthy notices of a non-urgent nature, including the following: certificates of Australian citizenship; registered tax agents; authorised celebrants; unclaimed deposits and moneys; Australian Public Service conditions of entry and advancement; appointments to the Australian Public Service; holders of import licences and tariff quotas. Issues are made at irregular intervals as re-

quired, at individual prices according to size. Advice of availability is given in the Government Notices, Business and Public Service issues immediately following the day of publication. Periodic issues are not available on subscription, but standing orders are accepted for all selected issues.

Purchasing and Disposals issues of the *Gazette* provide information on Commonwealth purchases and disposals and other matters of general interest to persons buying from or selling to the Commonwealth. These issues are published each Wednesday and sold at $3.95 or on subscription of $200.00 including postage for 50 issues.

Index issues contain references to entries in the Government Notices issues and entries in the Orders in Council, Notices under the Superannuation Act, Notices under the Public Service Act, and Determinations under the Public Service Act sections of the Public Service issues. Index issues are published quarterly, are available over the counter from Commonwealth Government Bookshops and are supplied without charge to annual subscribers to the Government Notices issues.

N.N.—8926839

ISSUE OF PERIODIC GAZETTES

The following Periodic issues of the *Gazette* have been published.

Copies may be purchased from Commonwealth government bookshops or by mail from the relevant address given on the front page of this *Gazette*.

Gazette number	*Date of publication*	*Subject*
P1	25.1.89	Tariff Quotas—Miscellaneous amendments to Determinations (1988)
P2	14.2.89	Tariff Quotas—Quota transactions for the period 1 October 1988 to 31 December
P3	15.2.89	Tariff Quotas—Textiles, Clothing and Footwear Ballot Quota Allocations—List of 1989 Tariff Quota Holders
P4	21.2.89	Tariff Quotas—Textiles, Clothing and Footwear base Quota Allocations—List of 1989 Tariff Quota Holders
P5	21.2.89	Tariff Quotas—Textiles, Clothing and Footwear tender Quota Allocations—List of 1989 Quota Holders

N.N.—8926840

Special Information

NOTICE OF CREATION OF STATUTORY LIEN IN RESPECT OF CERTAIN AIRCRAFT

Notice is hereby given that pursuant to section 69 (1) of the *Civil Aviation Act 1988*, a Statutory Lien has been vested in the Authority in respect of each of the aircraft described hereunder.

Lien No.	*Date and time created (EDST)*	*Description and registration*	*Payable by*
0726	14 March 1989, 3.57 p.m.	Bell 206B, VH-AHV	New World Aviation Pty Ltd t/a Helicopter Charter P/L Helicopter Terminal Heliport Pl KS Airport Mascot NSW
0727	15 March 1989, 4.00 p.m.	BAC 1-11 401AK, PK-PJF	Freeport Indonesia Inc. PO Box 616 Cairns Qld 4870
0728	16 March 1989, 9.00 a.m.	Bell 206B, VH-BHS	Helicopter Charter P/L Heliport Terminal Heliport Pl KS Airport Mascot NSW

Dated this 17th day of March 1989.

K. HUNT
Registrar of Statutory Liens

N.N.—8926841

Legislation

Acts of Parliament assented to

IT IS HEREBY NOTIFIED, for general information, that His Excellency the Governor-General, in the name of Her Majesty, assented, on 13 March 1989 to the undermentioned Act passed by the Senate and the House of Representatives in Parliament assembled, viz.:

No. 5 of 1989—An Act to amend various Acts relating to matters dealt with by the Department of Administrative Services (*Administrative Services Legislation Amendment Act 1989*)

A. R. BROWNING
Clerk of the House of Representatives
N.N.—8926842

Orders

NOTIFICATION OF THE MAKING OF ORDERS UNDER THE CIVIL AVIATION REGULATIONS

Notice is hereby given that the following amendment to Civil Aviation Orders Part 105, will become effective on 31 March 1989.

AD/ENST 28/31 : Main rotor transmission clutch assembly

Copies of the above Order are available for inspection and may be purchased over the counter from the:

Civil Aviation Authority
607 Swanston St
Carlton South Vic. 3053

or by mail from:

Civil Aviation Authority
Publications Centre
GPO Box 1986
Carlton South Vic. 3053

N.N.—8926843

NOTIFICATION OF THE MAKING OF ORDERS UNDER THE CIVIL AVIATION REGULATIONS

Notice is hereby given that the following amendment to Civil Aviation Orders Part 105, will become effective forthwith.

AD/DC9/44 Amdt 3 : AFT pressure bulkhead tee

Copies of the above Order are available for inspection and may be purchased over the counter from the:

Civil Aviation Authority
607 Swanston St
Carlton South Vic. 3053

or by mail from:

Civil Aviation Authority
Publications Centre
GPO Box 1986
Carlton South Vic. 3053

N.N.—8926844

NOTIFICATION OF THE MAKING OF ORDERS UNDER THE CIVIL AVIATION REGULATIONS

Notice is hereby given that the following amendments to Civil Aviation Orders Part 105, will become effective on 31 May 1989.

AD/F27/117 : Engine mounts—upper brace struts
AD/F50/13 : Accessory bay ventilation air outlet
AD/F50/14 : Outer wing end rib access panel

Copies of the above Orders are available for inspection and may be purchased over the counter from the:

Civil Aviation Authority
607 Swanston St
Carlton South Vic. 3053

or by mail from:

Civil Aviation Authority
Publications Centre
GPO Box 1986
Carlton South Vic. 3053

N.N.—8926845

NOTIFICATION OF THE MAKING OF ORDERS UNDER THE EXPORT CONTROL (ORDERS) REGULATIONS

Notice is hereby given that the undermentioned orders under the Export Control (Orders) Regulations have been made. Copies of the orders can be obtained from the Australian Government Publishing Service Bookshop at 70 Alinga St, Canberra ACT 2601 or by mail from:

Mail Order Sales
Australian Government Publishing Service
GPO Box 84
Canberra ACT 2601

Number of Orders	*Description of Orders*
No. 1 of 1989	Game, Poultry and Rabbit Meat Orders as amended (Amendment)

N.N.—8926846

Government Departments

Administrative Services

FORM 2

Lands Acquisition Act 1955

NOTICE OF THE ACQUISITION OF LAND BY THE COMMONWEALTH.

It is hereby notified that His Excellency the Governor-General acting with the advice of the Federal Executive Council has authorized pursuant to the provisions of the *Lands Acquisition Act* 1955, the acquisition by compulsory process of the land hereunder described, and I hereby declare that the said land is acquired by The Commonwealth of Australia under the said Act for the following public purpose approved by the Governor-General:–

TELECOMMUNICATIONS FACILIITIES

Dated this thirteenth day of March

One thousand nine hundred and eighty nine

Minister of State for Administrative Services

DESCRIPTION OF LAND.

(a) BALFOURS PEAK

FIRSTLY: All that piece of land situate at Gragin (Balfours Peak) in the Shire of Yallaroi Parish of Gragin County of Burnett State of New South Wales containing an area of 71.9 square metres more or less being Lot 147 in Deposited Plan 727834 and

SECONDLY: All that piece of land situate at Gragin (Balfours Peak) in the Shire of Yallaroi Parish of Gragin County of Burnett State of New South Wales containing an area of 213.6 square metres more or less being Lot 148 in Deposited Plan 737834.

(b) BLIGHTY

All that piece of land situate at Blighty in the Shire of Conargo Parish of Narrama County of Townsend State of New South Wales containing an area of 97.28 square metres more or less being Lot 1 in Deposited Plan 778724 excepting thereout the land acquired by Notice in the Commonwealth of Australia Gazette No.4 dated 13 January 1949.

(c) DIAMOND SWAMP

All that piece of land situate at Diamond Swamp in the Shire of Bingara containing an area of 2.021 hectares more or less being part of a Subdivision of Lot 6 in Deposited Plan 754852 and part of Reserved Road in the Parish of Munro County of Murchison State of New South Wales and being Lot 1 in plan catalogued in the New South Wales Branch of the Department of Administrative Services as Negative No.24513 NSW ; commencing on the southwestern side of Travelling Stock Route No.37243 at the most eastern intersection with Road 20.115 wide shown on Lands Department Plan R24240-1603 and bounded on the northeast by the southwestern boundary of the aforesaid Travelling Stock Route bearing 126 degrees 41 minutes 20 seconds 148.66 metres thence on the southeast by a line bearing 216 degrees 41 minutes 20 seconds 140 metres thence on the southwest by a line bearing 306 degrees 41 minutes 20 seconds 140 metres thence on the northwest by the southeastern side of the aforesaid Road bearing 33 degrees 9 minutes 140.27 metres to the point of commencement.

(d) HAMILTON PARK

All that piece of land situate at Louth in the Shire of Bourke County of Cowper Western Division of the State of New South Wales containing an area of 4 hectares more or less being Lot 10 in Deposited Plan 778424.

(e) MYALL VALE

All that piece of land situate at Myall Vale in the Shire of Narrabri containing an area of 225 square metres more or less being part of Travelling Stock Route 788 Parish of Gommel County of Jamison State of New South Wales and being Lot 100 in plan catalogued in the New South Wales Branch of the Department of Administrative Services Negative No.24602 NSW ; commencing at the western corner of Lot 100 at a point on the southeast boundary of Portion 80 Parish of Gommel bearing 44 degrees 57 minutes 23.5 metres from the southernmost corner of Portion 80 and thence bounded on the northwest by the southeastern boundary of Portion 80 bearing 44 degrees 57 minutes 15 metres thence on the northeast by a line bearing 134 degrees 57 minutes 15 metres thence on the southeast by a line bearing 224 degrees 57 minutes 15 metres thence on the southwest by a line bearing 314 degrees 57 minutes 15 metres to the point of commencement.

(f) OAKDENE

All that piece of land situate at Oakdene in the Shire of Balranald County of Kilfera Western Division of the State of New South Wales containing an area of 4 hectares more or less being Lot 1 in Deposited Plan 786214.

(g) OLD MARULAN

All that piece of land situate at Marulan in the Shire of Mulwaree Parish of Marulan County of Argyle State of New South Wales containing an area of 100 square metres more or less being Lot 1 in Deposited Plan 785885.

(h) ONE TREE

All that piece of land situate at Patterson (One Tree) in the Shire of Hay Parish of Patterson County of Waradgery State of New South Wales containing an area of 1.47 hectares more or less being Lot 1 in Deposited Plan 785699 together with a Right of Carriageway 5 metres wide.

(i) RAPPVILLE

All that piece of land situate at Rappville in the Shire of Richmond containing an area of 492.4 square metres more or less being part of a Subdivision of Portion 91 Parish of Hogarth County of Richmond State of New South Wales and being Lot 1 in plan catalogued in the New South Wales Branch of the Department of Administrative Services as Negative No.24577 NSW ; commencing at the southernmost corner of Portion 91 Parish of Hogarth and bounded thence on the southwest by the northeastern boundary of Portion 92 Parish of Hogarth bearing 323 degrees 20 metres thence on the northwest by a line bearing 43 degrees 25 metres thence on the northeast by a line bearing 143 degrees 25 metres thence on the southeast by part of the northwestern side of Clarks Road bearing 223 degrees 25 metres to the point of commencement.

(j) WARRANARY HILL

All that piece of land situate at Warranary Hill (Roto) in the Shire of Carrathool Parish of Malagadery County of Mossgiel State of New South Wales containing an area of 1.44 hectares more or less being Lot 1 in Deposited Plan 785671.

(k) WOODFORD ISLAND

All that piece of land situate at Woodford Island in the Shire of Maclean Parish of Woodford County of Clarence State of New South Wales containing an area of 3876 square metres more or less being Lot 1 in Deposited Plan 785697 excepting thereout the land acquired by Notice in the Commonwealth of Australia Gazette No.30 dated 22 May 1958.

N.N.-8926958

The Arts, Sport, the Environment, Tourism and Territories

COMMONWEALTH OF AUSTRALIA

Wildlife Protection (Regulation of Exports and Imports) Act 1982

Section 11

DECLARATION OF APPROVED INSTITUTIONS

I, JOHN DERRICK OVINGTON, the Designated Authority under subsection 18 (1) of the *Wildlife Protection (Regulation of Exports and Imports) Act 1982*, in pursuance of subsection 11 (1) of the Act, hereby declare each of the organisations specified in Column 2 of the Schedule, in an item in the Schedule, to be an approved institution in relation to the class, or classes, of specimens specified in column 3 of the Schedule in that item.

Dated this 16th day of March 1989.

J. D. OVINGTON
Designated Authority

SCHEDULE

Column 1 *Item*	*Column 2* *Name and country of approved institution*	*Column 3* *Approved class, or classes, of specimens*
1	S.P.M. Parc Zoologic de Barcelona SA Parc de la Ciutadella, s/n Barcelona Spain	*Tachyglossus aculeatus*
2	Pouakai Zoo Park 590 Carrington Rd RDI New Plymouth New Zealand	*Felis serval* *Macaca fascicularis*

N.N.—8926847

COMMONWEALTH OF AUSTRALIA

Wildlife Protection (Regulation of Exports and Imports) Act 1982

Section 12

DECLARATION OF APPROVED ZOOLOGICAL ORGANIZATIONS

I, JOHN DERRICK OVINGTON, the Designated Authority under subsection 18 (1) of the *Wildlife Protection (Regulation of Exports and Imports) Act 1982*, in pursuance of subsection 12 (1) of the Act, hereby declare each of the zoological organisations specified in Column 2 of the Schedule, in an item in the Schedule, to be an approved zoological organisation in relation to the class, or classes, of specimens specified in column 3 of the Schedule in that item.

Dated this 16th day of March 1989.

J. D. OVINGTON
Designated Authority

SCHEDULE

Column 1 *Item*	*Column 2* *Name and Country of Zoo*	*Column 3* *Approved class, or classes, of specimens*
1	S.P.M. Parc Zoologic de Barcelona SA Parc de la Ciutadella, s/n Barcelona Spain	*Tachyglossus aculeatus*
2	Pouakai Zoo Park 590 Carrington Rd RDI New Plymouth New Zealand	*Felis serval* *Macaca fascicularis*

N.N.—8926848

COMMONWEALTH OF AUSTRALIA

Wildlife Protection (Regulation of Exports and Imports) ACT 1982

SECTION 44

Notice

I, GRAHAM FREDERICK RICHARDSON, the Minister of State for Arts, Sport, the Environment, Tourism and Territories in pursuance of subsection 44 (1) of the *Wildlife Protection (Regulation of Exports and Imports) Act 1982*, hereby notify that I am considering giving authorities under section 44 of the Act to export over a period of six months, the specimens specified below, on condition that prior to export of each consignment, the exporter obtains the permission of the Director of the Australian National Parks and Wildlife Service or his nominee:

Caustis blakei:
cut stems collected from
(i) one 250 acre property and
(ii) one 200 acre property

In accordance with paragraph 44 (1) (f) of that Act, I invite interested persons to lodge with me comments in writing on the desirability of giving these authorities. Such comments should be lodged at the following address not later than ten days after the date of publication of this Notice:

The Director
Australian National Parks and Wildlife Service
GPO Box 636
Canberra ACT 2601

Attention: Wildlife Trade Section

Dated this 8th day of March 1989.

G. F. RICHARDSON
Minister of State for Arts, Sport,
the Environment, Tourism and Territories

N.N.—8926849

AUSTRALIAN CAPITAL TERRITORY

City Area Leases Ordinance 1936

INSTRUMENT OF APPROVAL UNDER SECTION 10

In pursuance of section 10 of the *City Area Leases Ordinance 1936*, I, PETER ROBERT GRIFFITHS being the officer for the time being occupying an office to the occupant of which the Minister has by instrument in writing under section 12C of the *Seat of Government (Administration) Act 1910* delegated his powers under section 10 of the said Ordinance hereby approve of Julia Kowalski ('the Applicant') carrying on the profession trade occupation or calling of general practitioner ('the business') on Block 7, Section 44, Division of Pearce known as 11 Brinsmead St, Pearce ('the land') subject to the following conditions relating to the use of the land being observed by the Applicant in carrying on the business:

(1) that this approval will remain valid only while the Applicant continues to be a bona fide resident of the land;

(2) that the Applicant will ensure that the conduct of the business does not cause an annoyance, a nuisance or danger and is not offensive to any tenants or occupiers of adjoining lands;

(3) that the Applicant will not erect or permit or suffer to be displayed or erected upon the land or any building thereon any advertising sign or hoarding whatever without the consent in writing of the National Capital Development Commission and the Building Controller;

(4) that the Applicant will conduct the business strictly in accordance with the application made by the Applicant under section 10 of the City Area Leases Ordinance unless otherwise stipulated in this Instrument;

(5) that no person other than the Applicant will conduct or in any way carry on the business on the land without the prior approval of the Minister;

(6) that the Applicant will ensure that all residence and business related vehicles are parked within the confines of the land;

(7) that the Applicant will not employ any assistants for the purpose of conducting or carrying on the business on the land without the prior approval of the Minister;

(8) that only one bedroom in the house be used for the conduct of the business;

(9) that the business will only be conducted on the land between the hours of 4.00 p.m. and 6.30 p.m. Saturday 4.00 p.m. and 6.00 p.m. Sunday and 9.00 a.m. and 11.00 a.m. Monday;

(10) that patients attending the practice shall do so by appointment only;

(11) that all sharps etc should be placed in puncture and tamper proof containers and sealed, and all contaminated waste should be placed in appropriate contaminated waste plastic bags, adequately sealed and marked 'contaminated waste';

(12) that all items in condition 11 should be taken to an approved incinerator for destruction;

(13) that the Applicant will conduct the business strictly by appointment, and that such appointments will be organised to ensure that only one patient is in attendance at any one time;

(14) that this approval will terminate on the 31st day of January 1990 or on such earlier date as the Minister determines in accordance with condition 15;

(15) upon any failure to comply with any or all of the foregoing conditions the Minister or his Delegate under the said Ordinance may give written notice requiring the Applicant to show cause within a period of fourteen days why this approval should not be revoked. At the expiration of this period the Minister or his Delegate may revoke the approval.

Dated this 7th day of March 1989.

P. R. GRIFFITHS
Delegate of the Minister of State
for the Arts and Territories

N.N.—8926850

AUSTRALIAN CAPITAL TERRITORY

City Area Leases Ordinance 1936

INSTRUMENT OF APPROVAL UNDER SECTION 10

In pursuance of section 10 of the *City Area Leases Ordinance 1936*, I, PETER ROBERT GRIFFITHS being the officer for the time being occupying an office to the occupant of which the Minister has by instrument in writing under section 12C of the *Seat of Government (Administration) Act 1910* delegated his powers under section 10 of the said Ordinance hereby approve of Richard Bertram Daintree and Ruth Alice Daintree ('the Applicant') carrying on the profession trade occupation or calling of locksmiths and security consultants ('the business') on Block 5, Section 3, Division of Curtin known as 10 Heales Pl, Curtin ('the land') subject to the following conditions relating to the use of the land being observed by the Applicant in carrying on the business:

(1) that this approval will remain valid only while the Applicant continues to be a bona fide resident of the land;

(2) that the Applicant will ensure that the conduct of the business does not cause an annoyance, a nuisance or danger and is not offensive to any tenants or occupiers of adjoining lands;

(3) that the Applicant will not erect or permit or suffer to be displayed or erected upon the land or any building thereon any advertising sign or hoarding whatever without the consent in writing of the Interim Territory Planning Authority and the Building Controller;

(4) that the Applicant will conduct the business strictly in accordance with the application made by the Applicant under section 10 of the City Area Leases Ordinance unless otherwise stipulated in this Instrument:

(5) that no person other than the Applicant will conduct or in any way carry on the business on the land without the prior approval of the Minister;

(6) that the Applicant will ensure that all residence and business related vehicles are parked within the confines of the land;

(7) that the Applicant will not employ any more than three assistants for the purpose of conducting or carrying on the business on the land without the prior approval of the Minister;

(8) that this approval will terminate on the 31st day of March 1990 or on such earlier date as the Minister determines in accordance with condition 9;

(9) upon any failure to comply with any or all of the foregoing conditions the Minister or his Delegate under the said Ordinance may give written notice requiring the Applicant to show cause within a period of fourteen days why this approval should not be revoked. At the expiration of this period the Minister or his Delegate may revoke the approval.

Dated this 7th day of March 1989.

P. R. GRIFFITHS
Delegate of the Minister of State
for the Arts and Territories

N.N.—8926851

AUSTRALIAN CAPITAL TERRITORY

City Area Leases Ordinance 1936

INSTRUMENT OF APPROVAL UNDER SECTION 10

In pursuance of section 10 of the *City Area Leases Ordinance 1936*, I, PETER ROBERT GRIFFITHS being the officer for the time being occupying an office to the occupant of which the Minister has by instrument in writing under section 12C of the *Seat of Government (Administration) Act 1910* delegated his powers under section 10 of the said Ordinance hereby approve of Anna Konstance Zunde ('the Applicant') carrying on the profession trade occupation or calling of beauty therapist ('the business') on Block 4, Section 17, Division of Scullin known as 23 Levien St, Scullin ('the land') subject to the following conditions relating to the use of the land being observed by the Applicant in carrying on the business:

(1) that this approval will remain valid only while the Applicant continues to be a bona fide resident of the land;

(2) that the Applicant will ensure that the conduct of the business does not cause an annoyance, a nuisance or danger and is not offensive to any tenants or occupiers of adjoining lands;

(3) that the Applicant will not erect or permit or suffer to be displayed or erected upon the land or any building thereon any advertising sign or hoarding whatever without the consent in writing of the Interim Territory Planning Authority and the Building Controller;

(4) that the Applicant will conduct the business strictly in accordance with the application made by the Applicant under section 10 of the City Area Leases Ordinance unless otherwise stipulated in this Instrument;

(5) that no person other than the Applicant will conduct or in any way carry on the business on the land without the prior approval of the Minister;

(6) that the Applicant will ensure that all residence and business related vehicles are parked within the confines of the land;

(7) that the Applicant will not employ any assistant for the purpose of conducting or carrying on the business on the land without the prior approval of the Minister;

(8) that only the main bedroom in the house be used for the conduct of the business;

(9) that the business will only be conducted on the land between the hours of 9.30 a.m. and 5.30 p.m. Tuesdays to Fridays only;

(10) that the Applicant will conduct the business strictly by appointment, only;

(11) that this approval will terminate on the 28th day of February 1990 or on such earlier date as the Minister determines in accordance with condition 12;

(12) upon any failure to comply with any or all of the foregoing conditions the Minister or his Delegate under the said Ordinance may give written notice requiring the Applicant to show cause within a period of fourteen days why this approval should not be revoked. At the expiration of this period the Minister or his Delegate may revoke the approval.

Dated this 14th day of March 1989.

P. R. GRIFFITHS
Delegate of the Minister of State
for the Arts and Territories

N.N.—8926852

AUSTRALIAN CAPITAL TERRITORY

City Area Leases Ordinance 1936

INSTRUMENT OF APPROVAL UNDER SECTION 10

In pursuance of section 10 of the *City Area Leases Ordinance 1936*, I, PETER ROBERT GRIFFITHS being the officer for the time being occupying an office to the occupant of which the Minister has by instrument in writing under section 12C of the *Seat of Government (Administration) Act 1910* delegated his powers under section 10 of the said Ordinance hereby approve of Paul Raymond Le Lievre ('the Applicant') carrying on the profession trade occupation or calling of chiropractor ('the business') on Block 1, Section 329, Division of Fadden known as 16 Partridge St, Fadden ('the land') subject to the following conditions relating to the use of the land being observed by the Applicant in carrying on the business:

(1) that this approval will remain valid only while the Applicant continues to be a bona fide resident of the land;

(2) that the Applicant will ensure that the conduct of the business does not cause an annoyance, a nuisance or danger and is not offensive to any tenants or occupiers of adjoining lands;

(3) that the Applicant will not erect or permit or suffer to be displayed or erected upon the land or any building thereon any advertising sign or hoarding whatever without the consent in writing of the Interim Territory Planning Authority and the Building Controller;

(4) that the Applicant will conduct the business strictly in accordance with the application made by the Applicant under section 10 of the City Area Leases Ordinance unless otherwise stipulated in this Instrument;

(5) that no person other than the Applicant will conduct or in any way carry on the business on the land without the prior approval of the Minister;

(6) that the Applicant will ensure that all residence and business related vehicles are parked within the confines of the land and that the vehicular access from Partridge St to the land be located no closer than eleven metres from the existing 'Action' Bus Stop;

(7) that the Applicant will not employ any more than one assistant for the purpose of conducting or carrying on the business on the land without the prior approval of the Minister;

(8) that the business will only be conducted on the land between the hours of 8.30 a.m. and 6.00 p.m. Monday to Friday and 9.00 a.m. and 11.00 a.m. Saturdays;

(9) that the Applicant will conduct the business strictly by appointment;

(10) that this approval will terminate on the 28th day of February 1990 or on such earlier date as the Minister determines in accordance with condition 11;

(11) upon any failure to comply with any or all of the foregoing conditions the Minister or his Delegate under the said Ordinance may give written notice requiring the Applicant to show cause within a period of fourteen days why this approval should not be revoked. At the expiration of this period the Minister or his Delegate may revoke the approval.

Dated this 14th day of March 1989.

P. R. GRIFFITHS
Delegate of the Minister of State
for the Arts and Territories

N.N.—8926853

AUSTRALIAN CAPITAL TERRITORY

City Area Leases Ordinance 1936

INSTRUMENT OF APPROVAL UNDER SECTION 10

In pursuance of section 10 of the *City Area Leases Ordinance 1936*, I, PETER ROBERT GRIFFITHS being the officer for the time being occupying an office to the occupant of which the Minister has by instrument in writing under section 12C of the *Seat of Government (Administration) Act 1910* delegated his powers under section 10 of the said Ordinance hereby approve of John Michael Beacher ('the Applicant') carrying on the profession trade occupation or calling of chiropractor ('the business') on Block 12, Section 26, Division of Page known as 82 Belconnen Way, Page ('the land') subject to the following conditions relating to the use of the land being observed by the Applicant in carrying on the business:

(1) that this approval will remain valid only while the Applicant continues to be a bona fide resident of the land;

(2) that the Applicant will ensure that the conduct of the business does not cause an annoyance, a nuisance or danger and is not offensive to any tenants or occupiers of adjoining lands;

(3) that the Applicant will not erect or permit or suffer to be displayed or erected upon the land or any building thereon any advertising sign or hoarding whatever without the consent in writing of the Interim Territory Planning Authority and the Building Controller;

(4) that the Applicant will conduct the business strictly in accordance with the application made by the Applicant under section 10 of the City Area Leases Ordinance unless otherwise stipulated in this Instrument;

(5) that no person other than the Applicant will conduct or in any way carry on the business on the land without the prior approval of the Minister;

(6) that the Applicant will ensure that all residence and business related vehicles are parked within the confines of the land;

(7) that the Applicant will not employ any assistant for the purpose of conducting or carrying on the business on the land without the prior approval of the Minister;

(8) that the business will only be conducted on the land between the hours of 1.00 p.m. and 6.00 p.m. Monday, Wednesday, Thursday, 9.00 a.m. and 2.00 p.m. Tuesday and Friday, 9.00 a.m. and 12 noon Saturday;

(9) that the Applicant will conduct the business strictly by appointment, and that such appointments will be restricted to twenty five per week;

(10) that this approval will terminate on the 28th day of February 1990 or on such earlier date as the Minister determines in accordance with condition 11;

(11) upon any failure to comply with any or all of the foregoing conditions the Minister or his Delegate under the said Ordinance may give written notice requiring the Applicant to show cause within a period of fourteen days why this approval should not be revoked. At the expiration of this period the Minister or his Delegate may revoke the approval.

Dated this 14th day of March 1989.

P. R. GRIFFITHS
Delegate of the Minister of State
for the Arts and Territories

N.N.—8926854

AUSTRALIAN CAPITAL TERRITORY

City Area Leases Ordinance 1936

INSTRUMENT OF APPROVAL UNDER SECTION 10

In pursuance of section 10 of the *City Area Leases Ordinance 1936*, I, PETER ROBERT GRIFFITHS being the officer for the time being occupying an office to the occupant of which the Minister has by instrument in writing under section 12C of the *Seat of Government (Administration) Act 1910* delegated his powers under section 10 of the said Ordinance hereby approve of John David Richards ('the Applicant') carrying on the profession trade occupation or calling of chartered accountant and tax agent ('the business') on Block 26, Section 6, Division of Holder known as 55 Calder Crs, Holder ('the land') subject to the following conditions relating to the use of the land being observed by the Applicant in carrying on the business:

(1) that this approval will remain valid only while the Applicant continues to be a bona fide resident of the land;

(2) that the Applicant will ensure that the conduct of the business does not cause an annoyance, a nuisance or danger and is not offensive to any tenants or occupiers of adjoining lands;

(3) that the Applicant will not erect or permit or suffer to be displayed or erected upon the land or any building thereon any advertising sign or hoarding whatever without the consent in writing of the Interim Territory Planning Authority and the Building Controller;

(4) that the Applicant will conduct the business strictly in accordance with the application made by the Applicant under section 10 of the City Area Leases Ordinance unless otherwise stipulated in this Instrument;

(5) that no person other than the Applicant will conduct or in any way carry on the business on the land without the prior approval of the Minister;

(6) that the Applicant will ensure that all residence and business related vehicles are parked within the confines of the land;

(7) that the Applicant will not without the prior approval of the Minister employ any more than one part-time assistant for the purpose of conducting or carrying on the business on the land;

(8) that the assistant shall only be employed during the months of November and December of each year and for a maximum of four hours per week;

(9) that the business will only be conducted on the land between the hours of 9.00 a.m. and 5.00 p.m. Monday to Friday;

(10) that this approval relates to the provision of office accommodation only;

(11) that this approval will terminate on the 28th day of February 1990 or on such earlier date as the Minister determines in accordance with condition 12;

(12) upon any failure to comply with any or all of the foregoing conditions the Minister or his Delegate under the said Ordinance may give written notice requiring the Applicant to show cause within a period of fourteen days why this approval should not be revoked. At the expiration of this period the Minister or his Delegate may revoke the approval.

Dated this 14th day of March 1989.

P. R. GRIFFITHS
Delegate of the Minister of State
for the Arts and Territories

N.N.—8926855

AUSTRALIAN CAPITAL TERRITORY

City Area Leases Ordinance 1936

INSTRUMENT OF APPROVAL UNDER SECTION 10

In pursuance of section 10 of the *City Area Leases Ordinance 1936*, I, PETER ROBERT GRIFFITHS being the officer for the time being occupying an office to the occupant of which the Minister has by instrument in writing under section 12C of the *Seat of Government (Administration) Act 1910* delegated his powers under section 10 of the said Ordinance hereby approve of Frederick Arthur Weston ('the Applicant') carrying on the profession trade occupation or calling of chiropractor ('the business') on Block 21, Section 78, Division of Narrabundah known as 36 Caley Cres, Narrabundah ('the land') subject to the following conditions relating to the use of the land being observed by the Applicant in carrying on the business:

(1) that this approval will remain valid only while the Applicant continues to be a bona fide resident of the land;

(2) that the Applicant will ensure that the conduct of the business does not cause an annoyance, a nuisance or danger and is not offensive to any tenants or occupiers of adjoining lands;

(3) that the Applicant will not erect or permit or suffer to be displayed or erected upon the land or any building thereon any advertising sign or hoarding whatever without the consent in writing of the Interim Territory Planning Authority and the Building Controller;

(4) that the Applicant will conduct the business strictly in accordance with the application made by the Applicant under section 10 of the City Area Leases Ordinance unless otherwise stipulated in this Instrument;

(5) that no person other than the Applicant will conduct or in any way carry on the business on the land without the prior approval of the Minister;

(6) that the Applicant will ensure that all residence and business related vehicles are parked within the confines of the land;

(7) that the Applicant will not employ any more than one assistant for the purpose of conducting or carrying on the business on the land without the prior approval of the Minister and that assistant shall be employed in the capacity of nurse or receptionist;

(8) that only two rooms in the house be used for the conduct of the business;

(9) that the business will only be conducted on the land between the hours of 9.00 a.m. and 6.30 Monday to Friday;

(10) that this approval relates to the conduct of a Chiropractic surgery only;

(11) that the Applicant will conduct the business strictly by appointment, and that such appointments will be organised to ensure that no more than two patients are in attendance at any one time;

(12) that this approval will terminate on the 28th day of February 1990 or on such earlier date as the Minister determines in accordance with condition 13;

(13) upon any failure to comply with any or all of the foregoing conditions the Minister or his Delegate under the said Ordinance may give written notice requiring the Applicant to show cause within a period of fourteen days why this approval should not be revoked. At the expiration of this period the Minister or his Delegate may revoke the approval.

Dated this 14th day of March 1989.

P. R. GRIFFITHS
Delegate of the Minister of State
for the Arts and Territories

N.N.—8926856

AUSTRALIAN CAPITAL TERRITORY

City Area Leases Ordinance 1936

INSTRUMENT OF APPROVAL UNDER SECTION 10

In pursuance of section 10 of the *City Area Leases Ordinance 1936*, I, PETER ROBERT GRIFFITHS being the officer for the time being occupying an office to the occupant of which the Minister has by instrument in writing under section 12C of the *Seat of Government (Administration) Act 1910* delegated his powers under section 10 of the said Ordinance hereby approve of Geoffrey Victor Halliday ('the Applicant') carrying on the profession trade occupation or calling of barrister and solicitor ('the business') on Block 19, Section 9, Division of Campbell known as 99 Blamey Cres, Campbell ('the land') subject to the following conditions relating to the use of the land being observed by the Applicant in carrying on the business:

(1) that this approval will remain valid only while the Applicant continues to be a bona fide resident of the land;

(2) that the Applicant will ensure that the conduct of the business does not cause an annoyance, a nuisance or danger and is not offensive to any tenants or occupiers of adjoining lands;

(3) that the Applicant will not erect or permit or suffer to be displayed or erected upon the land or any building thereon any advertising sign or hoarding whatever without the consent in writing of the Interim Territory Planning Authority and the Building Controller;

(4) that the Applicant will conduct the business strictly in accordance with the application made by the Applicant under section 10 of the City Area Leases Ordinance unless otherwise stipulated in this Instrument;

(5) that no person other than the Applicant will conduct or in any way carry on the business on the land without the prior approval of the Minister;

(6) that the Applicant will ensure that all residence and business related vehicles are parked within the confines of the land;

(7) that the Applicant will not employ any more than one assistant for the purpose of conducting or carrying on the business on the land without the prior approval of the Minister;

(8) that the business will only be conducted on the land between the hours of 9.00 a.m. and 5.30 p.m. Monday to Friday;

(9) that the Applicant will conduct the business strictly by appointment, and that such appointments will be organised to ensure that only two clients are in attendance at any one time;

(10) that this approval will terminate on the 28th day of February 1990 or on such earlier date as the Minister determines in accordance with condition 11;

(11) upon any failure to comply with any or all of the foregoing conditions the Minister or his Delegate under the said Ordinance may give written notice requiring the Applicant to show cause within a period of fourteen days why this approval should not be revoked. At the expiration of this period the Minister or his Delegate may revoke the approval.

Dated this 14th day of March 1989.

P. R. GRIFFITHS

Delegate of the Minister of State
for the Arts and Territories

N.N.—8926857

AUSTRALIAN CAPITAL TERRITORY

City Area Leases Ordinance 1936

INSTRUMENT OF APPROVAL UNDER SECTION 10

In pursuance of section 10 of the *City Area Leases Ordinance 1936*, I, PETER ROBERT GRIFFITHS being the officer for the time being occupying an office to the occupant of which the Minister has by instrument in writing under section 12C of the *Seat of Government (Administration) Act 1910* delegated his powers under section 10 of the said Ordinance hereby approve of Melinda Jan Doitschinov ('the Applicant') carrying on the profession trade occupation or calling of cello teaching, violin making and repairing ('the business') on Block 11, Section 10, Division of Hughes known as 34 Glynn Pl, Hughes ('the land') subject to the following conditions relating to the use of the land being observed by the Applicant in carrying on the business:

(1) that this approval will remain valid only while the Applicant continues to be a bona fide resident of the land;

(2) that the Applicant will ensure that the conduct of the business does not cause an annoyance, a nuisance or danger and is not offensive to any tenants or occupiers of adjoining lands;

(3) that the Applicant will not erect or permit or suffer to be displayed or erected upon the land or any building thereon any advertising sign or hoarding whatever without the consent in writing of the Interim Territory Planning Authority and the Building Controller;

(4) that the Applicant will conduct the business strictly in accordance with the application made by the Applicant under section 10 of the City Area Leases Ordinance unless otherwise stipulated in this Instrument;

(5) that no person other than the Applicant will conduct or in any way carry on the business on the land without the prior approval of the Minister;

(6) that the Applicant will ensure that all residence and business related vehicles are parked within the confines of the land;

(7) that the Applicant will employ one assistant and that assistant must be the applicant's husband for the purpose of conducting or carrying on the business on the land without the prior approval of the Minister;

(8) that this approval relates to cello teaching, hand making and repairing of violins;

(9) that the business will only be conducted on the land between the hours of 11.00 a.m. and 6.00 p.m. Monday to Friday, 9.00 a.m. and 1.00 p.m. Saturday;

(10) that the Applicant will conduct the business strictly by appointment, and that such appointments will be organised to ensure that no more than two clients are in attendance at any one time;

(11) that this approval will terminate on the 31st day of March 1990 or on such earlier date as the Minister determines in accordance with condition 12;

(12) upon any failure to comply with any or all of the foregoing conditions the Minister or his Delegate under the said Ordinance may give written notice requiring the Applicant to show cause within a period of fourteen days why this approval should not be revoked. At the expiration of this period the Minister or his Delegate may revoke the approval.

Dated this 8th day of March 1989.

P. R. GRIFFITHS

Delegate of the Minister of State
for the Arts and Territories

N.N.—8926858

AUSTRALIAN CAPITAL TERRITORY

City Area Leases Ordinance 1936

INSTRUMENT OF APPROVAL UNDER SECTION 10

In pursuance of section 10 of the *City Area Leases Ordinance 1936*, I, PETER ROBERT GRIFFITHS being the officer for the time being occupying an office to the occupant of which the Minister has by instrument in writing under section 12C of the *Seat of Government (Administration) Act 1910* delegated his powers under section 10 of the said Ordinance hereby approve of John Raymond Steggall ('the Applicant') carrying on the profession trade occupation or calling of printing sales representative ('the business') on Block 6, Section 91, Division of Narrabundah known as 98 Walker Cres, Narrabundah ('the land') subject to the following conditions relating to the use of the land being observed by the Applicant in carrying on the business:

(1) that this approval will remain valid only while the Applicant continues to be a bona fide resident of the land;

(2) that the Applicant will ensure that the conduct of the business does not cause an annoyance, a nuisance or danger and is not offensive to any tenants or occupiers of adjoining lands;

(3) that the Applicant will not erect or permit or suffer to be displayed or erected upon the land or any building thereon any advertising sign or hoarding whatever without the consent in writing of the Interim Territory Planning Authority and the Building Controller;

(4) that the Applicant will conduct the business strictly in accordance with the application made by the Applicant under section 10 of the City Area Leases Ordinance unless otherwise stipulated in this Instrument;

(5) that no person other than the Applicant will conduct or in any way carry on the business on the land without the prior approval of the Minister;

(6) that the Applicant will ensure that all residence and business related vehicles are parked within the confines of the land;

(7) that the Applicant will not employ any assistants for the purpose of conducting or carrying on the business on the land without the prior approval of the Minister;

(8) that only one room in the house be used for the conduct of the business;

(9) that the business will only be conducted on the land between the hours of 8.00 a.m. and 6.00 p.m. Monday to Friday;

(10) that the Applicant will conduct the business strictly by appointment, and that such appointments will be

organised to ensure that only one client is in attendance at any one time;

(11) that this approval will terminate on the 31st day of March 1990 or on such earlier date as the Minister determines in accordance with condition 12;

(12) upon any failure to comply with any or all of the foregoing conditions the Minister or his Delegate under the said Ordinance may give written notice requiring the Applicant to show cause within a period of fourteen days why this approval should not be revoked. At the expiration of this period the Minister or his Delegate may revoke the approval.

Dated this 14th day of March 1989.

P. R. GRIFFITHS
Delegate of the Minister of State
for the Arts and Territories

N.N.—8926859

Attorney-General

COMMONWEALTH OF AUSTRALIA

FEDERAL COURT OF AUSTRALIA ACT 1976

I, ALAN DOUGLAS ROSE, Secretary to the Attorney-General's Department and a delegate of the Attorney-General under subsection 17 (2) of the *Law Officers Act 1964*, pursuant to subsection 35 (1) of the *Federal Court of Australia Act 1976*, and subsection 33 (4) of the *Acts Interpretation Act 1901*, hereby:

(a) terminate the appointment of Ian Gregory Ritchard as a District Registrar for the Federal Court of Australia; and

(b) appoint Janet Frances Cooper as a District Registrar of the Federal Court of Australia commencing 13 March 1989.

Dated this 10th day of March 1989.

A. D. ROSE
Secretary to the
Attorney-General's Department

CA03F008 CR$ N.N.—8926860

COMMONWEALTH OF AUSTRALIA

BANKRUPTCY ACT 1966

I, ALAN DOUGLAS ROSE, Secretary to the Attorney-General's Department, pursuant to section 16 of the *Bankruptcy Act 1966*, hereby:

(a) terminate the appointment of Ian Gregory Ritchard as a Registrar in Bankruptcy for the Bankruptcy District of Tasmania; and

(b) appoint Janet Frances Cooper as a Registrar in Bankruptcy for the Bankruptcy District of Tasmania commencing on 13 March 1989.

Dated this 10th day of March 1989.

A. D. ROSE
Secretary to the
Attorney-General's Department

N.N.—8926861

Community Services and Health

COMMONWEALTH OF AUSTRALIA

National Health Act 1953

PHARMACEUTICAL BENEFITS—DECLARATION UNDER SUBSECTION 85 (2AA)

No. PB2 of 1989

I, IAN JAMES McNEIL, First Assistant Secretary, Health Benefits Division, Department of Community Services and Health and Delegate of the Minister of State for Community Services and Health, pursuant to subsection 85 (2AA) of the *National Health Act 1953*, hereby make the following Declaration:

1. This Declaration shall come into operation on 1 April 1989.
2. The drugs and medicinal preparations contained in the Schedule to this Declaration shall cease to be drugs and medicinal preparations to which Part VII of the National Health Act 1953 applies.

THE SCHEDULE

Ammonium Chloride B.P.
Benzyl Benzoate B.P.
Intraperitoneal Dialysis Solutions B.C.P. 1973
Sulphadimidine Tablets B.P.

Dated this 16th day of March 1989.

IAN McNEIL
First Assistant Secretary
Health Benefits Division
Delegate of the Minister
of State for
Community Services and Health

N.N.—8926864

COMMONWEALTH OF AUSTRALIA

National Health Act 1953

PHARMACEUTICAL BENEFITS—DETERMINATION UNDER SECTION 93

I, IAN JAMES McNEIL, First Assistant Secretary, Health Benefits Division, Department of Community Services and Health and Delegate of the Minister of State for Community Services and Health, pursuant to section 93 of the *National Health Act 1953*, hereby make the following Determination:

1. This Determination shall come into operation on the first day of April 1989.
2. The Determination under section 93 of the National Health Act made on 16 November 1988 with effect from 1 December 1988 is hereby revoked.
3. The pharmaceutical benefits referred to in this Determination shall be those contained in the Schedule to this Determination.
4. A medical practitioner is authorised for the purpose of section 93 of the Act to supply any of the pharmaceutical benefits obtained by the medical practitioner, or by another medical practitioner for whom the first-named medical practitioner is temporarily acting as a locum, in pursuance of this Determination.
5. Subject to this Determination, the maximum quantity or number of units of a pharmaceutical benefit that may be obtained by a medical practitioner in any one month for the purpose of section 93 of the Act is the number or quantity specified in the Schedule to this Department in relation to the pharmaceutical benefit.

6. Where a medical practitioner has obtained a pharmaceutical benefit for the purpose of section 93 of the Act, that medical practitioner is not entitled to obtain a further quantity or number of units of that pharmaceutical benefit for that purpose whilst in possession of a quantity or number of units of the pharmaceutical benefit obtained by the medical practitioner equal to or greater than the maximum quantity or number of units allowed for the pharmaceutical benefit by paragraph 5.
7. A medical practitioner is not entitled to obtain a pharmaceutical benefit for the purpose of section 93 of the Act more often than twice in any two months.

THE SCHEDULE

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Maximum quantity*
Adrenaline Injection B.P.	Adrenaline, 1 in 1,000, 1 mL	5
Aminophylline Injection B.P.	Ampoule, 250 mg in 10 mL	5
Atropine Sulphate Injection B.P.	Ampoule, 600 micrograms in 1 mL	5
Chlorpromazine Injection B.P.	Ampoule, 50 mg in 2 mL	10
OR		
Haloperidol B.P.	Injection, 5 mg in 1 mL amp	10
Diazepam Injection B.P.	10 mg in 2 mL	5
Digoxin Injection B.P.	Ampoule, 500 micrograms in 2 mL	5
Diphtheria and Tetanus Vaccine, Adsorbed B.P.	Injection, 0.5 mL amp	10
Diphtheria and Tetanus Vaccine, Adsorbed B.P., Diluted	Injection, 0.5 mL amp	10
Ergometrine Injection B.P.	Ampoule, 250 micrograms in 1 mL	5
Erythromycin Ethyl Succinate B.P.	Injection, 100 mg (base) in 2 mL	5
Frusemide Injection B.P.	Ampoule, 20 mg in 2 mL	5
Glucose Intravenous Infusion B.P.	Ampoule, 5 g in 10 mL	5
Hydrocortisone Sodium Succinate B.P.	Injection set containing equivalent of 100 mg hydrocortisone and 2 mL solvent	2
OR		
Hydrocortisone Sodium Succinate B.P.	Injection set containing equivalent of 250 mg hydrocortisone and 2 mL solvent	1
OR		
Dexamethasone Sodium Phosphate B.P.	Injection, 1 mL amp. containing equivalent of 4 mg dexamethasone phosphate	5
Lignocaine Hydrochloride B.P.	Injection, 100 mg in 5 mL	4
OR		
Lignocaine Hydrochloride Injection B.P.	Syringe, disposable, 300 mg in 3 mL	1
Metoclopramide Injection B.P.	Ampoule, 10 mg in 2 mL	10
OR		
Prochlorperazine Edisylate	Injection, 12.5 mg in 1 mL	10
OR		
Prochlorperazine Injection B.P.	Ampoule, 12.5 mg in 1 mL	10
Morphine Sulphate Injection B.P.	Ampoule, 15 mg in 1 mL	5
OR		
Morphine Sulphate Injection B.P.	Ampoule, 30 mg in 1 mL	5
Naloxone Hydrochloride	Injection, 2 mg in 5 mL disposable injection set	2
Pethidine Injection B.P.	Ampoule, 100 mg in 2 mL	5
Procaine Penicillin Injection B.P.	Syringe, disposable, 1.5 g	10
OR		
Benzylpenicillin Potassium B.P. with any determined brand of Water for Injections	Injection, 600 mg vial (with ampoule, 2 mL)	10
Promethazine Hydrochloride Injection B.P.	Ampoule, 50 mg in 2 mL	10
Terbutaline Sulphate B.P.	Injection, 100 micrograms in 1 mL amp.	5
OR		
Terbutaline Sulphate B.P.	Injection, 500 micrograms in 1 mL amp.	5
Tetanus Vaccine, Adsorbed B.P.	Injection, 0.5 mL amp.	10
Verapamil Hydrocholoride Injection B.P.	Ampoule, 5 mg in 2 mL	5

Dated this 16th day of March 1989.

IAN McNEIL
First Assistant Secretary
Health Benefits Division
Delegate of the Minister
of State for
Community Services and Health

N.N.—8926865

COMMONWEALTH OF AUSTRALIA

Health Insurance Act 1973

STATEMENT UNDER SECTION 106AA

On the 24th day of October 1988, I, NEAL BLEWETT, Minister of State for Community Services and Health, made a determination under section 106 of the *Health Insurance Act 1973* (the Act), in respect of Dr Jogenda Singh Sekhon of 172 Waminda Ave, Campbelltown New South Wales.

Particulars of Determination

A copy of the determination is at Attachment A.

Reasons for Determination

The determination was made by me on the basis of a report made under section 104 of the Act by the Medical Services Committee of Inquiry for the State of New South Wales, after its inquiry into the practice of Dr Sekhon.

The Committee was of the opinion that in respect of the patients under reference, certain of the services were excessive, in that they were not reasonably necessary for the adequate medical care of the patients concerned. The Committee arrived at this opinion by referring to all the evidence before it and bringing to bear the knowledge and experience of its members.

Comments

The Government is seriously concerned by the practice of doctors like Dr Sekhon who provide services which are not reasonably necessary for the adequate medical care of the patients concerned. Excessive services are a drain on public funds and every effort is being made to reduce the magnitude of the problem.

Dated this 16th day of December 1988.

NEAL BLEWETT
Minister for Community Services and Health

N.N.—8926866

COMMONWEALTH OF AUSTRALIA

Health Insurance Act 1973

DETERMINATION UNDER SECTION 106

WHEREAS

(a) The Medical Services Committee of Inquiry for the State of New South Wales, established under subsection 80 (1) of the *Health Insurance Act 1973*, has inquired into the matter of the rendering of professional services by Jogender Singh Sekhon, a legally qualified medical practitioner of 172 Waminda Ave, Campbelltown, in that State, referred to the Committee under section 82 of the Act;

(b) the said Committee, after having conducted a hearing into the abovementioned matter pursuant to section 94 of the Act, has reported to the Minister, under section 104 of the Act, and has expressed the opinion that the services identified in its report and which were rendered by the said Jogender Singh Sekhon were excessive services within the meaning of paragraph 79 (1B) of the Act;

(c) Medicare benefits within the meaning of subsection 3 (1) of the Act in respect of the abovementioned services have been paid or are payable to the said Jogender Singh Sekhon;

(d) the services included in the reference to the Committee were rendered on or after 1 February 1984;

(e) the said Committee has made recommendations pursuant to paragraphs 105 (2) (ca), 105 (2) (f) of the Act, and

(f) subsection 106 (1) of the Act provides that the Minister may make a Determination in writing in accordance with the said Committee's recommendations.

NOW THEREFORE I, NEAL BLEWETT, Minister of State for Community Services and Health, hereby determine that, in accordance with the said Committee's recommendations:

(i) under paragraph 105 (2) (ca) of the Act, the said Jogender Singh Sekhon be counselled; and

(ii) under paragraph 105 (2) (f) of the Act, the amount of Medicare benefits referred to in paragraph (c) herein be payable by the said Jogender Singh Sekhon to the Commonwealth of Australia, being as specified hereunder:

Amount	*Payable to*
$8 892.40	Commonwealth of Australia

Dated this 24th day of October 1988.

NEAL BLEWETT
Minister of State for
Community Services and Health

N.N.—8926867

COMMONWEALTH OF AUSTRALIA

Health Insurance Act 1973

STATEMENT UNDER SECTION 106AA

On the 24th day of October 1988, I, NEAL BLEWETT, Minister of State for Community Services and Health, made a determination under section 106 of the *Health Insurance Act 1973* (the Act), in respect of Dr Ian Raymond Gregory of 713 Hay St Mall, Perth WA 6000.

Particulars of Determination

A copy of the determination is at Attachment A.

Reasons for Determination

The determination was made by me on the basis of a report made under section 104 of the Act by the Medical Services Committee of Inquiry for the State of Western Australia, after its inquiry into the practice of Dr Gregory.

The Committee was of the opinion that in respect of the patients under reference, certain of the services were excessive, in that they were not reasonably necessary for the adequate medical care of the patients concerned. The Committee arrived at this opinion by referring to the information before it and bringing to bear the knowledge and experience of its members.

Comments

The Government is seriously concerned by the practice of doctors like Dr Gregory who provide services which are not reasonably necessary for the adequate medical care of the patients concerned. Excessive services are a drain on public funds and every effort is being made to reduce the magnitude of the problem.

Dated this 14th day of December 1988.

NEAL BLEWETT
Minister of State for
Community Services and Health

N.N.—8926868

COMMONWEALTH OF AUSTRALIA

Health Insurance Act 1973

DETERMINATION UNDER SECTION 106

WHEREAS

(a) The Medical Services Committee of Inquiry for the State of Western Australia, established under subsection 80 (1) of the *Health Insurance Act 1973*, has inquired into the matter of the rendering of professional services by Dr Ian Raymond Gregory, a legally qualified medical practitioner of 713 Hay St Mall, Perth, in that State, referred to the Committee under section 82 of the Act;

(b) the said Committee, after having conducted a hearing into the abovementioned matter pursuant to section 94

of the Act, has reported to the Minister, under section 104 of the Act, and has expressed the opinion that the services identified in its report and which were rendered by the said Dr Ian Raymond Gregory were excessive services within the meaning of paragraph 79 (1B) of the Act;

(c) Medicare benefits within the meaning of subsection 3 (1) of the Act in respect of the abovementioned services have been paid to the said Dr Ian Raymond Gregory or have been paid or are payable to another person or persons;

(d) the services included in the reference to the Committee were rendered on or after 1 February 1984;

(e) the said Committee has made recommendations pursuant to paragraphs 105 (2) (c), 105 (2) (ca), 105 (2) (f) of the Act, and

(f) subsection 106 (1) of the Act provides that the Minister may make a determination in writing in accordance with the said Committee's recommendations.

NOW THEREFORE I, NEAL BLEWETT, Minister of State for Community Services and Health, hereby determine that, in accordance with the said Committee's recommendations:

(i) under paragraph 105 (2) (c) of the Act, the said Dr Ian Raymond Gregory be reprimanded, and I do so reprimand him;

(ii) under paragraph 105 (2) (ca) of the Act, the said Dr Ian Raymond Gregory be counselled; and

(iii) under paragraph 105 (2) (f) of the Act, the amount of Medicare benefits referred to in paragraph (c) herein be payable by the said Dr Ian Raymond Gregory to the Commonwealth of Australia, being as specified hereunder:

Amount	*Payable to*
$1 626.25	Commonwealth of Australia

Dated this 24th day of October 1988.

NEAL BLEWETT
Minister of State for
Community Services and Health

N.N.—8926869

COMMONWEALTH OF AUSTRALIA

Nursing Homes Assistance Act 1974

NOTICE FOR THE PURPOSES OF PARAGRAPH 13 (1) (a) and (d)

I, NEAL BLEWETT, the Minister of State for Community Services and Health, pursuant to paragraphs 13 (1) (a) and (d) of the *Nursing Homes Assistance Act 1974*, hereby:

(a) revoke, with effect on 6 April 1989, the determination for the purposes of those paragraphs dated 10 May 1988 and published in the *Commonwealth of Australia Gazette* No. GN 22 of 22 June 1988; and

(b) determine that, on and from 6 April 1989:

(a) the rate for the purposes of paragraph 13 (1) (a) is $117.95 per week; and

(b) for the purposes of paragraph 13 (1) (d), the rate applicable to a qualified nursing home patient in a nursing home situated in a State specified in column 1 of the following table is:

(i) in the case of an ordinary care patient—the amount per week specified in column 2; and

(ii) in the case of an extensive care patient—the amount per week specified in column 3,

of that table opposite the name of that State specified in column 1:

Column 1	*Column 2*	*Column 3*
State	*Amount per week for ordinary care patient*	*Amount per week for extensive care patient*
	$	$
New South Wales	462.70	504.70
Victoria	548.87	590.87
Queensland	434.35	476.35
Western Australia	437.36	469.36
South Australia	496.09	538.09
Tasmania	435.19	477.19

Dated this 9th day of March 1989.

NEAL BLEWETT
Minister of State for
Community Services and Health

N.N.—8926870

AUSTRALIAN CAPITAL TERRITORY

Radiation Ordinance 1983

Section 73

NOTIFICATION OF DECISIONS

Pursuant to section 73 of the *Australian Capital Territory Radiation Ordinance 1983*, the Radiation Council hereby gives notice of the particulars of the following decisions of Council, made on 8 March 1989:

REGISTRATION OF IRRADIATING APPARATUS
(paragraph 73 (1) (d))

Owner: Joint House Department

Description: Baggage Inspection System, Philips Dynavision Model 510 Ser. No. 8552 140kVp, 200mA

Location: Parliament House, House of Representatives entrance security control 11A.G.058

Conditions: Baggage inspection

Owner: Joint House Department

Description: Baggage Inspection System, Philips Dynavision Model 520 Ser. No. 8183 400kVp, 400mA

Location: Parliament House, goods sorting area 25.B.18

Conditions: Baggage inspection

GRANTING OF LICENCE (paragraph 73 (1) (b))

Licencee: Peter Burgess

Address: 43 Limestone Ave, Braddon ACT 2601

Authorized activities: Own or have in possession/use, irradiating apparatus

Conditions: Veterinary radiography

Licencee: John Dominic Re

Address: Kaleen Health Centre, Dental Surgery, Maribyrnong Ave, Kaleen ACT 2617

Authorized activities: Use, irradiating apparatus

Conditions: Diagnostic dental radiography

Licencee: Olsen Engineering Company

Address: attn: Mr Raymond Olsen, 8 Arnold St, Cheltenham Vic. 3192

Authorized activities: Sell/own or have in possession/let on hire/use/cause or permit to use, irradiating apparatus

Conditions: Sell, install and maintain the following smoke detector units: for sale and service: Cerberus types F716, F922, and F600 (sold for replacement of same type only); Nittan types Nid58-AS, Nid58f and Nid28. For service only: Cerberus type F52 and Becon type C123

The Radiation Council hereby gives notice that subject to the provisions of the *Administrative Appeals Tribunal Act 1975*, a person whose interests are adversely affected by a decision of the Radiation Council is entitled to apply to the Administrative Appeals Tribunal for a review of the decision.

Dated this 8th day of March 1989.

DALE F. HEBBARD
Chairman
Radiation Council

N.N.—8926871

AUSTRALIAN CAPITAL TERRITORY

Radiation Ordinance 1983

Section 73

NOTIFICATION OF DECISIONS

Pursuant to section 73 of the *Australian Capital Territory Radiation Ordinance 1983*, the Radiation Council hereby gives notice of the particulars of the following decisions of Council, made on 9 November 1988:

REGISTRATION OF IRRADIATING APPARATUS (paragraph 73 (1) (d))

Owner: G. P. Boydell

Description: Veterinary x-ray unit 'Atomscope' 100P serial numbers 075/1211 100kVp, 10mA

Location: 103 Learmonth Dr, Kambah ACT 2902

Conditions: Veterinary radiography

Owner: Joint House Department

Description: Baggage inspection system Philips Dynavision model 510 Ser. No. 8553 140kVp, 200mA

Location: Parliament House, Area 6, Roof Entrance, Lift Lobby

Conditions: Baggage inspection

Owner: Joint House Department

Description: Baggage inspection system Philips Dynavision model 510 Ser. No. 8550 140kVp, 200mA

Location: Parliament House, Senate Entrance, Security Control Point 2A.G.022

Conditions: Baggage inspection

Owner: Joint House Department

Description: Baggage inspection system Philips Dynavision model 510 Ser. No. 8549 140kVp, 200mA

Location: Parliament House, Executive Entrance, Security Control Point 8D.G.001

Conditions: Baggage inspection

Owner: ACT Community and Health Service

Description: Dental x-ray unit trophy model CCX timer (DG073), S/N 3840 with model 708 tube, S/N G4275 70kVp, 8mA

Location: Belconnen Health Centre (Room 1-37), Benjamin Way, Belconnen

Conditions: Diagnostic dental examinations

Owner: S. W. Parsons

Description: Dental x-ray unit trophy model 708, S/N 844940 with model CCX timer, S/N G3489 371129 70kVp, 8mA

Location: 1st Floor, Ethos House, 28-36 Ainslie Ave., Canberra ACT 2600

Conditions: Diagnostic dental examinations

GRANTING OF LICENCE (paragraph 73 (1) (b))

Licensee: R. I. Evans

Address: 1st Floor, Ethos House, 28-36 Ainslie Ave., Canberra ACT 2600

Authorized activities: Use, iradiating apparatus

Conditions: Diagnostic dental radiography

APPROVAL FOR ALTERATION OR MODIFICATION OF REGISTERED IRRADIATING APPARATUS (paragraph 73 (1) (e))

Owner: Joint House Department

Description: Baggage inspection system Philips Dynavision model 520 Serial Number 8099 160kVp, 0.5mA

Location: Parliament House Loading Dock

Conditions: Baggage inspection

The Radiation Council hereby gives notice that subject to the provisions of the *Administrative Appeals Tribunal Act 1975*, a person whose interests are adversely affected by a decision of the Radiation Council is entitled to apply to the Administrative Appeals Tribunal for a review of the decision.

Dated this 9th day of November 1988.

DALE F. HEBBARD
Chairman
Radiation Council

N.N.—8926872

National Health Act 1953

PHARMACEUTICAL BENEFITS

DETERMINATION UNDER SECTIONS 85, 85A AND 88

I, IAN JAMES McNEIL, First Assistant Secretary, Health Benefits Division, Department of Community Services and Health and Delegate of the Minister of State for Community Services and Health, pursuant to sections 85, 85A and 88 of the *National Health Act 1953*, hereby make the following Determination:

1. This Determination shall come into operation on 1 April 1989.

2. The Determination under sections 85, 85A and 88 of the Act made on 16 November 1988 with effect from 1 December 1988, as amended with effect from 1 March 1989, is hereby revoked.

3. In the Schedules to this Determination:
'amp.' means ampoule;
'fl oz' means fluid ounce of 480 minims;
'g' means gram;
'I.M.' means intramuscular;
'I.U.' means international unit;
'I.V.' means intravenous;
'kg' means kilogram;
'L' means litre;
'lb' means pound of 16 ounces;
'm' means metre;
'mg' means milligram;
'mL' means millilitre;
'mm' means millimetre;
'mmol' means millimole;
'Sch. 2' means the Second Schedule to this Determination.

4. Where the strength, type of unit, size of unit or other particulars of form are specified in the column headed 'Form' in the First Schedule to this Determination in relation to a drug or medicinal preparation referred to in sub-section 85 (2) of the *National Health Act 1953* the name of which is specified in that Schedule, those particulars refer to the form or forms of the drug or medicinal preparation that is or are allowable for the purposes of Part VII of that Act to the effect that the drug or medicinal preparation in that form or in each of those forms is a pharmaceutical benefit when prescribed by a medical practitioner.

5. Where the strength, type of unit, size of unit or other particulars of form are specified in the column headed 'Form' in the Third Schedule to this Determination in relation to a drug or medicinal preparation referred to in sub-section 85 (2) of the *National Health Act 1953* the name of which is specified in that Schedule, those particulars refer to the form or forms of the drug or medicinal preparation that is or are allowable for the purposes of Part VII of that Act to the effect that the drug or medicinal preparation in that form or in each of those forms is a pharmaceutical benefit referred to in sub-section 88 (1A) of that Act for the supply of which a participating dental practitioner is authorized to write a prescription.

6. The purposes set out in the column headed 'Purposes' in Part 2 of the First Schedule to this Determination are the only purposes for which a medical practitioner may prescribe the maximum quantities and number of repeats specified in that Part in relation to those pharmaceutical benefits specified in that same Part.

7. The manner, if any, in which a pharmaceutical benefit specified in the First and Third Schedules to this Determination is to be administered in relation to the pharmaceutical benefit is set out in those Schedules in the column headed 'Manner of administration'.

8. The maximum quantity or number of units of a pharmaceutical benefit that may, in one prescription, be directed to be supplied on any one occasion is:

(a) where the name of the pharmaceutical benefit is specified—
  (i) in Part 1 of the First Schedule to this Determination—the quantity or number, if any, specified in that Part of the Schedule in the column headed 'Maximum quantity' in relation to the pharmaceutical benefit; or
  (ii) in Part 2 of the First Schedule to this Determination and the pharmaceutical benefit is prescribed in accordance with the provisions of the column headed 'Purposes'—the quantity or number, if any, in that Part of the Schedule in the column headed 'Maximum quantity' in relation to the pharmaceutical benefit; or
  (iii) if reference is made to the Second Schedule to this Determination in the column headed 'Maximum quantity' in the First Schedule to this Determination, the quantity or number, if any, specified in the column headed 'Maximum quantity' in the Second Schedule to this Determination in relation to the form of the pharmaceutical benefit; or
  (iv) in the Third Schedule to this Determination—the quantity or number, if any, specified in that Part of the Schedule in the column headed 'Maximum quantity' in relation to the pharmaceutical benefit; or
(b) in any other case—the quantity or number, if any, specified in the column headed 'Maximum quantity' in the Second Schedule to this Determination in relation to the form of the pharmaceutical benefit.

9. The maximum number of occasions, if any, on which the supply of a pharmaceutical benefit may, in one prescription, be directed by a medical practitioner to be repeated is:

(a) where the name of the pharmaceutical benefit is specified—
  (i) in Part 1 of the First Schedule to this Determination—the quantity or number, if any, specified in that Part of the Schedule in the column headed 'Number of repeats' in relation to the pharmaceutical benefit; or
  (ii) in Part 2 of the First Schedule to this Determination and the pharmaceutical benefit is prescribed in accordance with the provisions of the column headed 'Purposes'—the quantity or number, if any, in that Part of the Schedule in the column headed 'Number of repeats' in relation to the pharmaceutical benefit; or
  (iii) if reference is made to the Second Schedule to this Determination in the column headed 'Number of repeats' in the First Schedule to this Determination, the quantity or number, if any, specified in the column headed 'Number of repeats' in the Second Schedule to this Determination in relation to the form of the pharmaceutical benefit; or
(b) in any other case—the number, if any, specified in the column headed 'Number of repeats' in the Second Schedule to this Determination in relation to the form of the pharmaceutical benefit.

10. The following purposes are specified in relation to each pharmaceutical benefit the name of which is specified in Part 2 of the First Schedule to this Determination:

(a) Where a class of persons is specified in the column headed 'Purposes'—that the pharmaceutical benefit is to be supplied for the treatment of a person included in that class of persons;
(b) Where a disease or condition is specified in the column headed 'Purposes'—
  (i) if sub-sub-paragraph (ii) does not apply—that the pharmaceutical benefit is to be supplied for the treatment of that disease or condition in relation to any person; or
  (ii) if the disease or condition is specified in relation to a specified class of persons—that the pharmaceutical benefit is to be supplied for the treatment of that disease or condition in a person included in that class of persons;

(c) Where a purpose is specified in the column headed 'Purposes' that the pharmaceutical benefit is to be supplied for that purpose;

(d) Where it is specified in the column headed 'Purposes' that compliance with authority procedures set out in sub-paragraph 10 (d) is required--

(i) that an application for the written authority of the Secretary in relation to the supply of the pharmaceutical benefit has been made by a medical practitioner, on a form approved by the Secretary, and has been forwarded to the Secretary by that medical practitioner or on behalf of that medical practitioner by a person other than an approved pharmacist, and the Secretary has approved the application; or

(ii) where the medical practitioner believes that the supply of the pharmaceutical benefit is required urgently that the medical practitioner has prepared an Authority Prescription on a form approved by the Secretary and has:

(A) issued the original and duplicate of the form to the person for whom the pharmaceutical benefit is to be supplied;

(B) on the departmental copy of the form declared that the pharmaceutical benefit is prescribed in accordance with the provisions of the column headed 'Purposes' and signed that copy in the medical practitioner's handwriting; and

(C) forwarded the departmental copy to reach the Secretary within seven days from the date on which the original and duplicate were issued to the person for whom the pharmaceutical benefit is to be supplied.

11. Where a medical practitioner makes an application under sub-paragraph 10 (d) and the Secretary approves the application, the Secretary shall record the approval on a numbered authority and

(a) where, in the approval, the Secretary requires the medical practitioner to vary the prescription for the supply of the pharmaceutical benefit—return the approval to the medical practitioner; or

(b) in any other case return the approval to the medical practitioner or, if the medical practitioner so requests, forward the approval to the person to whom the pharmaceutical benefit is to be supplied.

12. The name of the manufacturer or the names of manufacturers denoted in accordance with the following table by letters appearing in the column headed 'Brand' in the First and Third Schedules to this Determination in relation to a drug or medicinal preparation the name of which is specified in those Schedules is the brand or brands under which the drug or medicinal preparation may be supplied under Part VII of the *National Health Act 1953* as a pharmaceutical benefit:

Letters	*Manufacturer's Name*
AB	Abbott Australasia Pty Ltd
AD	Amrad Pharmaceuticals Pty Ltd
AF	Alphapharm Pty Ltd
AG	Allergan Australia Pty Ltd
AM	Ames Company, Division of Miles Laboratories Australia Pty Ltd
AP	Astra Pharmaceuticals Pty Ltd
AQ	Alcon Laboratories (Australia) Pty Ltd
AS	Astral Medical (Aust.) Pty Ltd
AY	Ayerst Laboratories Pty Ltd
BC	Bristol Laboratories Pty Ltd
BF	Barnes-Hind Pty Limited
BH	Biopharm Pty Ltd
BL	David Bull Laboratories Proprietary Limited
BN	Bayer Pharmaceutical Company
BO	Boehringer Mannheim, GmbH, Germany
BR	Beecham Research Laboratories
BT	The Boots Company (Australia) Pty Ltd
BW	Wellcome Australia Limited
BX	Baxter Healthcare Pty Ltd
BY	Boehringer Ingelheim Pty Ltd
BZ	Boucher & Muir Pty Ltd
CG	Ciba-Geigy Australia Limited
CL	Cilag Pty Limited
CN	CSL-Novo Pty Limited
CS	Commonwealth Serum Laboratories
DH	Drug Houses of Australia Pty Ltd
DL	Dista Products (Australia) & Company
DY	Denyer Bros Pty Ltd
EG	Eagle Pharmaceuticals Pty Ltd
FA	F. H. Faulding and Co. Ltd
FC	Fisons Pty Ltd
FE	Farmitalia Carlo Erba
FM	Fawns and McAllan Pty Ltd
FR	Charles E. Frosst, Division of Merck Sharp & Dohme (Australia) Pty Ltd
GL	Glaxo
GP	G.P. Laboratories
HA	Hamilton Laboratories Pty Ltd
HO	Hollister Incorporated, U.S.A.
HP	Hoechst Australia Ltd
IC	ICI Australia Operations Pty Ltd
IQ	The Ioquin Company
JC	Janssen-Cilag Pty Ltd
JP	Janssen Pharmaceutica Pty Ltd
KM	Kendall McGaw Laboratories, Division of Kendall Australia Pty Ltd
KN	Knoll A. G., Germany
KY	Key Pharmaceuticals Pty Ltd
LA	L.A. Chemicals Pty Ltd
LE	Lederle Laboratories Division, Cyanamid Australia Pty Ltd
LH	Lipha Pharmaceuticals, London, U.K.
LY	Eli Lilly (Australia) and Company
MB	May & Baker Pharmaceuticals
MG	J. McGloin Pty Ltd
MJ	Mead Johnson
MK	Merck Sharp & Dohme (Australia) Pty Ltd
ML	Merrell Dow Pharmaceuticals Australia Pty Ltd
NN	Nelson Laboratories (Sales) Pty Ltd
NR	Nordia, Denmark
NS	Nicholas Kiwi Pty Ltd
NT	Nestlé Australia Ltd
NW	Norwich Eaton Pharmaceuticals Pty Limited
OL	Owen Laboratories
OR	Organon (Australia) Pty Ltd
PD	Parke Davis Pty Ltd
PF	Pfizer Pty Ltd
PS	Pharmacia (Australia) Pty Ltd
PT	CP Protea
QE	Queensland Ethicals
RC	Reckitts Pty Ltd
RG	Rorer Australia Pty Ltd
RK	Riker Laboratories Australia Pty Ltd
RL	Roussel Pharmaceuticals Pty Ltd
RO	Roche Products Pty Ltd
RS	A. H. Robins Pty Limited
RT	Rocke Tompsitt & Co. Ltd
SA	Sayco Pty Ltd
SB	Scientific Hospital Supplies (Australia) Pty Ltd
SC	Schering Pty Ltd, Australian subsidiary of Schering A. G., Berlin
SD	Syntex Pharmaceuticals Ltd
SE	Servier Laboratories (Aust.) Pty Ltd
SH	Essex Laboratories Pty Ltd, Australian subsidiary of Schering Corporation, U.S.A.
SI	Sigma Co. Ltd
SJ	Sharpe Laboratories Pty Ltd
SK	Smith Kline & French Laboratories (Aust.) Ltd
SN	Smith & Nephew (Aust.) Pty Ltd
SQ	E. R. Squibb & Sons Pty Ltd
SR	Searle Laboratories
ST	A. E. Stansen & Co. Pty Ltd
SU	Sauter Laboratories (Aust.) Pty Ltd
SV	Stafford-Miller Limited
SZ	Sandoz Australia Pty Ltd
TO	R. D. Toppin and Sons Pty Ltd
UP	Upjohn Pty Ltd
US	USV Pharmaceuticals, a Division of Rorer Australia Pty Ltd
UW	United Works of Pharmaceutical & Dietetic Products, Hungary
WH	H. W. Woods Pty Ltd
WL	Winthrop Laboratories
WW	Wm R. Warner & Co. Pty Ltd
WY	Wyeth Pharmaceuticals Pty Ltd
ZY	Zyma Pharmaceuticals

FIRST SCHEDULE PART I

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Acetazolamide B.P.	Capsule, 500 mg (sustained release)	Oral	50	3	LE
Acetazolamide Sodium with any determined brand of Water for Injections or other solvent	Injection, 500 mg vial (with required solvent)	Injection	1	..	LE
Acetazolamide Tablets B.P.	250 mg	Oral	100	3	LE
Acetylcysteine B.P.	Solution, 200 mg per mL, 10 mL	Inhalation	5	3	AP
Acrylic Resin	Solution, 125 g aerosol spray pack	Application	1	..	AP
Acyclovir	Eye ointment, 30 mg per g, 4.5 g	Application to the eye	1	..	BW
	Tablet, 200 mg	Oral	50	..	BW
	Tablet, 400 mg	Oral	70	..	BW
Adrenaline B.P.	Eye drops, 5 mg per mL, 7.5 mL	Application to the eye	1	5	BF
	Eye drops, 10 mg per mL, 7.5 mL	Application to the eye	1	5	BF
	Extemporaneously prepared eye drops	Application to the eye	Sch. 2	Sch. 2	
Adrenaline Hydrochloride	Eye drops, 5 mg (base) per mL, 10 mL	Application to the eye	1	5	AG
	Eye drops, 10 mg (base) per mL, 10 mL	Application to the eye	1	5	AG, AQ
	Eye drops, 20 mg (base) per mL, 10 mL	Application to the eye	1	5	AG, AQ
Adrenaline Injection B.P.	Adrenaline, 1 in 1,000, 1 mL	Injection	5	1	AP, SI
"Albumaid XP"	Powder, 200 g	Oral	10	5	SB
"Albumaid XPXT"	Powder, 200 g	Oral	10	5	SB
"Alfaré"	Powder, 400 g	Oral	2	20	NT
Allopurinol B.P.	Capsule, 100 mg	Oral	200	2	FM
	Capsule, 300 mg	Oral	60	2	FM
Allopurinol Tablets B.P.	100 mg	Oral	200	2	DH, PT
	300 mg	Oral	60	2	DH, PT
Alprenolol Tablets B.P.	100 mg	Oral	100	5	AP, BR
Aluminium Hydroxide and Magnesium Carbonate Co-dried Gel	Tablet, 375 mg	Oral	200	5	GL, WY
Aluminium Hydroxide, Dried B.P.	Tablet, 300 mg	Oral	200	5	WY
Aluminium Hydroxide, Dried B.P. with Magnesium Hydroxide B.P.	Tablet, 200 mg-200 mg	Oral	200	5	PD, WW
	Tablet, dispersible, 230 mg-230 mg	Oral	200	5	BW
Aluminium Hydroxide, Dried B.P. with Magnesium Trisilicate B.P. and Magnesium Hydroxide B.P.	Suspension, 250 mg-120 mg-120 mg per 5 mL, 500 mL	Oral	2	5	FM
	Tablet, 250 mg-120 mg-120 mg	Oral	200	5	FM
Aluminium Hydroxide Mixture B.P.	Suspension, 320 mg per 5 mL, 500 mL	Oral	2	5	DH, WY
Aluminium Hydroxide Mixture B.P. with Light Kaolin B.P. or Light Kaolin (Natural) B.P.	Suspension, 137 mg-1 g per 5 mL, 500 mL	Oral	1	2	WY
Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P.	Suspension, 200 mg-200 mg per 5 mL, 500 mL	Oral	2	5	DH, PD, SC, WW
	Suspension, 215 mg-80 mg per 5 mL, 500 mL	Oral	2	5	WY
	Suspension, 300 mg-100 mg per 5 mL, 500 mL	Oral	2	5	AY
Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P. and Oxethazaine	Suspension, 306 mg-97.5 mg-10 mg per 5 mL, 500 mL	Oral	2	5	AY
Amantadine Hydrochloride	Capsule, 100 mg	Oral	100	5	BT, CG
Ambenonium Chloride	Tablet, 10 mg	Oral	100	2	WL
Amiloride Hydrochloride Tablets B.P.	5 mg	Oral	100	1	AF, MK

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Aminacrine Hydrochloride B.P. 1968	Eye drops, 3 mg in 15 mL	Application to the eye	1	2	SI
Aminoglutethimide	Tablet, 250 mg	Oral	100	5	CG
"Aminogran Food Supplement"	Powder, 500 g	Oral	1	5	GL
"Aminogran Mineral Mixture"	Powder, 250 g	Oral	1	5	GL
Aminophylline B.P.	Mixture, 105 mg per 5 mL, 500 mL	Oral	1	5	FC
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Aminophylline Injection B.P.	Ampoule, 250 mg in 10 mL	I.V. injection	5	..	AP, SI
Aminophylline Tablets B.P.	100 mg	Oral	100	5	HA
Amiodarone Hydrochloride	Tablet, 100 mg	Oral	30	5	RC
	Tablet, 200 mg	Oral	30	5	RC
Amitriptyline Tablets B.P.	10 mg	Oral	50	2	AF, MK, PT, RO
	25 mg	Oral	50	2	AF, MK, NS, PT, RO
	50 mg	Oral	50	2	AF
Amoxycillin Capsules B.P.	250 mg (base)	Oral	20	1	AF, BR, CS, PT, SI
	500 mg (base)	Oral	20	1	AF, BR, CS, PT, SI
Amoxycillin Sodium	Injection, 250 mg (base) vial with 3 mL solvent	Injection	5	1	PT
	Injection, 500 mg (base) vial with 3 mL solvent	Injection	5	1	PT
	Injection, 1 g (base) vial with 4 mL solvent	Injection	5	1	PT
Amoxycillin Trihydrate B.P.	Tablet, chewable, 250 mg (base)	Oral	20	1	BR, CS
	Tablet, dispersible, 3 g (base)	Oral	1	..	BR, CS
Amoxycillin Trihydrate B.P. with Potassium Clavulanate	Tablet, 250 mg (base)-125 mg (acid)	Oral	15	1	BR
	Tablet, 500 mg (base)-125 mg (acid)	Oral	15	1	BR
Amoxycillin Trihydrate B.P. with Potassium Clavulanate and Purified Water B.P.	Powder for syrup, 125 mg (base)-31.25 mg (acid) per 5 mL, 75 mL	Oral	1	1	BR
	Powder for syrup, 250 mg (base)-62.5 mg (acid) per 5 mL, 75 mL	Oral	1	..	BR
Amoxycillin Trihydrate B.P. with Purified Water B.P.	Powder for paediatric drops, 100 mg (base) per mL, 20 mL	Oral	1	1	BR
	Powder for syrup, 125 mg (base) per 5 mL, 100 mL	Oral	1	1	BR, CS, PT, SI
	Powder for syrup, 250 mg (base) per 5 mL, 100 mL	Oral	1	..	BR, CS, PT, SI
Amphotericin B.P.	Cream, 30 mg per g, 15 g	Application	1	1	SQ
	Ointment, 30 mg per g, 15 g	Application	1	1	SQ
Amphotericin B.P. with any determined brand of Water for Injections or other solvent	Injection, 50 mg vial (with required solvent)	Injection	1	..	SQ
Amphotericin Lozenges B.P.	10 mg	Oral	20	1	SQ
Ampicillin Capsules B.P.	250 mg	Oral	24	1	AF, BR, PT
	500 mg	Oral	24	..	AF, BR, PT
Ampicillin Sodium B.P. with any determined brand of Water for Injections or other solvent	Injection, 250 mg (base) vial (with required solvent)	Injection	5	1	CS, PT
	Injection, 500 mg (base) vial (with required solvent)	Injection	5	1	BR, CS, PT
	Injection, 1 g (base) vial (with required solvent)	Injection	5	1	CS, PT
Ampicillin Trihydrate B.P. with Purified Water B.P.	Powder for syrup, 125 mg (base) per 5 mL, 100 mL	Oral	1	1	BR
	Powder for syrup, 250 mg (base) per 5 mL, 100 mL	Oral	1	..	BR

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Amylobarbitone Sodium B.P. with any determined brand of Water for Injections or other solvent	Injection, 500 mg amp. (with required solvent)	Injection	2	..	LY
Antazoline Phosphate with Naphazoline Hydrochloride	Eye drops, 5 mg-500 micrograms per mL, 15 mL	Application to the eye	1	2	AG
Antazoline Sulphate with Naphazoline Nitrate B.P.	Eye drops, 5 mg-250 micrograms per mL, 10 mL	Application to the eye	1	2	ZY
Aspirin B.P.	Tablet, 325 mg (buffered)	Oral	100	1	AP
	Tablet, 650 mg (enteric coated)	Oral	100	2	SK
	Tablet, 650 mg (sustained release)	Oral	100	2	BT
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Aspirin Tablets B.P.	300 mg	Oral	100	1	SI
Aspirin Tablets, Dispersible B.P.	300 mg	Oral	100	1	RC
Atenolol	Tablet, 50 mg	Oral	30	5	AF, IC
Atropine Eye Ointment B.P.	10 mg per g, 4 g	Application to the eye	1	..	PD
Atropine Sulphate B.P.	Eye drops, 5 mg per mL, 15 mL	Application to the eye	1	2	SI
	Eye drops, 10 mg per mL, 15 mL	Application to the eye	1	2	SI
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Atropine Sulphate Injection B.P.	Ampoule, 600 micrograms in 1 mL	Injection	5	1	AP, BT
	Ampoule, 1.2 mg in 1 mL	Injection	5	1	AP, BT
Atropine Sulphate Tablets B.P.	600 micrograms	Oral	100	2	FM
Auranofin	Tablet, 3 mg	Oral	60	5	SK
Aurothioglucose	Injection, 50 mg per mL, 10 mL	Injection	1	..	SH
Azathioprine Tablets B.P.	50 mg	Oral	100	2	AF, BW
Baclofen Tablets B.P.	10 mg	Oral	100	5	CG
	25 mg	Oral	100	5	CG
"Banish"	Liquid, 15 mL		1	..	DY
Beclomethasone Dipropionate B.P.	Capsule, 100 micrograms	Inhalation by mouth	100	5	GL
	Spray, metered aerosol, 50 micrograms per dose, 200 doses, 20.4 g	Inhalation by mouth	1	5	GL, SH
	Spray, metered aerosol, 100 micrograms per dose, 200 doses, 20.4 g	Inhalation by mouth	1	5	GL
	Spray, metered aerosol, 250 micrograms per dose, 200 doses, 20.4 g	Inhalation by mouth	1	5	GL
Bendrofluazide Tablets B.P.	2.5 mg	Oral	100	1	BT
	5 mg	Oral	100	1	BT, PT
Benzathine Penicillin B.P.	Injection, 1.8 g in 4 mL disposable syringe	Injection	1	..	WY
Benzathine Penicillin B.P. with Procaine Penicillin B.P., Benzylpenicillin Potassium B.P. and Water for Injections	Injection, 450 mg-300 mg-187 mg vial with 2 mL water for injections	Injection	1	..	WY
Benzhexol Tablets B.P.	2 mg	Oral	200	2	LE, PT
	5 mg	Oral	200	1	LE, PT
Benzoin Tincture, Compound B.P.	Spray, aerosol, 3.5 mL per 10 mL, 167 mL	Application	1	..	EG
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Benztropine Injection B.P.	Ampoule, 2 mg in 2 mL	Injection	5	..	MK
Benztropine Tablets B.P.	2 mg	Oral	60	2	MK
Benzyl Benzoate Application B.P.	50 g in 200 mL	Application	1	2	MG
Benzylpenicillin Potassium B.P. with any determined brand of Water for Injections or other solvent	Injection, 300 mg vial (with required solvent)	Injection	5	1	CS
	Injection, 600 mg vial (with required solvent)	Injection	5	1	CS

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
	Injection, 3 g vial (with required solvent)	Injection	10	..	CS
	Injection, 6 g vial (with required solvent)	Injection	10	..	CS
Betamethasone Acetate with Betamethasone Sodium Phosphate B.P.	Injection, 3 mg-3.9 mg in 1 mL amp.	Injection	5	..	SH
Betamethasone Dipropionate	Cream, 500 micrograms (base) per g, 15 g	Application	1	1	SH
	Ointment, 500 micrograms (base) per g, 15 g	Application	1	1	SH
	Scalp lotion, 500 micrograms (base) per mL, 30 mL	Application to the scalp	1	1	SH
Betamethasone Tablets B.P.	500 micrograms	Oral	30	4	SH
Betamethasone Valerate B.P.	Gel, 500 micrograms (base) per g, 15 g	Application	1	1	GL
Betamethasone Valerate Cream B.P.	200 micrograms (base) per g, 100 g	Application	2	..	GL, SH
	500 micrograms (base) per g, 15 g	Application	1	1	GL, SH
Betamethasone Valerate Ointment B.P.	200 micrograms (base) per g, 100 g	Application	2	..	SH
	500 micrograms (base) per g, 15 g	Application	1	1	GL, SH
Bethanechol Chloride	Injection, 5 mg in 1 mL amp.	Injection	2	..	MK
	Tablet, 10 mg	Oral	100	2	HA, MK
Biperiden Hydrochloride	Tablet, 2 mg	Oral	200	2	KN
Bisacodyl B.P.	Enema, 10 mg in 5 mL, 25	Enema	1	2	PT
Bisacodyl Suppositories B.P.	10 mg, 10		1	..	BY
Bisacodyl Tablets B.P.	5 mg	Oral	200	1	PT
Bismuth Subcitrate	Tablet, 107.7 mg (as Bi)	Oral	112	2	PD
Bleomycin Sulphate with any determined brand of Water for Injections or other solvent	Injections, 15 mg (base) (with required solvent), 10	Injection	1	..	BC
Bromocriptine Mesylate Capsules B.P.	5 mg (base)	Oral	60	5	SZ
	10 mg (base)	Oral	100	5	SZ
Bromocriptine Mesylate Tablets B.P.	2.5 mg (base)	Oral	30	..	SZ
Bumetanide	Tablet, 1 mg	Oral	100	1	AP
Busulphan Tablets B.P.	2 mg	Oral	100	..	BW
Butyl Monoester Polymer with Ethanol B.P.	Paste, 60 g	Application	1	..	SQ
Butyl Monoester Polymer with Isopropyl Alcohol B.P.	Protective dressing aerosol, 120 g	Application	1	..	DY
	Protective dressing solution, 59 mL	Application	1	..	DY
	Protective dressing wipes, 50		1	..	DY, SA
Calciferol Tablets, High-Strength B.P.	250 micrograms	Oral	100	5	GL
Calcitonin (Human) -Synthetic	Injection, 0.5 mg with 2 mL amp. solvent	Injection	15	5	CG
Calcitonin (Pork) B.P.	Injection, 160 I.U. vial with 2 mL vial gelatin solvent	Injection	20	5	RG
Calcitriol	Capsule, 0.25 micrograms	Oral	100	5	RO
Calcium Carbonate B.P.	Tablet, 1.5 g (equivalent to 600 mg calcium)	Oral	120	1	LE
	Tablet (chewable), 1.25 g (equivalent to 500 mg calcium)	Oral	120	1	RK
Calcium Carbonate B.P. with Calcium Lactate-Gluconate	Tablet, compound effervescent, equivalent to 1 g calcium	Oral	60	1	SZ
Calcium Folinate	Injection, 3 mg in 1 mL amp.	Injection	5	..	BL
	Tablet, 15 mg	Oral	10	..	LE

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Calcium Glubionate	Injection, 1.375 g in 10 mL amp.	Injection	5	1	SZ
Captopril	Tablet, 12.5 mg	Oral	90	5	SQ
	Tablet, 25 mg	Oral	90	5	SQ
	Tablet, 50 mg	Oral	90	5	SQ
Carbachol B.P. 1973	Eye drops, 15 mg per mL, 15 mL	Application to the eye	1	5	AQ
	Eye drops, 30 mg per mL, 15 mL	Application to the eye	1	5	AQ
Carbamazepine B.P.	Syrup, 100 mg per 5 mL, 300 mL	Oral	1	5	CG
Carbamazepine Tablets B.P.	100 mg	Oral	200	2	CG
	200 mg	Oral	200	2	AF, CG
Carbimazole Tablets B.P.	5 mg	Oral	200	2	NS
Carboplatin	Solution for I.V. injection, 50 mg in 5 mL vial	Injection	2	..	BC, BL
	Solution for I.V. injection, 150 mg in 15 mL vial	Injection	6	..	BC, BL
	Solution for I.V. injection, 450 mg in 45 mL vial	Injection	2	..	BC, BL
Carmellose Sodium B.P. with Pectin and Gelatin B.P.	Paste, 167 mg-167 mg-167 mg per g, 15 g	Application	1	..	SQ
	Powder, 333 mg-333 mg-333 mg per g, 15 g	Application	1	..	SQ
Cefaclor Monohydrate with Purified Water B.P.	Powder for oral suspension equivalent to 125 mg cefaclor per 5 mL, 100 mL	Oral	1	1	LY
Cefotaxime Sodium with any determined brand of Water for Injections or other solvent	Injection, 1 g (base) (with required solvent)	Injection	5	..	RL
	Injection, 2 g (base) (with required solvent)	Injection	5	..	RL
Ceftriaxone Sodium with any determined brand of Water for Injections or other solvent	Injection, 250 mg (base) (with required solvent)	Injection	2	..	RO
	Injection, 500 mg (base) (with required solvent)	Injection	2	..	RO
	Injection, 1 g (base) (with required solvent)	Injection	2	..	RO
	Injection, 2 g (base) (with required solvent)	Injection	2	..	RO
Cephalexin B.P. with Purified Water B.P.	Granules for syrup, 125 mg (base) per 5 mL, 100 mL	Oral	1	1	GL, LY
	Granules for syrup, 250 mg (base) per 5 mL, 100 mL	Oral	1	..	GL, LY
Cephalexin Capsules B.P.	250 mg	Oral	20	1	AF, GL, LY
	500 mg	Oral	20	1	AF, GL, LY
Cephalothin Sodium B.P. with any determined brand of Water for Injections or other solvent	Injection, 1 g (base) (with required solvent)	Injection	5	..	GL, LY
	Injection, 2 g (base) (with required solvent)	Injection	1	..	LY
	Injection, 4 g (base) (with required solvent)	Injection	1	..	LY
Cephazolin Sodium with any determined brand of Water for Injections or other solvent	Injection, 500 mg (base) (with required solvent)	Injection	5	..	LY
	Injection, 1 g (base) (with required solvent)	Injection	5	..	LY
Charcoal, Activated B.P.	Tablet, 300 mg	Oral	500	1	EG, QE, TO
Chloral Hydrate B.P.	Capsule, 500 mg	Oral	25	..	SQ
	Mixture, 250 mg per 5 mL, 200 mL	Oral	1	..	DH
Chlorambucil Tablets B.P.	2 mg	Oral	100	2	BW
	5 mg	Oral	100	2	BW
Chloramphenicol B.P.	Ear drops (aqueous), 5 mg per mL, 5 mL	Application to the ear	1	2	PD
Chloramphenicol B.P. with Polymyxin B Sulphate B.P.	Eye drops, 5 mg-5,000 units per mL, 10 mL	Application to the eye	1	2	PD
	Eye ointment, 10 mg-5,000 units per g, 4 g	Application to the eye	1	..	PD

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Chloramphenicol Capsules B.P.	250 mg	Oral	16	..	PD
Chloramphenicol Eye Drops B.P.	5 mg per mL, 10 mL	Application to the eye	1	2	AG, PD, SI
Chloramphenicol Eye Ointment B.P.	10 mg per g, 4 g	Application to the eye	1	..	PD, SI
Chloramphenicol Palmitate Mixture B.P.	125 mg per 5 mL, 100 mL	Oral	1	..	PD
Chloramphenicol Sodium Succinate B.P. with any determined brand of Water for Injections or other solvent	Injection, 1 g vial (with required solvent)	Injection	3	..	PD
Chlorhexidine Gluconate	Solution, 50 mg per mL, 200 mL		1	1	IC
Chlormethiazole Capsules B.P.	192 mg	Oral	50	..	AP
Chlormethiazole Edisylate B.P.	Injection, 8 mg per mL, 500 mL	Injection	1	..	AP
Chloroquine Phosphate Tablets B.P.	250 mg	Oral	100	..	PT
Chloroquine Sulphate B.P.	Tablet, 200 mg	Oral	100	..	MB
Chlorothiazide Tablets B.P.	500 mg	Oral	100	1	FM, FR
Chlorpromazine Elixir B.P.	25 mg per 5 mL, 100 mL	Oral	1	4	MB
Chlorpromazine Injection B.P.	Ampoule, 50 mg in 2 mL	Injection	10	..	MB
Chlorpromazine Suppositories B.P.	100 mg, 5		1	2	MB
Chlorpromazine Tablets B.P.	10 mg	Oral	100	1	MB, PT
	25 mg	Oral	100	1	MB, PT
	50 mg	Oral	100	1	MB, PT
	100 mg	Oral	100	1	MB, PT
Chlorpropamide Tablets B.P.	250 mg	Oral	100	5	PF
Chlorthalidone Tablets B.P.	25 mg	Oral	100	1	CG
Cholestyramine	Sachets, containing 9 g powder (equivalent to 4 g cholestyramine), 50	Oral	2	5	AP
Choline Theophyllinate B.P.	Elixir, 50 mg per 5 mL, 500 mL	Oral	1	5	PD
	Syrup, 50 mg per 5 mL, 500 mL	Oral	1	5	WW
	Tablet, 100 mg	Oral	100	5	WW
	Tablet, 200 mg	Oral	100	5	PD, WW
Chorionic Gonadotophin B.P.	Injection set containing 3 ampoules powder for injection 500 units and 3 ampoules solvent 1 mL	Injection	1	5	CS
	Injection set containing 3 ampoules powder for injection 1,000 units and 3 ampoules solvent 1 mL	Injection	1	5	CS
	Injection set containing 3 ampoules powder for injection 2,000 units and 3 ampoules solvent 1 mL	Injection	1	5	CS
	Injection set containing 1 ampoule powder for injection 5,000 units and 1 ampoule solvent 1 mL	Injection	2	..	CS
Cimetidine	Tablet, 200 mg	Oral	120	2	CS, SK
	Tablet, 400 mg	Oral	60	2	CS, SK
	Tablet, 800 mg	Oral	30	1	CS, SK
Ciprofloxacin Hydrochloride	Tablet, 250 mg (base)	Oral	14	..	BN
	Tablet, 500 mg (base)	Oral	14	..	BN
	Tablet, 750 mg (base)	Oral	14	..	BN
Clindamycin Capsules B.P.	75 mg	Oral	25	..	UP
	150 mg	Oral	25	..	UP
Clindamycin Palmitate Hydrochloride with Purified Water B.P.	Granules for syrup, 75 mg (base) per 5 mL, 100 mL	Oral	1	..	UP
Clioquinol B.P.	Cream, 10 mg per g, 30 g	Application	1	..	CG
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Clofibrate Capsules B.P.	500 mg	Oral	100	5	IC, PT

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Clomiphene Tablets B.P.	50 mg, 5	Oral	2	5	ML
Clomipramine Hydrochloride B.P.	Tablet, 25 mg	Oral	50	1	CG
Clonazepam	Injection, 1 mg in 2 mL (set containing solution 1 mg in 1 mL and 1 mL diluent)	Injection	5	..	RO
	Paediatric drops, 2.5 mg per mL, 10 mL	Oral	2	..	RO
	Tablet, 500 micrograms	Oral	200	2	RO
	Tablet, 2 mg	Oral	200	2	RO
Clonidine Hydrochloride Tablets B.P.	100 micrograms	Oral	100	5	BY
	150 micrograms	Oral	100	5	BY
Clopamide	Tablet, 5 mg	Oral	100	1	SZ
Clotrimazole B.P.	Cream, 10 mg per g, 20 g	Application	1	1	BN, SH
	Lotion, 10 mg per mL, 20 mL	Application	1	1	BN, SH
	Pessaries, 100 mg, 6		1	..	BN, SH
	Pessary, 500 mg		1	..	BN
	Vaginal cream, 50 mg per 5 g, 35 g		1	..	BN, SH
	Vaginal cream, 100 mg per 5 g, 20 g		1	..	BN
Cloxacillin Capsules B.P.	250 mg (base)	Oral	24	..	AF
	500 mg (base)	Oral	24	..	AF
Cloxacillin Sodium B.P. with any determined brand of Water for Injections or other solvent	Injection, 250 mg (base) (with required solvent)	Injection	5	..	CS
	Injection, 500 mg (base) (with required solvent)	Injection	5	..	BR, CS
	Injection, 1 g (base) (with required solvent)	Injection	5	..	BR, CS
Codeine Phosphate B.P. with Aspirin B.P.	Tablet, 30 mg-325 mg	Oral	20	..	BW
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Codeine Phosphate B.P. with Paracetamol B.P.	Tablet, 30 mg-500 mg	Oral	20	..	WL
Codeine Phosphate Tablets B.P.	30 mg	Oral	20	..	DH, FA, FM, US
Colchicine Tablets B.P.	500 micrograms	Oral	100	2	DH, PT, RT
Colestipol Hydrochloride	Sachets, 5 g, 120	Oral	1	5	UP
Colistin Sulphate B.P. with Neomycin Sulphate B.P.	Ear drops, 3 mg (base)-3.3 mg (base) per mL, 10 mL	Application to the ear	1	2	WW
Colistin Sulphomethate Sodium B.P. with any determined brand of Water for Injections or other solvent	Injection, 150 mg (with required solvent)	Injection	5	..	WW
Copper Sulphate B.P.C. 1973	Tablets, diagnostic compound, 36		2	3	AM
Cortisone Tablets B.P.	5 mg	Oral	50	4	PT
	25 mg	Oral	60	4	PT
Co-trimoxazole Mixture, Paediatric B.P.	40 mg-200 mg per 5 mL, 100 mL	Oral	1	1	AF, BW, PT, RO
Co-trimoxazole Tablets B.P.	80 mg-400 mg	Oral	10	..	AF, BW, PT, RO
	160 mg-800 mg	Oral	10	..	AF, BW, PT, RO
Cyclopenthiazide Tablets B.P.	500 micrograms	Oral	100	1	CG
Cyclophosphamide B.P. with any determined brand of Water for Injections or other solvent	Injection, 100 mg vial (with required solvent)	Injection	6	..	FE
	Injection, 200 mg vial (with required solvent)	Injection	6	..	FE
	Injection, 500 mg vial (with required solvent)	Injection	2	..	FE
	Injection, 1 g vial (with required solvent)	Injection	1	..	FE
Cyclophosphamide Tablets B.P.	50 mg	Oral	50	2	FE
Cyproheptadine Tablets B.P.	4 mg	Oral	100	2	FR
Cyproterone Acetate	Tablet, 50 mg	Oral	20	5	SC

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Cytarabine B.P.	Injection, 40 mg in 2 mL amp.	Injection	10	1	BT
	Injection, 100 mg in 5 mL amp.	Injection	10	1	BT
	Injection, 500 mg in 25 mL amp.	Injection	2	1	BT
	Injection set containing 100 mg and 5 mL solvent	Injection	10	1	BL, UP
	Injection set containing 500 mg and 10 mL solvent	Injection	2	1	BL
Danazol	Capsule, 100 mg	Oral	100	5	WL
	Capsule, 200 mg	Oral	100	5	WL
Dantrolene Sodium	Capsule, 25 mg	Oral	100	2	NW
	Capsule, 50 mg	Oral	100	2	NW
Debrisoquine Tablets B.P.	10 mg (base)	Oral	100	5	RO
	20 mg (base)	Oral	100	5	RO
"De-Lact Infant"	Powder, 500 g	Oral	2	..	SJ
Demeclocycline Capsules B.P.	150 mg	Oral	100	3	LE
Desipramine Tablets B.P.	25 mg	Oral	50	2	CG
Desmopressin	Nasal solution, 100 micrograms per mL, 2.5 mL dropper bottle	Nasal	5	2	FC
Dexamethasone B.P.	Eye drops, 1 mg per mL, 5 mL	Application to the eye	1	2	AQ
Dexamethasone B.P. with Framycetin Sulphate B.P. and Gramicidin	Ear ointment, 500 micrograms-5 mg-50 micrograms per g, 5 g	Application to the ear	1	2	RL
Dexamethasone Sodium Metasulphobenzoate with Framycetin Sulphate B.P. and Gramicidin	Ear drops, 500 micrograms (base)-5 mg-50 micrograms per mL, 8 mL	Application to the ear	1	2	RL
Dexamethasone Sodium Phosphate B.P.	Injection, 1 mL amp. containing equivalent of 4 mg Dexamethasone Phosphate	Injection	5	..	MK
	Injection, 1 mL vial containing equivalent of 5 mg Dexamethasone Phosphate	Injection	5	..	OR
	Injection, 2 mL vial containing equivalent of 8 mg Dexamethasone Phosphate	Injection	5	..	MK
	Injection, 5 mL vial containing equivalent of 120 mg Dexamethasone Phosphate	Injection	1	..	MK
Dexamethasone Tablets B.P.	500 micrograms	Oral	30	4	OR, PT
	4 mg	Oral	30	4	PT
Dexamphetamine Tablets B.P.	5 mg	Oral	100	5	SI
Dextran 40 Intravenous Infusion B.P. with Glucose B.P.	100 mg per mL-139 mmol per 500 mL, 500 mL	Injection	3	..	PS
Dextran 40 Intravenous Infusion B.P. with Sodium Chloride B.P.	100 mg per mL-77 mmol per 500 mL, 500 mL	Injection	3	..	PS
Dextran 70 Intravenous Infusion B.P. with Glucose B.P.	60 mg per mL-139 mmol per 500 mL, 500 mL	Injection	3	..	PS
Dextran 70 Intravenous Infusion B.P. with Sodium Chloride B.P.	60 mg per mL-77 mmol per 500 mL, 500 mL	Injection	3	..	PS
Diazepam B.P.	Syrup, 2 mg per 5 mL, 100 mL	Oral	1	..	RO
Diazepam Injection B.P.	10 mg in 2 mL	Injection	5	..	BL, RO
Diazepam Tablets B.P.	2 mg	Oral	50	..	AF, PT, RO, SU
	5 mg	Oral	50	..	AF, PT, RO, SU
Diazoxide Injection B.P.	300 mg in 20 mL	Injection	1	..	BL, SH
Dichlorphenamide Tablets B.P.	50 mg	Oral	50	6	MK
Diclofenac Sodium	Tablet, 25 mg (enteric coated)	Oral	50	3	CG
	Tablet, 50 mg (enteric coated)	Oral	50	3	CG

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Dienoestrol B.P.	Cream, 500 micrograms per 5 g, 85 g		1	1	JC
Difenoxin Hydrochloride with Atropine Sulphate B.P.	Tablet, 500 micrograms-25 micrograms	Oral	20	..	PT
Diflunisal Tablets B.P.	250 mg	Oral	50	3	MK
"Digestelact"	Powder, 500 g	Oral	2	20	SJ
Digoxin Elixir, Paediatric B.P.	50 micrograms per mL, 100 mL	Oral	1	3	BW
Digoxin Injection B.P.	Ampoule, 500 micrograms in 2 mL	Injection	5	1	BW
Digoxin Tablets B.P.	62.5 micrograms	Oral	200	1	BW
	250 micrograms	Oral	100	1	BW
Dihydroergotamine Mesylate B.P.	Injection, 1 mg in 1 mL amp.	Injection	5	..	SZ
Dihydrotachysterol B.P.	Capsule, 125 micrograms	Oral	100	5	WL
Diloxanide Furoate Tablets B.P.	500 mg	Oral	30	..	BT
Diltiazem Hydrochloride	Tablet, 60 mg	Oral	100	5	IC
Dimercaprol Injection B.P.	Ampoule, 100 mg in 2 mL	Injection	12	..	BT
Dimethicones B.P.	Solution, 100 mg per mL, 180 mL aerosol spray pack	Application	1	..	EG
Diphenoxylate Hydrochloride B.P. with Atropine Sulphate B.P.	Tablet, 2.5 mg-25 micrograms	Oral	20	..	SR
Diphtheria and Tetanus Vaccine, Adsorbed B.P.	Injection, 0.5 mL amp.	Injection	3	..	CS
Diphtheria and Tetanus Vaccine, Adsorbed B.P., Diluted	Injection, 0.5 mL amp. For immunization of adults and children over the age of 8 years	Injection	3	..	CS
Diphtheria Antitoxin B.P.	Injection, 10,000 units amp.	Injection	2	1	CS
Diphtheria, Tetanus and Pertussis Vaccine, Adsorbed B.P.	Injection, 0.5 mL amp.	Injection	3	..	CS, PD
Diphtheria Vaccine, Adsorbed B.P.	Injection, 0.5 mL amp.	Injection	2	1	CS
Diphtheria Vaccine, Adsorbed B.P., Diluted	Injection, 0.5 mL amp. For immunization of adults and children over the age of 8 years	Injection	2	..	CS
Dipivefrine Hydrochloride	Eye drops, 1 mg per mL, 10 mL	Application to the eye	1	6	AG
Disodium Etidronate	Tablet, 200 mg	Oral	60	5	NW
Disopyramide Capsules B.P.	100 mg	Oral	100	5	RL
	150 mg	Oral	100	5	RL
Disopyramide Phosphate Capsules B.P.	100 mg (base)	Oral	100	5	SR
	150 mg (base)	Oral	100	5	SR
Docusate Sodium B.P. with Bisacodyl B.P.	Suppositories, 100 mg-10 mg, 5		2	..	FM
Domperidone	Tablet, 10 mg	Oral	25	..	JC
Dothiepin Capsules B.P.	25 mg	Oral	50	2	BT
Dothiepin Hydrochloride B.P.	Tablet, 75 mg	Oral	30	2	BT
Doxepin Capsules B.P.	10 mg (base)	Oral	50	2	AF
	25 mg (base)	Oral	50	2	AF
Doxepin Hydrochloride B.P.	Tablet, 50 mg (base)	Oral	50	2	AF
Doxorubicin Hydrochloride	Powder for I.V. injection or intravesical administration, 10 mg vial	Injection or intravesical administration	4	..	FE
	Powder for I.V. injection or intravesical administration, 20 mg vial	Injection or intravesical administration	4	..	FE
	Powder for I.V. injection or intravesical administration, 50 mg vial	Injection or intravesical administration	3	..	FE

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Doxycycline Capsules B.P.	100 mg	Oral	7	1	PT
Doxycycline Hydrochloride B.P.	Capsule, 50 mg (base) (containing enteric coated pellets)	Oral	25	5	FA
	Capsule, 100 mg (base) (containing enteric coated pellets)	Oral	7	1	FA
	Tablet, 50 mg (base)	Oral	25	5	AF, PF
	Tablet, 100 mg (base)	Oral	7	1	AF, PF
Dydrogesterone Tablets B.P.	10 mg	Oral	50	5	JC
Econazole Nitrate B.P.	Lotion, 10 mg per mL, 20 mL	Application	1	1	SK, SQ
Econazole Nitrate Cream B.P.	10 mg per g, 20 g	Application	1	1	SK, SQ
	75 mg per 5 g, 35 g	Application	1	..	SQ
Econazole Nitrate Pessaries B.P.	150 mg, 3		1	..	SK, SQ
Ecothiopate Iodide B.P.	Eye drops, 300 micrograms per mL (1.5 mg and 5 mL vial of solvent)	Application to the eye	1	6	AY
	Eye drops, 600 micrograms per mL (3 mg and 5 mL vial of solvent)	Application to the eye	1	6	AY
	Eye drops, 1.25 mg per mL (6.25 mg and 5 mL vial of solvent)	Application to the eye	1	6	AY
	Eye drops, 2.5 mg per mL (12.5 mg and 5 mL vial of solvent)	Application to the eye	1	6	AY
Enalapril Maleate	Tablet, 5 mg	Oral	30	5	AD, MK
	Tablet, 10 mg	Oral	30	5	AD, MK
	Tablet, 20 mg	Oral	30	5	AD, MK
Ergometrine and Oxytocin Injection B.P.	Ampoule, 500 micrograms-5 units in 1 mL	Injection	5	..	SZ
Ergometrine Injection B.P.	Ampoule, 250 micrograms in 1 mL	Injection	5	..	BL
Ergometrine Tablets B.P.	200 micrograms	Oral	24	..	LY
Ergotamine Tablets B.P.	1 mg	Oral	50	2	WL
Ergotamine Tartrate B.P. with Caffeine B.P.	Suppositories, compound, 6		1	2	SZ
	Tablet, 1 mg-100 mg	Oral	50	2	SZ
Erythromycin B.P.	Capsule, 125 mg (containing enteric coated pellets)	Oral	25	1	FA
	Capsule, 175 mg (containing enteric coated pellets)	Oral	25	1	FA
	Capsule, 250 mg (containing enteric coated pellets)	Oral	25	1	FA, LY
Erythromycin Estolate B.P.	Drops, paediatric, 100 mg (base) per mL, 10 mL	Oral	1	1	LY
	Suspension, 125 mg (base) per 5 mL, 100 mL	Oral	1	1	LY
Erythromycin Ethyl Succinate B.P.	Injection, 100 mg (base) in 2 mL	I.M. injection	5	..	AB
	Tablet, chewable, 200 mg (base)	Oral	25	1	AB
	Tablet, 400 mg (base)	Oral	25	1	AB
Erythromycin Ethyl Succinate B.P. with Purified Water B.P.	Granules for suspension, 200 mg (base) per 5 mL, 100 mL	Oral	1	1	AB
Erythromycin Lactobionate	Infusion, I.V., 300 mg (base)	Injection	5	..	AB
	Infusion, I.V., 1 g (base)	Injection	1	..	AB
Erythromycin Stearate B.P.	Capsule, 250 mg (base)	Oral	25	1	AB
	Suspension, 125 mg (base) per 5 mL, 100 mL	Oral	1	1	AB
	Suspension, 250 mg (base) per 5 mL, 100 mL	Oral	1	..	AB
Erythromycin Stearate Tablets B.P.	250 mg (base)	Oral	25	1	AB
Erythromycin Tablets B.P.	250 mg	Oral	25	1	AB, UP
Ethacrynic Acid Tablets B.P.	50 mg	Oral	50	3	MK

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Ethinyloestradiol Tablets B.P.	10 micrograms	Oral	200	1	GL
	20 micrograms	Oral	200	1	GL
	50 micrograms	Oral	200	1	GL
Ethosuximide Capsules B.P.	250 mg	Oral	200	2	PD
Ethosuximide Elixir B.P.	250 mg per 5 mL, 250 mL	Oral	1	4	PD
Ethyloestrenol Tablets B.P.	2 mg	Oral	100	3	OR
Ethynodiol Diacetate B.P. with Ethinyloestradiol B.P.	Pack containing 21 tablets, 500 micrograms-50 micrograms and 7 inert tablets	Oral	4	2	SR
	Pack containing 21 tablets, 1 mg-50 micrograms and 7 inert tablets	Oral	4	2	SR
	Tablets, 500 micrograms-50 micrograms, 21	Oral	4	2	SR
	Tablets, 1 mg-50 micrograms, 21	Oral	4	2	SR
Etretinate	Capsule, 10 mg	Oral	100	5	RO
	Capsule, 25 mg	Oral	100	5	RO
Famotidine	Tablet, 20 mg	Oral	60	2	AD, MK
	Tablet, 40 mg	Oral	30	1	AD, MK
Felodipine	Tablet, 5 mg	Oral	60	5	AP, HP
	Tablet, 10 mg	Oral	60	5	AP, HP
Fenoterol Hydrobromide B.P.	Solution, 1 mg per mL, 20 mL	Inhalation	1	5	BY
	Spray, metered aerosol, 200 micrograms per dose, 300 doses, 21 g	Inhalation by mouth	1	5	BY
Ferrous Aminoacetosulphate	Syrup, 100 mL	Oral	1	4	NN
Ferrous Gluconate B.P.	Elixir, 300 mg per 5 mL, 100 mL	Oral	1	4	WL
Ferrous Gluconate Tablets B.P.	300 mg	Oral	100	2	WL
Ferrous Sulphate, Dried B.P.	Capsule, 320 mg, equivalent to 96 mg Ferrous Iron (delayed release)	Oral	30	2	SK
	Tablet, 320 mg, equivalent to 96 mg Ferrous Iron (delayed release)	Oral	30	2	CG
	Tablet, 350 mg, equivalent to 105 mg Ferrous Iron (sustained release)	Oral	30	2	AB, PT
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Ferrous Sulphate, Dried B.P. with Folic Acid B.P.	Capsule, 270 mg, equivalent to 80 mg Ferrous Iron-300 micrograms (delayed release)	Oral	30	2	SK
	Tablet, 270 mg, equivalent to 80 mg Ferrous Iron-300 micrograms (delayed release)	Oral	30	2	PT
	Tablet, 270 mg, equivalent to 80 mg Ferrous Iron-300 micrograms (sustained release)	Oral	30	2	AB
Flecainide Acetate	Tablet, 100 mg	Oral	60	5	RK
Fluclorolone Acetonide B.P.	Cream, 250 micrograms per g, 15 g	Application	1	1	SD
Flucloxacillin Capsules B.P.	250 mg (base)	Oral	24	..	AF, BR, CS
	500 mg (base)	Oral	24	..	AF, BR, CS
Flucloxacillin Magnesium B.P. with Purified Water B.P.	Powder for syrup, 125 mg (base) per 5 mL, 100 mL	Oral	1	..	BR, CS
	Powder for syrup, 250 mg (base) per 5 mL, 100 mL	Oral	1	..	BR, CS
Flucloxacillin Sodium B.P. with any determined brand of Water for Injections or other solvent	Injection, 250 mg (base) (with required solvent)	Injection	5	..	CS
	Injection, 500 mg (base) (with required solvent)	Injection	5	..	BR, CS
	Injection, 1 g (base) (with required solvent)	Injection	5	..	BR, CS
Flucytosine Tablets B.P.	500 mg	Oral	100	..	RO
Fludrocortisone Tablets B.P.	100 micrograms	Oral	200	1	SQ

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Flumethasone Pivalate with Clioquinol B.P.	Ear drops, 200 micrograms-10 mg per mL, 7.5 mL	Application to the ear	1	..	CG
Fluocortolone Pivalate and Fluocortolone Hexanoate Cream B.P.	1 mg-1 mg per g, 15 g	Application	1	1	SC
Fluocortolone Pivalate and Fluocortolone Hexanoate Ointment B.P.	1 mg-1 mg per g, 15 g	Application	1	1	SC
	Anhydrous base, 1 mg-1 mg per g, 15 g	Application	1	1	SC
Fluorometholone	Eye drops, 1 mg per mL, 5 mL	Application to the eye	1	6	AG, AQ
Fluorometholone Acetate	Eye drops, 1 mg per mL, 5 mL	Application to the eye	1	2	AQ
Fluorouracil Injection B.P.	Ampoule, 250 mg in 10 mL	Injection	10	..	RO
	Ampoule, 500 mg in 10 mL	Injection	5	1	FE
Fluoxymesterone Tablets B.P.	5 mg	Oral	100	3	UP
Fluphenazine Decanoate Injection B.P.	Ampoule, 12.5 mg in 0.5 mL	Injection	5	..	SQ
	Ampoule, 50 mg in 2 mL	Injection	5	..	SQ
	Syringe, disposable, 25 mg in 1 mL	Injection	5	..	SQ
Fluphenazine Tablets B.P.	1 mg	Oral	100	1	SQ
	2.5 mg	Oral	100	1	SQ
	5 mg	Oral	100	1	SQ
Folic Acid B.P.	Injection, 15 mg in 1 mL amp.	Injection	10	..	AB
Folic Acid Tablets B.P.	500 micrograms	Oral	200	..	DH, PT, SI
	5 mg	Oral	200	1	DH, FM, NN, PT, RT, SI, US
Fosfestrol Sodium B.P.	Injection, 250 mg in 5 mL	Injection	10	..	BC
	Tablet, 120 mg	Oral	100	2	BC
Framycetin Sulphate B.P.	Eye/ear drops, 5 mg per mL, 8 mL	Application to the eye/ear	1	2	RL
	Eye ointment, 5 mg per g, 5 g	Application to the eye	1	..	RL
Frusemide B.P.	Solution, 10 mg per mL, 30 mL	Oral	1	3	HP
Frusemide Injection B.P.	Ampoule, 20 mg in 2 mL	Injection	5	..	AF
Frusemide Tablets B.P.	20 mg	Oral	100	1	FM, HP
	40 mg	Oral	100	1	FM, PT
	500 mg	Oral	50	3	FM
Fusidic Acid Mixture B.P.	50 mg per mL, 90 mL	Oral	1	..	SK
Gas-gangrene Antitoxin, Mixed B.P.	Injection, 1 amp. containing 10,000 units Perfringens; 5,000 units Septicum; 10,000 units Novyi	Injection	2	1	CS
Gentamicin Eye Drops B.P.	3 mg (base) per mL, 5 mL	Application to the eye	1	2	AG
Gentamicin Injection B.P.	Ampoule, 40 mg (base) in 1 mL	Injection	5	..	BL, SH
	Ampoule, 60 mg (base) in 1.5 mL	Injection	5	..	BL, SH
	Ampoule, 80 mg (base) in 2 mL	Injection	5	..	BL, RL, SH
	Syringe, disposable, 80 mg (base)	Injection	5	..	SH
Glibenclamide Tablets B.P.	5 mg	Oral	100	5	AF
Gliclazide	Tablet, 80 mg	Oral	100	5	SE
Glipizide	Tablet, 5 mg	Oral	100	5	FE
Glucagon Hydrochloride	Injection, 1 I.U. with diluent	Injection	1	1	CN, LY
Glucose and Ketone Indicator—Urine	100 reagent strips		1	2	AM
Glucose, Anhydrous B.P., Sodium Chloride B.P., Potassium Chloride B.P., Citric Acid B.P. and Sodium Citrate B.P.	Powder, 36.354 g-354 mg-903 mg-606 mg-1.781 g per sachet, 6	Oral	1	..	DH

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Glucose Indicator—Blood	50 reagent strips (Ames-BG)		2	5	AM
	50 reagent strips (BM-Test-BG)		2	5	BO
	50 reagent strips (BM-Test-Glycemie 20-800)		2	5	BO
	50 reagent strips (Glucostix)		2	5	AM
	50 reagent strips (Hypoguard GA)		2	5	AS
Glucose Indicator—Urine	4 m dispenser		1	2	LY
	100 reagent strips (Clinistix)		1	2	AM
	100 reagent strips (Diastix)		1	2	AM
Glucose Intravenous Infusion B.P.	278 mmol per L, 1 L	Injection	5	1	AB, BX, KM
	555 mmol per L, 1 L	Injection	5	1	AB, BX
	1,110 mmol per L, 1 L	Injection	2	1	AB
	1,387 mmol per L, 1 L	Injection	2	1	AB, BX
	1,387 mmol per 500 mL, 500 mL	Injection	2	1	AB
	Ampoule, 5 g in 10 mL	Injection	5	..	AP
Glyceryl Trinitrate	Ointment, 20 mg per g, 60 g	Application	1	5	FC
	Transdermal disc, 16 mg	Application	30	2	SR
	Transdermal disc, 32 mg	Application	30	2	SR
	Transdermal pad, 25 mg	Application	30	2	CG
	Transdermal pad, 50 mg	Application	30	2	CG
Glyceryl Trinitrate Tablets B.P.	600 micrograms, 100	Oral	1	5	BW
Goserelin Acetate	Subcutaneous implant equivalent to 3.6 mg goserelin in pre-filled injection applicator	Subcutaneous implantation	1	5	IC
Griseofulvin Tablets B.P.	125 mg	Oral	100	2	GL, IC
	330 mg	Oral	28	2	SH
	500 mg	Oral	28	2	GL, IC
Haloperidol B.P.	Injection, 5 mg in 1 mL amp.	Injection	10	..	SR
Haloperidol Solution B.P.	2 mg per mL, 15 mL	Oral	1	2	SR
	2 mg per mL, 100 mL	Oral	1	1	SR
Haloperidol Tablets B.P.	1.5 mg	Oral	100	1	SR
	5 mg	Oral	50	1	SR
Heparin Injection B.P. (Calcium Salt)	5,000 I.U. in 0.2 mL	Injection	5	5	BL, CS, FC
	5,000 I.U. in 0.5 mL	Injection	5	5	CS
	12,500 I.U. in 0.5 mL	Injection	2	5	BL, CS
	25,000 I.U. in 1 mL	Injection	2	5	BL, CS
Heparin Injection B.P. (Sodium Salt)	Ampoule, 5,000 units in 0.2 mL	Injection	5	5	BL, CS, FC
	Ampoule, 5,000 units in 1 mL	Injection	5	5	BL, CS, FC
	Ampoule, 20,000 units in 20 mL	Injection	12	5	BL
	Ampoule, 25,000 units in 5 mL	Injection	2	5	CS, FC
	Vial, 35,000 units in 35 mL	Injection	12	5	CS, FC
Hexamine Hippurate	Tablet, 1 g	Oral	100	5	RK
Hexamine Mandelate	Tablet, 250 mg	Oral	200	2	WW
	Tablet, 500 mg	Oral	200	2	WW
	Tablet, 1 g	Oral	100	5	WW
Homatropine Hydrobromide B.P.	Eye drops, 20 mg per mL, 15 mL	Application to the eye	1	2	AG, AQ
	Eye drops, 50 mg per mL, 15 mL	Application to the eye	1	2	AG, AQ
Hydralazine Hydrochloride Tablets B.P.	25 mg	Oral	200	2	AF, PT
	50 mg	Oral	200	2	AF, PT
Hydrochlorothiazide B.P. with Amiloride Hydrochloride B.P.	Tablet, 50 mg-5 mg	Oral	100	1	MK, PT
Hydrochlorothiazide B.P. with Triamterene B.P.	Tablet, 25 mg-50 mg	Oral	100	1	SK
Hydrochlorothiazide Tablets B.P.	25 mg	Oral	100	1	CG, MK
	50 mg	Oral	100	1	CG, MK
Hydrocortisone B.P.	Tablet, 4 mg	Oral	50	4	PT
	Tablet, 20 mg	Oral	60	4	PT

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Hydrocortisone Acetate B.P.	Eye drops, 5 mg per mL, 10 mL	Application to the eye	1	2	SI
	Eye drops, 10 mg per mL, 10 mL	Application to the eye	1	2	SI
	Eye drops, 25 mg per mL, 5 mL	Application to the eye	1	2	SI
	Eye drops, 25 mg per mL, 10 mL	Application to the eye	1	2	SI
	Eye ointment, 5 mg per g, 4 g	Application to the eye	1	..	UP
	Eye ointment, 5 mg per g, 5 g	Application to the eye	1	..	SI
	Eye ointment, 10 mg per g, 5 g	Application to the eye	1	..	SI
	Rectal foam, 100 mg per g, aerosol, 25 g		2	3	SV
Hydrocortisone Acetate B.P. with Neomycin Sulphate B.P.	Ear drops, 15 mg-3.5 mg (base) per mL, 5 mL	Application to the ear	1	..	UP
	Ear ointment, 15 mg-3.5 mg (base) per g, 4 g	Application to the ear	1	2	UP
Hydrocortisone Acetate Cream B.P.	10 mg per g, 30 g	Application	1	1	NN, PD, SI, SQ, UP, US
	10 mg per g, 50 g	Application	1	1	NN, PD, SI, SQ, UP
Hydrocortisone Acetate Injection B.P.	Ampoule, 25 mg in 1 mL	Intra-articular injection	5	..	PT
Hydrocortisone Acetate Ointment B.P.	10 mg per g, 30 g	Application	1	1	NN, PD, SI, SQ, UP
	10 mg per g, 50 g	Application	1	1	NN, PD, SI, SQ, UP
Hydrocortisone Sodium Succinate B.P.	Injection set containing equivalent of 100 mg Hydrocortisone and 2 mL solvent	Injection	2	..	NR, UP
	Injection set containing equivalent of 250 mg Hydrocortisone and 2 mL solvent	Injection	1	..	UP
	Injection set containing equivalent of 500 mg Hydrocortisone and 4 mL solvent	Injection	2	..	UP
Hydroxocobalamin Injection B.P.	1 mg in 1 mL amp.	Injection	3	..	GL
Hydroxychloroquine Tablets B.P.	200 mg	Oral	100	1	WL
Hydroxyurea Capsules B.P.	500 mg	Oral	100	..	SQ
Hyoscyamine Hydrobromide with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P.	Tablet, 101.1 micrograms-14.8 micrograms-10.7 micrograms	Oral	100	2	FM
	Tablet, 151.6 micrograms-22.2 micrograms-16.0 micrograms	Oral	100	2	FM
Hyoscyamine Sulphate B.P. with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P.	Tablet, 103.7 micrograms-19.4 micrograms-6.5 micrograms	Oral	100	2	RS
Hypromellose 4500 B.P.	Eye drops, 5 mg per mL, 15 mL	Application to the eye	1	5	AG, AQ, SI
	Eye drops, 10 mg per mL, 15 mL	Application to the eye	1	5	SI
Hypromellose 4500 B.P. with Dextran 70	Eye drops, 3 mg-1 mg per mL, 15 mL	Application to the eye	1	5	AQ
Ibuprofen Tablets B.P.	200 mg	Oral	50	3	AF, BT, PT
	400 mg	Oral	50	3	BT, PT
Idoxuridine B.P.	Eye ointment, 5 mg per g, 5 g	Application to the eye	1	..	SK
	Ointment, 5 mg per g, 5 g	Topical application	1	..	SK
Idoxuridine Eye Drops B.P.	1 mg per mL, 15 mL	Application to the eye	1	2	AG, SK

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Imipramine Hydrochloride B.P.	Injection, 25 mg in 2 mL amp.	Injection	10	..	CG
Imipramine Tablets B.P.	10 mg	Oral	50	2	CG, PT
	25 mg	Oral	50	2	CG, PT, UW
Indapamide	Tablet, 2.5 mg	Oral	60	1	SE
Indomethacin Capsules B.P.	25 mg	Oral	50	3	AF, MK, PT
Indomethacin Suppositories B.P.	100 mg		40	3	MK
Influenza Vaccine (Split Virion), Inactivated B.P.	Injection containing antigens representative of the following types: A/Victoria/36/88 (H1N1)-like strain 15 micrograms haemagglutinin; A/Sichuan/2/87 (H3N2)-like strain 15 micrograms haemagglutinin; B/Beijing/1/87-like strain 15 micrograms haemagglutinin; 0.5 mL pre-filled syringe	Injection	1	..	CS, MB
Insect Allergen Extract Honey Bee Venom	Injection set containing 550 micrograms vial with 9 mL vial solvent and 3 vials diluent 1.8 mL	Injection	1	..	BN
Insect Allergen Extract—Paper Wasp Venom	Injection set containing 550 micrograms vial with 9 mL vial solvent and 3 vials diluent 1.8 mL	Injection	1	..	BN
Insulin Injection, Acid B.P.	Vial, (bovine) 100 units per mL, 10 mL	Injection	5	2	CN
	Vial, (bovine) 300 units per mL, 5 mL	Injection	10	2	CN
Insulin Injection, Biphasic B.P.	Vial, (mixed porcine/bovine) 100 units per mL, 10 mL	Injection	5	2	CN
Insulin Injection, Isophane B.P.	Vial, (bovine) 100 units per mL, 10 mL	Injection	5	2	CN, FC
	Vial, (porcine) 100 units per mL, 10 mL	Injection	5	2	BW, CN
Insulin Injection, Isophane B.P. and Insulin Injection, Neutral B.P.	Vial, (porcine) 50 units-50 units per mL, 10 mL	Injection	5	2	BW
	Vial, (porcine) 70 units-30 units per mL, 10 mL	Injection	5	2	BW, CN
Insulin Injection, Neutral B.P.	Cartridges, (porcine) 100 units per mL, 2 mL, 5	Injection	5	2	BW
	Vial, (bovine) 100 units per mL, 10 mL	Injection	5	2	FC
	Vial, (porcine) 100 units per mL, 10 mL	Injection	5	2	BW, CN
Insulin Injection, Protamine Zinc B.P.	Vial, (bovine) 100 units per mL, 10 mL	Injection	5	2	CN
Insulin Isophane, Human (Synthetic)	Injection, 100 units per mL, 10 mL vial	Injection	5	2	BW, CN, LY
	Injection, cartridges, 100 units per mL, 1.5 mL, 5	Injection	7	2	CN
	Injection, cartridges, 100 units per mL, 2.5 mL, 5	Injection	4	2	BW
Insulin Isophane, Human (Synthetic) and Insulin Neutral, Human (Synthetic)	Injection, 50 units-50 units per mL, 10 mL vial	Injection	5	2	BW
	Injection, 70 units-30 units per mL, 10 mL vial	Injection	5	2	BW, CN
	Injection, cartridges, 70 units-30 units per mL, 1.5 mL, 5	Injection	7	2	CN
	Injection, cartridges, 70 units-30 units per mL, 2.5 mL, 5	Injection	4	2	BW

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Insulin Neutral, Human (Synthetic)	Injection, 100 units per mL, 10 mL vial	Injection	5	2	BW, CN, LY
	Injection, cartridges, 100 units per mL, 1.5 mL, 5	Injection	7	2	CN
	Injection, cartridges, 100 units per mL, 2.5 mL, 5	Injection	4	2	BW
Insulin Zinc Suspension B.P.	Injection, (bovine) 100 units per mL, 10 mL vial	Injection	5	2	CN
	Injection, (porcine) 100 units per mL, 10 mL vial	Injection	5	2	CN
Insulin Zinc Suspension (Amorphous) B.P.	Injection, (porcine) 100 units per mL, 10 mL vial	Injection	5	2	CN
Insulin Zinc Suspension (Crystalline) B.P.	Injection, (bovine) 100 units per mL, 10 mL vial	Injection	5	2	CN
Insulin Zinc Suspension (Crystalline), Human (Synthetic)	Injection, 100 units per mL, 10 mL vial	Injection	5	2	CN, LY
Insulin Zinc Suspension, Human (Synthetic)	Injection, 100 units per mL, 10 mL vial	Injection	5	2	CN, LY
Ipratropium Bromide	Nebuliser solution, 250 micrograms per mL, 20 mL	Inhalation	2	2	BY
	Spray, metered aerosol, 20 micrograms per dose, 200 doses, 10 mL	Inhalation by mouth	1	5	BY
Iron Dextran Injection B.P.	Ampoule, 2 mL	Injection	5	..	FC
Iron Polymaltose Complex	Injection, 100 mg (Iron) in 2 mL amp.	Injection	5	..	SI
	Tablet, 40 mg (Iron)	Oral	100	2	SI
Isoconazole Nitrate	Cream, 10 mg per g, 20 g	Application	1	1	SC
	Pessaries, 300 mg, 2		1	..	SC
Isoniazid Tablets B.P.	100 mg	Oral	100	2	FM
Isopropyl Monoester Polymer with Isopropyl Alcohol B.P.	Gel, adhesive protective, 28.35 g	Application	1	..	HO
Isosorbide Dinitrate Tablets B.P.	5 mg (sublingual)	Oral	200	2	AY, PD
	10 mg	Oral	200	2	AY, PD
Isotretinoin	Capsule, 10 mg	Oral	60	3	RO
	Capsule, 20 mg	Oral	60	3	RO
Kaolin, Light B.P. or Light Kaolin (Natural) B.P. with Pectin	Suspension, 5.91 g-132 mg per 30 mL, 375 mL	Oral	1	2	UP
Ketoconazole	Tablet, 200 mg	Oral	30	5	JC
Ketoprofen B.P.	Capsule, 100 mg (sustained release)	Oral	50	3	MB
	Suppository, 100 mg		40	3	MB
Ketoprofen Capsules B.P.	50 mg	Oral	50	3	MB
	100 mg	Oral	50	3	MB
Labetalol Hydrochloride Tablets B.P.	100 mg	Oral	100	5	AF
	200 mg	Oral	100	5	AF
Lactulose Solution B.P.	3.34 g per 5 mL, 500 mL	Oral	1	5	JC
Lauramine Oxide with Octoxinol	Cleansing solution, compound, 80 mg-10 mg per g, 240 mL		1	..	DY
Leuprorelin Acetate	Injection, 5 mg per mL, 2.8 mL vial	Injection	2	2	AB
Levodopa and Carbidopa Tablets B.P.	100 mg-10 mg	Oral	100	5	MK
	100 mg-25 mg	Oral	100	5	MK
	250 mg-25 mg	Oral	100	5	MK
Levodopa B.P. with Benserazide	Capsule, 50 mg-12.5 mg	Oral	100	5	RO
	Capsule, 100 mg-25 mg	Oral	100	5	RO
	Capsule, 200 mg-50 mg	Oral	100	5	RO
	Tablet, 200 mg-50 mg	Oral	100	5	RO
Levodopa Tablets B.P.	100 mg	Oral	50	5	RO
	250 mg	Oral	100	5	RO
	500 mg	Oral	250	5	RO
Levonorgestrel B.P.	Tablets, 30 micrograms, 28	Oral	4	2	SC, WY
Levonorgestrel B.P. with Ethinyloestradiol B.P.	Pack containing 21 tablets, 125 micrograms-50 micrograms and 7 inert tablets	Oral	4	2	SC, WY

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
	Pack containing 21 tablets, 150 micrograms-30 micrograms and 7 inert tablets	Oral	4	2	SC, WY
	Pack containing 21 tablets, 250 micrograms-50 micrograms and 7 inert tablets	Oral	4	2	WY
	Pack containing 11 tablets, 50 micrograms-50 micrograms and 10 tablets, 125 micrograms-50 micrograms	Oral	4	2	WY
	Pack containing 11 tablets, 50 micrograms-50 micrograms, 10 tablets, 125 micrograms-50 micrograms and 7 inert tablets	Oral	4	2	SC, WY
	Pack containing 6 tablets, 50 micrograms-30 micrograms, 5 tablets, 75 micrograms-40 micrograms and 10 tablets, 125 micrograms-30 micrograms	Oral	4	2	SC, WY
	Pack containing 6 tablets, 50 micrograms-30 micrograms, 5 tablets, 75 micrograms-40 micrograms, 10 tablets, 125 micrograms-30 micrograms and 7 inert tablets	Oral	4	2	SC, WY
	Tablets, 125 micrograms-50 micrograms, 21	Oral	4	2	SC
	Tablets, 150 micrograms-30 micrograms, 21	Oral	4	2	SC, WY
	Tablets, 250 micrograms-50 micrograms, 21	Oral	4	2	WY
Lignocaine Hydrochloride B.P.	Injection, 100 mg in 5 mL Forms specified in Sch. 2	Injection	2 Sch. 2	.. Sch. 2	AP
Lignocaine Hydrochloride Injection B.P.	Syringe, disposable, 300 mg in 3 mL	I.M. injection	1	..	AP
	500 mg in 5 mL	Infusion	5	..	AP
Lincomycin Injection B.P.	Ampoule, 300 mg (base) in 1 mL	Injection	5	..	UP
	Ampoule, 600 mg (base) in 2 mL	Injection	5	..	UP
Lindane B.P.	Head lotion, 2 mg per mL, 200 mL	Application	1	..	IC
	Lotion concentrate, 10 mg per mL, 200 mL	Application	1	..	IC
Lindane Cream B.P.	10 mg per g, 200 g	Application	1	2	IC
Liothyronine Tablets B.P.	20 micrograms	Oral	100	2	GL
Lithium Carbonate B.P.	Tablet, 400 mg (delayed release)	Oral	200	1	PT
Lithium Carbonate Tablets B.P.	250 mg	Oral	200	2	DH, PT
"Locasol New Formula"	Powder, 450 g	Oral	2	20	KY
"Lofenalac"	Powder, 1 lb	Oral	5	5	MJ
Loperamide Hydrochloride	Capsule, 2 mg	Oral	12	..	JC
Lypressin	Spray, nasal, 50 units per mL, 5 mL	Nasal spray	10	2	SZ
"Maxamaid RVHB"	Powder, 200 g	Oral	5	5	SB
"Maxamaid XP"	Powder, 200 g	Oral	5	5	SB
"Maxamum XP"	Powder, 200 g	Oral	5	5	SB
Medroxyprogesterone Acetate B.P.	Injection, 50 mg in 1 mL vial	Injection	1	..	UP
	Injection, 150 mg in 1 mL vial	Injection	1	..	UP
	Injection, 500 mg in 2.5 mL vial	Injection	1	..	FE
	Oral suspension, 100 mg per mL, 100 mL	Oral	1	2	UP
	Tablet, 10 mg	Oral	30	5	UP

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
	Tablet, 100 mg	Oral	100	2	FE, UP
	Tablet, 200 mg	Oral	60	2	FE, UP
	Tablet, 250 mg	Oral	60	2	UP
	Tablet, 500 mg	Oral	30	2	FE, UP
Medrysone	Eye drops, 10 mg per mL, 5 mL	Application to the eye	1	6	AG
Mefenamic Acid Capsules B.P.	250 mg	Oral	50	2	AF, PD
Mefruside	Tablet, 25 mg	Oral	100	1	BN
Megestrol Acetate B.P.	Tablet, 40 mg	Oral	100	2	BC
Melphalan Tablets B.P.	2 mg	Oral	100	..	BW
	5 mg	Oral	100	..	BW
Menopausal Gonadotrophin, Human	Injection set containing 10 ampoules powder for injection providing 75 units follicle stimulating hormone and 75 units luteinizing hormone and 10 ampoules solvent 1 mL	Injection	1	5	CS, OR
Mercaptopurine Tablets B.P.	50 mg	Oral	100	2	BW
Metformin Tablets B.P.	500 mg	Oral	100	5	AF, FC, LH
Methacycline Hydrochloride B.P. 1973	Capsule, 150 mg	Oral	21	1	WW
	Capsule, 300 mg	Oral	10	1	WW
Methadone Injection B.P.	Ampoule, 10 mg in 1 mL	Injection	5	..	BW
Methadone Tablets B.P.	5 mg	Oral	20	..	BW
	10 mg	Oral	20	..	BW
Methdilazine Hydrochloride	Tablet, 4 mg	Oral	100	2	GL
	Tablet, 8 mg	Oral	100	2	GL
Methenolone Acetate	Tablet, 5 mg	Oral	100	3	SC
Methotrexate B.P. with any determined brand of Water for Injections or other solvent	Injection, 50 mg vial (with required solvent)	Injection	5	..	LE
Methotrexate Injection B.P.	Vial, 5 mg in 2 mL	Injection	5	..	FE, LE
	Vial, 50 mg in 2 mL	Injection	5	..	BL, FE, LE
Methotrexate Tablets B.P.	2.5 mg	Oral	100	2	FE, LE
	10 mg	Oral	100	2	FE
Methsuximide	Capsule, 300 mg	Oral	200	2	PD
Methyclothiazide	Tablet, 2.5 mg	Oral	100	1	AB
	Tablet, 5 mg	Oral	100	1	AB
Methyldopa Tablets B.P.	125 mg	Oral	100	5	MK
	250 mg	Oral	100	5	AF, MK, US
Methylphenobarbitone B.P.	Tablet, 60 mg	Oral	200	2	WL
	Tablet, 200 mg	Oral	200	2	WL
Methylprednisolone Acetate Injection B.P.	Vial, 40 mg in 1 mL	Injection	5	..	UP
Methylprednisolone Sodium Succinate	Injection, 40 mg (base) in 1 mL amp.	Injection	5	..	UP
Methyl Salicylate Liniment A.P.F.	100 mL	Application	1	1	DH, MG, NN, QE, SI, TO
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Methyltestosterone Tablets B.P.	5 mg	Oral	100	2	PT
	25 mg	Oral	100	2	PT
	50 mg	Oral	100	2	PT
Methysergide Tablets B.P.	1 mg (base)	Oral	100	2	SZ
Metoclopramide Hydrochloride B.P.	Syrup, 5 mg per 5 mL, 100 mL	Oral	1	..	BR
Metoclopramide Injection B.P.	Ampoule, 10 mg in 2 mL	Injection	10	..	BR
Metoclopramide Tablets B.P.	10 mg	Oral	25	..	AF, BR, PT
Metolazone	Tablet, 2.5 mg	Oral	100	1	SR
Metoprolol Tartrate	Tablet, 50 mg	Oral	100	5	AP, CG
	Tablet, 100 mg	Oral	60	5	AP, CG
Metronidazole Benzoate	Suspension, 320 mg per 5 mL, 100 mL	Oral	1	..	MB

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Metronidazole B.P.	Intravenous infusion, 500 mg in 100 mL	Injection	1	..	BL, MB
Metronidazole Suppositories B.P.	500 mg, 10		1	..	MB, PT
	1 g, 10		1	..	MB
Metronidazole Tablets B.P.	200 mg	Oral	21	1	AF, MB, PT, SR
	250 mg	Oral	21	1	JC
	400 mg	Oral	5	1	AF, MB
	500 mg	Oral	4	1	JC
Mexiletine Hydrochloride Capsules B.P.	50 mg	Oral	100	5	BY
	200 mg	Oral	100	5	BY
Mianserin Hydrochloride Tablets B.P.	10 mg	Oral	50	5	OR
	20 mg	Oral	50	5	OR
Miconazole	Oral gel, 20 mg per mL, 20 g	Oral	1	1	JC
	Tincture, 20 mg per mL, 20 mL	Application	1	1	JC
Miconazole Nitrate B.P.	Lotion, 20 mg per g, 20 g	Application	1	1	JC
	Pessaries, 100 mg, 7		1	..	CL, JP
	Pessaries, 200 mg, 3		1	..	JC
Miconazole Nitrate Cream B.P.	20 mg per g, 20 g	Application	1	1	CL, JP
	20 mg per g, 40 g	Application	1	..	CL, JP
Minocycline Hydrochloride	Capsule, 100 mg	Oral	11	..	LE
Minoxidil	Tablet, 10 mg	Oral	100	5	UP
	Tablet, 25 mg	Oral	100	5	UP
Misoprostol	Tablet, 200 micrograms	Oral	120	1	SR
Mithramycin	Injection, 2.5 mg (with required solvent)	Injection	5	..	PF
Mitozantrone Hydrochloride	Injection, 20 mg (base) in 10 mL vial	Injection	1	..	LE
	Injection, 25 mg (base) in 12.5 mL vial	Injection	1	..	LE
	Injection, 30 mg (base) in 15 mL vial	Injection	1	..	LE
Morphine Sulphate B.P. with Tacrine Hydrochloride	Tablet, 30 mg-15 mg	Oral	20	..	WH
Morphine Sulphate Injection B.P.	Ampoule, 10 mg in 1 mL	Injection	5	..	AP, BL, SI
	Ampoule, 15 mg in 1 mL	Injection	5	..	AP, BL, SI
	Ampoule, 30 mg in 1 mL	Injection	5	..	BL
Morphine Sulphate Tablets B.P.	30 mg	Oral	20	..	FM
"M.S.U.D. AID"	Powder, 200 g	Oral	5	5	SB
Mustine Hydrochloride B.P. with any determined brand of Water for Injections or other solvent	Injection, 10 mg amp. (with required solvent)	Injection	4	..	BT
Nalidixic Acid Tablets B.P.	500 mg	Oral	56	2	WL
Naloxone Hydrochloride	Injection, 40 micrograms in 2 mL amp.	Injection	5	..	BT
	Injection, 400 micrograms in 1 mL disposable injection set	Injection	1	..	CS
	Injection, 800 micrograms in 2 mL disposable injection set	Injection	1	..	CS
	Injection, 2 mg in 5 mL disposable injection set	Injection	1	..	CS
Nandrolone Decanoate Injection B.P.	Disposable syringe, 50 mg in 1 mL	Injection	1	3	OR
Nandrolone Phenylpropionate Injection B.P.	Ampoule, 25 mg in 1 mL	Injection	3	3	OR
Naphazoline Hydrochloride	Eye drops, 1 mg per mL, 15 mL	Application to the eye	1	2	AG
Naproxen B.P.	Suppository, 500 mg		40	3	SD
Naproxen Tablets B.P.	250 mg	Oral	50	3	AF, SD
	500 mg	Oral	50	3	SD
Neomycin Sulphate Eye Drops B.P.	5 mg per mL, 10 mL	Application to the eye	1	2	SI

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Neomycin Tablets B.P.	500 mg	Oral	25	1	PT
Neomycin Undecenoate with Bacitracin Zinc B.P.	Ear ointment, 12 mg (3.5 mg base)-400 units per g, 10 g	Application to the ear	1	..	HA
Neostigmine Injection B.P.	Ampoule, 500 micrograms in 1 mL	Injection	5	3	RO
	Ampoule, 2.5 mg in 1 mL	Injection	5	3	RO
Neostigmine Tablets B.P.	15 mg	Oral	200	1	RO
Niclosamide Tablets B.P.	500 mg	Oral	4	..	BN
Nicotinic Acid Tablets B.P.	25 mg	Oral	100	2	DH, US
	50 mg	Oral	100	2	DH, RT, SI, US
	100 mg	Oral	100	2	DH, US
	250 mg	Oral	200	5	DH
Nifedipine	Capsule, 5 mg	Oral	100	5	BN
	Capsule, 10 mg	Oral	100	5	BN
	Tablet, 20 mg	Oral	60	5	BN
Nitrazepam Tablets B.P.	5 mg	Oral	25	..	AF, RO
Nitrofurantoin B.P.	Capsule, 50 mg	Oral	30	1	NW
	Capsule, 100 mg	Oral	30	1	NW
Nitrofurantoin Mixture B.P.	25 mg per 5 mL, 200 mL	Oral	1	..	NW
Nitrofurantoin Tablets B.P.	50 mg	Oral	25	1	NW
	100 mg	Oral	25	1	NW
Norethisterone Acetate B.P.	Tablet, 10 mg	Oral	100	2	SC
Norethisterone B.P. with Ethinyloestradiol B.P.	Pack containing 21 tablets, 500 micrograms-35 micrograms and 7 inert tablets	Oral	4	2	SD
	Pack containing 21 tablets, 1 mg-35 micrograms and 7 inert tablets	Oral	4	2	SD
	Pack containing 12 tablets, 500 micrograms-35 micrograms and 9 tablets, 1 mg-35 micrograms	Oral	4	2	SD
	Pack containing 12 tablets, 500 micrograms-35 micrograms, 9 tablets, 1 mg-35 micrograms and 7 inert tablets	Oral	4	2	SD
	Tablets, 500 micrograms-35 micrograms, 21	Oral	4	2	SD
	Tablets, 1 mg-35 micrograms, 21	Oral	4	2	SD
Norethisterone B.P. with Mestranol B.P.	Pack containing 21 tablets, 1 mg-50 micrograms and 7 inert tablets	Oral	4	2	SD
	Tablets, 1 mg-50 micrograms, 21	Oral	4	2	JC, SD
Norethisterone Tablets B.P.	350 micrograms, 28	Oral	4	2	JC, SD
	5 mg	Oral	30	5	SC
Norfloxacin	Tablet, 400 mg	Oral	14	1	MK
Nortriptyline Hydrochloride B.P.	Elixir, 10 mg per 5 mL, 100 mL	Oral	1	4	DL
Nortriptyline Tablets B.P.	10 mg	Oral	50	2	DL, SQ
	25 mg	Oral	50	2	DL, SQ
"Nutramigen"	Powder, 1 kg	Oral	1	20	MJ
Nystatin B.P.	Capsule, 500,000 units	Oral	50	..	LE, SQ
	Cream, 100,000 units per g, 15 g	Application	1	1	LE, SQ
	Gel, 100,000 units per g, 15 g	Application	1	1	SQ
	Lozenge, 100,000 units	Oral	20	1	LE
	Tablet, 500,000 units	Oral	50	..	LE
	Vaginal cream, 100,000 units per 4 g, 75 g		1	1	SQ
	Vaginal cream, 100,000 units per 5 g, 75 g		1	1	LE

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Nystatin Mixture B.P.	100,000 units per mL, 24 mL	Oral	1	1	LE, SQ
Nystatin Ointment B.P.	100,000 units per g, 15 g	Application	1	1	LE, SQ
Nystatin Pessaries B.P.	100,000 units, 15		1	1	LE, SQ
	100,000 units (cream base), 15		1	1	LE
Nystatin Tablets B.P.	500,000 units	Oral	50	..	SQ
"Odorgon"	Liquid, 15 mL		1	..	LA
Oestradiol Valerate	Injection, 10 mg in 1 mL amp.	Injection	3	..	SC
	Tablets, 1 mg, 28	Oral	2	2	SC
	Tablets, 2 mg, 28	Oral	2	2	SC
Oestriol	Vaginal cream, 1 mg per g, 15 g		1	1	OR
Oestrogens—Conjugated	Tablets, 300 micrograms, 28	Oral	2	2	AY
	Tablets, 625 micrograms, 28	Oral	2	2	AY
Oestrone B.P.C. 1954	Pessaries, 100 micrograms, 12		1	1	OR
	Pessaries, 1 mg, 12		1	1	OR
Olsalazine Sodium	Capsule, 250 mg	Oral	100	5	PS
Orphenadrine Hydrochloride Tablets B.P.	50 mg	Oral	200	2	RK
Oxazepam Tablets B.P.	15 mg	Oral	25	..	AF, AY, WY
	30 mg	Oral	25	..	AF, AY, WY
Oxprenolol Hydrochloride B.P. with any determined brand of Water for Injections or other solvent	Injection, 2 mg (with required solvent)	Injection	5	..	CG
Oxprenolol Tablets B.P.	20 mg	Oral	100	5	AF
	40 mg	Oral	100	5	AF
Oxycodone Hydrochloride	Tablet, 5 mg	Oral	20	..	BT
Oxycodone Pectinate	Suppositories, 30 mg (base), 12		1	..	BT
Oxymetholone Tablets B.P.	50 mg	Oral	100	5	SD
	100 mg	Oral	100	5	PD
Oxytocin Injection B.P.	Ampoule, 2 units in 2 mL	Injection	5	..	SZ
	Ampoule, 5 units in 1 mL	Injection	5	..	SZ
	Ampoule, 10 units in 1 mL	Injection	5	..	SZ
Pancreatin B.P.	Capsule, providing not less than 6,500 B.P. units of lipase activity	Oral	500	10	RS
	Tablet, providing not less than 6,500 B.P. units of lipase activity	Oral	500	10	RS
Pancrelipase	Capsule, providing not less than 5,000 B.P. units of lipase activity	Oral	500	10	JC
	Capsule, providing not less than 10,000 B.P. units of lipase activity	Oral	500	10	OR
Papaveretum B.P.C. 1973	Injection, 20 mg in 1 mL amp.	Injection	5	..	RO
Papaveretum B.P.C. 1973 with Hyoscine Hydrobromide B.P.	Injection, 20 mg-400 micrograms in 1 mL amp.	Injection	5	..	RO
Paracetamol B.P.	Mixture, 120 mg per 5 mL, 100 mL	Oral	1	2	BW, WL
Paracetamol Tablets B.P.	500 mg	Oral	100	1	BW, DH, FM, WL
Paraffin, Soft White B.P.	Cream, compound, 85 g	Application	1	..	DY
	Ointment, compound, 70 g	Application	1	..	DY
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Paraffin, Soft White B.P. with Liquid Paraffin B.P.	Eye ointment, compound, 3.5 g	Application to the eye	1	5	AQ
	Eye ointment, compound, 7 g	Application to the eye	1	5	AG
	Forms specified in Sch. 2		Sch. 2	Sch. 2	

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Penicillamine Tablets B.P.	125 mg	Oral	100	1	DL
	250 mg	Oral	100	1	DL
Perhexiline Maleate	Tablet, 100 mg	Oral	100	5	ML
Pericyazine	Tablet, 2.5 mg	Oral	100	1	MB
	Tablet, 10 mg	Oral	100	1	MB
Pethidine Injection B.P.	Ampoule, 50 mg in 1 mL	Injection	5	..	AP, BL, SI
	Ampoule, 100 mg in 2 mL	Injection	5	..	AP, BL, SI
Pethidine Tablets B.P.	50 mg	Oral	20	..	SI
Phenelzine Tablets B.P.	15 mg	Oral	50	2	WW
Phenethicillin Capsules B.P.	250 mg	Oral	25	1	SI
	500 mg	Oral	25	1	SI
Phenethicillin Potassium B.P. with Purified Water B.P.	Powder for syrup, 125 mg (Phenethicillin) per 5 mL, 100 mL	Oral	1	1	SI
	Powder for syrup, 250 mg (Phenethicillin) per 5 mL, 100 mL	Oral	1	..	SI
Phenethicillin Tablets B.P.	250 mg	Oral	25	1	SI
Phenindione Tablets B.P.	10 mg	Oral	100	2	GL
	50 mg	Oral	100	2	GL
Phenobarbitone Injection B.P.	Ampoule, 200 mg in 1 mL	Injection	5	..	FM
Phenobarbitone Tablets B.P.	30 mg	Oral	200	4	DH, FM, SI
Phenoxybenzamine Capsules B.P.	10 mg	Oral	100	5	SK
Phenoxymethylpenicillin (Benzathine Salt)	Suspension, 125 mg per 5 mL, 100 mL	Oral	1	1	CS, SI
	Suspension, 250 mg per 5 mL, 100 mL	Oral	1	1	CS, SI
Phenoxymethylpenicillin (Hydrabamine Salt)	Suspension, 125 mg per 5 mL, 100 mL	Oral	1	1	AB
	Suspension, 250 mg per 5 mL, 100 mL	Oral	1	1	AB
	Tablet, 125 mg	Oral	25	1	AB
Phenoxymethylpenicillin Potassium Capsules B.P.	250 mg	Oral	25	1	AB, CS, LY, SI
	500 mg	Oral	25	1	CS, SI
Phenoxymethylpenicillin Potassium Tablets B.P.	250 mg	Oral	25	1	AB, CS, LY, SI
	500 mg	Oral	25	1	AB, LY
Phensuximide B.P.C. 1973	Capsule, 500 mg	Oral	200	2	PD
Phenylephrine Hydrochloride B.P.	Eye drops, 1.2 mg per mL, 15 mL	Application to the eye	1	2	AQ
	Ointment, compound, 60 g		1	1	RL
	Suppositories, compound, 12		1	1	RL
Phenytoin B.P.	Tablet, 50 mg	Oral	200	2	PD
Phenytoin Capsules B.P.	30 mg	Oral	200	2	PD
	100 mg	Oral	200	2	PD
Phenytoin Mixture B.P.	30 mg per 5 mL, 500 mL	Oral	1	3	PD
Phytomenadione Injection B.P.	Ampoule, 1 mg	Injection	5	..	RO
	Ampoule, 10 mg	Injection	5	..	RO
Pilocarpine	Eye disc, 5 mg (releasing 20 micrograms per hour)	Application to the eye	8	5	PT
	Eye disc, 11 mg (releasing 40 micrograms per hour)	Application to the eye	8	5	PT
Pilocarpine Hydrochloride B.P.	Eye drops, 5 mg per mL, 15 mL	Application to the eye	1	5	AG, AQ, IQ, SI
	Eye drops, 10 mg per mL, 15 mL	Application to the eye	1	5	AG, AQ, IQ, SI
	Eye drops, 20 mg per mL, 15 mL	Application to the eye	1	5	AG, AQ, IQ, SI
	Eye drops, 30 mg per mL, 15 mL	Application to the eye	1	5	AG, AQ, IQ, SI
	Eye drops, 40 mg per mL, 15 mL	Application to the eye	1	5	AG, AQ, IQ, SI
	Eye drops, 60 mg per mL, 15 mL	Application to the eye	1	5	AG, AQ, SI
	Forms specified in Sch. 2		Sch. 2	Sch. 2	

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Pindolol B.P.	Injection, 400 micrograms in 2 mL amp.	Injection	5	..	SZ
Pindolol Tablets B.P.	5 mg	Oral	100	5	AF, SZ
	15 mg	Oral	50	5	AF, SZ
Piperazine Oestrone Sulphate	Tablets, 730 micrograms, 28	Oral	2	2	AB
	Tablets, 1.46 mg, 28	Oral	2	2	AB
Piroxicam	Capsule, 10 mg	Oral	50	3	PF
	Capsule, 20 mg	Oral	25	3	PF
Pizotifen Malate	Tablet, 500 micrograms (base)	Oral	100	2	SZ
"PK AID I"	Powder, 250 g	Oral	2	5	SB
"PK AID II"	Powder, 250 g	Oral	2	5	SB
Pneumococcal Vaccine, Polyvalent	Injection, 0.5 mL in disposable syringe (17 valent)	Injection	1	..	SK
	Injection, 0.5 mL vial (23 valent)	Injection	1	..	CS
Polygeline	Intravenous infusion, 17.5 g per 500 mL with Na^+ 145 mmol per L, K^+ 5.1 mmol per L, Ca^{2+} 6.25 mmol per L and Cl^- 145 mmol per L; 500 mL	Injection	3	..	HP
Polyisobutylene	Wafers, compound adhesive, pack of 5	Topical	1	5	DY, HO
	Wafers, compound adhesive with discs, pack of 5	Topical	1	5	BH, SQ
Polymyxin B Sulphate B.P. with Bacitracin B.P. 1968 and Neomycin Sulphate B.P.	Eye ointment, 5,000 units-400 units-5 mg per g, 4 g	Application to the eye	1	..	UP
Polymyxin B Sulphate B.P. with Bacitracin Zinc B.P. and Neomycin Sulphate B.P.	Ear drops, 10,000 units-500 units-3.5 mg (base) per mL, 15 mL	Application to the ear	1	..	JC
	Eye ointment, 5,000 units-400 units-5 mg per g, 4 g	Application to the eye	1	..	BW
Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Gramicidin	Eye drops, 5,000 units-2.5 mg-25 micrograms per mL, 10 mL	Application to the eye	1	2	BW
Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Hydrocortisone B.P.	Ear drops, 10,000 units-5 mg-10 mg per mL, 7 mL	Application to the ear	1	2	BW
Polyvinyl Alcohol	Eye drops, 14 mg per mL, 15 mL	Application to the eye	1	5	AG
	Eye drops, 30 mg per mL, 15 mL	Application to the eye	1	5	AG
Polyvinyl Alcohol with Povidone B.P.	Eye drops, 14 mg-6 mg per mL, 15 mL	Application to the eye	1	5	AG
Polyvinylpyrrolidone and Vinyl Acetate Copolymer	Spray, aerosol, 60 mg per mL, 121 mL	Application	1	..	EG
"Portagen"	Powder, 450 g	Oral	2	20	MJ
Potassium Chloride B.P.	Elixir, 1.5 g per 15 mL, 500 mL	Oral	2	1	SC
	Tablet, 600 mg (sustained release)	Oral	200	1	AF, CG, PT
Potassium Chloride B.P. with Potassium Bicarbonate Effervescent Tablets	14 mmol K^+ and 8 mmol Cl^-	Oral	60	1	PT
Pralidoxime Iodide	Injection, 500 mg	Injection	5	..	AB
Prazosin Hydrochloride	Tablet, 1 mg (base)	Oral	100	5	PF
	Tablet, 2 mg (base)	Oral	100	5	PF
	Tablet, 5 mg (base)	Oral	100	5	PF
Prednisolone Acetate	Eye drops, 5 mg per mL, 5 mL	Application to the eye	1	6	AQ
Prednisolone Acetate with Phenylephrine Hydrochloride B.P.	Eye drops, 10 mg-1.2 mg per mL, 10 mL	Application to the eye	1	2	AG
Prednisolone Sodium Phosphate B.P.	Enema, retention, 20 mg in 100 mL	Enema	28	3	GL

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
	Eye/ear drops, 5 mg per mL, 5 mL	Application to the eye/ear	1	6	GL
	Suppositories, 5 mg (base), 10		3	3	GL
Prednisolone Stearoylglycolate	Tablet, 6.65 mg	Oral	60	1	FE
Prednisolone Tablets B.P.	1 mg	Oral	100	4	PT
	5 mg	Oral	60	4	FM, NN, PT, UP, US
	25 mg	Oral	30	4	FM, PT
Prednisone Tablets B.P.	1 mg	Oral	100	4	PT
	5 mg	Oral	60	4	DH, FM, NN, PT, US
	25 mg	Oral	30	4	FM, PT
"Pregestimil"	Powder, 454 g	Oral	2	20	MJ
Primaquine Tablets B.P.	Tablet, equivalent to 7.5 mg Primaquine base	Oral	42	..	IC
Primidone Tablets B.P.	250 mg	Oral	200	2	IC
Probenecid Tablets B.P.	500 mg	Oral	100	5	FR
Probucol	Tablet, 250 mg	Oral	112	5	ML
Procainamide Hydrochloride B.P.	Capsule, 250 mg	Oral	200	1	SQ
	Capsule, 375 mg	Oral	100	2	SQ
Procainamide Injection B.P.	Vial, 100 mg per mL, 10 mL	Injection	2	..	SQ
Procaine Penicillin Injection B.P.	Syringe, disposable, 1 g	Injection	5	..	SI
	Syringe, disposable, 1.5 g	Injection	5	..	SI
Procarbazine Hydrochloride	Capsule, 50 mg	Oral	100	2	RO
Prochlorperazine	Suppositories, 3 mg, equivalent to 5 mg Prochlorperazine Maleate, 5		1	2	MB
	Suppositories, 15 mg, equivalent to 25 mg Prochlorperazine Maleate, 5		1	2	MB
Prochlorperazine Edisylate	Injection, 12.5 mg in 1 mL	Injection	10	..	SK
Prochlorperazine Injection B.P.	Ampoule, 12.5 mg in 1 mL	Injection	10	..	MB
Prochlorperazine Tablets B.P.	5 mg	Oral	25	..	MB, SK
Procyclidine Tablets B.P.	5 mg	Oral	200	2	BW
Promethazine Hydrochloride Injection B.P.	Ampoule, 50 mg in 2 mL	Injection	10	..	BL
Promethazine Theoclate Tablets B.P.	25 mg	Oral	30	1	MB
Propantheline Tablets B.P.	15 mg	Oral	200	2	PT
Propranolol Injection B.P.	1 mg in 1 mL	Injection	5	..	IC
Propranolol Tablets B.P.	10 mg	Oral	100	5	AF
	40 mg	Oral	100	5	AF, PT
	160 mg	Oral	50	5	AF, PT
Propylthiouracil Tablets B.P.	50 mg	Oral	200	2	JC
Protamine Sulphate Injection B.P.	Ampoule, 10 mg per mL, 10 mL	Injection	6	..	BT
Pyrantel Embonate	Tablet, 125 mg (base)	Oral	6	..	AF
	Tablet, 250 mg (base)	Oral	6	..	AF
Pyridostigmine Tablets B.P.	10 mg	Oral	100	2	RO
	60 mg	Oral	100	2	RO
	180 mg (sustained release)	Oral	100	1	RO
Pyridoxine Hydrochloride B.P.	Injection, 50 mg in 1 mL amp.	Injection	5	1	FM
Pyridoxine Hydrochloride Tablets B.P.	25 mg	Oral	100	..	DH, FM, PT
Pyrimethamine Tablets B.P.	25 mg	Oral	50	..	BW
Quinethazone	Tablet, 50 mg	Oral	100	1	LE
Quinidine Bisulphate B.P.	Tablet, 250 mg (sustained release)	Oral	100	5	AP
Quinidine Sulphate B.P.	Tablet, 300 mg (sustained release)	Oral	100	5	RS
Quinidine Sulphate Tablets B.P.	200 mg	Oral	100	5	BW, DH, NN, QE

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Quinine Bisulphate Tablets B.P.	300 mg	Oral	50	2	AF, DH, FM, NN, PT, SI, US
Quinine Sulphate Tablets B.P.	300 mg	Oral	50	2	AF, DH, FM, NN, PT, SI, US
Ranitidine Hydrochloride	Tablet, 150 mg (base)	Oral	60	2	GL
	Tablet, 300 mg (base)	Oral	30	1	GL
Red-back Spider Antivenom	Injection, 500 units amp.	Injection	2	..	CS
Rifampicin B.P.	Capsule, 150 mg	Oral	10	..	AF
	Capsule, 300 mg	Oral	10	..	AF
Rolitetracycline	Injection, 275 mg amp. and 10 mL solvent	I.V. injection	5	..	HP
	Injection, 350 mg amp. and 2 mL solvent	I.M. injection	5	..	HP
Salbutamol B.P.	Spray, metered aerosol, 100 micrograms per dose, 200 doses, 17 g	Inhalation by mouth	2	5	GL
Salbutamol Sulphate B.P.	Capsule, 200 micrograms (base)	Inhalation by mouth	100	5	GL
	Solution, 2.5 mg (base) in 2.5 mL ampoules, 30	Inhalation	1	5	GL
	Solution, 5 mg (base) in 2.5 mL ampoules, 30	Inhalation	1	5	GL
	Solution, 5 mg (base) per mL, 30 mL	Inhalation	2	2	GL, RK
	Spray, metered aerosol, 100 micrograms (base) per dose, 200 doses, 13.5 g	Inhalation by mouth	2	5	RK
	Spray, metered aerosol, 100 micrograms (base) per dose, 400 doses, 13.5 g	Inhalation by mouth	1	5	RK
	Syrup, 2 mg (base) per 5 mL, 300 mL	Oral	1	5	GL
Salbutamol Tablets B.P.	4 mg	Oral	100	5	GL
Salcatonin Injection B.P.	50 I.U. in 1 mL amp.	Injection	30	5	SZ
	80 I.U. in 0.8 mL amp.	Injection	15	5	SZ
	100 I.U. in 1 mL amp.	Injection	15	5	RG, SZ
	400 I.U. in 2 mL vial	Injection	4	5	RG
Semisodium Valproate	Tablet, 135 mg (enteric coated)	Oral	200	2	AB
	Tablet, 269 mg (enteric coated)	Oral	200	2	AB
	Tablet, 538 mg (enteric coated)	Oral	200	2	AB
Silver Sulphadiazine with Chlorhexidine Gluconate	Cream, 10 mg-2 mg per g, 50 g	Application	1	..	SN
	Cream, 10 mg-2 mg per g, 100 g	Application	1	..	SN
	Cream, 10 mg-2 mg per g, 500 g	Application	1	..	SN
Sodium Acid Citrate B.P.	Mixture, 5.5 g per 20 mL, 500 mL	Oral	1	4	PD
Sodium Acid Phosphate B.P.	Tablet, compound effervescent, equivalent to 500 mg phosphorus	Oral	100	5	SZ
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Sodium Aurothiomalate Injection B.P.	Ampoule, 10 mg	Injection	5	..	MB
	Ampoule, 20 mg	Injection	10	1	MB
	Ampoule, 50 mg	Injection	10	1	MB
Sodium Bicarbonate Intravenous Infusion B.P.	100 mmol in 100 mL	Injection	5	..	AB
Sodium Cellulose Phosphate	Oral powder, sachet, 5 g	Oral	100	5	RK
Sodium Chloride and Glucose Intravenous Infusion B.P.	31 mmol-222 mmol per L, 1 L	Injection	5	1	AB, BX, KM
	19 mmol-104 mmol per 500 mL, 500 mL	Injection	5	1	AB, BX

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
	39 mmol-69 mmol per 500 mL, 500 mL	Injection	5	1	AB, BX
	154 mmol-278 mmol per L, 1 L	Injection	2	1	AB, BX
Sodium Chloride B.P. with Potassium Chloride B.P. and Calcium Chloride B.P. in Water for Injections	Sodium Chloride Compound Injection—1 L	Injection	4	1	AB, BX
Sodium Chloride B.P. with Sodium Acetate B.P., Sodium Gluconate, Potassium Chloride B.P. and Magnesium Chloride B.P.	Electrolyte Replacement Solution, 5.26 g-3.68 g-5.02 g-370 mg-300 mg per L, 1 L	Injection	2	1	AB, BX
Sodium Chloride Intravenous Infusion B.P.	Ampoule, 9 mg per mL, 2 mL	Injection	5	1	AP, BT
	Ampoule, 9 mg per mL, 5 mL	Injection	5	1	AP, BT
	Ampoule, 9 mg per mL, 10 mL	Injection	5	1	AP, BT
	154 mmol per L, 1 L	Injection	5	1	AB, BX, KM
	513 mmol per L, 1 L	Injection	2	1	BX
Sodium Citro-Tartrate	Granules, effervescent, 100 g	Oral	1	4	AB, PT
Sodium Cromoglycate B.P.	Eye drops, 20 mg per mL, 10 mL	Application to the eye	1	5	FC
	Nebuliser solution, 20 mg per 2 mL, ampoule	Inhalation	120	3	FC
	Spray, metered aerosol, 1 mg per dose, 200 doses, 13.87 g	Inhalation by mouth	1	5	FC
Sodium Cromoglycate Insufflation B.P.	Capsule, 20 mg	Inhalation by mouth	100	5	FC
Sodium Fusidate B.P.	Tablet, 250 mg (enteric coated)	Oral	36	..	SK
Sodium Lactate Compound Intravenous Infusion B.P.	1 L	Injection	5	1	AB, BX, KM
Sodium Lactate Compound Intravenous Infusion B.P. with Anhydrous Glucose B.P.	278 mmol per L, 1 L	Injection	2	1	AB, BX
Sodium Nitroprusside B.P.	Infusion, 50 mg	Injection	10	..	RO
Sodium Valproate B.P.	Oral liquid, 200 mg per 5 mL, 200 mL	Oral	3	2	RC
	Oral liquid, 200 mg per 5 mL, 300 mL	Oral	2	2	RC
	Tablet, 200 mg (enteric coated)	Oral	200	2	RC
	Tablet, 500 mg (enteric coated)	Oral	200	2	RC
	Tablet, crushable, 100 mg	Oral	200	2	RC
Sodium Valproate Elixir B.P.	200 mg per 5 mL, 200 mL	Oral	3	2	RC
	200 mg per 5 mL, 300 mL	Oral	2	2	RC
Sotalol Hydrochloride	Tablet, 160 mg	Oral	60	5	AP
Spectinomycin Hydrochloride B.P.	Injection, 2 g (base) with 3.2 mL diluent	Injection	1	..	UP
	Injection, 4 g (base) with 6.5 mL diluent	Injection	1	..	UP
Spironolactone Tablets B.P.	25 mg	Oral	100	5	SR
Staphylococcus Toxoid B.P. 1968	Injection, 5 mL (diluted 1 in 10)	Injection	1	..	CS
	Injection, 5 mL (undiluted)	Injection	1	..	CS
Sterculia B.P.	Discs, 12		1	5	BH
	Paste, 127.6 g		1	..	HO
	Powder, 71 g		1	..	DY
	Squares, 6		1	5	BH
Sterculia B.P. with Frangula Bark B.P.	Granules, 473 mg-83 mg per g, 250 g	Oral	2	1	SC
Streptokinase B.P. with any determined brand of Water for Injections or other solvent	Injection, 100,000 I.U. (with required solvent)	Injection	2	..	PS
	Injection, 250,000 I.U. (with required solvent)	Injection	2	..	HP, PS

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
	Injection, 600,000 I.U. (with required solvent)	Injection	5	..	PS
	Injection, 750,000 I.U. (with required solvent)	Injection	5	..	HP
Sucralfate	Tablet, 1 g	Oral	120	2	BT
Sulindac Tablets B.P.	100 mg	Oral	50	3	FR
Sulphacetamide Sodium B.P.	Eye drops, 100 mg per mL, 15 mL	Application to the eye	1	2	AG, SI
	Eye drops, 200 mg per mL, 15 mL	Application to the eye	1	2	SI
Sulphafurazole B.P.	Eye drops, 40 mg per mL, 10 mL	Application to the eye	1	2	RO
Sulphamethizole Tablets B.P.	500 mg	Oral	40	2	WW
	1 g	Oral	20	2	WW
Sulphasalazine	Tablet, 500 mg	Oral	200	5	AF, PS
	Tablet, 500 mg (enteric coated)	Oral	200	5	PS
Sulphinpyrazone Tablets B.P.	100 mg	Oral	100	5	CG
Sulthiame Tablets B.P.	50 mg	Oral	200	2	BN
	200 mg	Oral	200	2	BN
"Super Banish"	Liquid, 7.5 mL		1	..	DY
Surgical Cement	Skin Bond Adhesive, 118 mL	Application	1	2	DY
Surgical Cement Solvent	227 mL	Application	1	2	DY
	240 mL	Application	1	2	EG
	250 mL	Application	1	2	EG
Tamoxifen Citrate Tablets B.P.	10 mg (base)	Oral	60	5	IC
	20 mg (base)	Oral	60	5	IC
Temazepam	Capsule, 10 mg	Oral	25	..	AF, SI, WY
Terbutaline Sulphate B.P.	Elixir, 300 micrograms per mL, 300 mL	Oral	1	5	AP
	Injection, 100 micrograms in 1 mL amp.	Injection	5	..	AP
	Injection, 500 micrograms in 1 mL amp.	Injection	5	..	AP
	Nebuliser solution, 10 mg per mL, 50 mL	Inhalation	1	5	AP
	Spray, metered aerosol, 250 micrograms per dose, 400 doses, 14 g	Inhalation by mouth	1	5	AP
Terbutaline Sulphate Tablets B.P.	5 mg	Oral	100	5	AP
Testosterone Enanthate B.P.	Injection, 250 mg in 1 mL amp.	Injection	3	3	SC
Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P. and Testosterone Isocaproate B.P.	Injection, 20 mg-40 mg-40 mg amp.	Injection	3	3	OR
Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P., Testosterone Isocaproate B.P. and Testosterone Decanoate B.P.	Injection, 30 mg-60 mg-60 mg-100 mg amp.	Injection	3	3	OR
Testosterone Propionate Injection B.P.	Ampoule, 50 mg in 1 mL	Injection	9	..	SC
Tetanus Vaccine, Adsorbed B.P.	Injection, 0.5 mL amp.	Injection	3	..	CS
Tetrabenazine	Tablet, 25 mg	Oral	100	2	RO
Tetracosactrin Zinc Injection B.P.	Ampoule, 500 micrograms in 1 mL	Injection	5	5	CG
	Ampoule, 1 mg in 1 mL	Injection	5	5	CG
Tetracycline B.P. with a buffering agent	Capsule, 250 mg	Oral	25	1	AP, CS, FM, HP, LE, SQ
Tetracycline B.P. with a buffering agent and Nystatin B.P.	Capsule, 250 mg-250,000 units	Oral	25	1	SQ
Tetracycline Capsules B.P.	250 mg	Oral	25	1	BZ, LE, UP
Tetracycline Hydrochloride B.P.	Eye ointment, 10 mg per g, 5 g	Application to the eye	1	..	BZ

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Tetracycline Hydrochloride B.P. with Nystatin B.P.	Capsule, 250 mg-250,000 units	Oral	25	1	AP, LE
Theophylline B.P.	Capsule, 50 mg (containing sustained release beads)	Oral	100	5	RG, RK
	Capsule, 100 mg (containing sustained release beads)	Oral	100	5	RG, RK
	Capsule, 100 mg (controlled release)	Oral	100	5	FC
	Capsule, 250 mg (controlled release)	Oral	100	5	FC
	Elixir, 80 mg per 15 mL, 500 mL	Oral	1	5	SC
	Syrup, 80 mg per 15 mL, 500 mL	Oral	1	5	RK
	Tablet, 50 mg	Oral	100	5	RK
	Tablet, 125 mg	Oral	100	5	RK
	Tablet, 200 mg	Oral	100	5	RK
	Tablet, 200 mg (sustained release)	Oral	100	5	AP
	Tablet, 250 mg (sustained release)	Oral	100	5	RK
	Tablet, 300 mg (sustained release)	Oral	100	5	AP
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Thiabendazole Tablets B.P.	500 mg	Oral	16	..	MK
Thiamine Hydrochloride Injection B.P.	Ampoule, 100 mg in 1 mL	Injection	5	1	FM
Thiamine Hydrochloride Tablets B.P.	100 mg	Oral	100	2	FM, NN, US
Thiethylperazine Malate	Injection, 6.5 mg (base) in 1 mL amp.	Injection	10	..	SZ
Thiethylperazine Maleate	Tablet, 6.5 mg (base)	Oral	50	..	SZ
	Suppositories, 6.5 mg (base), 6		1	2	SZ
Thioguanine Tablets B.P.	40 mg	Oral	25	1	BW
Thiopropazate Hydrochloride Tablets B.P.	5 mg	Oral	100	1	SR
Thioridazine Hydrochloride B.P.	Solution, 30 mg per mL, 30 mL	Oral	1	4	SZ
Thioridazine Tablets B.P.	10 mg	Oral	100	1	AF, SZ
	25 mg	Oral	100	1	AF, SZ
	50 mg	Oral	100	1	AF, SZ
	100 mg	Oral	100	1	AF, SZ
Thiotepa B.P. with any determined brand of Water for Injections or other solvent	Eye drops, set, 15 mg with required solvent	Application to the eye	1	5	LE
	Injection, 15 mg (solvent required)	Injection	2	1	LE
Thyroxine Tablets B.P.	50 micrograms	Oral	200	1	BW
	100 micrograms	Oral	200	1	BW
	200 micrograms	Oral	200	1	BW
Ticarcillin Sodium with any determined brand of Water for Injections or other solvent	Injection, vial containing equivalent 1 g Ticarcillin (with required solvent)	Injection	10	..	BR, CS
	Injection, vial containing equivalent 3 g Ticarcillin (with required solvent)	Injection	10	..	BR, CS
Timolol Maleate Eye Drops B.P.	2.5 mg per mL, 5 mL	Application to the eye	1	6	FR, SI
	5 mg per mL, 5 mL	Application to the eye	1	6	FR, SI
Timolol Maleate Tablets B.P.	5 mg	Oral	100	5	FR
Tinidazole	Tablet, 500 mg	Oral	4	..	PF
Tobramycin B.P.	Eye drops, 3 mg per mL, 5 mL	Application to the eye	1	2	AQ
	Eye ointment, 3 mg per g, 3.5 g	Application to the eye	1	..	AQ

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Tobramycin Injection B.P.	40 mg	Injection	5	..	LY
	80 mg	Injection	5	..	LY
Tolazamide Tablets B.P.	250 mg	Oral	100	5	UP
Tolbutamide Tablets B.P.	500 mg	Oral	200	2	HP
	1 g	Oral	100	5	HP
Tranexamic Acid Tablets B.P.	500 mg	Oral	100	2	PS
Tranylcypromine Tablets B.P.	10 mg	Oral	50	2	SK
Triamcinolone Acetonide B.P.	Injection, 10 mg in 1 mL amp.	Injection	5	..	SQ
Triamcinolone Acetonide B.P. with Neomycin Sulphate B.P., Gramicidin and Nystatin B.P.	Ear cream, 1 mg-2.5 mg (base)-250 micrograms-100,000 units per g, 5 g	Application to the ear	1	2	SQ
	Ear drops, 1 mg-2.5 mg (base)-250 micrograms-100,000 units per g, 7.5 mL	Application to the ear	1	2	SQ
	Ear ointment, 1 mg-2.5 mg (base)-250 micrograms-100,000 units per g, 5 g	Application to the ear	1	2	SQ
Triamcinolone Acetonide Cream B.P.	200 micrograms per g, 45 g	Application	1	..	SQ
	200 micrograms per g, 100 g	Application	2	..	LE, SQ
	500 micrograms per g, 15 g	Application	1	1	LE, SQ
Triamcinolone Acetonide Ointment B.P.	200 micrograms per g, 45 g	Application	1	..	SQ
	200 micrograms per g, 100 g	Application	2	..	LE, SQ
	500 micrograms per g, 15 g	Application	1	1	LE, SQ
Triamterene B.P.	Tablet, 100 mg	Oral	100	1	SK
Trifluoperazine Hydrochloride B.P.	Injection, 1 mg (base) in 1 mL amp.	Injection	10	..	SK
Trifluoperazine Hydrochloride Tablets B.P.	1 mg	Oral	100	1	PT
	2 mg	Oral	100	1	PT, SK
	5 mg	Oral	100	1	PT
Triglycerides Oil, Medium Chain	1 L	Oral	1	5	KY
Trimethoprim Tablets B.P.	300 mg	Oral	7	1	AF
Trimipramine	Capsule, 50 mg	Oral	50	2	MB
Trimipramine Tablets B.P.	25 mg (base)	Oral	50	2	MB
Trioxysalen	Tablet, 5 mg	Oral	100	2	PT
Urea Cream B.P.	100 mg per g, 100 g	Application	1	2	AG, HA, NW, OL, PS
Vancomycin Hydrochloride B.P.	Capsule, 125 mg (125,000 I.U.) vancomycin activity	Oral	40	..	LY
	Capsule, 250 mg (250,000 I.U.) vancomycin activity	Oral	40	..	LY
Vancomycin Hydrochloride B.P. with any determined brand of Water for Injections or other solvent	Injection, 500 mg (500,000 I.U.) vancomycin activity (with required solvent)	Injection	5	..	LY
Vasopressin Tannate	Injection, (oily) 5 units in 1 mL amp.	Injection	10	1	PD
Verapamil Hydrochloride B.P.	Tablet, 40 mg	Oral	100	5	KN, SC
	Tablet, 80 mg	Oral	100	5	KN, SC
Verapamil Hydrochloride Injection B.P.	Ampoule, 5 mg in 2 mL	Injection	5	..	KN, SC
Verapamil Hydrochloride Tablets B.P.	40 mg	Oral	100	5	AF, PT, US
	80 mg	Oral	100	5	AF, PT, US
	120 mg	Oral	100	5	KN, PT, SC, US
	160 mg	Oral	60	5	KN, SC
Vidarabine	Eye ointment, 30 mg per g, 3.5 g	Application to the eye	1	..	PD
Vinblastine Sulphate B.P.	Injection, 10 mg and 10 mL solvent	Injection	2	..	BL
Vinblastine Sulphate B.P. with any determined brand of Water for Injections or other solvent	Injection, 10 mg (with required solvent)	Injection	2	..	LY

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Vincristine Sulphate B.P.	Injection, 1 mg and 10 mL solvent	Injection	5	..	BL, LY
	Injection, 5 mg and 10 mL solvent	Injection	1	..	BL
Warfarin Tablets B.P.	1 mg	Oral	50	2	BT, GL
	2 mg	Oral	50	2	BT
	2.5 mg	Oral	50	2	BT
	3 mg	Oral	50	2	GL
	5 mg	Oral	50	2	BT, GL
	7.5 mg	Oral	50	2	BT
	10 mg	Oral	50	2	BT
Water for Injections B.P.	Ampoule, 2 mL	Injection	5	3	AP, BT, BZ, SI
	Ampoule, 5 mL	Injection	5	3	AP, BT, BZ, SI
	Ampoule, 10 mL	Injection	5	3	AP, BT, BZ, SI
Wool Alcohols Ointment B.P.	100 g		1	1	SN
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Zinc Oxide B.P.	Ointment, compound, 50 g		1	1	WW
	Suppositories, compound, 12		1	1	WW
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Zinc Sulphate B.P. with Phenylephrine Hydrochloride B.P.	Eye drops, 2.5 mg-1.2 mg per mL, 15 mL	Application to the eye	1	2	AG, AQ

FIRST SCHEDULE—PART 2

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Purposes*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Acyclovir	Tablets, 200 mg, 90	In compliance with authority procedures set out in sub-paragraph 10 (d): Moderate to severe recurrent (more than ten attacks per year) genital herpes, confirmed by appropriate microbiological technique	Oral	1	2	BW
		In compliance with authority procedures set out in sub-paragraph 10 (d): Suppression of genital herpes in severely immunocompromised patients	Oral	1	5	BW
Bromocriptine Mesylate Tablets B.P.	2.5 mg (base)	In compliance with authority procedures set out in sub-paragraph 10 (d): Acromegaly, prior to surgery or radiotherapy or where surgery or radiotherapy is inappropriate Parkinson's disease Pathological hyperprolactinaemia where appropriate surgery or radiotherapy is not indicated or has already been used with incomplete resolution	Oral	60	5	SZ
Cimetidine	Tablet, 200 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): Scleroderma oesophagus	Oral	120	5	CS, SK
		In compliance with authority procedures set out in sub-paragraph 10 (d): Zollinger-Ellison syndrome	Oral	240	5	CS, SK
	Tablet, 400 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): Scleroderma oesophagus	Oral	60	5	CS, SK
		In compliance with authority procedures set out in sub-paragraph 10 (d): Zollinger-Ellison syndrome	Oral	120	5	CS, SK
	Tablet, 800 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): Zollinger-Ellison syndrome	Oral	60	5	CS, SK
Codeine Phosphate B.P. with Aspirin B.P.	Tablet, 30 mg-325 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): Severe disabling pain not responding to non-narcotic analgesics	Oral	40	..	BW
Codeine Phosphate B.P. with Paracetamol B.P.	Tablet, 30 mg-500 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): Severe disabling pain not responding to non-narcotic analgesics	Oral	40	..	WL
Cyproterone Acetate	Tablet, 50 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): Inoperable carcinoma of the prostate	Oral	50	5	SC

Name of Pharmaceutical Benefit	Form (strength, type, size, etc.)	Purposes	Manner of administration	Maximum quantity	Number of repeats	Brand
Diazepam B.P.	Syrup, 2 mg per 5 mL, 100 mL	In compliance with authority procedures set out in sub-paragraph 10 (d): Disabling spasticity For use by patients receiving long-term nursing care in hospitals and nursing homes who have been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal Malignant neoplasia (late stage)	Oral	2	..	RO
Diazepam Injection B.P.	10 mg in 2 mL	In compliance with authority procedures set out in sub-paragraph 10 (d): Disabling spasticity For use by patients receiving long-term nursing care in hospitals and nursing homes who have been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal Malignant neoplasia (late stage)	Injection	10	..	BL, RO
Diazepam Tablets B.P.	2 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): Disabling spasticity For use by patients receiving long-term nursing care in hospitals and nursing homes who have been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal Malignant neoplasia (late stage)	Oral	100	..	AF, PT, RO, SU
	5 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): Disabling spasticity For use by patients receiving long-term nursing care in hospitals and nursing homes who have been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal Malignant neoplasia (late stage)	Oral	100	..	AF, PT, RO, SU
Doxycyline Capsules B.P.	100 mg	Urethritis	Oral	21	..	PT
Doxycycline Hydrochloride B.P.	Capsule, 100 mg (base) (containing enteric coated pellets)	Urethritis	Oral	21	..	FA
	Tablet, 100 mg (base)	Urethritis	Oral	21	..	AF, PF

Name of Pharmaceutical Benefit	Form (strength, type, size, etc.)	Purposes	Manner of administration	Maximum quantity	Number of repeats	Brand
Famotidine	Tablet, 20 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): Zollinger-Ellison syndrome	Oral	120	5	AD, MK
	Tablet, 40 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): Zollinger-Ellison syndrome	Oral	60	5	AD, MK
Hydrocortisone Sodium Succinate B.P.	Injection set containing equivalent of 100 mg Hydrocortisone and 2 mL solvent	For use in a hospital	Injection	6	..	NR, UP
	Injection set containing equivalent of 250 mg Hydrocortisone and 2 mL solvent	For use in a hospital	Injection	6	..	UP
Medroxyprogesterone Acetate B.P.	Tablet, 10 mg	Endometriosis	Oral	100	2	UP
Methadone Injection B.P.	Ampoule, 10 mg in 1 mL	In compliance with authority procedures set out in sub-paragraph 10 (d): Severe disabling pain associated with proven malignant neoplasia Severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Injection	10	..	BW
Methadone Tablets B.P.	5 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): Severe disabling pain associated with proven malignant neoplasia Severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Oral	40	..	BW
	10 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): Severe disabling pain associated with proven malignant neoplasia Severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Oral	40	..	BW
Metronidazole Tablets B.P.	400 mg	Treatment of anaerobic infections	Oral	21	1	AF, MB
Morphine Sulphate Tablets B.P.	30 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): Severe disabling pain associated with proven malignant neoplasia Severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Oral	40	..	FM

Name of Pharmaceutical Benefit	Form (strength, type, size, etc.)	Purposes	Manner of administration	Maximum quantity	Number of repeats	Brand
Niclosamide Tablets B.P.	500 mg	Hymenolepiasis nana	Oral	16	..	BN
Nitrazepam Tablets B.P.	5 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): For use by patients receiving long-term nursing care in hospitals and nursing homes who have been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal Myoclonic epilepsy	Oral	50	5	AF, RO
Oxazepam Tablets B.P.	15 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): For use by patients receiving long-term nursing care in hospitals and nursing homes who have been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal	Oral	50	5	AF, AY, WY
	30 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): For use by patients receiving long-term nursing care in hospitals and nursing homes who have been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal	Oral	50	5	AF, AY, WY
Oxycodone Hydrochloride	Tablet, 5 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): Severe disabling pain associated with proven malignant neoplasia Severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Oral	40	..	BT
Oxycodone Pectinate	Suppositories, 30 mg (base), 12	In compliance with authority procedures set out in sub-paragraph 10 (d): Severe disabling pain associated with proven malignant neoplasia Severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)		2	..	BT
Pethidine Injection B.P.	Ampoule, 50 mg in 1 mL	In compliance with authority procedures set out in sub-paragraph 10 (d): Late stage malignant neoplasia	Injection	10	..	AP, BL, SI
	Ampoule, 100 mg in 2 mL	In compliance with authority procedures set out in sub-paragraph 10 (d): Late stage malignant neoplasia	Injection	10	..	AP, BL, SI
Phenethicillin Capsules B.P.	250 mg	Prophylaxis of recurrent streptococcal infections (including rheumatic fever)	Oral	50	5	SI
Phenethicillin Tablets B.P.	250 mg	Prophylaxis of recurrent streptococcal infections (including rheumatic fever)	Oral	50	5	SI

Name of Pharmaceutical Benefit	Form (strength, type, size, etc.)	Purposes	Manner of administration	Maximum quantity	Number of repeats	Brand
Phenoxymethylpenicillin (Hydrabamine Salt)	Tablet, 125 mg	Prophylaxis of recurrent streptococcal infections (including rheumatic fever)	Oral	50	5	AB
Phenoxymethylpenicillin Potassium Capsules B.P.	250 mg	Prophylaxis of recurrent streptococcal infections (including rheumatic fever)	Oral	50	5	AB, CS, LY, SI
Phenoxymethylpenicillin Potassium Tablets B.P.	250 mg	Prophylaxis of recurrent streptococcal infections (including rheumatic fever)	Oral	50	5	AB, CS, LY, SI
Prochlorperazine Tablets B.P.	5 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): Emesis associated with malignant disease Rotational vertigo	Oral	100	5	MB, SK
Ranitidine Hydrochloride	Tablet, 150 mg (base)	In compliance with authority procedures set out in sub-paragraph 10 (d): Scleroderma oesophagus	Oral	60	5	GL
		In compliance with authority procedures set out in sub-paragraph 10 (d): Zollinger-Ellison syndrome	Oral	120	5	GL
	Tablet, 300 mg (base)	In compliance with authority procedures set out in sub-paragraph 10 (d): Zollinger-Ellison syndrome	Oral	60	5	GL
Rifampicin B.P.	Capsule, 150 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): Leprosy in adults	Oral	100	..	AF
	Capsule, 300 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): Leprosy in adults	Oral	100	..	AF
Temazepam	Capsule, 10 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): For use by patients receiving long-term nursing care in hospitals and nursing homes who have been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal	Oral	50	5	AF, SI, WY
Tetracycline B.P with a buffering agent	Capsule, 250 mg	Bronchiectasis in patients over the age of 8 years Chronic bronchitis in patients over the age of 8 years Severe acne	Oral	50	5	AP, CS, FM, HP, LE, SQ
Tetracycline B.P with a buffering agent and Nystatin B.P.	Capsule, 250 mg-250,000 units	Bronchiectasis in patients over the age of 8 years Chronic bronchitis in patients over the age of 8 years Severe acne	Oral	50	5	SQ
Tetracycline Capsules B.P.	250 mg	Bronchiectasis in patients over the age of 8 years Chronic bronchitis in patients over the age of 8 years Severe acne	Oral	50	5	BZ, LE, UP
Tetracycline Hydrochloride B.P. with Nystatin B.P.	Capsule, 250 mg-250,000 units	Bronchiectasis in patients over the age of 8 years Chronic bronchitis in patients over the age of 8 years Severe acne	Oral	50	5	AP, LE

SECOND SCHEDULE

Form of Pharmaceutical Benefit	*Maximum quantity*	*Number of repeats*
Creams	100 g	1
Ear Drops	15 mL	2
Elixirs	100 mL	4
Eye Drops		
Cocaine	15 mL	..
Pilocarpine	15 mL	6
Others	15 mL	6
Eye Lotions	200 mL	1
Gargles	200 mL	4
Glycerins	100 mL	1
Inhalations	50 mL	1
Inhalations, Solid	4 g	1
Linctuses	100 mL	2
Liniments	100 mL	1
Lotions	200 mL	2
Mixtures	200 mL	4
Mixtures for Children	100 mL	4
Mouth Washes	200 mL	1
Nasal Instillations	15 mL	2
Ointments and Waxes	100 g	1
Paints	25 mL	1
Pastes		
Cocaine	25 g	..
Others	100 g	1
Powders, Dusting	100 g	1
Powders for Internal Use	100 g	2
Powders, Irrigation	100 g	1
Soaps	200 mL	1
Solutions	200 mL	2
Syrups	100 mL	4
Tinctures	25 mL	1

THIRD SCHEDULE

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Amoxycillin Capsules B.P.	250 mg (base)	Oral	20	..	AF, BR, CS, PT, SI
	500 mg (base)	Oral	20	..	AF, BR, CS, PT, SI
Amoxycillin Trihydrate B.P.	Tablet, chewable, 250 mg (base)	Oral	20	..	BR, CS
	Tablet, dispersible, 3 g (base)	Oral	1	..	BR, CS
Amoxycillin Trihydrate B.P. with Purified Water B.P.	Powder for syrup, 125 mg (base) per 5 mL, 100 mL	Oral	1	..	BR, CS, PT, SI
	Powder for syrup, 250 mg (base) per 5 mL, 100 mL	Oral	1	..	BR, CS, PT, SI
Amphotericin B.P.	Lozenge, 10 mg	Oral	20	..	SQ
	Ointment, 30 mg per g, 15 g	Application	1	..	SQ
Ampicillin Sodium B.P. with any determined brand of Water for Injections or other solvent	Injection, 250 mg (base) vial (with required solvent)	Injection	5	..	CS, PT
	Injection, 500 mg (base) vial (with required solvent)	Injection	5	..	BR, CS, PT
	Injection, 1 g (base) vial (with required solvent)	Injection	5	..	CS, PT
Aspirin Mixture A.P.F. 13 with Codeine Phosphate B.P.	Mixture, 500 mg-30 mg per 10 mL	Oral	200 mL	..	
Benzylpenicillin Potassium B.P. with any determined brand of Water for Injections or other solvent	Injection, 300 mg vial (with required solvent)	Injection	5	..	CS
	Injection, 600 mg vial (with required solvent)	Injection	5	..	CS
	Injection, 3 g vial (with required solvent)	Injection	5	..	CS
Cephalexin B.P. with Purified Water B.P.	Granules for syrup, 125 mg (base) per 5 mL, 100 mL	Oral	1	..	GL, LY
	Granules for syrup, 250 mg (base) per 5 mL, 100 mL	Oral	1	..	GL, LY
Cephalexin Capsules B.P.	250 mg	Oral	20	..	AF, GL, LY
	500 mg	Oral	20	..	AF, GL, LY
Cephalothin Sodium B.P. with any determined brand of Water for Injections or other solvent	Injection, 1 g (base) (with required solvent)	Injection	5	..	GL, LY
	Injection, 2 g (base) (with required solvent)	Injection	1	..	LY
	Injection, 4 g (base) (with required solvent)	Injection	1	..	LY
Codeine Phosphate B.P. with Aspirin B.P.	Tablet, 30 mg-325 mg	Oral	20	..	BW
Codeine Phosphate B.P. with Paracetamol B.P.	Tablet, 30 mg-500 mg	Oral	20	..	WL
Co-trimoxazole Mixture, Paediatric B.P.	40 mg-200 mg per 5 mL, 100 mL	Oral	1	..	AF, BW, PT, RO
Co-trimoxazole Tablets B.P.	80 mg-400 mg	Oral	10	..	AF, BW, PT, RO
	160 mg-800 mg	Oral	10	..	AF, BW, PT, RO
Doxycycline Capsules B.P.	100 mg	Oral	7	..	PT
Doxycycline Hydrochloride B.P.	Capsule, 100 mg (base) (containing enteric coated pellets)	Oral	7	..	FA
	Tablet, 100 mg (base)	Oral	7	..	AF, PF
Erythromycin B.P.	Capsule, 125 mg (containing enteric coated pellets)	Oral	25	..	FA
	Capsule, 250 mg (containing enteric coated pellets)	Oral	25	..	FA, LY
Erythromycin Estolate B.P.	Drops, paediatric, 100 mg (base) per mL, 10 mL	Oral	1	..	LY
	Suspension, 125 mg (base) per 5 mL, 100 mL	Oral	1	..	LY
Erythromycin Ethyl Succinate B.P.	Tablet, chewable, 200 mg (base)	Oral	25	..	AB
	Tablet, 400 mg (base)	Oral	25	..	AB
Erythromycin Ethyl Succinate B.P. with Purified Water B.P.	Granules for suspension, 200 mg (base) per 5 mL, 100 mL	Oral	1	..	AB

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Erythromycin Stearate B.P.	Capsule, 250 mg (base)	Oral	25	..	AB
	Suspension, 125 mg (base) per 5 mL, 100 mL	Oral	1	..	AB
	Suspension, 250 mg (base) per 5 mL, 100 mL	Oral	1	..	AB
Erythromycin Stearate Tablets B.P.	250 mg (base)	Oral	25	..	AB
Erythromycin Tablets B.P.	250 mg	Oral	25	..	AB, UP
Metronidazole Tablets B.P.	200 mg	Oral	21	..	AF, MB, PT, SR
	250 mg	Oral	21	..	JC
Nystatin B.P.	Lozenge, 100,000 units	Oral	20	..	LE
	Tablet, 500,000 units	Oral	25	..	LE
Nystatin Mixture B.P.	100,000 units per mL, 24 mL	Oral	1	..	LE, SQ
Nystatin Tablets B.P.	500,000 units	Oral	25	..	SQ
Paracetamol B.P.	Mixture, 120 mg per 5 mL, 100 mL	Oral	1	..	BW, US, WL
Phenethicillin Capsules B.P.	250 mg	Oral	25	..	SI
	500 mg	Oral	25	..	SI
Phenethicillin Potassium B.P. with Purified Water B.P.	Powder for syrup, 125 mg (Phenethicillin) per 5 mL, 100 mL	Oral	1	..	SI
	Powder for syrup, 250 mg (Phenethicillin) per 5 mL, 100 mL	Oral	1	..	SI
Phenethicillin Tablets B.P.	250 mg	Oral	25	..	SI
Phenoxymethylpenicillin (Benzathine Salt)	Suspension, 125 mg per 5 mL, 100 mL	Oral	1	..	CS, SI
	Suspension, 250 mg per 5 mL, 100 mL	Oral	1	..	CS, SI
Phenoxymethylpenicillin (Hydrabamine Salt)	Suspension, 125 mg per 5 mL, 100 mL	Oral	1	..	AB
	Suspension, 250 mg per 5 mL, 100 mL	Oral	1	..	AB
	Tablet, 125 mg	Oral	25	..	AB
Phenoxymethylpenicillin Potassium Capsules B.P.	250 mg	Oral	25	..	AB, CS, LY, SI
	500 mg	Oral	25	..	CS, SI
Phenoxymethylpenicillin Potassium Tablets B.P.	250 mg	Oral	25	..	AB, CS, LY, SI
	500 mg	Oral	25	..	AB, LY
Procaine Penicillin Injection B.P.	Syringe, disposable, 1 g	Injection	5	..	SI
	Syringe, disposable, 1.5 g	Injection	5	..	SI
Tetracycline B.P. with a buffering agent	Capsule, 250 mg	Oral	25	..	AP, CS, FM, HP, LE, SQ
Tetracycline Capsules B.P.	250 mg	Oral	25	..	BZ, LE, UP
Water for Injections B.P.	Ampoule, 2 mL	Injection	5	..	AP, BT, BZ, SI
	Ampoule, 5 mL	Injection	5	..	AP, BT, BZ, SI
	Ampoule, 10 mL	Injection	5	..	AP, BT, BZ, SI

Dated this 16th day of March 1989.

IAN McNEIL
First Assistant Secretary
Health Benefits Division
Delegate of the Minister of State for Community Services and Health

N.N.—8852513

COMMONWEALTH OF AUSTRALIA

National Health Act 1953

PHARMACEUTICAL BENEFITS

DECLARATION UNDER SUB-SECTION 85 (2)

No. PB 1 of 1989

I, IAN JAMES MCNEIL, First Assistant Secretary, Health Benefits Division, Department of Community Services and Health and Delegate of the Minister of State for Community Services and Health, pursuant to sub-section 85 (2) of the *National Health Act 1953*, hereby make the following Declaration:

1. This Declaration shall come into operation on 1 April 1989.
2. Declaration No. PB 5 under sub-section 85 (2) of the Act made on 16 November 1988 with effect from 1 December 1988 is hereby revoked.
3. In this Declaration:

   "the Act" means the *National Health Act 1953*;

   "approved pharmacist" has the same meaning as in sub-section 84 (1) of the Act;

   "ready-prepared pharmaceutical benefit" means a drug or medicinal preparation in respect of which there is in force a determination under sub-section 85 (6) of the Act;

   "extemporaneously-prepared pharmaceutical benefit" means a pharmaceutical benefit other than a ready-prepared pharmaceutical benefit.
4. Part VII of the Act applies in relation to each of the drugs and medicinal preparations as are specified in Schedule 1.
5. A medicinal preparation composed of a compound that includes a pharmaceutical benefit specified in column 1 of Schedule 2, other than a compound specified in column 2 of that Schedule opposite to that pharmaceutical benefit, is not a medicinal preparation to which Part VII of the Act applies, unless that pharmaceutical benefit is also specified in Schedule 3, in which case the provisions of paragraphs 7 and 8 apply.
6. Part VII of the Act does not apply in relation to a medicinal preparation composed of a compound that includes a ready-prepared pharmaceutical benefit, other than Water for Injections or a pharmaceutical benefit specified in column 1 of Schedule 2.
7. Part VII of the Act applies in relation to medicinal preparations composed of one or more of the drugs or medicinal preparations specified in Schedule 3.
8. Part VII of the Act applies in relation to medicinal preparations composed of one or more of the drugs or medicinal preparations specified in Schedule 3 with the addition of one or more of the substances specified in Schedule 4.
9. The substances specified in Schedule 4 are additives for the purposes of paragraph 85 (2) (b) of the Act.
10. Part VII of the Act applies in relation to each of the drugs and medicinal preparations as are specified in Schedule 5.
11. The drugs and medicinal preparations specified in Schedule 5 are additional pharmaceutical benefits made available under arrangements provided for by section 100 of the Act.
12. Where circumstances are specified in column 2 of Schedule 1 or Schedule 3 opposite the name of a pharmaceutical benefit specified in column 1 of either of those Schedules, that pharmaceutical benefit is a relevant pharmaceutical benefit for the purposes of section 88A of the Act.
13. Where circumstances are specified in column 2 of Schedule 3 opposite the name of a pharmaceutical benefit specified in column 1 of that Schedule, those circumstances are also specified in relation to any medicinal preparation containing that pharmaceutical benefit.
14. The following circumstances are specified in relation to each relevant pharmaceutical benefit for the purposes of section 88A of the Act:
    (a) Where a class of persons is specified in column 2 of Schedule 1 or Schedule 3—that the pharmaceutical benefit is to be supplied for the treatment of a person included in that class of persons;
    (b) Where a disease or condition is specified in column 2 of Schedule 1 or Schedule 3—
        (i) if sub-sub-paragraph (ii) does not apply—that the pharmaceutical benefit is to be supplied for the treatment of that disease or condition in relation to any person; or
        (ii) if the disease or condition is specified in relation to a specified class of persons—that the pharmaceutical benefit is to be supplied for the treatment of that disease or condition in a person included in that class of persons;
    (c) Where a purpose is specified in column 2 of Schedule 1 or Schedule 3—that the pharmaceutical benefit is to be supplied for that purpose;
    (d) Where it is specified in column 2 of Schedule 1 or Schedule 3 that compliance with authority procedures set out in sub-paragraph 14 (d) is required—
        (i) that an application for the written authority of the Secretary in relation to the supply of the pharmaceutical benefit has been made by a medical practitioner, on a form approved by the Secretary, and has been forwarded to the Secretary by that medical practitioner or on behalf of that medical practitioner by a person other than an approved pharmacist, and the Secretary has approved the application; or
        (ii) where the medical practitioner believes that the supply of the pharmaceutical benefit is required urgently—that the medical practitioner has prepared an Authority Prescription on a form approved by the Secretary and has:
            (A) issued the original and duplicate of the form to the person for whom the pharmaceutical benefit is to be supplied;
            (B) on the departmental copy of the form declared that the circumstances specified in column 2 of Schedule 1 or Schedule 3 apply and signed that copy in the medical practitioner's handwriting; and
            (C) forwarded the departmental copy to reach the Secretary within 7 days from the date on which the original and duplicate were issued to the person for whom the pharmaceutical benefit is to be supplied.

15. Where a medical practitioner makes an application under sub-paragraph 14 (d) and the Secretary approves the application, the Secretary shall record the approval on a numbered authority and—
    (a) where, in the approval, the Secretary requires the medical practitioner to vary the prescription for the supply of the pharmaceutical benefit—return the approval to the medical practitioner; or
    (b) in any other case—return the approval to the medical practitioner or, if the medical practitioner so requests, forward the approval to the person to whom the pharmaceutical benefit is to be supplied.

SCHEDULE 1

Ready-prepared pharmaceutical benefits

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Acetazolamide B.P.	—
Acetazolamide Sodium	—
Acetazolamide Tablets B.P.	—
Acetylcysteine	Bronchiectasis Cystic fibrosis (mucoviscidosis)
Acrylic Resin	Ileostomy or colostomy conditions
Acyclovir	In respect of the eye ointment: Eye infections caused by herpes simplex virus In respect of the tablet, 200 mg: In compliance with authority procedures set out in subparagraph 14 (d): Moderate to severe initial genital herpes, complicated by severe pain, systemic symptoms or urinary retention In respect of the tablet, 400 mg: In compliance with authority procedures set out in subparagraph 14 (d): Treatment of patients with herpes zoster with severe pain who are over 60 years of age and in whom the duration of rash is less than 72 hours
Adrenaline B.P.	—
Adrenaline Hydrochloride	—
Adrenaline Injection B.P.	—
"Albumaid XP"	Phenylketonuria
"Albumaid XPXT"	Tyrosinaemia
"Alfaré"	In compliance with authority procedures set out in subparagraph 14 (d): Biliary atresia Chyloascites Chylothorax Cystic fibrosis Enterokinase deficiency Intolerance to both milk protein and soya protein Severe diarrhoea of greater than two weeks duration in infants under the age of 4 months
Allopurinol B.P.	—
Allopurinol Tablets B.P.	—
Alprenolol Tablets B.P.	—
Aluminium Hydroxide and Magnesium Carbonate Co-dried Gel	—
Aluminium Hydroxide, Dried B.P.	—
Aluminium Hydroxide, Dried B.P. with Magnesium Hydroxide B.P.	—
Aluminium Hydroxide, Dried B.P. with Magnesium Trisilicate B.P. and Magnesium Hydroxide B.P.	—
Aluminium Hydroxide Mixture B.P.	—
Aluminium Hydroxide Mixture B.P. with Light Kaolin B.P. or Light Kaolin (Natural) B.P.	—
Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P.	—
Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P. and Oxethazaine	—
Amantadine Hydrochloride	The treatment of Parkinson's disease caused otherwise than by treatment with a drug
Ambenonium Chloride	—
Amiloride Hydrochloride Tablets B.P.	—
Aminacrine Hydrochloride B.P. 1968	—
Aminoglutethimide	In compliance with authority procedures set out in subparagraph 14 (d): Post-menopausal metastatic breast cancer in patients who have failed to respond adequately to endocrine manipulation Cushing's syndrome

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
"Aminogran Food Supplement"	Phenylketonuria
"Aminogran Mineral Mixture"	Phenylketonuria
Aminophylline B.P.	—
Aminophylline Injection B.P.	—
Aminophylline Tablets B.P.	—
Amiodarone Hydrochloride	In compliance with authority procedures set out in sub-paragraph 14 (d): For the continuing treatment of severe refractory cardiac arrhythmias where treatment with amiodarone hydrochloride was initiated in a hospital (in-patient or out-patient)
Amitriptyline Tablets B.P.	—
Amoxycillin Capsules B.P.	—
Amoxycillin Sodium	—
Amoxycillin Trihydrate B.P.	—
Amoxycillin Trihydrate B.P. with Potassium Clavulanate	—
Amoxycillin Trihydrate B.P. with Potassium Clavulanate and Purified Water B.P.	—
Amoxycillin Trihydrate B.P. with Purified Water B.P.	—
Amphotericin B.P.	—
Amphotericin Lozenges B.P.	—
Ampicillin Capsules B.P.	—
Ampicillin Sodium B.P.	—
Ampicillin Trihydrate B.P. with Purified Water B.P.	—
Amylobarbitone Sodium B.P.	Epilepsy
Antazoline Phosphate with Naphazoline Hydrochloride	—
Antazoline Sulphate with Naphazoline Nitrate B.P.	—
Aspirin B.P.	—
Aspirin Tablets B.P.	—
Aspirin Tablets, Dispersible B.P.	—
Atenolol	—
Atropine Eye Ointment B.P.	—
Atropine Sulphate B.P.	—
Atropine Sulphate Injection B.P.	—
Atropine Sulphate Tablets B.P.	—
Auranofin	—
Aurothioglucose	—
Azathioprine Tablets B.P.	—
Baclofen Tablets B.P.	—
"Banish"	Ileostomy or colostomy conditions
Beclomethasone Dipropionate B.P.	In respect of the capsules and the sprays, metered aerosol, 50 micrograms per dose, 200 doses, 20.4 g and 100 micrograms per dose, 200 doses, 20.4 g: Asthma In respect of the spray, metered aerosol, 250 micrograms per dose, 200 doses, 20.4 g: In compliance with authority procedures set out in sub-paragraph 14 (d): Severe chronic asthma not responding to lower doses of beclomethasone dipropionate aerosol
Bendrofluazide Tablets B.P.	—
Benzathine Penicillin B.P.	—
Benzathine Penicillin B.P. with Procaine Penicillin B.P., Benzylpenicillin Potassium B.P. and Water for Injections	—
Benzhexol Tablets B.P.	—
Benzoin Tincture, Compound B.P.	Ileostomy or colostomy conditions
Benztropine Injection B.P.	—
Benztropine Tablets B.P.	—
Benzyl Benzoate Application B.P.	—
Benzylpenicillin Potassium B.P.	—

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Betamethasone Acetate with Betamethasone Sodium Phosphate B.P.	Alopecia areata For local intra-articular or peri-articular infiltration Granulomata, dermal Keloid Lichen planus hypertrophic Lichen simplex chronicus Lupus erythematosus, chronic discoid Necrobiosis lipoidica Uveitis
Betamethasone Dipropionate	—
Betamethasone Tablets B.P.	—
Betamethasone Valerate B.P.	—
Betamethasone Valerate Cream B.P.	—
Betamethasone Valerate Ointment B.P.	—
Bethanechol Chloride	—
Biperiden Hydrochloride	—
Bisacodyl B.P.	Any disease or condition in a paraplegic or quadriplegic patient
Bisacodyl Suppositories B.P.	Any disease or condition in a paraplegic or quadriplegic patient For use by patients who are receiving long-term extensive nursing care in hospitals or nursing homes For use by patients for whose care a Commonwealth Domiciliary Nursing Care Benefit is approved
Bisacodyl Tablets B.P.	Any disease or condition in a paraplegic or quadriplegic patient For use by patients who are receiving long-term extensive nursing care in hospitals or nursing homes For use by patients for whose care a Commonwealth Domiciliary Nursing Care Benefit is approved
Bismuth Subcitrate	—
Bleomycin Sulphate	Germ cell neoplasms Lymphoma Squamous cell carcinoma
Bromocriptine Mesylate Capsules B.P.	In compliance with authority procedures set out in subparagraph 14 (d): Acromegaly, prior to surgery or radiotherapy or where surgery or radiotherapy is inappropriate Parkinson's disease Pathological hyperprolactinaemia where appropriate surgery or radiotherapy is not indicated or has already been used with incomplete resolution
Bromocriptine Mesylate Tablets B.P.	Urgent suppression of physiological lactation In compliance with authority procedures set out in subparagraph 14 (d): Acromegaly, prior to surgery or radiotherapy or where surgery or radiotherapy is inappropriate Parkinson's disease Pathological hyperprolactinaemia where appropriate surgery or radiotherapy is not indicated or has already been used with incomplete resolution
Bumetanide	—
Busulphan Tablets B.P.	—
Butyl Monoester Polymer with Ethanol B.P.	Ileostomy or colostomy conditions
Butyl Monoester Polymer with Isopropyl Alcohol B.P.	Ileostomy or colostomy conditions
Calciferol Tablets, High-Strength B.P.	Hypocalcaemia Hypoparathyroidism Osteomalacia following gastrectomy, severe steatorrhoea or renal failure Vitamin D-resistant rickets
Calcitonin (Human)—Synthetic	In compliance with authority procedures set out in subparagraph 14 (d): Proven active Paget's disease of bone, or hypercalcaemia, in patients unable to tolerate both pork and salmon calcitonin or who are resistant to treatment with either pork or salmon calcitonin

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Calcitonin (Pork) B.P.	In compliance with authority procedures set out in sub-paragraph 14 (d): Proven active Paget's disease of bone causing pain or disability Treatment initiated in a hospital (in-patient or out-patient) of hypercalcaemia For the continuation of treatment of patients already established on calcitonin under arrangements provided for by section 100 of the Act
Calcitriol	In compliance with authority procedures set out in sub-paragraph 14 (d): Hypocalcaemia due to renal disease Hypoparathyroidism Hypophosphataemic rickets Vitamin D-resistant rickets
Calcium Carbonate B.P.	Hypocalcaemia Osteoporosis Proven malabsorption
Calcium Carbonate B.P. with Calcium Lactate-Gluconate	Hypocalcaemia Osteoporosis Proven malabsorption
Calcium Folinate	Antidote to folic acid antagonists
Calcium Glubionate	—
Captopril	In compliance with authority procedures set out in sub-paragraph 14 (d): Cardiac failure where treatment was initiated in a hospital (in-patient or out-patient) Hypertension where other drug therapy has failed or is inappropriate
Carbachol B.P. 1973	—
Carbamazepine B.P.	—
Carbamazepine Tablets B.P.	—
Carbimazole Tablets B.P.	—
Carboplatin	In compliance with authority procedures set out in sub-paragraph 14 (d): Advanced stage ovarian carcinoma
Carmellose Sodium B.P. with Pectin and Gelatin B.P.	Ileostomy or colostomy conditions
Cefaclor Monohydrate with Purified Water B.P.	—
Cefotaxime Sodium	In compliance with authority procedures set out in sub-paragraph 14 (d): Treatment where less costly alternative therapy is inappropriate for: Infections where positive bacteriological evidence confirms that cefotaxime sodium is an appropriate therapeutic agent Septicaemia, suspected or proven
Ceftriaxone Sodium	In compliance with authority procedures set out in sub-paragraph 14 (d): Treatment where less costly alternative therapy is inappropriate for: Infections where positive bacteriological evidence confirms that ceftriaxone sodium is an appropriate therapeutic agent Septicaemia, suspected or proven
Cephalexin B.P. with Purified Water B.P.	—
Cephalexin Capsules B.P.	—
Cephalothin Sodium B.P.	—
Cephazolin Sodium	In compliance with authority procedures set out in sub-paragraph 14 (d): Treatment where less costly alternative therapy is inappropriate for: Infections where positive bacteriological evidence confirms that cephazolin sodium is an appropriate therapeutic agent Septicaemia, suspected or proven
Charcoal, Activated B.P.	Ileostomy or colostomy conditions

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Chloral Hydrate B.P.	—
Chlorambucil Tablets B.P.	—
Chloramphenicol B.P.	—
Chloramphenicol B.P. with Polymyxin B Sulphate B.P.	—
Chloramphenicol Capsules B.P.	Bacterial meningitis Intracranial bacterial infections Intraocular infections Rickettsioses Typhoid Other serious infections where positive bacteriological evidence confirms that chloramphenicol is the only appropriate antibiotic
Chloramphenicol Eye Drops B.P.	—
Chloramphenicol Eye Ointment B.P.	—
Chloramphenicol Palmitate Mixture B.P.	Bacterial meningitis Intracranial bacterial infections Intraocular infections Rickettsioses Typhoid Other serious infections where positive bacteriological evidence confirms that chloramphenicol is the only appropriate antibiotic
Chloramphenicol Sodium Succinate B.P.	Bacterial meningitis Intracranial bacterial infections Intraocular infections Rickettsioses Typhoid Other serious infections where positive bacteriological evidence confirms that chloramphenicol is the only appropriate antibiotic
Chlorhexidine Gluconate	—
Chlormethiazole Capsules B.P.	In compliance with authority procedures set out in subparagraph 14 (d): Short-term alcohol or drug withdrawal therapy in a hospital or approved centre Status epilepticus
Chlormethiazole Edisylate B.P.	Short-term alcohol or drug withdrawal therapy in a hospital or approved centre Status epilepticus
Chloroquine Phosphate Tablets B.P.	—
Chloroquine Sulphate B.P.	—
Chlorothiazide Tablets B.P.	—
Chlorpromazine Elixir B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years
Chlorpromazine Injection B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Chlorpromazine Suppositories B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years
Chlorpromazine Tablets B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years
Chlorpropamide Tablets B.P.	—
Chlorthalidone Tablets B.P.	—
Cholestyramine	In compliance with authority procedures set out in subparagraph 14 (d): Treatment where less costly alternative therapy is inappropriate for: Bile salt malabsorption Hypercholesterolaemia Pruritus associated with partial biliary obstruction not responding to other therapy Severe diarrhoea associated with pelvic irradiation
Choline Theophyllinate B.P.	—
Chorionic Gonadotrophin B.P.	In respect of the injection set containing 1 ampoule powder for injection 5,000 units and 1 ampoule solvent 1mL: In compliance with authority procedures set out in subparagraph 14 (d): For use with bromocriptine mesylate in infertility associated with hyperprolactinaemia In respect of the other injection sets: In compliance with authority procedures set out in subparagraph 14 (d): For the treatment of anovulatory infertility in females under 41 years of age with no more than 2 live children by their present union For the treatment of infertility in males due to hypogonadotrophic hypogonadism For the treatment of infertility in males associated with isolated luteinizing hormone deficiency For the treatment of males who have combined deficiency of human growth hormone and gonadotrophins and in whom the absence of secondary sexual characteristics indicates a lag in maturation For the treatment of males over the age of 16 years who show clinical evidence of hypogonadism or delayed puberty
Cimetidine	In respect of the tablets, 200 mg and 400 mg: In compliance with authority procedures set out in subparagraph 14 (d): Duodenal ulcer (including pyloric and stomal ulcers), proven by current or prior x-ray, endoscopy or surgery Gastric ulcer, proven by x-ray, endoscopy or surgery within the previous two years Scleroderma oesophagus Severe ulcerating (erosive) oesophagitis, proven by endoscopy and unresponsive to other measures Zollinger-Ellison syndrome

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
	In respect of the tablet, 800 mg: In compliance with authority procedures set out in sub-paragraph 14 (d): Duodenal ulcer (including pyloric and stomal ulcers), proven by current or prior x-ray, endoscopy or surgery Gastric ulcer, proven by x-ray, endoscopy or surgery within the previous two years Zollinger-Ellison syndrome
Ciprofloxacin Hydrochloride	In compliance with authority procedures set out in sub-paragraph 14 (d): Serious infections for which no other antimicrobial agent is appropriate
Clindamycin Capsules B.P.	Gram-positive coccal infections where the infection cannot be safely and effectively treated with penicillin or a derivative of penicillin
Clindamycin Palmitate Hydrochloride with Purified Water B.P.	Gram-positive coccal infections where the infection cannot be safely and effectively treated with penicillin or a derivative of penicillin
Clioquinol B.P.	—
Clofibrate Capsules B.P.	In compliance with authority procedures set out in sub-paragraph 14 (d): Hypercholesterolaemia Hypertriglyceridaemia
Clomiphene Tablets B.P.	Anovulatory infertility Patients undergoing in-vitro fertilisation
Clomipramine Hydrochloride B.P.	Cataplexy associated with narcolepsy Obsessive compulsive disorders and phobic disorders in adults
Clonazepam	—
Clonidine Hydrochloride Tablets B.P.	—
Clopamide	—
Clotrimazole B.P.	—
Cloxacillin Capsules B.P.	—
Cloxacillin Sodium B.P.	—
Codeine Phosphate B.P. with Aspirin B.P.	—
Codeine Phosphate B.P. with Paracetamol B.P.	—
Codeine Phosphate Tablets B.P.	—
Colchicine Tablets B.P.	—
Colestipol Hydrochloride	In compliance with authority procedures set out in sub-paragraph 14 (d): Treatment where less costly alternative therapy is inappropriate for hypercholesterolaemia
Colistin Sulphate B.P. with Neomycin Sulphate B.P.	—
Colistin Sulphomethate Sodium B.P.	—
Copper Sulphate B.P.C. 1973	—
Cortisone Tablets B.P.	—
Co-trimoxazole Mixture, Paediatric B.P.	—
Co-trimoxazole Tablets B.P.	—
Cyclopenthiazide Tablets B.P.	—
Cyclophosphamide B.P.	—
Cyclophosphamide Tablets B.P.	—
Cyproheptadine Tablets B.P.	Prevention of migraine
Cyproterone Acetate	In compliance with authority procedures set out in sub-paragraph 14 (d): Idiopathic precocious puberty Inoperable carcinoma of the prostate Moderate to severe androgenisation in non-pregnant women
Cytarabine B.P.	—
Danazol	In compliance with authority procedures set out in sub-paragraph 14 (d): Endometriosis, proven by visual means Hereditary angio-oedema Menorrhagia, intractable primary
Dantrolene Sodium	Treatment of chronic spasticity

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Debrisoquine Tablets B.P.	—
"De-Lact Infant"	Acute gastro-enteritis complicated by lactose intolerance in infants under the age of 12 months Proven lactose intolerance in infants under the age of 12 months
Demeclocycline Capsules B.P.	Syndrome of inappropriate antidiuretic hormone secretion, caused otherwise than by treatment with a drug
Desipramine Tablets B.P.	—
Desmopressin	—
Dexamethasone B.P.	—
Dexamethasone B.P. with Framycetin Sulphate B.P. and Gramicidin	—
Dexamethasone Sodium Metasulphobenzoate with Framycetin Sulphate B.P. and Gramicidin	—
Dexamethasone Sodium Phosphate B.P.	In respect of the injection, 5 mL vial containing equivalent of 120 mg dexamethasone phosphate: For use in a hospital In respect of the other injections: —
Dexamethasone Tablets B.P.	—
Dexamphetamine Tablets B.P.	In compliance with authority procedures set out in sub-paragraph 14 (d): For the treatment of a patient under the age of 21 years and who is hyperkinetic as a result of brain damage Narcolepsy
Dextran 40 Intravenous Infusion B.P. with Glucose B.P.	—
Dextran 40 Intravenous Infusion B.P. with Sodium Chloride B.P.	—
Dextran 70 Intravenous Infusion B.P. with Glucose B.P.	—
Dextran 70 Intravenous Infusion B.P. with Sodium Chloride B.P.	—
Diazepam B.P.	—
Diazepam Injection B.P.	—
Diazepam Tablets B.P.	—
Diazoxide Injection B.P.	—
Dichlorphenamide Tablets B.P.	—
Diclofenac Sodium	—
Dienoestrol B.P.	—
Difenoxin Hydrochloride with Atropine Sulphate B.P.	—
Diflunisal Tablets B.P.	—
"Digestelact"	In compliance with authority procedures set out in sub-paragraph 14 (d): Lactose intolerance
Digoxin Elixir, Paediatric B.P.	—
Digoxin Injection B.P.	—
Digoxin Tablets B.P.	—
Dihydroergotamine Mesylate B.P.	—
Dihydrotachysterol B.P.	In compliance with authority procedures set out in sub-paragraph 14 (d): Hypoparathyroidism Osteomalacia following gastrectomy, severe steatorrhoea or renal failure Vitamin D-resistant rickets
Diloxanide Furoate Tablets B.P.	—
Diltiazem Hydrochloride	In compliance with authority procedures set out in sub-paragraph 14 (d): Angina where treatment with verapamil hydrochloride or nifedipine has failed or is inappropriate
Dimercaprol Injection B.P.	—
Dimethicones B.P.	Ileostomy or colostomy conditions
Diphenoxylate Hydrochloride B.P. with Atropine Sulphate B.P.	—

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Diphtheria and Tetanus Vaccine, Adsorbed B.P.	—
Diphtheria and Tetanus Vaccine, Adsorbed B.P., Diluted	—
Diphtheria Antitoxin B.P.	—
Diphtheria, Tetanus and Pertussis Vaccine, Adsorbed B.P.	—
Diphtheria Vaccine, Adsorbed B.P.	—
Diphtheria Vaccine, Adsorbed B.P., Diluted	—
Dipivefrine Hydrochloride	—
Disodium Etidronate	In compliance with authority procedures set out in subparagraph 14 (d): Active Paget's disease of bone when calcitonin has been found to be unsatisfactory due to lack of efficacy or unacceptable side effects
Disopyramide Capsules B.P.	—
Disopyramide Phosphate Capsules B.P.	—
Docusate Sodium B.P. with Bisacodyl B.P.	Any disease or condition in a paraplegic or quadriplegic patient For use by patients who are receiving long-term extensive nursing care in hospitals or nursing homes For use by patients for whose care a Commonwealth Domiciliary Nursing Care Benefit is approved
Domperidone	—
Dothiepin Capsules B.P.	—
Dothiepin Hydrochloride B.P.	—
Doxepin Capsules B.P.	—
Doxepin Hydrochloride B.P.	—
Doxorubicin Hydrochloride	—
Doxycycline Capsules B.P.	—
Doxycycline Hydrochloride B.P.	In respect of the capsules, 50 mg (base) (containing enteric coated pellets) and the tablets, 50 mg (base): Bronchiectasis in patients over the age of 8 years Chronic bronchitis in patients over the age of 8 years Severe acne In respect of the other capsules and tablets: —
Dydrogesterone Tablets B.P.	In compliance with authority procedures set out in subparagraph 14 (d): Endometriosis, proven by visual means
Econazole Nitrate B.P.	—
Econazole Nitrate Cream B.P.	—
Econazole Nitrate Pessaries B.P.	—
Ecothiopate Iodide B.P.	—
Enalapril Maleate	In compliance with authority procedures set out in subparagraph 14 (d): Cardiac failure where treatment was initiated in a hospital (in-patient or out-patient) Hypertension where other drug therapy has failed or is inappropriate
Ergometrine and Oxytocin Injection B.P.	—
Ergometrine Injection B.P.	—
Ergometrine Tablets B.P.	—
Ergotamine Tablets B.P.	—
Ergotamine Tartrate B.P. with Caffeine B.P.	—
Erythromycin B.P.	—
Erythromycin Estolate B.P.	—
Erythromycin Ethyl Succinate B.P.	—
Erythromycin Ethyl Succinate B.P. with Purified Water B.P.	—
Erythromycin Lactobionate	—
Erythromycin Stearate	—
Erythromycin Stearate Tablets B.P.	—
Erythromycin Tablets B.P.	—
Ethacrynic Acid Tablets B.P.	Patients who are hypersensitive to other oral diuretics

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Ethinyloestradiol Tablets B.P.	—
Ethosuximide Capsules B.P.	—
Ethosuximide Elixir B.P.	—
Ethyloestrenol Tablets B.P.	In compliance with authority procedures set out in sub-paragraph 14 (d): Osteoporosis Patients on long-term treatment with corticosteroids
Ethynodiol Diacetate B.P. with Ethinyloestradiol B.P.	—
Etretinate	In compliance with authority procedures set out in sub-paragraph 14 (d): Darier's disease Erythrokeratoderma Pityriasis rubra pilaris Severe congenital ichthyosis (lamellar, bullous and sex linked) Severe intractable psoriasis Severe lichen planus Severe palmo-plantar keratoderma
Famotidine	In compliance with authority procedures set out in sub-paragraph 14 (d): Duodenal ulcer (including pyloric and stomal ulcers), proven by current or prior x-ray, endoscopy or surgery Gastric ulcer, proven by x-ray, endoscopy or surgery within the previous two years Zollinger-Ellison syndrome
Felodipine	In compliance with authority procedures set out in sub-paragraph 14 (d): Treatment where less costly alternative therapy is inappropriate
Fenoterol Hydrobromide B.P.	—
Ferrous Aminoacetosulphate	—
Ferrous Gluconate B.P.	—
Ferrous Gluconate Tablets B.P.	—
Ferrous Sulphate, Dried B.P.	—
Ferrous Sulphate, Dried B.P. with Folic Acid B.P.	—
Flecainide Acetate	In compliance with authority procedures set out in sub-paragraph 14 (d): Treatment where less costly alternative therapy is inappropriate for cardiac arrhythmias where treatment was initiated in a hospital (in-patient or out-patient)
Fluclorolone Acetonide B.P.	—
Flucloxacillin Capsules B.P.	—
Flucloxacillin Magnesium B.P. with Purified Water B.P.	—
Flucloxacillin Sodium B.P.	—
Flucytosine Tablets B.P.	Invasive or systemic fungal infections such as candidiasis, cryptococcosis and chromoblastomycosis
Fludrocortisone Tablets B.P.	—
Flumethasone Pivalate with Clioquinol B.P.	—
Fluocortolone Pivalate and Fluocortolone Hexanoate Cream B.P.	—
Fluocortolone Pivalate and Fluocortolone Hexanoate Ointment B.P.	—
Fluorometholone	—
Fluorometholone Acetate	—
Fluorouracil Injection B.P.	—
Fluoxymesterone Tablets B.P.	In compliance with authority procedures set out in sub-paragraph 14 (d): Aplastic anaemias, proven Carcinoma of the breast Hypogonadism Osteoporosis
Fluphenazine Decanoate Injection B.P.	Chorea Hyperactive states of organic or toxic delirium Major pyschoses including: Major organic pyschoses including arteriopathic dementia Manic depressive disorder—manic phase

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
	Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness
Fluphenazine Tablets B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic pyschoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness
Folic Acid B.P.	—
Folic Acid Tablets B.P.	—
Fosfestrol Sodium B.P.	Carcinoma of the prostate
Framycetin Sulphate B.P.	—
Frusemide B.P.	—
Frusemide Injection B.P.	—
Frusemide Tablets B.P.	In respect of the 500 mg strength: Renal failure In respect of the other strengths: —
Fusidic Acid Mixture B.P.	In compliance with authority procedures set out in sub-paragraph 14 (d): Treatment where less costly alternative therapy is inappropriate, when used in combination with another antibiotic in the treatment of proven serious staphylococcal infections
Gas-gangrene Antitoxin, Mixed B.P.	—
Gentamicin Eye Drops B.P.	Invasive ocular infection Perioperative use Suspected pseudomonal eye infection
Gentamicin Injection B.P.	—
Glibenclamide Tablets B.P.	—
Gliclazide	—
Glipizide	—
Glucagon Hydrochloride	—
Glucose and Ketone Indicator—Urine	—
Glucose, Anhydrous B.P., Sodium Chloride B.P., Potassium Chloride B.P., Citric Acid B.P. and Sodium Citrate B.P.	—
Glucose Indicator—Blood	—
Glucose Indicator—Urine	—
Glucose Intravenous Infusion B.P.	—
Glyceryl Trinitrate	—
Glyceryl Trinitrate Tablets B.P.	—
Goserelin Acetate	In compliance with authority procedures set out in sub-paragraph 14 (d): Advanced carcinoma of the prostate
Griseofulvin Tablets B.P.	Kerion Recalcitrant tinea infections
Haloperidol B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic pyschoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Haloperidol Solution B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic pyschoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness
Haloperidol Tablets B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness
Heparin Injection B.P. (Calcium Salt)	—
Heparin Injection B.P. (Sodium Salt)	—
Hexamine Hippurate	—
Hexamine Mandelate	—
Homatropine Hydrobromide B.P.	—
Hydralazine Hydrochloride Tablets B.P.	—
Hydrochlorothiazide B.P. with Amiloride Hydrochloride B.P.	—
Hydrochlorothiazide B.P. with Triamterene B.P.	—
Hydrochlorothiazide Tablets B.P.	—
Hydrocortisone B.P.	—
Hydrocortisone Acetate B.P.	In respect of the rectal foam: Proctitis Ulcerative colitis In respect of the other forms: —
Hydrocortisone Acetate B.P. with Neomycin Sulphate B.P.	—
Hydrocortisone Acetate Cream B.P.	—
Hydrocortisone Acetate Injection B.P.	Alopecia areata For local intra-articular or peri-articular infiltration Granulomata, dermal Keloid Lichen planus hypertrophic Lichen simplex chronicus Lupus erythematosus, chronic discoid
Hydrocortisone Acetate Ointment B.P.	—
Hydrocortisone Sodium Succinate B.P.	In respect of the injection set containing equivalent of 500 mg hydrocortisone and 4 mL solvent: Any disease or condition in a patient receiving treatment in a hospital In respect of the other injection sets: —
Hydroxocobalamin Injection B.P.	Pernicious anaemia and other proven vitamin B12 deficiencies Post-gastrectomy treatment Sub-acute combined degeneration of the cord
Hydroxychloroquine Tablets B.P.	—
Hydroxyurea Capsules B.P.	—
Hyoscyamine Hydrobromide with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P.	—
Hyoscyamine Sulphate B.P. with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P.	—
Hypromellose 4500 B.P.	—
Hypromellose 4500 B.P. with Dextran 70	—
Ibuprofen Tablets B.P.	—
Idoxuridine B.P.	—
Idoxuridine Eye Drops B.P.	—

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Imipramine Hydrochloride B.P.	—
Imipramine Tablets B.P.	—
Indapamide	—
Indomethacin Capsules B.P.	—
Indomethacin Suppositories B.P.	—
Influenza Vaccine (Split Virion), Inactivated B.P.	For prophylaxis of persons at special risk of adverse consequences from infections of the lower respiratory tract
Insect Allergen Extract—Honey Bee Venom	—
Insect Allergen Extract—Paper Wasp Venom	—
Insulin Injection, Acid B.P.	—
Insulin Injection, Biphasic B.P.	—
Insulin Injection, Isophane B.P.	—
Insulin Injection, Isophane B.P. and Insulin Injection, Neutral B.P.	—
Insulin Injection, Neutral B.P.	—
Insulin Injection, Protamine Zinc B.P.	—
Insulin Isophane, Human (Synthetic)	Diabetics exhibiting lipoatrophy, lipohypertrophy, local allergy or immunologic resistance Newly diagnosed insulin dependent diabetics
Insulin Isophane, Human (Synthetic) and Insulin Neutral, Human (Synthetic)	Diabetics exhibiting lipoatrophy, lipohypertrophy, local allergy or immunologic resistance Newly diagnosed insulin dependent diabetics
Insulin Neutral, Human (Synthetic)	Diabetics exhibiting lipoatrophy, lipohypertrophy, local allergy or immunologic resistance Newly diagnosed insulin dependent diabetics
Insulin Zinc Suspension B.P.	—
Insulin Zinc Suspension (Amorphous) B.P.	—
Insulin Zinc Suspension (Crystalline) B.P.	—
Insulin Zinc Suspension (Crystalline), Human (Synthetic)	Diabetics exhibiting lipoatrophy, lipohypertrophy, local allergy or immunologic resistance Newly diagnosed insulin dependent diabetics
Insulin Zinc Suspension, Human (Synthetic)	Diabetics exhibiting lipoatrophy, lipohypertrophy, local allergy or immunologic resistance Newly diagnosed insulin dependent diabetics
Ipratropium Bromide	—
Iron Dextran Injection B.P.	—
Iron Polymaltose Complex	—
Isoconazole Nitrate	—
Isoniazid Tablets B.P.	—
Isopropyl Monoester Polymer with Isopropyl Alcohol B.P.	Ileostomy or colostomy conditions
Isosorbide Dinitrate Tablets B.P.	—
Isotretinoin	In compliance with authority procedures set out in subparagraph 14(d): Severe cystic acne not responsive to other therapy
Kaolin, Light B.P. or Light Kaolin (Natural) B.P. with Pectin	—
Ketoconazole	In compliance with authority procedures set out in subparagraph 14(d): Systemic or deep mycoses where other forms of therapy have failed
Ketoprofen B.P.	—
Ketoprofen Capsules B.P.	—
Labetalol Hydrochloride Tablets B.P.	—
Lactulose Solution B.P.	In compliance with authority procedures set out in subparagraph 14(d): Hepatic coma or pre-coma (chronic portosystemic encephalopathy) Terminal malignant neoplasia
Lauramine Oxide with Octoxinol	Ileostomy or colostomy conditions
Leuprorelin Acetate	In compliance with authority procedures set out in subparagraph 14 (d): Advanced cancer of the prostate

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Levodopa and Carbidopa Tablets B.P.	—
Levodopa B.P. with Benserazide	—
Levodopa Tablets B.P.	—
Levonorgestrel B.P.	—
Levonorgestrel B.P. with Ethinyloestradiol B.P.	—
Lignocaine Hydrochloride B.P.	—
Lignocaine Hydrochloride Injection B.P.	—
Lincomycin Injection B.P.	—
Lindane B.P.	—
Lindane Cream B.P.	—
Liothyronine Tablets B.P.	—
Lithium Carbonate B.P.	—
Lithium Carbonate Tablets B.P.	—
"Locasol New Formula"	In compliance with authority procedures set out in sub-paragraph 14(d): Hypercalcaemia in children under the age of 2 years Osteopetrosis
"Lofenalac"	Phenylketonuria
Loperamide Hydrochloride	—
Lypressin	In compliance with authority procedures set out in sub-paragraph 14(d): Treatment where less costly alternative therapy is inappropriate
"Maxamaid RVHB"	Pyridoxine non-responsive homocystinuria
"Maxamaid XP"	Phenylketonuria
"Maxamum XP"	Phenylketonuria
Medroxyprogesterone Acetate B.P.	In respect of the injections, 50 mg in 1 mL vial and 500 mg in 2.5 mL vial, the oral suspension and the tablets, 100 mg, 200 mg and 250 mg: Breast cancer Endometrial cancer Renal cell cancer In respect of the injection, 150 mg in 1 mL vial: Breast cancer Endometrial cancer Endometriosis Renal cell cancer In respect of the tablet, 10 mg: — In respect of the tablet, 500 mg: Advanced breast cancer
Medrysone	—
Mefenamic Acid Capsules B.P.	Dysmenorrhoea Menorrhagia
Mefruside	—
Megestrol Acetate B.P.	Breast cancer
Melphalan Tablets B.P.	—
Menopausal Gonadotrophin, Human	In compliance with authority procedures set out in sub-paragraph 14(d): For the treatment of anovulatory infertility in females under 41 years of age with no more than 2 live children by their present union For the treatment of infertility in males due to hypogonadotrophic hypogonadism
Mercaptopurine Tablets B.P.	—
Metformin Tablets B.P.	—
Methacycline Hydrochloride B.P.C. 1973	—
Methadone Injection B.P.	Severe disabling pain not responding to non-narcotic analgesics
Methadone Tablets B.P.	Severe disabling pain not responding to non-narcotic analgesics
Methdilazine Hydrochloride	Prevention of migraine

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Methenolone Acetate	In compliance with authority procedures set out in subparagraph 14(d): Osteoporosis Patients on long-term treatment with corticosteroids
Methotrexate B.P.	—
Methotrexate Injection B.P.	—
Methotrexate Tablets B.P.	—
Methsuximide	In compliance with authority procedures set out in subparagraph 14(d): Treatment where less costly alternative therapy is inappropriate
Methyclothiazide	—
Methyldopa Tablets B.P.	—
Methylphenobarbitone B.P.	Epilepsy
Methylprednisolone Acetate Injection B.P.	For local intra-articular or peri-articular infiltration
Methylprednisolone Sodium Succinate	—
Methyl Salicylate Liniment A.P.F.	—
Methyltestosterone Tablets B.P.	In respect of the 5 mg strength: Hypogonadism in patients under the age of 16 years In respect of the other strengths: Carcinoma of the breast Hypogonadism Klinefelter's syndrome (seminiferous tubule dysgenesis)
Methysergide Tablets B.P.	—
Metoclopramide Hydrochloride B.P.	—
Metoclopramide Injection B.P.	—
Metoclopramide Tablets B.P.	—
Metolazone	—
Metoprolol Tartrate	—
Metronidazole Benzoate	—
Metronidazole B.P.	Prophylaxis in large bowel surgery Treatment, in a hospital, of acute anaerobic sepsis
Metronidazole Suppositories B.P.	—
Metronidazole Tablets B.P.	—
Mexiletine Hydrochloride Capsules B.P.	—
Mianserin Hydrochloride Tablets B.P.	In compliance with authority procedures set out in subparagraph 14(d): Depressive illness in persons with cardiovascular disease, bladder neck dysfunction or glaucoma
Miconazole	—
Miconazole Nitrate B.P.	—
Miconazole Nitrate Cream B.P.	—
Minocycline Hydrochloride	—
Minoxidil	In compliance with authority procedures set out in subparagraph 14(d): For the continuing treatment of severe refractory hypertensive disease where treatment with minoxidil was initiated in a hospital (in-patient or out-patient) For the continuing treatment of a patient who has already received, for more than 6 months, therapy with minoxidil for severe refractory hypertension
Misoprostol	In compliance with authority procedures set out in subparagraph 14(d): Duodenal ulcer (including pyloric and stomal ulcers), proven by x-ray, endoscopy or surgery within 3 months of application Gastric ulcer, proven by x-ray, endoscopy or surgery within 3 months of application
Mithramycin	For use in a hospital for: Inoperable testicular neoplasm Symptomatic hypercalcaemia and hypercalcinuria associated with advanced neoplasia
Mitozantrone Hydrochloride	Leukaemia Metastatic or locally advanced breast cancer Non-Hodgkin's lymphoma

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Morphine Sulphate B.P. with Tacrine Hydrochloride	Severe intractable pain
Morphine Sulphate Injection B.P.	—
Morphine Sulphate Tablets B.P.	Severe disabling pain not responding to non-narcotic analgesics
"M.S.U.D. AID"	Maple syrup urine disease
Mustine Hydrochloride B.P.	—
Nalidixic Acid Tablets B.P.	For use as a urinary antiseptic in patients with neurogenic bladder Urinary tract infections where current clinical and bacteriological evidence confirm that nalidixic acid is an appropriate therapeutic agent
Naloxone Hydrochloride	—
Nandrolone Decanoate Injection B.P.	In compliance with authority procedures set out in subparagraph 14(d): Carcinoma of the breast Osteoporosis Patients on long-term treatment with corticosteroids
Nandrolone Phenylpropionate Injection B.P.	In compliance with authority procedures set out in subparagraph 14(d): Carcinoma of the breast Osteoporosis Patients on long-term treatment with corticosteroids
Naphazoline Hydrochloride	—
Naproxen B.P.	—
Naproxen Tablets B.P.	—
Neomycin Sulphate Eye Drops B.P.	—
Neomycin Tablets B.P.	Acute leukaemia during induction of remission with chemotherapy Bowel sterilisation preparatory to major surgery Encephalopathy, hepatic
Neomycin Undecenoate with Bacitracin Zinc B.P.	—
Neostigmine Injection B.P.	—
Neostigmine Tablets B.P.	—
Niclosamide Tablets B.P.	—
Nicotinic Acid Tablets B.P.	—
Nifedipine	—
Nitrazepam Tablets B.P.	—
Nitrofurantoin B.P.	—
Nitrofurantoin Mixture B.P.	—
Nitrofurantoin Tablets B.P.	—
Norethisterone Acetate B.P.	Carcinoma of the breast Carcinoma of the prostate
Norethisterone B.P. with Ethinyloestradiol B.P.	—
Norethisterone B.P. with Mestranol B.P.	—
Norethisterone Tablets B.P.	—
Norfloxacin	Acute bacterial enterocolitis Urinary tract infection
Nortriptyline Hydrochloride B.P.	—
Nortriptyline Tablets B.P.	—
"Nutramigen"	In compliance with authority procedures set out in subparagraph 14(d): Allergy to both cows' milk and soy protein in children under the age of 2 years Cystic fibrosis (mucoviscidosis) Galactosaemia Glycogen storage disease due to glucose-6-phosphatase deficiency in children under the age of 2 years Homocystinuria Lactose intolerance
Nystatin B.P.	—
Nystatin Mixture B.P.	—
Nystatin Ointment B.P.	—
Nystatin Pessaries B.P.	—

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Nystatin Tablets B.P.	—
"Odorgon"	Ileostomy or colostomy conditions
Oestradiol Valerate	—
Oestriol	—
Oestrogens—Conjugated	—
Oestrone B.P.C. 1954	—
Olsalazine Sodium	In compliance with authority procedures set out in sub-paragraph 14(d): Inflammatory bowel disease involving the colon in patients with proven hypersensitivity to sulphonamides or sustained intolerance to sulphasalazine
Orphenadrine Hydrochloride Tablets B.P.	Parkinsonism
Oxazepam Tablets B.P.	—
Oxprenolol Hydrochloride B.P.	—
Oxprenolol Tablets B.P.	—
Oxycodone Hydrochloride	Severe disabling pain not responding to non-narcotic analgesics
Oxycodone Pectinate	Severe disabling pain not responding to non-narcotic analgesics
Oxymetholone Tablets B.P.	In compliance with authority procedures set out in sub-paragraph 14(d): Aplastic anaemias, proven Myelosclerosis
Oxytocin Injection B.P.	—
Pancreatin B.P.	Cystic fibrosis (mucoviscidosis) Following pancreatico-duodenectomy Pancreatic steatorrhoea
Pancrelipase	Cystic fibrosis (mucoviscidosis) Following pancreatico-duodenectomy Pancreatic steatorrhoea
Papaveretum B.P.C. 1973	—
Papaveretum B.P.C. 1973 with Hyoscine Hydrobromide B.P.	—
Paracetamol B.P.	—
Paracetamol Tablets B.P.	—
Paraffin, Soft White B.P.	Ileostomy or colostomy conditions
Paraffin, Soft White B.P. with Liquid Paraffin B.P.	—
Penicillamine Tablets B.P.	Acute heavy metal intoxication Cystinosis Cystinuria with calculus formation Haemoglobinuria, paroxysmal cold Severe rheumatoid arthritis Wilson's disease (hepatolenticular degeneration)
Perhexiline Maleate	In compliance with authority procedures set out in sub-paragraph 14(d): Angina not responding to other therapy
Pericyazine	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years
Pethidine Injection B.P.	—
Pethidine Tablets B.P.	In compliance with authority procedures set out in sub-paragraph 14(d): Disabling pain associated with proven malignant neoplasia
Phenelzine Tablets B.P.	Depressive illness resistant to treatment with either tricyclic antidepressants or electroconvulsive therapy Phobic states

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Phenethicillin Capsules B.P.	—
Phenethicillin Potassium B.P. with Purified Water B.P.	—
Phenethicillin Tablets B.P.	—
Phenindione Tablets B.P.	Patients stabilised on phenindione for more than 6 months
Phenobarbitone Injection B.P.	Epilepsy
Phenobarbitone Tablets B.P.	Epilepsy
Phenoxybenzamine Capsules B.P.	In compliance with authority procedures set out in subparagraph 14(d): Neurogenic urinary retention Phaeochromocytoma
Phenoxymethylpenicillin (Benzathine Salt)	—
Phenoxymethylpenicillin (Hydrabamine Salt)	—
Phenoxymethylpenicillin Potassium Capsules B.P.	—
Phenoxymethylpenicillin Potassium Tablets B.P.	—
Phensuximide B.P.C. 1973	In compliance with authority procedures set out in subparagraph 14(d): Treatment where less costly alternative therapy is inappropriate
Phenylephrine Hydrochloride B.P.	—
Phenytoin B.P.	—
Phenytoin Capsules B.P.	—
Phenytoin Mixture B.P.	—
Phytomenadione Injection B.P.	—
Pilocarpine	In compliance with authority procedures set out in subparagraph 14(d): Chronic glaucoma when other miotics are not tolerated
Pilocarpine Hydrochloride B.P.	—
Pindolol B.P.	—
Pindolol Tablets B.P.	—
Piperazine Oestrone Sulphate	—
Piroxicam	—
Pizotifen Malate	—
"PK AID I"	Phenylketonuria
"PK AID II"	Phenylketonuria
Pneumococcal Vaccine, Polyvalent	Splenectomised persons over the age of 2 years Persons with Hodgkin's disease Persons at high risk of pneumococcal infections
Polygeline	—
Polyisobutylene	Ileostomy or colostomy conditions
Polymyxin B Sulphate B.P. with Bacitracin B.P. 1968 and Neomycin Sulphate B.P.	—
Polymyxin B Sulphate B.P. with Bacitracin Zinc B.P. and Neomycin Sulphate B.P.	—
Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Gramicidin	—
Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Hydrocortisone B.P.	—
Polyvinyl Alcohol	—
Polyvinyl Alcohol with Povidone B.P.	—
Polyvinylpyrrolidone and Vinyl Acetate Copolymer	Ileostomy or colostomy conditions
"Portagen"	In compliance with authority procedures set out in subparagraph 14(d): Chyloascites Chylothorax Patients requiring a ketogenic diet for intractable childhood epilepsy Proven malabsorption
Potassium Chloride B.P.	—
Potassium Chloride B.P. with Potassium Bicarbonate Effervescent Tablets	—
Pralidoxime Iodide	—
Prazosin Hydrochloride	—

Column 1	*Column 2*
Pharmaceutical benefit	*Circumstances (if any) specified for the purposes of section 88A of the Act*
Prednisolone Acetate	In respect of the injection: For local intra-articular or peri-articular infiltration In respect of the eye drops: —
Prednisolone Acetate with Phenylephrine Hydrochloride B.P.	Corneal grafts Uveitis
Prednisolone Sodium Phosphate B.P.	In respect of the retention enema: In compliance with authority procedures set out in subparagraph 14(d): Treatment where less costly alternative therapy is inappropriate for: Proctitis Ulcerative colitis In respect of the suppositories: Proctitis Ulcerative colitis In respect of the eye/ear drops: —
Prednisolone Stearoylglycolate	—
Prednisolone Tablets B.P.	—
Prednisone Tablets B.P.	—
"Pregestimil"	In compliance with authority procedures set out in subparagraph 14(d): Biliary atresia Chyloascites Chylothorax Cystic fibrosis Enterokinase deficiency Intolerance to both milk protein and soya protein Severe diarrhoea of greater than two weeks duration in infants under the age of 4 months
Primaquine Tablets B.P.	—
Primidone Tablets B.P.	—
Probenecid Tablets B.P.	—
Probucol	In compliance with authority procedures set out in subparagraph 14(d): Familial hypercholesterolaemia inadequately responsive to diet and a cholesterol lowering resin
Procainamide Hydrochloride B.P.	—
Procainamide Injection B.P.	—
Procaine Penicillin Injection B.P.	—
Procarbazine Hydrochloride	—
Prochlorperazine	—
Prochlorperazine Edisylate	—
Prochlorperazine Injection B.P.	—
Prochlorperazine Tablets B.P.	—
Procyclidine Tablets B.P.	—
Promethazine Hydrochloride Injection B.P.	—
Promethazine Theoclate Tablets B.P.	—
Propantheline Tablets B.P.	Chronic neurogenic incontinence of urine
Propranolol Injection B.P.	—
Propranolol Tablets B.P.	—
Propylthiouracil Tablets B.P.	—
Protamine Sulphate Injection B.P.	—
Pyrantel Embonate	—
Pyridostigmine Tablets B.P.	—
Pyridoxine Hydrochloride B.P.	—
Pyridoxine Hydrochloride Tablets B.P.	Anaemia proved to be responsive to pyridoxine Convulsions responsive to pyridoxine Homocystinuria Primary hyperoxaluria Radiation sickness Sideroblastic (refractory) anaemia Treatment and prophylaxis of peripheral neuritis caused or likely to be caused by isoniazid therapy

Column 1 Pharmaceutical benefit	Column 2 Circumstances (if any) specified for the purposes of section 88A of the Act
Pyrimethamine Tablets B.P.	—
Quinethazone	—
Quinidine Bisulphate B.P.	—
Quinidine Sulphate B.P.	—
Quinidine Sulphate Tablets B.P.	—
Quinine Bisulphate Tablets B.P.	—
Quinine Sulphate Tablets B.P.	—
Ranitidine Hydrochloride	In respect of the tablet, 150 mg (base): In compliance with authority procedures set out in sub-paragraph 14(d): Duodenal ulcer (including pyloric and stomal ulcers), proven by current or prior x-ray, endoscopy or surgery Gastric ulcer, proven by x-ray, endoscopy or surgery within the previous 2 years Scleroderma oesophagus Severe ulcerating (erosive) oesophagitis, proven by endoscopy and unresponsive to other measures Zollinger-Ellison syndrome In respect of the tablet, 300 mg (base): In compliance with authority procedures set out in sub-paragraph 14(d): Duodenal ulcer (including pyloric and stomal ulcers), proven by current or prior x-ray, endoscopy or surgery Gastric ulcer, proven by x-ray, endoscopy or surgery within the previous 2 years Zollinger-Ellison syndrome
Red-back Spider Antivenom	—
Rifampicin B.P.	Prophylactic treatment of contacts of patients with Haemophilus influenzae type B Prophylaxis of meningococcal disease in close contacts and carriers In compliance with authority procedures set out in sub-paragraph 14(d): Leprosy in adults
Rolitetracycline	—
Salbutamol B.P.	—
Salbutamol Sulphate B.P.	—
Salbutamol Tablets B.P.	—
Salcatonin Injection B.P.	In compliance with authority procedures set out in sub-paragraph 14(d): Proven active Paget's disease of bone causing pain or disability Treatment initiated in a hospital (in-patient or out-patient) of hypercalcaemia For the continuation of treatment of patients already established on calcitonin under arrangements provided for by section 100 of the Act
Semisodium Valproate	—
Silver Sulphadiazine with Chlorhexidine Gluconate	In respect of the cream, 10 mg-2 mg per g, 50 g and the cream, 10 mg-2 mg per g, 100 g: For the prevention and treatment of infection in partial or full skin thickness loss due to burns or epidermolysis bullosa Stasis ulcers In respect of the cream, 10 mg-2 mg per g, 500 g: In compliance with authority procedures set out in sub-paragraph 14(d): Treatment, in a hospital, of burns
Sodium Acid Citrate B.P.	—
Sodium Acid Phosphate B.P.	In compliance with authority procedures set out in sub-paragraph 14(d): Familial hypophosphataemia Hypercalcaemia Hypophosphataemic rickets Vitamin D-resistant rickets
Sodium Aurothiomalate Injection B.P.	—

Column 1 Pharmaceutical benefit	Column 2 Circumstances (if any) specified for the purposes of section 88A of the Act
Sodium Bicarbonate Intravenous Infusion B.P.	—
Sodium Cellulose Phosphate	In compliance with authority procedures set out in sub-paragraph 14 (d): Treatment of recurrent renal calculi in patients with urine calcium in excess of 8 millimoles per 24 hours who are unresponsive to dietary measures and thiazides
Sodium Chloride and Glucose Intravenous Infusion B.P.	—
Sodium Chloride B.P. with Potassium Chloride B.P. and Calcium Chloride B.P. in Water for Injections	—
Sodium Chloride B.P. with Sodium Acetate B.P., Sodium Gluconate, Potassium Chloride B.P. and Magnesium Chloride B.P.	—
Sodium Chloride Intravenous Infusion B.P.	—
Sodium Citro-Tartrate	—
Sodium Cromoglycate B.P.	In respect of the eye drops: In compliance with authority procedures set out in sub-paragraph 14(d): Vernal kerato-conjunctivitis In respect of the nebuliser solution: Use in a power-operated nebuliser for prophylaxis of asthma in persons who are unable to use the capsule or metered aerosol spray for oral inhalation In respect of the metered aerosol spray: —
Sodium Cromoglycate Insufflation B.P.	—
Sodium Fusidate B.P.	In compliance with authority procedures set out in sub-paragraph 14(d): Treatment where less costly alternative therapy is inappropriate, when used in combination with another antibiotic in the treatment of proven serious staphylococcal infections
Sodium Lactate Compound Intravenous Infusion B.P.	—
Sodium Lactate Compound Intravenous Infusion B.P. with Anhydrous Glucose B.P.	—
Sodium Nitroprusside B.P.	—
Sodium Valproate B.P.	—
Sodium Valproate Elixir B.P.	—
Sotalol Hydrochloride	In compliance with authority procedures set out in sub-paragraph 14(d): For the continuing treatment of severe refractory cardiac arrhythmias where treatment with sotalol hydrochloride was initiated in a hospital (in-patient or out-patient)
Spectinomycin Hydrochloride B.P.	—
Spironolactone Tablets B.P.	Female hirsutism Hyperaldosteronism
Staphylococcus Toxoid B.P. 1968	—
Sterculia B.P.	Ileostomy or colostomy conditions
Sterculia B.P. with Frangula Bark B.P.	Any disease or condition in a paraplegic or quadriplegic patient For use by patients who are receiving long-term extensive nursing care in hospitals or nursing homes For use by patients for whose care a Commonwealth Domiciliary Nursing Care Benefit is approved
Streptokinase B.P.	—
Sucralfate	—
Sulindac Tablets B.P.	—
Sulphacetamide Sodium B.P.	—
Sulphafurazole B.P.	—
Sulphamethizole Tablets B.P.	—
Sulphasalazine	Crohn's disease Rheumatoid arthritis Ulcerative colitis

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Sulphinpyrazone Tablets B.P.	Glomerulonephritis Gout Renal transplantation
Sulthiame Tablets B.P.	—
"Super Banish"	Ileostomy or colostomy conditions
Surgical Cement	Any disease or condition in a paraplegic or quadriplegic patient For use with surgical appliances Ileostomy or colostomy conditions
Surgical Cement Solvent	Any disease or condition in a paraplegic or quadriplegic patient For use with surgical appliances Ileostomy or colostomy conditions
Tamoxifen Citrate Tablets B.P.	Breast cancer in post-menopausal women with positive hormone receptor levels and local lymph node involvement with or without other evidence of metastases Recurrent or metastatic breast cancer
Temazepam	—
Terbutaline Sulphate B.P.	—
Terbutaline Sulphate Tablets B.P.	—
Testosterone Enanthate B.P.	Hypogonadism Klinefelter's syndrome (seminiferous tubule dysgenesis)
Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P. and Testosterone Isocaproate B.P.	Gigantism Hypogonadism Klinefelter's syndrome (seminiferous tubule dysgenesis)
Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P., Testosterone Isocaproate B.P. and Testosterone Decanoate B.P.	Gigantism Hypogonadism Klinefelter's syndrome (seminiferous tubule dysgenesis)
Testosterone Propionate Injection B.P.	Hypogonadism Klinefelter's syndrome (seminiferous tubule dysgenesis)
Tetanus Vaccine, Adsorbed B.P.	—
Tetrabenazine	Chorea not adequately controlled by other drug therapy
Tetracosactrin Zinc Injection B.P.	In compliance with authority procedures set out in subparagraph 14(d): Hypsarrhythmia Multiple sclerosis, acute exacerbation Treatment of children who need long-term corticosteroid therapy but who are in danger of growth suppression as a result Treatment of patients who are being withdrawn from long-term corticosteroid therapy Ulcerative colitis, proven, not responding to parenteral corticosteroids
Tetracycline B.P. with a buffering agent	—
Tetracycline B.P. with a buffering agent and Nystatin B.P.	—
Tetracycline Capsules B.P.	—
Tetracycline Hydrochloride B.P.	—
Tetracycline Hydrochloride B.P. with Nystatin B.P.	—
Theophylline B.P.	—
Thiabendazole Tablets B.P.	—
Thiamine Hydrochloride Injection B.P.	—
Thiamine Hydrochloride Tablets B.P.	—
Thiethylperazine Malate	—
Thiethylperazine Maleate	—
Thioguanine Tablets B.P.	—
Thiopropazate Hydrochloride Tablets B.P.	Chorea
Thioridazine Hydrochloride B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
	Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years
Thioridazine Tablets B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years
Thiotepa B.P.	—
Thyroxine Tablets B.P.	—
Ticarcillin Sodium	In compliance with authority procedures set out in subparagraph 14(d): Treatment where less costly alternative therapy is inappropriate for: Infections where positive bacteriological evidence confirms that ticarcillin sodium is an appropriate therapeutic agent Septicaemia, suspected or proven
Timolol Maleate Eye Drops B.P.	—
Timolol Maleate Tablets B.P.	—
Tinidazole	—
Tobramycin B.P.	Invasive ocular infection Perioperative use Suspected pseudomonal eye infection
Tobramycin Injection B.P.	In compliance with authority procedures set out in subparagraph 14(d): Treatment where less costly alternative therapy is inappropriate for: Infections where positive bacteriological evidence confirms that tobramycin is an appropriate antibiotic Septicaemia, suspected or proven
Tolazamide Tablets B.P.	—
Tolbutamide Tablets B.P.	—
Tranexamic Acid Tablets B.P.	Hereditary angio-oedema
Tranylcypromine Tablets B.P.	Depressive illness resistant to treatment with either tricyclic antidepressants or electroconvulsive therapy Phobic states
Triamcinolone Acetonide B.P.	Alopecia areata For local intra-articular or peri-articular infiltration Granulomata, dermal Keloid Lichen planus hypertrophic Lichen simplex chronicus Lupus erythematosus, chronic discoid Necrobiosis lipoidica Psoriasis
Triamcinolone Acetonide B.P. with Neomycin Sulphate B.P., Gramicidin and Nystatin B.P.	—
Triamcinolone Acetonide Cream B.P.	—
Triamcinolone Acetonide Ointment B.P.	—
Triamterene B.P.	—
Trifluoperazine Hydrochloride B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
	Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years
Trifluoperazine Hydrochloride Tablets B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years
Triglycerides Oil, Medium Chain	In compliance with authority procedures set out in subparagraph 14(d): Abetalipoproteinaemia Chyloascites Chylothorax Intestinal lymphangiectasia Intractable childhood epilepsy requiring a ketogenic diet Short-term nutritional support in severe steatorrhoea Steatorrhoea due to distal small bowel resection
Trimethoprim Tablets B.P.	—
Trimipramine	—
Trimipramine Tablets B.P.	—
Trioxysalen	Vitiligo
Urea Cream B.P.	—
Vancomycin Hydrochloride B.P.	In respect of the capsules: In compliance with authority procedures set out in subparagraph 14(d): Treatment where less costly alternative therapy is inappropriate for antibiotic associated colitis In respect of the injection: In compliance with authority procedures set out in subparagraph 14(d): Treatment where less costly alternative therapy is inappropriate for: Any disease or condition in a patient receiving treatment in a hospital Endophthalmitis
Vasopressin Tannate	—
Verapamil Hydrochloride B.P.	—
Verapamil Hydrochloride Injection B.P.	—
Verapamil Hydrochloride Tablets B.P.	—
Vidarabine	Eye infections caused by herpes simplex virus
Vinblastine Sulphate B.P.	—
Vincristine Sulphate B.P.	—
Warfarin Tablets B.P.	—
Water for Injections B.P.	—
Wool Alcohols Ointment B.P.	—
Zinc Oxide B.P.	—
Zinc Sulphate B.P. with Phenylephrine Hydrochloride B.P.	—

SCHEDULE 2

Allowable compounds of ready-prepared pharmaceutical benefits

Column 1 *Pharmaceutical benefit*	*Column 2* *Allowable compounds*
Aluminium Hydroxide, Dried B.P.	Aluminium Hydroxide, Dried B.P. with Magnesium Hydroxide B.P. Aluminium Hydroxide, Dried B.P. with Magnesium Hydroxide B.P. and Magnesium Trisilicate B.P.
Aluminium Hydroxide Mixture B.P.	Aluminium Hydroxide Mixture B.P. with Light Kaolin B.P. or Light Kaolin (Natural) B.P. Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P. Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P. and Oxethazaine
Amiloride Hydrochloride B.P.	Hydrochlorothiazide B.P. with Amiloride Hydrochloride B.P.
Amoxycillin Trihydrate B.P.	Amoxycillin Trihydrate B.P. with Potassium Clavulanate Amoxycillin Trihydrate B.P. with Potassium Clavulanate and Purified Water B.P. Amoxycillin Trihydrate B.P. with Purified Water B.P.
Ampicillin Trihydrate B.P.	Ampicillin Trihydrate B.P. with Purified Water B.P.
Antazoline Phosphate	Antazoline Phosphate with Naphazoline Hydrochloride
Antazoline Sulphate	Antazoline Sulphate with Naphazoline Nitrate B.P.
Aspirin B.P.	Codeine Phosphate B.P. with Aspirin B.P.
Atropine Sulphate B.P.	Difenoxin Hydrochloride with Atropine Sulphate B.P. Diphenoxylate Hydrochloride B.P. with Atropine Sulphate B.P. Hyoscyamine Hydrobromide with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P. Hyoscyamine Sulphate B.P. with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P.
Bacitracin B.P. 1968	Polymyxin B Sulphate B.P. with Bacitracin B.P. 1968 and Neomycin Sulphate B.P.
Bacitracin Zinc B.P.	Neomycin Undecenoate with Bacitracin Zinc B.P. Polymyxin B Sulphate B.P. with Bacitracin Zinc B.P. and Neomycin Sulphate B.P.
Benserazide	Levodopa B.P. with Benserazide
Benzathine Penicillin B.P.	Benzathine Penicillin B.P. with Procaine Penicillin B.P., Benzylpenicillin Potassium B.P. and Water for Injections
Benzylpenicillin Potassium B.P.	Benzathine Penicillin B.P. with Procaine Penicillin B.P., Benzylpenicillin Potassium B.P. and Water for Injections
Betamethasone Acetate	Betamethasone Acetate with Betamethasone Sodium Phosphate B.P.
Betamethasone Sodium Phosphate B.P.	Betamethasone Acetate with Betamethasone Sodium Phosphate B.P.
Bisacodyl B.P.	Docusate Sodium B.P. with Bisacodyl B.P.
Butyl Monoester Polymer	Butyl Monoester Polymer with Ethanol B.P. Butyl Monoester Polymer with Isopropyl Alcohol B.P.
Caffeine B.P.	Ergotamine Tartrate B.P. with Caffeine B.P.
Calcium Carbonate B.P.	Calcium Carbonate B.P. with Calcium Lactate-Gluconate
Calcium Chloride B.P.	Sodium Chloride B.P. with Potassium Chloride B.P. and Calcium Chloride B.P. in Water for Injections
Calcium Lactate-Gluconate	Calcium Carbonate B.P. with Calcium Lactate-Gluconate
Carmellose Sodium B.P.	Carmellose Sodium B.P. with Pectin and Gelatin B.P.
Cefaclor Monohydrate	Cefaclor Monohydrate with Purified Water B.P.
Cephalexin B.P.	Cephalexin B.P. with Purified Water B.P.
Chloramphenicol B.P.	Chloramphenicol B.P. with Polymyxin B Sulphate B.P.
Chlorhexidine Gluconate	Silver Sulphadiazine with Chlorhexidine Gluconate
Citric Acid B.P.	Glucose, Anhydrous B.P., Sodium Chloride B.P., Potassium Chloride B.P., Citric Acid B.P. and Sodium Citrate B.P.
Clindamycin Palmitate Hydrochloride	Clindamycin Palmitate Hydrochloride with Purified Water B.P.
Codeine Phosphate B.P.	Codeine Phosphate B.P. with Aspirin B.P. Codeine Phosphate B.P. with Paracetamol B.P.
Colistin Sulphate B.P.	Colistin Sulphate B.P. with Neomycin Sulphate B.P.
Dexamethasone B.P.	Dexamethasone B.P. with Framycetin Sulphate B.P. and Gramicidin

Column 1 *Pharmaceutical benefit*	*Column 2* *Allowable compounds*
Dexamethasone Sodium Metasulphobenzoate	Dexamethasone Sodium Metasulphobenzoate with Framycetin Sulphate B.P. and Gramicidin
Dextran 40 Intravenous Infusion B.P.	Dextran 40 Intravenous Infusion B.P. with Glucose B.P. Dextran 40 Intravenous Infusion B.P. with Sodium Chloride B.P.
Dextran 70	Hypromellose 4500 B.P. with Dextran 70
Dextran 70 Intravenous Infusion B.P.	Dextran 70 Intravenous Infusion B.P. with Glucose B.P. Dextran 70 Intravenous Infusion B.P. with Sodium Chloride B.P.
Difenoxin Hydrochloride	Difenoxin Hydrochloride with Atropine Sulphate B.P.
Diphenoxylate Hydrochloride B.P.	Diphenoxylate Hydrochloride B.P. with Atropine Sulphate B.P.
Docusate Sodium B.P.	Docusate Sodium B.P. with Bisacodyl B.P.
Ergotamine Tartrate B.P.	Ergotamine Tartrate B.P. with Caffeine B.P.
Erythromycin Ethyl Succinate B.P.	Erythromycin Ethyl Succinate B.P. with Purified Water B.P.
Ethanol B.P.	Butyl Monoester Polymer with Ethanol B.P.
Ethinyloestradiol B.P.	Ethynodiol Diacetate B.P. with Ethinyloestradiol B.P. Levonorgestrel B.P. with Ethinyloestradiol B.P. Norethisterone B.P. with Ethinyloestradiol B.P.
Ethynodiol Diacetate B.P.	Ethynodiol Diacetate B.P. with Ethinyloestradiol B.P.
Ferrous Sulphate, Dried B.P.	Ferrous Sulphate, Dried B.P. with Folic Acid B.P.
Flucloxacillin Magnesium B.P.	Flucloxacillin Magnesium B.P. with Purified Water B.P.
Flumethasone Pivalate	Flumethasone Pivalate with Clioquinol B.P.
Folic Acid B.P.	Ferrous Sulphate, Dried B.P. with Folic Acid B.P.
Framycetin Sulphate B.P.	Dexamethasone B.P. with Framycetin Sulphate B.P. and Gramicidin Dexamethasone Sodium Metasulphobenzoate with Framycetin Sulphate B.P. and Gramicidin
Frangula Bark B.P.	Sterculia B.P. with Frangula Bark B.P.
Gelatin B.P.	Carmellose Sodium B.P. with Pectin and Gelatin B.P.
Glucose B.P.	Dextran 40 Intravenous Infusion B.P. with Glucose B.P. Dextran 70 Intravenous Infusion B.P. with Glucose B.P.
Glucose, Anhydrous B.P.	Glucose, Anhydrous B.P., Sodium Chloride B.P., Potassium Chloride B.P., Citric Acid B.P. and Sodium Citrate B.P. Sodium Lactate Compound Intravenous Infusion B.P. with Anhydrous Glucose B.P.
Gramicidin	Dexamethasone B.P. with Framycetin Sulphate B.P. and Gramicidin Dexamethasone Sodium Metasulphobenzoate with Framycetin Sulphate B.P. and Gramicidin Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Gramicidin Triamcinolone Acetonide B.P. with Neomycin Sulphate B.P., Gramicidin and Nystatin B.P.
Hydrochlorothiazide B.P.	Hydrochlorothiazide B.P. with Amiloride Hydrochloride B.P. Hydrochlorothiazide B.P. with Triamterene B.P.
Hydrocortisone B.P.	Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Hydrocortisone B.P.
Hydrocortisone Acetate B.P.	Hydrocortisone Acetate B.P. with Neomycin Sulphate B.P.
Hyoscine Hydrobromide B.P.	Hyoscyamine Hydrobromide with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P. Hyoscyamine Sulphate B.P. with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P. Papaveretum B.P.C. 1973 with Hyoscine Hydrobromide B.P.
Hyoscyamine Hydrobromide	Hyoscyamine Hydrobromide with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P.
Hyoscyamine Sulphate B.P.	Hyoscyamine Sulphate B.P. with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P.
Hypromellose 4500 B.P.	Hypromellose 4500 B.P. with Dextran 70
Insulin Injection, Isophane B.P.	Insulin Injection, Isophane B.P. and Insulin Injection, Neutral B.P.
Insulin Injection, Neutral B.P.	Insulin Injection, Isophane B.P. and Insulin Injection, Neutral B.P.

Column 1 *Pharmaceutical benefit*	*Column 2* *Allowable compounds*
Insulin Isophane, Human (Synthetic)	Insulin Isophane, Human (Synthetic) and Insulin Neutral, Human (Synthetic)
Insulin Neutral, Human (Synthetic)	Insulin Isophane, Human (Synthetic) and Insulin Neutral, Human (Synthetic)
Isopropyl Alcohol B.P.	Butyl Monoester Polymer with Isopropyl Alcohol B.P. Isopropyl Monoester Polymer with Isopropyl Alcohol B.P.
Isopropyl Monoester Polymer	Isopropyl Monoester Polymer with Isopropyl Alcohol B.P.
Kaolin, Light B.P. or Light Kaolin (Natural) B.P.	Aluminium Hydroxide Mixture B.P. with Light Kaolin B.P. or Light Kaolin (Natural) B.P. Kaolin, Light B.P. or Light Kaolin (Natural) B.P. with Pectin
Lauramine Oxide	Lauramine Oxide with Octoxinol
Levodopa B.P.	Levodopa B.P. with Benserazide
Levonorgestrel B.P.	Levonorgestrel B.P. with Ethinyloestradiol B.P.
Magnesium Chloride B.P.	Sodium Chloride B.P. with Sodium Acetate B.P., Sodium Gluconate, Potassium Chloride B.P. and Magnesium Chloride B.P.
Magnesium Hydroxide B.P.	Aluminium Hydroxide, Dried B.P. with Magnesium Hydroxide B.P. Aluminium Hydroxide, Dried B.P. with Magnesium Trisilicate B.P. and Magnesium Hydroxide B.P. Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P. Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P. and Oxethazaine
Magnesium Trisilicate B.P.	Aluminium Hydroxide, Dried B.P. with Magnesium Trisilicate B.P. and Magnesium Hydroxide B.P.
Mestranol B.P.	Norethisterone B.P. with Mestranol B.P.
Morphine Sulphate B.P.	Morphine Sulphate B.P. with Tacrine Hydrochloride B.P.
Naphazoline Hydrochloride	Antazoline Phosphate with Naphazoline Hydrochloride
Naphazoline Nitrate B.P.	Antazoline Sulphate with Naphazoline Nitrate B.P.
Neomycin Sulphate B.P.	Colistin Sulphate B.P. with Neomycin Sulphate B.P. Hydrocortisone Acetate B.P. with Neomycin Sulphate B.P. Polymyxin B Sulphate B.P. with Bacitracin B.P. 1968 and Neomycin Sulphate B.P. Polymyxin B Sulphate B.P. with Bacitracin Zinc B.P. and Neomycin Sulphate B.P. Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Gramicidin Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Hydrocortisone B.P. Triamcinolone Acetonide B.P. with Neomycin Sulphate B.P., Gramicidin and Nystatin B.P.
Neomycin Undecenoate	Neomycin Undecenoate with Bacitracin Zinc B.P.
Norethisterone B.P.	Norethisterone B.P. with Ethinyloestradiol B.P. Norethisterone B.P. with Mestranol B.P.
Nystatin B.P.	Tetracycline B.P. with a buffering agent and Nystatin B.P. Tetracycline Hydrochloride B.P. with Nystatin B.P. Triamcinolone Acetonide B.P. with Neomycin Sulphate B.P., Gramicidin and Nystatin B.P.
Octoxinol	Lauramine Oxide with Octoxinol
Oxethazaine	Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P. and Oxethazaine
Papaveretum B.P.C. 1973	Papaveretum B.P.C. 1973 with Hyoscine Hydrobromide B.P.
Paracetamol B.P.	Codeine Phosphate B.P. with Paracetamol B.P.
Paraffin, Liquid B.P.	Paraffin, Soft White B.P. with Liquid Paraffin B.P.
Paraffin, Soft White B.P.	Paraffin, Soft White B.P. with Liquid Paraffin B.P.
Pectin	Carmellose Sodium B.P. with Pectin and Gelatin B.P. Kaolin, Light B.P. or Light Kaolin (Natural) B.P. with Pectin
Phenethicillin Potassium B.P.	Phenethicillin Potassium B.P. with Purified Water B.P.
Phenylephrine Hydrochloride B.P.	Prednisolone Acetate with Phenylephrine Hydrochloride B.P. Zinc Sulphate B.P. with Phenylephrine Hydrochloride B.P.

Column 1 *Pharmaceutical benefit*	*Column 2* *Allowable compounds*
Polymyxin B Sulphate B.P.	Chloramphenicol B.P. with Polymyxin B Sulphate B.P. Polymyxin B Sulphate B.P. with Bacitracin B.P. 1968 and Neomycin Sulphate B.P. Polymyxin B Sulphate B.P. with Bacitracin Zinc B.P. and Neomycin Sulphate B.P. Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Gramicidin Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Hydrocortisone B.P.
Polyvinyl Alcohol	Polyvinyl Alcohol with Povidone B.P.
Potassium Chloride B.P.	Glucose, Anhydrous B.P., Sodium Chloride B.P., Potassium Chloride B.P., Citric Acid B.P. and Sodium Citrate B.P. Sodium Chloride B.P. with Potassium Chloride B.P. and Calcium Chloride B.P. in Water for Injections Sodium Chloride B.P. with Sodium Acetate B.P., Sodium Gluconate, Potassium Chloride B.P. and Magnesium Chloride B.P.
Potassium Clavulanate	Amoxycillin Trihydrate B.P. with Potassium Clavulanate Amoxycillin Trihydrate B.P. with Potassium Clavulanate and Purified Water B.P.
Povidone B.P.	Polyvinyl Alcohol with Povidone B.P.
Prednisolone Acetate	Prednisolone Acetate with Phenylephrine Hydrochloride B.P.
Procaine Penicillin B.P.	Benzathine Penicillin B.P. with Procaine Penicillin B.P., Benzylpenicillin Potassium B.P. and Water for Injections
Silver Sulphadiazine	Silver Sulphadiazine with Chlorhexidine Gluconate
Sodium Acetate B.P.	Sodium Chloride B.P. with Sodium Acetate B.P., Sodium Gluconate, Potassium Chloride B.P. and Magnesium Chloride B.P.
Sodium Chloride B.P.	Dextran 40 Intravenous Infusion B.P. with Sodium Chloride B.P. Dextran 70 Intravenous Infusion B.P. with Sodium Chloride B.P. Glucose, Anhydrous B.P., Sodium Chloride B.P., Potassium Chloride B.P., Citric Acid B.P. and Sodium Citrate B.P. Sodium Chloride B.P. with Potassium Chloride B.P. and Calcium Chloride B.P. in Water for Injections Sodium Chloride B.P. with Sodium Acetate B.P., Sodium Gluconate, Potassium Chloride B.P. and Magnesium Chloride B.P.
Sodium Citrate B.P.	Glucose, Anhydrous B.P., Sodium Chloride B.P., Potassium Chloride B.P., Citric Acid B.P. and Sodium Citrate B.P.
Sodium Gluconate	Sodium Chloride B.P. with Sodium Acetate B.P., Sodium Gluconate, Potassium Chloride B.P. and Magnesium Chloride B.P.
Sodium Lactate Compound Intravenous Infusion B.P.	Sodium Lactate Compound Intravenous Infusion B.P. with Anhydrous Glucose B.P.
Sterculia B.P.	Sterculia B.P. with Frangula Bark B.P.
Tacrine Hydrochloride	Morphine Sulphate B.P. with Tacrine Hydrochloride
Testosterone Decanoate B.P.	Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P., Testosterone Isocaproate B.P. and Testosterone Decanoate B.P.
Testosterone Isocaproate B.P.	Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P. and Testosterone Isocaproate B.P. Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P., Testosterone Isocaproate B.P. and Testosterone Decanoate B.P.
Testosterone Phenylpropionate B.P.	Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P. and Testosterone Isocaproate B.P. Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P., Testosterone Isocaproate B.P. and Testosterone Decanoate B.P.
Testosterone Propionate B.P.	Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P. and Testosterone Isocaproate B.P. Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P., Testosterone Isocaproate B.P. and Testosterone Decanoate B.P.

Column 1 *Pharmaceutical benefit*	*Column 2* *Allowable compounds*
Tetracycline B.P.	Tetracycline B.P. with a buffering agent Tetracycline B.P. with a buffering agent and Nystatin B.P.
Tetracycline Hydrochloride B.P.	Tetracycline Hydrochloride B.P. with Nystatin B.P.
Triamcinolone Acetonide B.P.	Triamcinolone Acetonide B.P. with Neomycin Sulphate B.P., Gramicidin and Nystatin B.P.
Triamterene B.P.	Hydrochlorothiazide B.P. with Triamterene B.P.
Water, Purified B.P.	Amoxycillin Trihydrate B.P. with Potassium Clavulanate and Purified Water B.P. Amoxycillin Trihydrate B.P. with Purified Water B.P. Ampicillin Trihydrate B.P. with Purified Water B.P. Cefaclor Monohydrate with Purified Water B.P. Cephalexin B.P. with Purified Water B.P. Clindamycin Palmitate Hydrochloride with Purified Water B.P. Erythromycin Ethyl Succinate B.P. with Purified Water B.P. Flucloxacillin Magnesium B.P. with Purified Water B.P. Phenethicillin Potassium B.P. with Purified Water B.P.
Zinc Sulphate B.P.	Zinc Sulphate B.P. with Phenylephrine Hydrochloride B.P.

SCHEDULE 3

Drugs or medicinal preparations which may be used as ingredients of extemporaneously-prepared pharmaceutical benefits

Column 1	*Column 2*
Pharmaceutical benefit	*Circumstances (if any) specified for the purposes of section 88A of the Act*
Acacia B.P.	—
Acetic Acid (33 per cent) B.P.	—
Acriflavine B.P.C. 1963	—
Adrenaline B.P.	May only be prescribed in eye drops
Alum B.P.	—
Aluminium Acetate Solution B.P.	—
Aminophylline B.P.	—
Ammonia Spirit, Aromatic B.P.	—
Ammoniated Mercury B.P. 1973	—
Ascorbic Acid B.P.	Use as ingredient of Ferrous Sulphate Mixture A.P.F. and Ferrous Sulphate Mixture C.F. A.P.F. 13
Aspirin B.P.	—
Atropine Sulphate B.P.	—
Beeswax, White B.P.	—
Belladonna Tincture B.P.	—
Bentonite B.P.	—
Benzocaine B.P.	—
Benzoic Acid B.P.	—
Benzoin Tincture, Compound B.P.	—
Cade Oil B.P.C. 1973	—
Calamine B.P.	—
Calcium Hydroxide B.P.	—
Camphor Spirit, Compound A.P.F.	—
Cetomacrogol Emulsifying Wax B.P.	—
Cetostearyl Alcohol B.P.	—
Cetrimide B.P.	—
Chlorbutol B.P.	—
Chlorinated Lime B.P.	—
Chlorocresol B.P.	—
Citric Acid Monohydrate B.P.	—
Clioquinol B.P.	—
Coal Tar B.P.	—
Coal Tar, Prepared B.P. 1973	—
Coal Tar Solution B.P.	—
Cocaine Hydrochloride B.P.	—
Coconut Oil B.P.	—
Codeine Phosphate B.P.	—
Collodion, Flexible B.P.	—
Crystal Violet B.P.	—
Dithranol B.P.	—
Emulsifying Wax B.P.	—
Ephedrine Hydrochloride B.P.	May only be prescribed in nasal instillations
Ferrous Sulphate B.P.	—
Ferrous Sulphate, Dried B.P.	—
Formaldehyde Solution B.P.	—
Gentian Infusion, Compound, Concentrated B.P.	—
Glycerol B.P.	—
Hydrochloric Acid B.P.	—
Hyoscyamus Liquid Extract B.P.C. 1973	—
Ichthammol B.P.	—
Iodine B.P.	—
Ipecacuanha Tincture B.P.	—
Kaolin, Light B.P.	—
Kaolin, Light (Natural) B.P.	—
Lactic Acid B.P.	—

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Lactose B.P.	—
Lavender Oil, Spike B.P.C. 1968	—
Lemon Spirit B.P.	—
Lignocaine Hydrochloride B.P.	—
Liquorice Liquid Extract B.P.	—
Lobelia Tincture, Ethereal B.P.C. 1973	—
Magnesium Carbonate, Light B.P.	—
Magnesium Sulphate B.P.	May only be prescribed for other than oral use
Magnesium Trisilicate B.P.	—
Menthol B.P.	—
Methyl Salicylate B.P.	—
Methyl Salicylate Ointment, Compound A.P.F. 1934	—
Morphine Hydrochloride B.P.	—
Oily Cream A.P.F.	—
Oleic Acid B.P.	—
Opium Tincture B.P.	—
Orange Tincture B.P.	—
Paraffin, Hard B.P.	—
Paraffin, Light Liquid B.P.	—
Paraffin, Liquid B.P.	May only be prescribed for other than oral use
Paraffin, Soft White B.P.	—
Paraffin, Soft Yellow B.P.	—
Phenobarbitone B.P.	May only be prescribed for the treatment of epilepsy
Phenobarbitone Sodium B.P.	May only be prescribed for the treatment of epilepsy
Phenol B.P.	May not be prescribed in ear drops
Phenoxyethanol B.P.	—
Pilocarpine Hydrochloride B.P.	—
Pilocarpine Nitrate B.P.	—
Podophyllum Resin B.P.	—
Potassium Citrate B.P.	—
Potassium Iodide B.P.	—
Potassium Permanganate B.P.	—
Propylene Glycol B.P.	—
Pumilio Pine Oil B.P.	—
Raspberry Syrup B.P.	—
Red Syrup A.P.F.	—
Resorcinol B.P.	—
Salicylic Acid B.P.	—
Siberian Fir Oil B.P.C. 1949	—
Silver Nitrate B.P.	—
Soap, Soft B.P.	—
Sodium Acid Phosphate B.P.	—
Sodium Bicarbonate B.P.	—
Sodium Chloride B.P.	—
Sodium Citrate B.P.	—
Sodium Phosphate B.P.	—
Starch B.P.	—
Stramonium Tincture B.P.	—
Sulphur, Precipitated B.P.	—
Sulphurated Potash B.P.C. 1973	—
Syrup B.P.	—
Talc, Purified B.P., sterilised	—
Testosterone B.P.	May only be prescribed in creams
Theophylline B.P.	—
Thymol B.P.	—
Thymol Mouth Wash, Compound A.P.F.	—
Titanium Dioxide B.P.	—

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Tolu Syrup B.P.	—
Tragacanth B.P.	—
Tragacanth Powder, Compound B.P.	—
Trichloroacetic Acid B.P.	—
Triethanolamine B.P.	—
Turpentine Liniment B.P.	—
Water for Injections B.P.	May only be prescribed in eye drops and eye lotions
Water, Purified B.P.	—
Wool Alcohols B.P.	—
Wool Fat B.P.	—
Wool Fat, Hydrous B.P.	—
Zinc Oxide B.P.	—
Zinc Sulphate B.P.	—

SCHEDULE 4

Additives

Acetone B.P.
Anise Water, Concentrated B.P.
Arachis Oil B.P.
Borax B.P.
Boric Acid B.P.
Castor Oil B.P.
Chlorhexidine Acetate B.P.
Chlorhexidine Gluconate Solution B.P.
Chloroform B.P.
Ethanol (96 per cent) B.P.
Ethanols, Dilute B.P.
Ether, Solvent B.P.
Eucalyptus Oil B.P.
Glucose for Oral Use B.P.
Honey, Purified B.P.
Industrial Methylated Spirit B.P.
Olive Oil B.P. 1973
Peppermint Oil B.P.
Peppermint Water, Concentrated A.P.F.
Pholcodine Citrate Syrup B.P.C. 1959
Sodium Thiosulphate B.P.
Turpentine Oil B.P.

SCHEDULE 5

Additional pharmaceutical benefits made available under arrangements provided for by section 100 of the Act

Anti-Haemophilic Factor of Animal Origin
Carmellose Sodium B.P.
Methadone Hydrochloride B.P.
Somatrem

Dated this 16th day of March 1989.

IAN MCNEIL
First Assistant Secretary
Health Benefits Division
Delegate of the Minister of State for Community Services and Health

N.N.—8852514

Defence

Naval Defence Act 1910

TERMINATION OF APPOINTMENT

In pursuance of subsection 12 (1) of the *Naval Defence Act 1910* and Regulation 40C of the Naval Forces Regulations, Lieutenant Michael Alphonsus Hayes appointment is terminated with effect 23 March 1989.

R. KELLY
Minister of State for Defence
Science and Personnel

N.N.—8926873

Naval Defence Act 1910

COMMISSIONS

In pursuance of section 8 (1) of the *Naval Defence Act 1910*, Commissions are issued to the officers nominated in the Schedule attached.

KIM BEAZLEY
Minister of State for Defence

N.N.—8926874

SCHEDULE A

Name	*Date of Appointment*
Lex Nankervis	16 January 1984
Mark Kenneth Napier	16 January 1984
Christopher Paul Nelms	1 January 1986
Walter Franz Neulist	15 January 1988
Michael Denis O'Grady	7 January 1985
Stephen John O'Keefe	16 January 1984
Francis Michael Stanislaus Ostrowski	21 March 1988
George Edward Parker	1 February 1988
Ian Gerard Parker	14 February 1986
Gregory Joseph Peek	16 January 1987
William Dawkins Reddin	3 January 1986
Roone Francis Richardson	16 January 1984
Alan William Robertson	15 January 1988
Michael Robert Robertson	16 May 1986
Peter Edwin Robinson	15 January 1988
Elizabeth Ruth Royal	23 January 1987
Gregory John Sammut	16 January 1984
Rohan Andrew Sheid	14 February 1986
Gregory Anthony Scott	16 January 1984
Ashley Morrell Shanks	14 January 1985
Darren John Shirlaw	14 January 1985
Carl Brendan Skipworth	28 February 1986
Lucas Angelo Skoufa	31 August 1984
Barry George Spencer	26 April 1988
Kenneth Lawrence Spicer	1 January 1986
Simon Robert Taylor	13 February 1987
Nigel Aubrey Townsend	16 January 1984
Milton Jay Treeby	16 January 1984
Maria Triantos	13 February 1987
David John Turner	4 January 1985
David Thomas Turner	15 January 1988
Leon Adrian Volz	14 February 1986
Edward George Walsh	28 March 1988
Helen Yvonne Ward	13 February 1987
David Scott Wenzel	1 January 1986
Neil Westphalen	23 January 1987
Ian Stuart Wheeler	6 February 1987
David James White	16 January 1984
David James Wilson	16 January 1984
Anthony James Withers	16 January 1984
John Anthony Wood	13 February 1987
David Anthony Wright	16 January 1984
Paul Gregory Wright	16 January 1984

N.N.—8926875

Naval Defence Act 1910

TERMINATION OF APPOINTMENT

In pursuance of subsection 12 (1) of the *Naval Defence Act 1910* and Regulation 40C of the Naval Forces Regulations Lieutenant Andrew John Frank Aherns appointment is terminated on 30 April 1989.

R. KELLY
Minister of State for Defence
Science and Personnel

N.N.—8926876

Naval Defence Act 1910

TERMINATION OF APPOINTMENT—SUB LIEUTENANT DONALD LAURENCE KERR

In pursuance of subsection 12 (1) of the *Naval Defence Act 1910* and Regulation 40C of the Naval Forces Regulations Sub Lieutenant Donald Laurence Kerrs appointment is terminated on 20 March 1989.

R. KELLY
Minister of State for Defence
Science and Personnel

N.N.—8926877

Industrial Relations

Form R 16

Regulation 23

Industrial Relations Act 1988

AUSTRALIAN INDUSTRIAL RELATIONS COMMISSION

NOTICE OF VARIATION OF COMMON RULE AWARD

In the matter of:

STOREMEN AND PACKERS (OIL AGENTS/CONTRACTORS AWARD 1984

C No 32649 of 1988

Dated this 13th day of May 1985.

And in the matter of the variation of the award.

Notice is hereby given:

(a) That on 28 February 1989, the Commission varied the term [or terms] of the above-mentioned award referred to in the Schedule below

(b) that the variation will be a common rule of the Northern Territory with effect from 28 October 1988 and 24 April 1989; and

(c) that any organisation or person interested and having an objection to the variation binding that person or organisation and wanting to be heard in relation to the abovementioned variation is invited to lodge with the Commission a notice of that objection.

A copy of the award may be inspected at the office of the Australian Industrial Registry at 1 Briggs St, Darwin, free of charge.

SCHEDULE

TERMS TO BE VARIED

Clause No.	*Subject*	*Substance of variation*
PRINT NUMBER S141CR V010 M PRINT H5600		
15	Wage rates	National Wage Case, August 1988
15 (a)	Wage rates	No extra Claims

Dated this 14th day of March 1989.

LYNDALL SOETENS
Deputy Industrial Registrar

N.N.—8926878

Form R 16

Regulation 23

Industrial Relations Act 1988

AUSTRALIAN INDUSTRIAL RELATIONS COMMISSION

NOTICE OF VARIATION OF COMMON RULE AWARD

In the matter of:

NORTHERN TERRITORY MEAT PROCESSING AWARD 1984

C No 22367 of 1988

Dated this 29th day of April 1985.

And in the matter of the variation of the award.

Notice is hereby given:

(a) That on 6 March 1989, the Commission varied the term [or terms] of the above-mentioned award referred to in the Schedule below

(b) that the variation will be a common rule of the Northern Territory with effect from 14 September 1988; and

(c) that any organisation or person interested and having an objection to the variation binding that person or organisation and wanting to be heard in relation to the abovementioned variation is invited to lodge with the Commission a notice of that objection.

A copy of the award may be inspected at the office of the Australian Industrial Registry at 1 Briggs St, Darwin, free of charge.

SCHEDULE

TERMS TO BE VARIED

Clause No.	*Subject*	*Substance of variation*
PRINT NUMBER N041CR V012 M PRINT H6632		
7	Wage rates	National Wage Case, August 1988
8 (e) (i)	Allowances	National Wage Case, August 1988
8 (e) (ii)	Allowances	National Wage Case, August 1988
8 (e) (iii)	Allowances	National Wage Case, August 1988
8 (f)	Allowances	National Wage Case, August 1988
8 (g)	Allowances	National Wage Case, August 1988
15 (b)	Sick leave	National Wage Case, August 1988

Dated this 14th day of March 1989.

LYNDALL SOETENS
Deputy Industrial Registrar

N.N.—8926879

Form R 16

Regulation 23

Industrial Relations Act 1988

AUSTRALIAN INDUSTRIAL RELATIONS COMMISSION

NOTICE OF VARIATION OF COMMON RULE AWARD

In the matter of:

SADDLERY, LEATHER, CANVAS AND PLASTIC MATERIAL WORKERS AWARD 1985

C No 22741 of 1988

Dated this 17th day of December 1985.

And in the matter of the variation of the award.

Notice is hereby given:

(a) That on 23 February 1989, the Commission varied the term [or terms] of the above-mentioned award referred to in the Schedule below

(b) that the variation will be a common rule of the Northern Territory with effect from 20 October 1989 and

(c) that any organisation or person interested and having an objection to the variation binding that person or organisation and wanting to be heard in relation to the abovementioned variation is invited to lodge with the Commission a notice of that objection.

A copy of the award may be inspected at the office of the Australian Industrial Registry at 1 Briggs St, Darwin, free of charge.

SCHEDULE

TERMS TO BE VARIED

Clause No.	*Subject*	*Substance of variation*
PRINT NUMBER S001CR V011 M PRINT H5921		
2	Arrangement	New Clause Title
46A	Adoption leave	New Clause

Dated this 14th day of March 1989.

LYNDALL SOETENS
Deputy Industrial Registrar

N.N.—8926880

Form R16

Regulation 23

Industrial Relations Act 1988

AUSTRALIAN INDUSTRIAL RELATIONS COMMISSION

NOTICE OF VARIATION OF COMMON RULE AWARD

In the matter of:

CLEANING CONTRACTORS (HYGIENE AND POLLUTION CONTROL) INDUSTRY (NORTHERN TERRITORY) AWARD 1986

C No 21901 of 1988

Dated this 12th day of February 1987.

And in the matter of the variation of the award.

Notice is hereby given:

(a) That on 6 March 1989, the Commission varied the term [or terms] of the above-mentioned award referred to in the Schedule below

(b) that the variation will be a common rule of the Northern Territory with effect from 1 October 1988 and 1 April 1989; and

(c) that any organisation or person interested and having an objection to the variation binding that person or organisation and wanting to be heard in relation to the abovementioned variation is invited to lodge with the Commission a notice of that objection.

A copy of the award may be inspected at the office of the Australian Industrial Registry at 1 Briggs St, Darwin, free of charge.

SCHEDULE
TERMS TO BE VARIED

Clause No.	*Subject*	*Substance of variation*
PRINT NUMBER C073CR V007 M PRINT H3606		
9 (a)	Wage rates	National Wage Case, August 1988
9 (b)	Wage rates	National Wage Case, August 1988
10	Wage rates	No Extra Claims

Dated this 14th day of March 1989.

LYNDALL SOETENS
Deputy Industrial Registrar

N.N.—8926881

Form R16
Regulation 23
Industrial Relations Act 1988
AUSTRALIAN INDUSTRIAL RELATIONS COMMISSION
NOTICE OF VARIATION OF COMMON RULE AWARD
In the matter of:
AUTOMOTIVE SERVICES (NORTHERN TERRITORY) CONSOLIDATED AWARD 1980
C No 22386 of 1988
Dated this 19th day of February 1981.
And in the matter of the variation of the award.
Notice is hereby given:

(a) That on 6 March 1989, the Commission varied the term [or terms] of the above-mentioned award referred to in the Schedule below
(b) that the variation will be a common rule of the Northern Territory with effect from 1 October 1988 and 1 April 1989; and
(c) that any organisation or person interested and having an objection to the variation binding that person or organisation and wanting to be heard in relation to the abovementioned variation is invited to lodge with the Commission a notice of that objection.

A copy of the award may be inspected at the office of the Australian Industrial Registry at 1 Briggs St, Darwin, free of charge.

SCHEDULE
TERMS TO BE VARIED

Clause No.	*Subject*	*Substance of variation*
PRINT NUMBER A188CR V038 M PRINT H6643		
8 (a)	Wage rates	National Wage Decision, August 1988
8A	Wage rates	No Extra Claims

Dated this 14th day of March 1989.

LYNDALL SOETENS
Deputy Industrial Registrar

N.N.—8926882

Form R16
Regulations 23
Industrial Relations Act 1988
AUSTRALIAN INDUSTRIAL RELATIONS COMMISSION
NOTICE OF VARIATION OF COMMON RULE AWARD
In the matter of:
MISCELLANEOUS WORKERS (NORTHERN TERRITORY) AWARD 1985
C No 23326 of 1988
Dated this 4th day of October 1985.
And in the matter of the variation of the award.
Notice is hereby given:

(a) That on 6 March 1989, the Commission varied the term [or terms] of the above-mentioned award referred to in the Schedule below
(b) that the variation will be a common rule of the Northern Territory with effect from 1 February 1989; and
(c) that any organisation or person interested and having an objection to the variation binding that person or organisation and wanting to be heard in relation to the abovementioned variation is invited to lodge with the Commission a notice of that objection.

A copy of the award may be inspected at the office of the Australian Industrial Registry at 1 Briggs St, Darwin, free of charge.

SCHEDULE
TERMS TO BE VARIED

Clause No.	*Subject*	*Substance of variation*
PRINT NUMBER M237CR V010 M PRINT H7059		
12 (b) (i)	Allowances	Veterinary Assistant and Kennelhands
14 (d)	Allowances	Meal Allowance
28 (c)	Allowances	Clothing Allowance
34 (d)	Allowances	Locomotion Allowance

Dated this 14th day of March 1989.

LYNDALL SOETENS
Deputy Industrial Registrar

N.N.—8926883

Industry, Technology and Commerce

COMMONWEALTH OF AUSTRALIA

Customs Act 1901

APPOINTMENTS UNDER SECTION 17 (b)

APPOINTMENT NOTICE NO. Q89/02

I, ADRIAN MURRAY, Delegate of the Comptroller-General of Customs, in pursuance of Paragraph (b) of section 17 of the *Customs Act 1901*, hereby appoint the place identified in the following Schedule as a place for the examination of goods on landing.

ADRIAN MURRAY
Regional Manager
Barrier Control
Queensland

Dated this 24th day of February 1989.

THE SCHEDULE

Place Name	*Location*
Overseas Packers & Shippers Pty Ltd	That part of property which is indicated by hatching on Scale Drawing Q89/02 held by Senior Inspector, Shipping and Cargo, Australian Customs Service, Brisbane, and is situated on land at present known as Store 19, Hedley Ave, Hendra, Brisbane Queensland 4011

N.N.—8926884

REVOCATION OF AIR AND SEA CARGO DEPOTS APPOINTED UNDER SECTION 17 (b)

REVOCATION NOTICE

I, ADRIAN MURRAY, Delegate of the Comptroller-General of Customs, hereby revoke from the Schedule to Customs Appointment Notice No. Q.4.

Overseas Packers & Shippers Pty Ltd
Store 19, Hedley Ave
Hendra Qld 4011

originally appointed for the examination of goods on landing under section 17 (b) of the *Customs Act 1901*.

ADRIAN MURRAY
Regional Manager
Barrier Control
Queensland

Dated this 24th day of February 1989.

N.N.—8926885

COMMONWEALTH OF AUSTRALIA

Customs Act 1901

APPOINTMENTS UNDER SECTION 17 (b)

APPOINTMENT NOTICE NOS. VAP 17 AND VAP 18

I, THOMAS GERARD FAHY, being a delegate of the Comptroller General of Customs, in pursuance of paragraph (b) of section 17 of the *Customs Act 1901*, hereby appoint the places identified in the following schedule as places for the examination of goods on landing.

THOMAS GERARD FAHY
Regional Manager
Barrier Operations
Victoria

Dated this 14th day of February 1989.

THE SCHEDULE

Premises Name	*Location*
Burlington Air Express	That part of the building which is indicated by hatching on scale drawing No. VAP 17, held by inspector, cargo control and accounting, Melbourne Airport, and is situated on land at present known as Lot 1, International Trade Park, Melrose Dr, Tullamarine Victoria 3043
Tradex Transport P/L	That part of the building which is indicated by hatching on scale drawing No. VAP 18, held by inspector, cargo control and accounting, Melbourne Airport, and is situated on land at present known as Lot 8, International Trade Park, Melrose Dr, Tullamarine Victoria 3043

N.N.—8926886

EXCISE ACT 1901

EXCISE BY-LAW (AMENDMENT) 1989 NO. 3

I , DANIEL EDMUND LEE, delegate of the Comptroller-General of Customs, hereby make the following By-law under the Excise Act 1901.

Dated this 14th day of March 1989

D.E. LEE
Delegate of the
Comptroller-General of Customs

Commencement

1. Section 2 shall be deemed to have come into operation on 13 January 1988.

Amendment of Excise By-law No. 99

2. Excise By-law No. 99 is amended :

by inserting after Flounder A22 in sub-paragraph 2A -

"Flounder A-27:

4460.0 to 4490.5 m"

NOTES

1. Excise By-law No. 99 has been amended by Excise By-law Nos. 1 and 2 of 1989.

N.N.-8926959

COMMONWEALTH OF AUSTRALIA
CUSTOMS ACT 1901

NOTICE OF FAIR RATES OF EXCHANGE

I, BARRY ALEXANDER HARALDSON, delegate of the Comptroller-General of Customs, hereby specify, pursuant to paragraph (a) of sub-section 161B(2) of the *Customs Act 1901* that the rates of exchange specified in Columns 3 to 7 of the Schedule hereunder are fair rates of exchange for the conversion of the foreign currencies of countries specified opposite in Columns 1 and 2 into Australian dollars on the dates under which the specified rates of exchange appear for the purposes of Division 2 of Part VIII of the *Customs Act 1901*.

SCHEDULE

Column 1 Country	Column 2 Foreign Currency	(Foreign Currency = AUS $1) Column 3 Date 08/03/89	Column 4 Date 09/03/89	Column 5 Date 10-12/03	Column 6 Date 13/03/89	Column 7 Date 14/03/89
AUSTRIA	Schillings	10.5100	10.6600	10.7200	10.7400	10.7100
BELGIUM/LUX	Francs	31.3200	31.7800	31.9600	32.0200	31.9000
BRAZIL	Cruzado	0.8029	0.8101	0.8175	0.8167	0.8122
CANADA	Dollars	0.9676	0.9779	0.9835	0.9835	0.9776
CHINA	New Yuan	2.9958	3.0229	3.0504	3.0474	3.0307
DENMARK	Kroner	5.8284	5.9149	5.9456	5.9589	5.9399
FIJI	Dollars	1.1445	1.1632	1.1654	1.1778	1.1720
FINLAND	Marks	3.4850	3.5343	3.5593	3.5636	3.5534
FRANCE	Francs	5.0790	5.1505	5.1753	5.1854	5.1609
GERMANY F.R.	Deutschmarks	1.4948	1.5174	1.5255	1.5295	1.5238
GREECE	Drachmas	125.7200	127.4800	126.5800	128.6200	128.0200
HONG KONG	Dollars	6.2944	6.3505	6.4084	6.4021	6.3670
INDIA	Rupees	12.3827	12.4973	12.6170	12.6283	12.5865
INDONESIA	Rupiahs	1408.0000	1421.0000	1434.0000	1434.0000	1426.3500
IRELAND	Pounds	0.5599	0.5684	0.5707	0.5719	0.5697
ISRAEL	Shekel	1.4556	1.4684	1.4830	1.4820	1.4751
ITALY	Lire	1098.0000	1112.9600	1119.5400	1121.4700	1116.9200
JAPAN	Yen	103.8700	105.1700	105.8600	106.2800	106.2100
KOREA	Won	540.9200	545.8900	550.8800	550.3500	547.3300
MALAYSIA	Dollars	2.2234	2.2418	2.2623	2.2565	2.2482
NETHERLANDS	Guilders	1.6870	1.7121	1.7212	1.7247	1.7184
NEW ZEALAND	Dollars	1.3143	1.3264	1.3321	1.3306	1.3298
NORWAY	Kroner	5.4495	5.5177	5.5551	5.5631	5.5465
PAKISTAN	Rupees	15.5600	15.7000	15.8400	15.8300	15.7400
PNG	Kina	0.6787	0.6834	0.6874	0.6873	0.6849
PHILIPPINES	Pesos	16.8600	17.0200	17.1300	17.1100	17.0200
PORTUGAL	Escudos	123.1500	124.6900	125.5800	125.7100	125.1800
SINGAPORE	Dollars	1.5594	1.5760	1.5919	1.5928	1.5828
SOLOMON IS.	Dollars	1.7603	1.7685	1.7861	1.7859	1.7808
SOUTH AFRICA	Rand	2.0287	2.0521	2.0730	2.0746	2.0646
SPAIN	Pesetas	93.1100	94.3200	94.8300	95.1000	94.6300
SRI LANKA	Rupees	26.7400	27.0200	27.2700	27.2400	27.1400
SWEDEN	Kroner	5.1210	5.1869	5.2209	5.2281	5.2159
SWITZERLAND	Francs	1.2769	1.2952	1.3026	1.3059	1.3031
TAIWAN	Dollars	22.3900	22.6000	22.8200	22.7600	22.5400
THAILAND	Bahts	20.5000	20.6900	20.8900	20.8700	20.7700
UK	Pounds	0.4691	0.4745	0.4768	0.4776	0.4766
USA	Dollars	0.8069	0.8142	0.8216	0.8208	0.8163

B.A. HARALDSON
Delegate of the
Comptroller-General of Customs
CANBERRA A.C.T.
15/03/89

N.N.-8926960

Primary Industries and Energy

FISHERIES REGULATIONS

Log-book Notice No. 17

I, JOHN CHARLES KERIN, the Minister of State for Primary Industries and Energy, being satisfied that information in relation to the taking of certain kinds of fish in Australian waters and the sale or disposal of such fish is required in pursuit of objectives of the *Fisheries Act 1952*:

(a) hereby revoke, with effect from 30 March 1989, the instrument known as Log-book Notice No. 6 published in *Gazette* No. S 373 on 21 September 1984;

(b) pursuant to subregulation 16 (1) of the Fisheries Regulations, have caused to be published the form of log-book CR2 in which information can be entered in respect of southern bluefin tuna taken in proclaimed waters; and

(c) pursuant to subregulation 17 (2) of the Fisheries Regulations, hereby determine:

(i) that subregulations 18 (1), 18 (2) and 18 (3) of those regulations shall apply in respect of the form of logbook referred to in paragraph (b) of this Notice during the period beginning on 30 March 1989 and ending on 29 March 1992; and

(ii) that copies of the form of log-book referred to in paragraph (b) of this notice can be obtained, during ordinary business hours, from the Australian Fisheries Service, Department of Primary Industries and Energy, Edmund Barton Building, Broughton St, Barton ACT 2600.

Dated this 10th day of March 1989.

JOHN KERIN

N.N.—8926887

FISHERIES REGULATIONS

Log-book Notice No. 18

I, JOHN CHARLES KERIN, the Minister of State for Primary Industries and Energy, being satisfied that information in relation to the taking of certain kinds of fish in Australian waters and the sale or disposal of such fish is required in pursuit of objectives of the *Fisheries Act 1952*:

(a) hereby revoke, with effect from 30 March 1989, the instrument known as Log-book Notice No. 3 published in *Gazette* No. S 179 on 18 August 1983;

(b) pursuant to subregulation 16 (1) of the Fisheries Regulations, have caused to be published the form of log-book NP06 in which information can be entered in respect of prawns taken in the area of the Northern Prawn Fishery; and

(c) pursuant to subregulation 17 (2) of the Fisheries Regulations, hereby determine:

(i) that subregulations 18 (1), 18 (2) and 18 (3) of those regulations shall apply in respect of the form of logbook referred to in paragraph (b) of this Notice during the period beginning on 30 March 1989 and ending on 29 March 1992; and

(ii) that copies of the form of log-book referred to in paragraph (b) of this notice can be obtained, during ordinary business hours, from the Australian Fisheries Service, Department of Primary Industries and Energy, Edmund Barton Building, Broughton St, Barton ACT 2600.

Dated this 10th day of March 1989.

JOHN KERIN

N.N.—8926888

FISHERIES REGULATIONS

Log-book Notice No. 19

I, JOHN CHARLES KERIN, the Minister of State for primary Industries and Energy, being satisfied that information in relation to the taking of certain kinds of fish in Australian waters and the sale or disposal of such fish is required in pursuit of the objectives of the *Fisheries Act 1952*:

(a) hereby revoke, with effect from 30 March 1989, the ionstrument known as Log-book Notice No. 9 published in *Gazette* No. S74 on 27 February 1986;

(b) pursuant to subregulation 16 (1) of the Fisheries Regulations, have caused to be published:

(i) the form of log-book TP05 in which information can be entereed in respect of pelagic fish taken by pole and line method in proclaimed waters;

(ii) the form of log-book TP06 in which information can be entered in respect of pelagic fish taken by the pole and line method in proclaimed waters that lie to the west of longitude 127° East;

(iii) the form of log-book SF05 in which information can be entered in respect of pelagic fish taken by the purse seine method in proclaimed waters; and

(c) pursuant to subregulation 17 (2) of the Fisheries Regulations, hereby determine:

(i) that subregulations 18 (1), 18 (2) and 18 (3) of those regulations shall apply in respect of the forms of log-book referred to in paragraph (b) of this Notice during the period beginning on 30 March 1989 and ending on 29 march 1992; and

(ii) that copies of the form of log-book referred to in paragraph (b) of this notice can be obtained, during ordinary business hours, from the Australian Fisheries Service, Department of Primary Industries and Energy, Edmund Barton Building, Broughton St, Barton ACT 2600

Dated this 10th day of March 1989.

JOHN KERIN

N.N.—8926889

AUSTRALIAN DRIED FRUITS CORPORATION

CONTRACTS FOR CARRIAGE OF DRIED FRUITS

In pursuance of section 11 (1) of the *Australian Dried Fruits Corporation Act 1978*, the Australian Dried Fruits Corporation hereby approves the Shipping Conferences and Companies listed in Column 1 of the following schedule to carry Australian dried fruit to the places designated in Column 2 of the Schedule. This schedule supersedes schedules notified in previous *Gazettes*.

SCHEDULE

Column 1	*Column 2*
Polish Ocean Line	United Kingdom, Ireland and Continent of Europe
A B C Containerline	
Australia to Europe Shipping Conference	
Associated Container Transportation (Australia) Ltd	
Blue Star Line Limited	
Ellerman Lines PLC	
Port Line Limited	
P & O Containers Ltd	
Compagnie Generale Maritime	
Hapag-Lloyd Aktiengesellschaft	
Nedlloyd Lijnen B.V. (Nedlloyd Lines)	
Lloyd Triestino di Navigazione Societa per Azioni	
Naviera Garcia—Minaur/Marasia	
Jadranska Slobodna Plovidba (Yugoslav Line)	
Scancarriers A/S	
Aktieselskabet Det Ostasiatiske Kompagni (The East Asiatic Company, Limited)	
Rederiaktiebolaget Transocean	
Wilh Wilhelmsen Limited A/S	
The Australian National Line	
Baltic Shipping Company	
Eagle Container Line	Philippines, Hong Kong and Taiwan
EAC-Hil Australia Service	
Scancarriers A/S	
Australia Northbound Shipping Conference	
East Asia Section	
Asia Australia Express Limited	
Australian National Line	
Knutsen Line A/S.	
Mitsui—OSK Lines Ltd	
Nippon Yusen Kaisha	
Orient Overseas Container Line	
Yang Ming Marine Transport Corporation	
Kawasaki Kisen Kaisha Ltd	
Nippon Liner System Ltd	
Fesco Australia Line	Japan and Korea
EAC-Hil Australia Service	
Scancarriers A/S	
Bridge Line	
Australia Northbound Shipping Conference	
Japan/Korea Section	
Australia Japan Container Line	
Australian National Line	
Kawasaki Kisen Kaisha Ltd	
Knutsen Line A/S	
Mitsui-OSK Lines Ltd	
Nippon Yusen Kaisha	
Orient Overseas Container Line Ltd./Chinese Maritime Transport Ltd (Japan only)	
Cho Yang Shipping Co. Ltd (Korea only)	
Dong Young Shipping Co. Ltd (Korea only)	
Nippon Liner System, Ltd	
ABC Container Line	North America, East Coast USA and Canada
Australia East Coast North America Shipping Conference	
Australia-Eastern Canada Shipping Conference	
Columbus Line	
Pace Line	
Associated Container Transportation (Australia) Ltd	
Hong Kong Island Line	North America, West Coast USA and Canada
Australia-Pacific Coast Rate Agreement	
FMC 1002	
Columbus Line	
Pace Line	
Associated Container Transportation (Australia) Ltd	

Column 1	*Column 2*
Union Steamship Company of New Zealand Ltd	New Zealand
Australian National Line/The Shipping Corporation of New Zealand Limited (Tranztas Service)	
Tasman Express Line Ltd	
BHP Transport	

In pursuance of section 11 (2) of the *Australian Dried Fruits Corporation Act 1978*, the Australian Dried Fruits Corporation has determined that the arrangements are subject to such variations in the rates, terms and conditions relating to carriage of Australian dried fruit to export markets as agreed between the Australian Shippers' Council and the Shipping Conference or Carrier concerned and approved by the Corporation.

ALLAN W. KNIGHTS
General Manager
Australian Dried Fruits Corporation

N.N.—8926890

Social Security

Social Security Act 1947

APPOINTMENT OF SENIOR MEMBER TO THE SOCIAL SECURITY APPEALS TRIBUNAL

Recommended for the approval of His Excellency the Governor-General in Council that pursuant to subsection 218 (1) of the *Social Security Act 1947* he appoint Peter Donald McNab as a Senior Member, Social Security Appeals Tribunal, by instrument in the attached form.

B. HOWE
Minister of State
for Social Security

N.N.—8926891

COMMONWEALTH OF AUSTRALIA

Social Security Act 1947

APPOINTMENT OF SENIOR MEMBER

I, WILLIAM GEORGE HAYDEN, Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, pursuant to subsection 218 (1) of the *Social Security Act 1947*, hereby appoint Peter Donald McNab as a part-time Senior Member of the Social Security Appeals Tribunal for a term of one year.

Dated this 13th day of March 1989.

BILL HAYDEN
Governor-General

By His Excellency's Command
BRIAN HOWE
Minister of State
for Social Security

N.N.—8926892

COMMONWEALTH OF AUSTRALIA

Social Security Act 1947

NOTICE UNDER SUB-SECTION 12B(2)

I, DEREK VOLKER, Secretary to the Department of Social Security, specify in pursuance of sub-section 12B(2) of the Social Security Act 1947 that each class of market-linked investments specified in column B of the Schedule is an investment product and that the person or body specified in column A of the Schedule opposite each named investment product is the fund manager in relation to that investment product.

SCHEDULE

A FUND MANAGER	B INVESTMENT PRODUCT
ACC Fund Management Ltd	Managed Growth Fund
ACC Fund Management Ltd	Managed Income Fund
ACC Fund Management Ltd	Property Securities Fund
ACC Fund Management Ltd	Australian Leaders Trust
ACC Fund Management Ltd	Quartet Growth Fund
ACC Life Ltd	Managed Growth Bond
ACC Life Ltd	International Bond
Advance Asset Management	Advance Split Property Fund–Income Units
Advance Asset Management	Advance Split Property Fund–Growth Units
Advance Asset Management	Advance Split Property Fund–Combined Units
Advance Asset Management	Advance Property Fund No 5 – Capital Growth
Advance Asset Management	Advance Imputation Fund
Advance Asset Management	Advance International Sharemarket Fund
Advance Asset Management	Advance High Performance Fund
Advance Asset Management	Advance Approved Deposit Growth Fund
Advance Asset Management	Advance Property Fund No 1
Advance Asset Management	Advance Property Fund No 3
Advance Asset Management	Advance Property Fund No 4
Advance Asset Management	Advance Australian Sharemarket 1
AMEV Life Assurance Co Ltd	Horizon Investment Plan – Managed Fund
AMEV Life Assurance Co Ltd	Horizon Investment Plan – Sharemarket Fund
AMEV Life Assurance Co Ltd	Horizon Investment Plan – Property Fund
AMEV Life Assurance Co Ltd	Navigator Investment Bond – Managed Fund
AMEV Life Assurance Co Ltd	Navigator Investment Bond – Sharemarket Fund
AMEV Life Assurance Co Ltd	Navigator Investment Bond – Property Fund
AMEV Life Assurance Co Ltd	Navigator RODA Managed Fund
AMEV Life Assurance Co Ltd	Navigator RODA Sharemarket Fund
AMEV Life Assurance Co Ltd	Navigator RODA Property Fund

AMP Investment Management Limited	AMP Property Trust
AMP Investment Management Limited	AMP Equity Trust
AMP Investment Management Limited	AMP Imputation Trust
AMP Investment Management Limited	AMP International Trust
AMP Investment Management Limited	AMP Blue Chip Trust
AMP Investment Management Limited	AMP Resource Trust
AMP Investment Management Limited	AMP Small Companies Trust
AMP Investment Management Limited	AMP Gold Trust
AMP Society	Investment Linked Insurance Bond–Managed Balanced
AMP Society	Investment Linked Insurance Bond–Managed Broadly Based
AMP Society	Investment Linked Insurance Bond–Managed Equity Based
AMP Society	Investment Linked Insurance Bond–Australian Equities
AMP Society	Investment Linked Insurance Bond–International
AMP Society	Deferred Annuity (Table ULK) – Broadly Based
AMP Society	Deferred Annuity (Table ULK) – Market Based
AMP Society	Deferred Annuity (Table ULK) – Equity Based
AMP Society	Deferred Annuity (Table ULK) – Australian Equities
AMP Society	Deferred Annuity (Table ULK) – International
AMP Society	Deferred Annuity (Table ULK) – Property
AMP Society	Ampak (Table IAA) – Asset Value Component
AMP Society	AMP Investment Account Insurance Bond (Table FSB) – Asset Value 20%
AMP Society	AMP Investment Account Deferred Annuity (Table FSB) – Asset Value Component
Armstrong Jones Life Assurance Ltd	Insurance Bond Balanced Fund
Armstrong Jones Life Assurance Ltd	Insurance Bond Sharemarket Fund
Armstrong Jones Life Assurance Ltd	Deferred Annuity Bond–Balanced Fund
Armstrong Jones Life Assurance Ltd	Deferred Annuity Bond–Sharemarket Fund
Armstrong Jones Management Ltd	Armstrong Jones Property Fund Growth Units
Armstrong Jones Management Ltd	Armstrong Jones Property Fund Income Units
Armstrong Jones Management Ltd	Armstrong Jones Property Income Fund
Armstrong Jones Management Ltd	Armstrong Jones Property Income Fund Investment Plan Units
Armstrong Jones Management Ltd	Armstrong Jones Australian Growth Fund Growth Units
Armstrong Jones Management Ltd	Armstrong Jones Australian Growth Fund Investment Plan Units
Armstrong Jones Management Ltd	Armstrong Jones Australian Growth Fund Income Units
Armstrong Jones Management Ltd	Armstrong Jones Property Approved Deposit Fund
Armstrong Jones Management Ltd	Armstrong Jones Tax Effective Fund
Armstrong Jones Management Ltd	Armstrong Jones Prime Investment Fund
Audant Investment Management Services Ltd	Audant Resources Trust
Audant Investment Management Services Ltd	Audant High Performance Fund
Austore Ltd	Austore Property Trust
Australian Natives' Association Friendly Society	ANA Performance Bond
Australian Natives' Association Friendly Society	ANA Managed Bond
Breakwater Island Limited	Breakwater Island Trust
BT Financial Services Ltd	Split Trust–Growth
BT Financial Services Ltd	Split Trust–Income
BT Financial Services Ltd	Lump Sum Fund ADF–Investment Units
BT Financial Services Ltd	Lump Sum Fund ADF–Property Units
BT Financial Services Ltd	Select Markets Trust–Equity Imputation
BT Financial Services Ltd	Select Markets Trust–American Growth
BT Financial Services Ltd	Select Markets Trust–European Growth
BT Financial Services Ltd	Select Markets Trust–Pacific Basin
BT Financial Services Ltd	Select Markets Trust–International Growth
BT Financial Services Ltd	Split Property Trust–Growth
BT Financial Services Ltd	Split Property Trust–Income
BT Financial Services Ltd	Split Property Trust–Combined Units
Burswood Management Ltd	Burswood Property Trust
Capital Property Management Ltd	Capital Property Trust

Clayton Robard Management Ltd	Equity Performance Fund No 1
Clayton Robard Management Ltd	Equity Performance Fund No 2
Clayton Robard Management Ltd	Equity Performance Fund No 3
Clayton Robard Management Ltd	Equity Performance Fund No 4
Clayton Robard Management Ltd	Equity Performance Fund No 5
Clayton Robard Management Ltd	Equity Performance Fund No 6
Clayton Robard Management Ltd	Equity Performance Fund No 7
Clayton Robard Management Ltd	Equity Performance Fund No 8
Clayton Robard Management Ltd	Equity Performance Fund No 9
Clayton Robard Management Ltd	Equity Performance Fund No 10
Clayton Robard Management Ltd	First International Equity Performance Fund
Clayton Robard Management Ltd	International Equity Fund No 2
Clayton Robard Management Ltd	First International Income Fund
Clayton Robard Management Ltd	Tiger Fund
Clayton Robard Management Ltd	Special Situations Fund
Clayton Robard Management Ltd	Clayton Robard Gold Fund
Clayton Robard Management Ltd	Approved Deposit Fund
Clayton Robard Management Ltd	Property Performance Fund No 1
Clayton Robard Management Ltd	Property Performance Fund No 2
Clayton Robard Management Ltd	Property Performance Fund No 3
Clayton Robard Management Ltd	Property Performance Fund No 4
Clayton Robard Management Ltd	Property Performance Fund No 5
Clayton Robard Management Ltd	Clayton Robard Listed Property Trust
Commonwealth Life Limited	Insurance Bond–Managed Fund
Commonwealth Management Services Limited	Managed Investment Fund
Corcarr Funds Management Ltd	Corcarr Equity High Income Fund
Corcarr Funds Management Ltd	Corcarr Equity Investment Fund
County Natwest Australia Investment Management	Approved Deposit Fund–Growth Fund
Elders Portfolio Management Ltd	Elders Equity Trust
Equitable Group Ltd	Equitable Property Trust
Equitable Group Ltd	Equitable Property Growth Trust
Equity Life Ltd	Managed Investment Bond
Equity Life Ltd	Balanced Investment Bond
Equity Life Ltd	Managed Roll–Over Annuity
Fidelity Life Insurance Co of Australia Ltd	Managed Investment Policy Investment Linked–Managed
Fidelity Life Insurance Co of Australia Ltd	Managed Investment Policy International Fund
First National Managers Ltd	First National Resource Trust
Friends Investment Management Ltd	Ethical Income Test
Friends Investment Management Ltd	Ethical Growth Trust
Friends Investment Management Ltd	International Growth Trust
Friends Investment Management Ltd	Managed Growth Trust
Friends Investment Management Ltd	Australian Imputation Trust
Friends Investment Management Ltd	Property Securities Trust
Friends Investment Management Ltd	Friends Managed Growth Approved Deposit Fund
GIO Life Ltd	Good Life Insurance Bond–'O' Units
GIO Life Ltd	Good Life Insurance Bond–'L' Units
GIO Life Ltd	Good Life Insurance Bond–'F' Units
GIO Life Ltd	Grip RODA – 'O' Units
GIO Life Ltd	Grip RODA – 'L' Units
GIO Life Ltd	Grip RODA – 'F' Units
GIO of NSW	Good Life Insurance Bond–'O' Units
GIO of NSW	Good Life Insurance Bond–'L' Units
GIO of NSW	Good Life Insurance Bond–'F' Units
GIO of NSW	Grip RODA – 'O' Units
GIO of NSW	Grip RODA – 'L' Units
GIO of NSW	Grip RODA – 'F' Units
GIO (Unit Trust Division)	Growth Fund
GIO (Unit Trust Division)	Property Fund
GIO (Unit Trust Division)	International Fund

Global Funds Management (NSW) Limited	Global Property Income Fund
Global Funds Management (NSW) Limited	Global Residential Property Development Fund
Global Funds Management (NSW) Limited	Global Property Growth Fund
Global Funds Management (NSW) Limited	Global ADF Capital Growth Fund
Global Funds Management (NSW) Limited	Global ADF Capital Preservation Fund
Global Funds Management (VIC) Limited	HOA Investment Fund
Global Funds Management (VIC) Limited	Global High Yield Imputation Fund
Global Funds Management (VIC) Limited	Global Special Situations Fund
Global Funds Management (VIC) Limited	Global Small Companies Fund
Global Funds Management (VIC) Limited	Global Top 100 Companies Fund
Global Funds Management (VIC) Limited	Global Resources Fund
Hambros Australia Investment Management Ltd	Australia International Split Trust–International Growth Fund
Hambros Australia Investment Management Ltd	Australia International Split Trust–North America Fund
Hambros Australia Investment Management Ltd	Australia International Split Trust–Europe Fund
Hambros Australia Investment Management Ltd	Australia International Split Trust–Japan & Asia Fund
Hambros Australia Investment Management Ltd	Australia International Split Trust–South East Asia Fund
Hambros Australia Investment Management Ltd	Australia International Split Trust–Australia Growth Fund
Hambros Australia Investment Management Ltd	Australia International Split Trust–Dividend Imputation Fund
Hambros Australia Investment Management Ltd	Australia International Split Trust–Property Securities Fund
Hambros Australia Investment Management Ltd	Hambros Australia Approved Deposit Fund– Managed Investment Fund
Hambros Australia Investment Management Ltd	Hambros Australia Approved Deposit Fund–Property Securities Fund
Hambros Australia Investment Management Ltd	Hambros Australia Approved Deposit Fund–International Growth Fund
Hambros Australia Investment Management Ltd	Australia International Split Trust–United Kingdom Fund
Jardine Fleming Australia Management Ltd	Jardine Fleming Pacific Growth Trust
Jardine Fleming Australia Management Ltd	Jardine Fleming United States Growth Trust
Jardine Fleming Australia Management Ltd	Jardine Fleming European Growth Trust
Jardine Fleming Australia Management Ltd	Jardine Fleming Japan Growth Trust
Jardine Fleming Australia Management Ltd	Jardine Fleming Australia Growth Trust
Jardine Fleming Australia Management Ltd	Jardine Fleming Global Fund
Jardine Fleming Australia Management Ltd	Jardine Fleming International ADF
Jardine Fleming Australia Management Ltd	Jardine Fleming Pacific Growth Trust No 2
Jupiters Management Ltd	Jupiters Trust
Kern Property Management Ltd	Kern Property Fund–Ordinary Units
Kern Property Management Ltd	Kern Property Fund–Special Units
Liberty Life Ltd	Prime Investment Bond–Prime Performance Fund
Liberty Life Ltd	Deferred Annuity Prime Performance Fund
Lumley Financial Services Ltd	Lumley All Ordinaries Index Trust
Lumley Financial Services Ltd	International Trust
Lumley Life Ltd	Flexibond (Managed)
Lumley Life Ltd	Flexibond (Managed Rollover D/A)
Lumley Life Ltd	IFMA Flexibond (Managed)
Lumley Life Ltd	IFMA Flexibond (Managed RODA)
Lumley Life Ltd	Collection Bonds (International Bond)
Lumley Life Ltd	Collection Bonds (Growth Bond I)
Lumley Life Ltd	Collection Bonds (Growth Bond II)
Lumley Life Ltd	Collection Bonds (Managed Bond)
Lumley Life Ltd	Collection Bonds (Property Bond)
McNamara Properties Ltd	McNamara Australia Property Trust
Mercantile Mutual Global Ltd	Mercantile Mutual Global Property Trust
Mercantile Mutual Life Insurance Co Ltd	Investment Bond–Managed Growth Units
Mercantile Mutual Life Insurance Co Ltd	Deferred Annuity–Managed Growth Units
Mercury Securities Ltd	Mercury Australia Equity Fund
Mercury Securities Ltd	Mercury International Equity Fund

Mercury Securities Ltd	Mercury Composite Fund
Mirvac Funds Ltd	Mirvac Premier Property Trust
Mirvac Funds Ltd	Mirvac Property Growth Trust
Mirvac Funds Ltd	Mirvac Income and Growth Trust
Mirvac Funds Ltd	Mirvac Split Trust No 2-Growth Units
Mirvac Funds Ltd	Mirvac Split Trust No 2-Income Units
Mirvac Funds Management Ltd	Mirvac Split Trust-Growth Units
Mirvac Funds Management Ltd	Mirvac Split Trust-Income Units
Mirvac Funds Security Ltd	Mirvac Property Equities Fund-Growth Units
Mirvac Funds Security Ltd	Mirvac Property Equities Fund-Income Units
MLC Life Ltd	MLC Five Star Investment Bond-The Australian Equity Opti
MLC Life Ltd	MLC Five Star Investment Bond-The Balanced Option
MLC Life Ltd	MLC Five Star Investment Bond-The Growth Option
MLC Life Ltd	MLC Five Star Investment Bond-The International Equity Option
MLC Life Ltd	MLC Five Star Investment Bond-The Property Trust Option
MLC Life Ltd	MLC Five Star Investment Bond-The Share Index Option
MLC Life Ltd	MLC Five Star Investment Roll-Over-The Australian Equity Option
MLC Life Ltd	MLC Five Star Investment Roll-Over-The Balanced Option
MLC Life Ltd	MLC Five Star Investment Roll-Over-The Growth Option
MLC Life Ltd	MLC Five Star Investment Roll-Over-The International Equity Option
MLC Life Ltd	MLC Five Star Investment Roll-Over-The Property Trust Option
MLC Life Ltd	MLC Five Star Investment Roll-Over-The Share Index Optio
National Mutual Life Association	Approved Deposit Fund-Super Managed
National Mutual Life Association	Managed Investment Plan-Managed Fund
National Mutual Life Association	Super Guard Deferred Annuity-Managed Fund
National Mutual Life Association	Personal Investment Bond-Managed Fund
National Mutual Life Association	Personal Investment Bond-International Fund
National Mutual Life Association	Super Guard Plus Deferred Annuity-Managed Fund
National Mutual Life Association	Flexible Security Plan-Managed Fund
Nomura Goode Management Co Ltd	Japan Growth Trust
Northern Securities Management Ltd	Northern Securities Approved Deposit Fund-Australian Growth Units
Northern Securities Management Ltd	Northern Securities Approved Deposit Fund-International Securities Units
Norwich Australia Asset Management Ltd	Norwich Investment ADF
Norwich Australia Asset Management Ltd	Norwich Managed Equities Trust
Norwich Australia Asset Management Ltd	Norwich Imputation Trust
Norwich Union Life Australia Ltd	Investment Bond Growth Fund
Norwich Union Life Australia Ltd	Investment Bond Managed Fund
Norwich Union Life Australia Ltd	Nulink Growth Fund
Norwich Union Life Australia Ltd	Nulink Managed Fund
Norwich Union Life Australia Ltd	Blueprint Growth Fund
Norwich Union Life Australia Ltd	Blueprint Managed Fund
Norwich Union Life Australia Ltd	Dimension Growth Fund
Norwich Union Life Australia Ltd	Dimension Managed Fund
Norwich Union Life Australia Ltd	Deferred Annuity Growth Fund
Norwich Union Life Australia Ltd	Deferred Annuity Managed Fund
NRMA Life Ltd	NRMA Life Insurance Savings Bond-Managed
NRMA Life Ltd	NRMA Roll-Over Bond-Managed
NZI Investment Services	Savings Policy-Australian Managed Fund
NZI Investment Services	Insurance Bond-Australian Fund
NZI Investment Services	Insurance Bond-International Fund
NZI Investment Services	Rollover Annuity-Australian Fund
NZI Investment Services	Rollover Annuity-International Fund
Pertarc Management Ltd	PA Property Trust

Potter Warburg Asset Management Ltd	Potter Warburg Trading Trust
Potter Warburg Asset Management Ltd	Potter Warburd Growth Trust
Potter Warburg Asset Management Ltd	Potter Warburg Imputation Trust
Potter Warburg Asset Management Ltd	Potter Warburg Income Trust
Potter Warburg Asset Management Ltd	Potter Warburg Resource Trust
Potter Warburg Asset Management Ltd	Potter Warburg International Trust
Potter Warburg Asset Management Ltd	Potter Warburg Capital Growth ADF
Potter Warburg Asset Management Ltd	Potter Warburg Growth Bond
Prudential Assurance	Managed Investment Bond
Prudential Assurance	Prudential Rollover Plan Linked Account
Prudential Fund Managers Ltd	Prudential Total Performance Income Fund
Prudential Fund Managers Ltd	Prudential Total Performance Growth Fund
Prudential Fund Managers Ltd	Prudential Equity Imputation Fund
R&I Property Trust Management Group	R&I Property Trust
Rothschild Australia Asset Management Ltd	Five Arrows Approved Deposit Fund-Investment Units
Rothschild Australia Asset Management Ltd	Five Arrows Australian Equity Trust
Rothschild Australia Asset Management Ltd	Five Arrows International Equity Trust
Rothschild Australia Asset Management Ltd	Five Arrows Australian Resources Trust
Rothschild Australia Asset Management Ltd	Five Arrows Smaller Companies Trust
SBC Australia Fund Management Ltd	Swiss International Trust
Schroders Australia Management Ltd	Australis Fund
Schroders Australia Management Ltd	Schroders Australia Share Trust
Schroders Australia Property Management Limited	International Property Trust
Schroders Australia Property Management Limited	Property Trust - Ordinary Units
Schroders Australia Property Management Limited	Property Trust - Capital Units
Schroders Australia Property Management Limited	Property Trust - Special Units
Selected Equities Ltd	Benwood Property Trust
Socdet Management Ltd	Sydney Oil Company Drilling & Exploration Trust
Southern Rural Property Management Limited	Southern Rural Property Trust
Standard Chartered Investment Management Limited	Standard Chartered ADF-Growth Investment Units
Standard Chartered Investment Management Limited	Standard Chartered Share Performance Trust
Standard Chartered Investment Management Limited	Standard Chartered Property Securities - Performance Trust
State Bank Victoria	Supersafe Growth Approved Deposit Fund
State Bank Victoria	State Bank Premium Growth Trust
Stirling Commerical Property Management Ltd	Stirling Property Trust
Stirling Commercial Property Management Ltd	Canberra Commercial Property Trust
Sun Alliance Life Assurance Ltd	Investment Bond-Managed Fund
Sun Alliance Life Assurance Ltd	Investment Bond-Growth Fund
Sun Alliance Life Assurance Ltd	Retirement Rollover Plan Deferred Annuity-Growth Fund
Sun Alliance Life Assurance Ltd	Retirement Roda-Managed Fund
Suncorp Insurance and Finance	Rollover Deposit No 2 Fund
Suncorp Insurance and Finance	Premier Bond
Town and Country Properties Ltd	Town & Country Housing Trust
UHF Friendly Society	The Intelligent Investor's Bond
Wardley Investment Management Ltd	Wardley Australia Growth Trust
Wardley Investment Management Ltd	Wardley Australia General Investment Trust
Wardley Investment Management Ltd	Wardley Australia World Trust
Wardley Investment Management Ltd	Wardley Australia International Trust
Wardley Investment Management Ltd	Wardley Australia Dragon Trust
Wardley Investment Management Ltd	Wardley Australia Approved Deposit Fund Capital Growth
Wardley Investment Management Ltd	Wardley Australia Approved Deposit Fund International
Westfield Management Limited	Westfield Trust

15 March 1989

Derek Volker
Secretary
Department of Social Security N.N.-8926961

Transport and Communications

AUSTRALIAN BROADCASTING TRIBUNAL

Licence renewal

COMMERCIAL TELEVISION SERVICE, BCV BENDIGO—NOTICE OF COMMENCEMENT OF INQUIRY

Submissions invited

The Australian Broadcasting Tribunal has commenced an inquiry into the renewal of the licence for the above service, which is due to expire on 30 June 1989.

The application for the renewal of the licence has been lodged by Victorian Broadcasting Network (1983) Pty Ltd, licensee of BCV Bendigo.

The issue to be considered in the inquiry is whether the Tribunal should refuse to renew the licence for any of the reasons set out in section 86AA of the *Broadcasting Act 1942*, and in particular:

(a) whether the licensee has complied with its undertaking to provide an adequate and comprehensive service pursuant to the licence, and to use and encourage the use of Australian creative resources;

(b) whether the licensee is no longer a fit and proper person to hold the licence;

(c) whether the licensee has the necessary financial, technical and management capabilities to operate the service effectively;

(d) whether a condition of the licence has not been complied with;

(e) whether the service is commercially viable.

If you wish to make a submission relating to the inquiry on any of these matters, you should lodge it with the Tribunal's North Sydney office by 5.00 p.m. on Wednesday 3 May 1989. Before lodging a submission, you should inspect the relevant inquiry file in respect of the inquiry (containing the application and other useful background information) and read the Tribunal's Guide for Submitters, copies of which are available from the Tribunal and are attached to the inquiry file.

The inquiry file can be inspected during business hours at the Tribunal's offices at:

Marland House
570 Bourke St
Melbourne Vic.

Contact officer
Mr Colin Jones
Phone (03) 670 1777

and at

North Central Goldfields Library
Hargreaves St
Bendigo Vic.
Phone (054) 43 5100

and

Tandem House
76 Berry St
North Sydney NSW

Contact officer
Mr Peter Masters
Phone (02) 959 7811

N.N.—8926893

AUSTRALIAN BROADCASTING TRIBUNAL

Licence renewal

COMMERCIAL TELEVISION SERVICE, GLV LA TROBE VALLEY—NOTICE OF COMMENCEMENT OF INQUIRY

Submissions invited

The Australian Broadcasting Tribunal has commenced an inquiry into the renewal of the licence for the above service, which is due to expire on 30 June 1989.

The application for the renewal of the licence has been lodged by Victorian Broadcasting Network (1983) Pty Ltd, licensee of GLV La Trobe Valley.

The issue to be considered in the inquiry is whether the Tribunal should refuse to renew the licence for any of the reasons set out in section 86AA of the *Broadcasting Act 1942*, and in particular:

(a) whether the licensee has complied with its undertaking to provide an adequate and comprehensive service pursuant to the licence, and to use and encourage the use of Australian creative resources;

(b) whether the licensee is no longer a fit and proper person to hold the licence;

(c) whether the licensee has the necessary financial, technical and management capabilities to operate the service effectively;

(d) whether a condition of the licence has not been complied with;

(e) whether the service is commercially viable.

If you wish to make a submission relating to the inquiry on any of these matters, you should lodge it with the Tribunal's North Sydney office by 5.00 p.m. on Wednesday 3 May 1989. Before lodging a submission, you should inspect the relevant inquiry file in respect of the inquiry (containing the application and other useful background information) and read the Tribunal's Guide for Submitters, copies of which are available from the Tribunal and are attached to the inquiry file.

The inquiry file can be inspected during business hours at the Tribunal's offices at:

Marland House
570 Bourke St
Melbourne Vic.

Contact officer
Mr Colin Jones
Phone (03) 670 1777

and at

Morwell Branch Library
Hazelwood Rd
Morwell Vic.
Phone (051) 34 1047

Traralgon Branch Library
Grey St
Traralgon Vic.
Phone (051) 74 2534

Moe Branch Library
Kirk St
Moe Vic.
Phone (051) 27 3854

and

Tandem House
76 Berry St
North Sydney NSW

Contact officer
Ms Sharonne Moore
Phone (02) 959 7811

N.N.—8926894

AUSTRALIAN BROADCASTING TRIBUNAL

Licence Renewal

Commercial Radio Service, 3NE Wangaratta—

NOTICE OF COMMENCEMENT OF INQUIRY

Submissions invited

The Australian Broadcasting Tribunal has commenced an inquiry into the renewal of the licence for the above service, which is due to expire on 30 June 1989.

The application for the renewal of the licence has been lodged by North East Broadcasters Pty Ltd, licensee of station 3NE Wangaratta.

The issue to be considered in the inquiry is whether the tribunal should refuse to renew the licence for any of the reasons set out in section 86AA of the *Broadcasting Act 1942*, and in particular:

(a) whether the licensee has complied with its undertaking to provide an adequate and comprehensive service pursuant to the licence, and to use and encourage the use of Australian creative resources;

(b) whether the licensee is no longer a fit and proper person to hold the licence;

(c) whether the licensee has the necessary financial, technical and management capabilities to operate the station effectively;

(d) whether a condition of the licence has not been complied with;

(e) whether the service is commercially viable.

If you wish to make a submission relating to the inquiry on any of these matters, you should lodge it with the Tribunal's North Sydney office by 5.00 p.m. on Wednesday 3 May 1989. Before lodging a submission, you should inspect the relevant inquiry file in respect of this inquiry (containing the application and other useful background information) and read the Tribunal's Guide for Submitters, copies of which are available from the Tribunal and are attached to the inquiry file.

The inquiry file can be inspected during business hours at the Tribunal's offices at:

Marland House
570 Bourke St
Melbourne Vic.

Contact officer
Mr Colin Jones
Phone (03) 670 1777

and at

Wangaratta Regional Library
100 Murphy St
Wangaratta Vic.
Phone (057) 21 2366

and

Tandem House
76 Berry St
North Sydney NSW

Contact officer
Mr Stephen Kelen
Phone (02) 959 7811

N.N.—8926895

AUSTRALIAN BROADCASTING TRIBUNAL

Licence renewal

COMMERCIAL RADIO SERVICE, 3CS COLAC—
NOTICE OF COMMENCEMENT OF INQUIRY

Submissions invited

The Australian Broadcasting Tribunal has commenced an inquiry into the renewal of the licence for the above service, which is due to expire on 30 June 1989.

The application for the renewal of the licence has been lodged by Enterprise Broadcasters Pty Ltd, licensee of station 3CS Colac.

The issue to be considered in the inquiry is whether the Tribunal should refuse to renew the licence for any of the reasons set out in section 86AA of the *Broadcasting Act 1942*, and in particular:

(a) whether the licensee has complied with its undertaking to provide an adequate and comprehensive service pursuant to the licence, and to use and encourage the use of Australian creative resources;

(b) whether the licensee is no longer a fit and proper person to hold the licence;

(c) whether the licensee has the necessary financial, technical and management capabilities to operate the station effectively;

(d) whether a condition of the licence has not been complied with;

(e) whether the service is commercially viable.

If you wish to make a submission relating to the inquiry on any of these matters, you should lodge it with the Tribunal's North Sydney office by 5.00 p.m. on Wednesday 3 May 1989. Before lodging a submission, you should inspect the relevant inquiry file in respect of the inquiry (containing the application and other useful background information) and read the Tribunal's Guide for Submitters, copies of which are available from the Tribunal and are attached to the inquiry file.

The inquiry file can be inspected during business hours at the Tribunal's offices at:

Marland House
570 Bourke St
Melbourne Vic.

Contact officer
Mr Colin Jones
Telephone (03) 670 1777

and at

Corangamite Regional Library
Gellibrand St
Colac Vic.
Telephone (052) 31 4613

and

Tandem House
76 Berry St
North Sydney NSW

Contact officer
Ms Margaret Kaluza
Telephone (02) 959 7811

N.N.—8926896

AUSTRALIAN BROADCASTING TRIBUNAL

Broadcasting Act 1942

DECISION BY THE AUSTRALIAN BROADCASTING TRIBUNAL

Inquiry File: IO/88/19

The Australian Broadcasting Tribunal has approved pursuant to section 90J of the *Broadcasting Act 1942* the acquisition by Lanson Investments Pty Ltd (formerly known as Skeg Pty Ltd) of all the issued capital of 5AU Broadcasters Pty Ltd and River Murray Broadcasters Pty Ltd, licensees of radio services 5AU and 5RM respectively.

The applications, documents and the Tribunal's reason for its decision may be inspected at the Tribunal's office at 76 Berry St, North Sydney.

N.N.—8926897

AUSTRALIAN BROADCASTING TRIBUNAL

Broadcasting Act 1942

DECISION BY THE AUSTRALIAN BROADCASTING TRIBUNAL

Inquiry File: IO/88/171

The Australian Broadcasting Tribunal has approved pursuant to section 90J of the *Broadcasting Act 1942* the acquisition by Pax Pasha Pty Ltd of 243 000 fully paid ordinary shares in Midwest Radio Ltd, licensee of radio service 2LT.

Inquiry File: IO/88/220

The Australian Broadcasting Tribunal has approved pursuant to section 90J of the *Broadcasting Act 1942* the acquisition by Shepparton Broadcasting Services Pty Ltd of all issued capital in Hanor Pty Ltd and Ellamone Pty Ltd, licensees of radio services 3SR and 3UL respectively.

The applications, documents and the Tribunal's reason for its decision may be inspected at the Tribunal's office at 76 Berry St, North Sydney.

N.N.—8926898

AUSTRALIAN BROADCASTING TRIBUNAL

Broadcasting Act 1942

DECISION BY THE AUSTRALIAN BROADCASTING TRIBUNAL

Inquiry File: IO/89/46

The Australian Broadcasting Tribunal has approved pursuant to section 89A (1) of the *Broadcasting Act 1942* the transfer of the rebroadcasting licence for Lithgow from Country Television Services Ltd to Prime Television (Southern) Pty Ltd.

The full report and reasons for the Tribunal's decision will be published shortly. The application, related documents and the Tribunal's reasons for decision may be inspected at the Tribunal's office at 76 Berry St, North Sydney, or by arrangement at the Tribunal's State Offices, during normal business hours.

Contact officer John Souter

Telephone (02) 959 7866

N.N.—8926899

AUSTRALIAN BROADCASTING TRIBUNAL

Broadcasting Act 1942

SHARE TRANSACTION—COMMERCIAL RADIO SERVICE 6VA-ALBANY

Notice of Inquiry

Submissions Invited

The Tribunal commenced an inquiry into the acquisition by the WA State Government Insurance Commission of 64 089 346 shares in The Bell Group Ltd. The WA State Government Insurance Commission previously held 70 000 shares in the Bell Group Ltd, it has increased its holdings to 64 159 346 shares which represents 19.9% of the issued capital of The Bell Group Ltd. The Bell Group Ltd owns 100% of the issued capital of Albany Broadcasters Ltd, licensee of commercial radio service 6VA.

The issues to be considered in the inquiry are whether, if the application was for consent to the transfer of the licence under section 89A of the *Broadcasting Act 1942*, the Tribunal should refuse consent having regard particularly to:

(a) whether it would be advisable in the public interest, because:

(i) the applicant is not a fit and proper person to hold the licence;

(ii) the applicant does not have the necessary financial, technical and management capabilities to provide an adequate and comprehensive service pursuant to the licence;

(iii) the applicant is not capable of complying with the conditions of the licence;

(b) the applicants compliance with the undertaking to provide an adequate and comprehensive service, and to use and encourage the use of Australian creative resources;

(c) whether if consent was given, contraventions of section 90C (limitations of interest), section 90F (limitations of directorships), section 90G (foreign ownership provisions), section 92JB (cross media ownerships) or section 92JD (cross media directorships) would occur.

Any person wishing to lodge a submission on these issues may lodge it with the Tribunal by 5 May 1989.

Before you lodge a submision, it would assist you to inspect the relevant inquiry file (containing the application and other useful background information) and read the Tribunal's *'Guide for Submitters'* (copies are available from the Tribunal and are attached to the inquiry files). Background papers on the transaction can be obtained and the inquiry files can be inspected during business hours at the following addresses:

Australian Broadcasting Tribunal
Tandem House
76 Berry St
North Sydney NSW 2060

Contact officer Terri Hygate
Telephone (02) 959 7865

Albany Public Library
and Information Service
22 York St
Albany WA 6630

Telephone (098) 41 2333

Australian Broadcasting Tribunal
251 Adelaide Tce
Perth WA 6000

Contact officer Bernie Doyle
Telephone (09) 325 7041

N.N.—8926900

AUSTRALIAN BROADCASTING TRIBUNAL

GRANT OF A PUBLIC RADIO LICENCE TO SERVE THE PARRAMATTA AREA OF SYDNEY

Notice of Commencement of Inquiry

Submissions Invited

1. The Tribunal has received one application for the grant of a public radio licence to serve the Parramatta area of Sydney, as a community broadcasting service. The application was lodged by Cumberland Media Association Incorporated.

The issues to be considered

2. The issues to be considered in the inquiry include, in outline:

(a) whether the applicant meets the statutory criteria set out in the Act, including its:

(i) fitness and propriety to hold the licence; and

(ii) financial, technical and management capabilities necessary to provide an adequate and comprehensive service pursuant to the licence;

(b) the commercial viability of existing radio and television broadcasting services in the Sydney area;

(c) whether the Tribunal should refuse to grant the licence;

(d) whether the applicant meets the public radio planning guidelines, issued by the Department of Communications in August 1985, in relation to the specified purpose of the licence.

(For greater detail concerning the criteria for public licence grants, consult the *Broadcasting Act 1942* and especially section 83C).

Inquiry file

3. A copy of the inquiry file, (IL/89/58) which contains a copy of the application and other related documents, is available for inspection at the following locations:

Sydney

Australian Broadcasting Tribunal
Tandem House
76 Berry St
North Sydney NSW 2000

Monday to Friday
9.00 a.m.—5.00 p.m.

Parramatta

Parramatta Library
Central Branch
Civic Pl
Parramatta NSW 2150

Monday to Friday
10.00 a.m.—8.00 p.m.

Saturday
9.30 a.m.—4.00 p.m.

The inquiry file will be updated progressively and will contain all material on which the Tribunal will rely in reaching its decision, including submissions made by interested persons (see below), subject to any direction relating to restricted material.

Submissions by interested persons

4. Interested persons may make submissions to the Tribunal in relation to this inquiry by forwarding them to reach the Tribunal's North Sydney office not later than 5.00 p.m. on 10 May 1989. This call for submissions is in addition to the invitation extended by the Minister for communications in his notice of 8 December 1988.
5. In order to comply with the regulations, submissions must be lodged in accordance with the regulations. A *'Guide to Submitters'* is available on request from the Tribunal. A copy has been placed on the inquiry file for reference.
6. A copy of any submissions will generally be placed on the inquiry file, although the Tribunal has the power to do otherwise.
7. Further details about the lodgement of submissions may be obtained by contacting Charlotte Berger on: (02) 959 7904

N.N.—8926901

Treasurer

COMMONWEALTH OF AUSTRALIA

Banks (Shareholdings) Act 1972

VARIATION OF PERCENTAGE UNDER SUBSECTION 10 (5)

I, SIR NINIAN MARTIN STEPHEN, Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council and being satisfied that it is in the national interest to do so, hereby, after application made to the Treasurer by each of the corporations specified in the Schedule, vary under subsection 10 (5) of the *Banks (Shareholdings) Act 1972* the instrument published in the *Gazette* on 16 May 1986 fixing under subsection 10 (4) of that Act for the purposes of section 10 of that Act in its application to each of those corporations a percentage of 75 in respect of Bank of America Australia Limited, by omitting '75' and substituting '100'.

SCHEDULE

Bank America Corporation, being the corporation formed or incorporated under that name in the United States of America

Bank of America National Trust and Savings Association, being the corporation formed or incorporated under that name in the United States of America.

Dated this 25th day of January 1989.

N. M. STEPHEN
Governor-General

By His Excellency's Command
J. S. DAWKINS
Minister of State for Employment, Education and Training for and on behalf of the Treasurer

N.N.—8926902

Printed by R. D. RUBIE, Commonwealth Government Printer, Canberra

Commonwealth of Australia Gazette

No. S 87, Monday, 13 March 1989

Published by the Australian Government Publishing Service, Canberra

SPECIAL

COMMONWEALTH OF AUSTRALIA

ADMINISTRATIVE ARRANGEMENTS

ORDERED BY HIS EXCELLENCY THE GOVERNOR-GENERAL

I, WILLIAM GEORGE HAYDEN, Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby approve the following administrative arrangements in substitution for the arrangements in operation immediately before the date of this Order:

1. The matters dealt with by each Department of State include the matters specified in the second column of the Schedule to this Order opposite to the name of that Department in the first column of that Schedule and other matters arising under the enactments administered by the Minister of State or each of the Ministers of State, as the case may be, administering that Department.

2. The enactments administered by a Minister of State administering a Department are the enactments specified in the third column of the Schedule to this Order opposite to the name of that Department and any enactment (whether passed before or after the date of this Order) that relates to a matter dealt with by that Department, not being an enactment specified in that column opposite to the name of another Department.

GIVEN under my Hand and
(L.S.) the Great Seal of Australia
on 13 March 1989.

BILL HAYDEN
Governor-General

By His Excellency's Command
R. J. L. HAWKE
Prime Minister
(Ex. Min. No. 6)

THE SCHEDULE

First Column *Name of Department*	*Second Column* *Principal Matters dealt with*	*Third Column* *Enactments*
The Department of Aboriginal Affairs	Policies and programs for the advancement of the Aboriginal and Torres Strait Island peoples, including consultation and co-ordination	*Aboriginal Affairs (Arrangements with the States) Act 1973* *Aboriginal and Torres Strait Islander Heritage Protection Act 1984* *Aboriginal and Torres Strait Islanders (Queensland Discriminatory Laws) Act 1975* *Aboriginal and Torres Strait Islanders (Queensland Reserves and Communities Self-management) Act 1978* *Aboriginal Councils and Associations Act 1976* *Aboriginal Development Commission Act 1980* *Aboriginal Land Grant (Jervis Bay Territory) Act 1986* *Aboriginal Land (Lake Condah and Framlingham Forest) Act 1987* *Aboriginal Land Rights (Northern Territory) Act 1976* *Australian Institute of Aboriginal Studies Act 1964* States Grants (Aboriginal Advancement) Acts States Grants (Aboriginal Assistance) Acts
The Department of Administrative Services	Acquisition, leasing, management and disposal of land and property in Australia and overseas Transport and storage services Co-ordination of purchasing policy and civil purchasing Disposal of goods Protective services at Commonwealth establishments and diplomatic and consular premises	*Australian Capital Territory (Planning and Land Management) Act 1988*, section 27 insofar as it relates to the declaration of land in the Australian Capital Territory to be National Land where the land is required for Commonwealth purposes other than for the special purposes of Canberra as the National Capital *Archives Act 1983* *Australian Protective Service Act 1987* *Commonwealth Electoral Act 1918*

11129/89 Cat. No. 89 5901 5

First Column *Name of Department*	*Second Column* *Principal Matters dealt with*	*Third Column* *Enactments*
The Department of Administrative Services—*continued*	Analytical laboratory services Meteorology Ionospheric prediction Management of government records Valuation services Geodesy, mapping and surveying services Planning, execution and maintenance of Commonwealth Government works Design and maintenance of Government furniture, furnishings and fittings Government printing and publishing services Electoral matters Australian honours and symbols policy Provision of facilities for members of Parliament other than in Parliament House Administrative support for Royal Commissions and certain other inquiries	*Commonwealth Grants Commission Act 1973* *Defence (Transitional Provisions) Act 1946* and *Defence Transition (Residual Provisions) Act 1952*, insofar as they relate to National Security (General) Regulations 54, 55AA, 55A, 60B, 60G and 60J to 60M *Flags Act 1953* *Lands Acquisition Act 1955* *Lands Acquisition (Defence) Act 1968* *Lands Acquisition (Northern Territory Pastoral Leases) Act 1981* *Members of Parliament (Staff) Act 1984* *Meteorology Act 1955* *Ministers of State Act 1952* *Northern Territory (Commonwealth Lands) Act 1980* *Northern Territory (Self-Government) Act 1978*, sections 69 and 70 *Parliament House Construction Authority Act 1979* *Parliamentary Allowances Act 1952* *Parliamentary Precincts Act 1988* *Procurement of Goods, Works and Services Act 1981* *Public Accounts Committee Act 1951* *Public Works Committee Act 1969* *Referendum (Machinery Provisions) Act 1984* *Representation Act 1983*
The Department of the Arts, Sport, the Environment, Tourism and Territories	Cultural affairs, including support for the arts National collections National heritage Sport and recreation Environment and conservation Tourism, including the tourist industry International expositions and support for international conferences and special events Information co-ordination and services within Australia, including advertising Administration of the Australian Capital Territory Administration of the Jervis Bay Territory, the Territory of Cocos (Keeling) Islands, the Territory of Christmas Island, the Coral Sea Islands Territory, the Territory of Ashmore and Cartier Islands, the Australian Antarctic Territory, and the Territory of Heard Island and the McDonald Islands, and of Commonwealth responsibilities on Norfolk Island Constitutional development of the Northern Territory of Australia	*ACT Self-Government (Consequential Provisions) Act 1988* *Antarctic Marine Living Resources Conservation Act 1981* *Antarctic Treaty Act 1960* *Antarctic Treaty (Environment Protection) Act 1980* *Ashmore and Cartier Islands Acceptance Act 1933* *Australia Council Act 1975* *Australian Antarctic Territory Acceptance Act 1933* *Australian Antarctic Territory Act 1954* *Australian Capital Territory (Electoral) Act 1988* *Australian Capital Territory (Planning and Land Management) Act 1988*, except to the extent administered by the Minister for Administrative Services *Australian Capital Territory (Self-Government) Act 1988* *Australian Capital Territory Stamp Duty Act 1969* *Australian Capital Territory Tax (Cheques) Act 1969* *Australian Capital Territory Tax (Hire Purchase Business) Act 1969* *Australian Capital Territory Tax (Insurance Business) Act 1969* *Australian Capital Territory Tax (Life Insurance Business) Act 1981* *Australian Capital Territory Tax (Purchases of Marketable Securities) Act 1969* *Australian Capital Territory Tax (Sales of Marketable Securities) Act 1969* *Australian Capital Territory Tax (Transfers of Marketable Securities) Act 1986* *Australian Capital Territory Tax (Vehicle Registration) Act 1981* *Australian Capital Territory Taxation (Administration) Act 1969* *Australian Film Commission Act 1975* *Australian Film, Television and Radio School Act 1973* *Australian Heritage Commission Act 1975* *Australian Institute of Sport Act 1986* *Australian Institute of Sport (Consequential Provisions) Act 1986* *Australian Sports Commission Act 1985* *Australian Tourist Commission Act 1987*

First Column	*Second Column*	*Third Column*
Name of Department	*Principal Matters dealt with*	*Enactments*
The Department of the Arts, Sport, the Environment, Tourism and Territories—*continued*		*Australian Tourist Commission (Transitional Provisions) Act 1987* *Canberra College of Advanced Education Act 1967* *Canberra Water Supply (Googong Dam) Act 1974* *Captains Flat (Abatement of Pollution) Agreement Act 1975* *Christmas Island Act 1958* Christmas Island Agreement Acts *Cocos (Keeling) Islands Act 1955* *Commonwealth Functions (Statutes Review) Act 1981*, Part II *Commonwealth Teaching Service Act 1972* *Coral Sea Islands Act 1969* *Darwin Lands Acquisition Act 1945* *Environment (Financial Assistance) Act 1977* *Environment Protection (Alligator Rivers Region) Act 1978* *Environment Protection (Impact of Proposals) Act 1974* *Environment Protection (Nuclear Codes) Act 1978* *Environment Protection (Sea Dumping) Act 1981* *Great Barrier Reef Marine Park Act 1975* *Great Barrier Reef Marine Park Amendment Act 1988* *Heard Island and McDonald Islands Act 1953* *Historic Shipwrecks Act 1976* *Jervis Bay Territory Acceptance Act 1915* *Koongarra Project Area Act 1981* *Lemonthyme and Southern Forests (Commission of Enquiry) Act 1987* *National Fitness Act 1941* *National Gallery Act 1975* *National Library Act 1960* *National Museum of Australia Act 1980* *National Parks and Wildlife Conservation Act 1975* *Norfolk Island Act 1979* *Northern Territory Acceptance Act 1910* *Northern Territory (Self-Government) Act 1978*, except sections 69 and 70 *Parliament Act 1974* *Pay-roll Tax (Territories) Act 1971* *Pay-roll Tax (Territories) Assessment Act 1971* *Protection of Movable Cultural Heritage Act 1986* *Public Lending Right Act 1985* *Removal of Prisoners (Australian Capital Territory) Act 1968* *Removal of Prisoners (Territories) Act 1923*, insofar as it relates to the Northern Territory of Australia (except to the extent administered by the Attorney-General) and to Norfolk Island, the Territory of Cocos (Keeling) Islands, the Territory of Christmas Island, the Coral Sea Islands Territory, the Territory of Ashmore and Cartier Islands, the Heard Island and McDonald Islands Territory and the Australian Antarctic Territory *Sea Installations Act 1987* *Sea Installations Levy Act 1987* *Sea Installations (Miscellaneous Amendments) Act 1987* Seat of Government Acceptance Acts *Seat of Government Act 1908* Seat of Government (Administration) Acts *States Grants (Air Quality Monitoring) Act 1976* *States Grants (Nature Conservation) Act 1974* *Urban and Regional Development (Financial Assistance) Act 1974*, insofar as it relates to national estate grants *Whale Protection Act 1980* *Wildlife Protection (Regulation of Exports and Imports) Act 1982* *World Heritage Properties Conservation Act 1983*

First Column	*Second Column*	*Third Column*
Name of Department	*Principal Matters dealt with*	*Enactments*
The Attorney-General's Department	Law and justice including— Administrative law Bankruptcy and insolvency Business law and practice Censorship Consumer affairs Copyright Courts and tribunals Human rights Law reform Legal aid Marriage and family law and related services Legal services to the Commonwealth Criminal law and law enforcement National security, counter terrorism and protective security policy and co-ordination	*Acts Citation Act 1976* *Acts Interpretation Act 1901* *Administrative Appeals Tribunal Act 1975* Administrative Changes (Consequential Provisions) Acts *Administrative Decisions (Judicial Review) Act 1977* *Admiralty Act 1988* *Amendments Incorporation Act 1905* *Arbitration (Foreign Awards and Agreements) Act 1974* *Australia Act 1986* *Australia (Request and Consent) Act 1985* *Australian Capital Territory Evidence (Temporary Provisions) Act 1971* *Australian Capital Territory Supreme Court Act 1933* *Australian Federal Police Act 1979*, except to the extent administered by the Minister for Industrial Relations *Australian Security Intelligence Organization Act 1979* *Bankruptcy Act 1966* *Bills of Exchange Act 1909* *Cash Transaction Reports Act 1988* *Cheques and Payment Orders Act 1986* *Civil Aviation (Offenders on International Aircraft) Act 1970* *Coastal Waters (Northern Territory Powers) Act 1980* *Coastal Waters (Northern Territory Title) Act 1980* *Coastal Waters (State Powers) Act 1980* *Coastal Waters (State Title) Act 1980* *Common Informers (Parliamentary Disqualifications) Act 1975* *Commonwealth Legal Aid Act 1977* *Commonwealth Motor Vehicles (Liability) Act 1959* *Commonwealth Places (Application of Laws) Act 1970* *Commonwealth Prisoners Act 1967* *Companies (Acquisition of Shares) Act 1980* *Companies (Acquisition of Shares—Fees) Act 1980* *Companies Act 1981* *Companies and Securities (Interpretation and Miscellaneous Provisions) Act 1980* *Companies (Fees) Act 1981* *Companies (Transitional Provisions) Act 1981* *Complaints (Australian Federal Police) Act 1981*, except to the extent administered by the Prime Minister *Conciliation and Arbitration Act 1904*, sections 98 to 103B inclusive; sections 132H, 132J, 141A, 141B, 168, section 198 (insofar as it relates to prescribing the practice and procedure, fees to be charged, and matters with respect to costs and expenses, the taxation of costs and expenses, and the review of any such taxation, in proceedings before Courts exercising jurisdiction under the Act) and such other provisions of the Act as relate to the functions, practice and procedure of Courts exercising jurisdiction under the Act *Copyright Act 1968* *Crimes Act 1914* *Crimes (Aircraft) Act 1963* *Crimes at Sea Act 1979* *Crimes (Biological Weapons) Act 1976* *Crimes (Currency) Act 1981* *Crimes (Foreign Incursions and Recruitment) Act 1978* *Crimes (Hijacking of Aircraft) Act 1972* *Crimes (Internationally Protected Persons) Act 1976* *Crimes (Overseas) Act 1964* *Crimes (Protection of Aircraft) Act 1973*

First Column	*Second Column*	*Third Column*
Name of Department	*Principal Matters dealt with*	*Enactments*
The Attorney-General's Department—*continued*		*Crimes (Torture) Act 1988* *Criminology Research Act 1971* *Crown Debts (Priority) Act 1981* *Customs Act 1901*, section 9 in respect of powers under Division 1A of Part XII and Division 3 of Part XIII, section 50 insofar as it relates to the making of regulations making provisions in the nature of censorship of imported goods (including printed matter and films), Division 1A of Part XII and Division 3 of Part XIII *Death Penalty Abolition Act 1973* *Defence Force Discipline Appeals Act 1955* *Defence (Re-establishment) Act 1965*, Part III; and section 59 in respect of powers and functions under Part III *Defence (Transitional Provisions) Act 1946*, and *Defence Transition (Residual Provisions) Act 1952*, in relation to National Security (Supplementary) Regulation 100 *Defence (Visiting Forces) Act 1963* *Director of Public Prosecutions Act 1983* *Domicile Act 1982* *Environment Protection (Northern Territory Supreme Court) Act 1978* *Evidence Act 1905* *Extradition Act 1988* *Extradition (Repeal and Consequential Provisions) Act 1988* *Family Law Act 1975* *Federal Court of Australia Act 1976* *Federal Court of Australia (Consequential Provisions) Act 1976* *Federal Proceedings (Costs) Act 1981* *Foreign Proceedings (Excess of Jurisdiction) Act 1984* *Foreign States Immunities Act 1985* *Freedom of Information Act 1982* *Futures Industry Act 1986* *Futures Industry (Fees) Act 1986* *Geneva Conventions Act 1957*, other than Part IV *Genocide Convention Act 1949* *High Court Justices (Long Leave Payments) Act 1979* *High Court of Australia Act 1979* *Human Rights and Equal Opportunity Commission Act 1986* *Human Rights and Equal Opportunity Commission (Transitional Provisions and Consequential Amendments) Act 1986* *Industrial Relations Act 1988*, Division 1 of Part XII, and section 348 in respect of powers under Division 1 of Part XII *Judges (Long Leave Payments) Act 1979* *Judges' Pensions Act 1968* *Judicial Appointment (Western Samoa) Act 1980* *Judiciary Act 1903* *Judiciary (Diplomatic Representation) Act 1977* *Jurisdiction of Courts (Cross-vesting) Act 1987* Jurisdiction of Courts (Miscellaneous Amendments) Acts *Jury Exemption Act 1965* *Law Courts (Sydney) Act 1977* *Law Officers Act 1964* *Law Reform Commission Act 1973* *Maintenance Orders (Commonwealth Officers) Act 1966* *Marine Insurance Act 1909* *Marriage Act 1961* *Matrimonial Causes Act 1971* *Mutual Assistance in Criminal Matters Act 1987*

First Column	*Second Column*	*Third Column*
Name of Department	*Principal Matters dealt with*	*Enactments*
The Attorney-General's Department—*continued*		*Mutual Assistance in Criminal Matters (Consequential Amendments) Act 1987* *National Companies and Securities Commission Act 1979* *National Crime Authority Act 1984* *National Crime Authority (Status and Rights of Chairman) Act 1984* *Nauru (High Court Appeals) Act 1976* Ordinances and Regulations (Notification) Acts *Parliamentary Counsel Act 1970* *Parliamentary Papers Act 1908* *Parliamentary Privileges Act 1987* *Privacy Act 1988* *Privy Council (Appeals from the High Court) Act 1975* *Privy Council (Limitation of Appeals) Act 1968* *Proceeds of Crime Act 1987* *Public Order (Protection of Persons and Property) Act 1971* *Racial Discrimination Act 1975* *Re-establishment and Employment Act 1945*, Part IX; Division 1 of Part XI insofar as it extends Part IX; and Part XII insofar as it applies or may be applied in relation to the foregoing *Removal of Prisoners (Territories) Act 1923*, insofar as it relates to the release of prisoners and criminal lunatics removed from the Northern Territory of Australia *Secret Commissions Act 1905* *Securities Industry Act 1980* *Securities Industry (Fees) Act 1980* *Service and Execution of Process Act 1901* *Sex Discrimination Act 1984* *Special Prosecutors Act 1982* *State and Territorial Laws and Records Recognition Act 1901* Statute Law (Miscellaneous Amendments) Acts, except to the extent administered by the Minister for Industry, Technology and Commerce Statute Law (Miscellaneous Provisions) Acts Statute Law Revision Acts *Statute of Westminster Adoption Act 1942* *Statutory Declarations Act 1959* *Statutory Rules Publication Act 1903* *Telecommunications (Interception) Act 1979* *Trade Practices Act 1974*, except to the extent administered by the Minister for Transport and Communications *Transfer of Prisoners Act 1983* *War Crimes Act 1945*
The Department of Community Services and Health	Services for the aged, people with disabilities and families with children Community support services Housing assistance Public health, research and preventive medicine Health promotion and disease prevention Pharmaceutical benefits Health benefits schemes Specific health services, including human quarantine National drug abuse strategy	*Acoustic Laboratories Act 1948* *Aged or Disabled Persons Homes Act 1954* *Aged or Disabled Persons Hostels Act 1972* *Australian Institute of Health Act 1987* *Child Care Act 1972* Commonwealth and State Housing Agreements Acts *Commonwealth Serum Laboratories Act 1961* *Defence (Re-establishment) Act 1965*, Parts V and VA, and section 59 in respect of powers and functions under Parts V and VA, except in relation to payments to individuals *Delivered Meals Subsidy Act 1970* *Disability Services Act 1986* *Disability Services (Transitional Provisions and Consequential Amendments) Act 1986* *Epidemiological Studies (Confidentiality) Act 1981* *First Home Owners Act 1983* *Handicapped Persons Assistance Act 1974* *Health Insurance Act 1973* *Health Insurance Commission Act 1973* *Home and Community Care Act 1985* *Home Deposit Assistance Act 1982*

First Column *Name of Department*	*Second Column* *Principal Matters dealt with*	*Third Column* *Enactments*
The Department of Community Services and Health—*continued*		*Homeless Persons Assistance Act 1974* *Home Nursing Subsidy Act 1956* Home Savings Grants Acts Housing Agreements Acts Housing Assistance Acts *Medical Research Endownment Act 1937* *Narcotic Drugs Act 1967*, sections 9, 10, 11, 13, 19 and 23 and sub-section 24 (1), and so much of the remaining provisions of the Act (other than sections 12 and 22 and sub-section 24 (2)) as relates to powers and functions under those sections *National Health Act 1953* *Nursing Homes Assistance Act 1974* *Quarantine Act 1908*, in relation to human quarantine *Quarantine (Validation of Fees) Act 1985*, in relation to human quarantine *Re-establishment and Employment Act 1945*, Part VIII; Division 1 of Part XI insofar as it extends Part VIII; Division 3 of Part XI except in relation to payments to individuals; and Part XII insofar as it applies or may be applied to the foregoing *Social Welfare Commission (Repeal) Act 1976* *States Grants (Home Care) Act 1969* *States Grants (Housing) Act 1971* *States Grants (Nurse Education Transfer Assistance) Act 1985* *States Grants (Paramedical Services) Act 1969* *Supported Accommodation Assistance Act 1985* *Therapeutic Goods Act 1966* *Tuberculosis Act 1948* *World Health Organisation Act 1947*
The Department of Defence	Defence, including— civil defence defence production defence purchasing, including offsets for defence purposes	*Air Force Act 1923* *Approved Defence Projects Protection Act 1947* *Cockatoo and Schnapper Islands Act 1949* *Control of Naval Waters Act 1918* *Defence Act 1903*, other than sections 58A to 58Y, 61, 61A, 61B, 61C, 118A and 118B and paragraph 124(1)(qba) *Defence Force Discipline Act 1982* *Defence Force Retirement and Death Benefits Act 1973* Defence Force Retirement and Death Benefits (Pension Increases) Acts Defence Forces Retirement Benefits Acts *Defence Forces Retirement Benefits Fund (Distribution of Surplus to Pensioners) Act 1976* Defence Forces Retirement Benefits (Pension Increases) Acts *Defence Housing Authority Act 1987* *Defence (Parliamentary Candidates) Act 1969* *Defence (Special Undertakings) Act 1952* *Geneva Conventions Act 1957*, Part IV *Naval Defence Act 1910* *Royal Australian Air Force Veterans' Residences Act 1953* *Services Trust Funds Act 1947* *Supply and Development Act 1939* *War Service Estates Act 1942* *Williamstown Dockyard Employees Act 1987*
The Department of Employment, Education and Training	Education, other than migrant adult education Youth Affairs Employment and training Commonwealth Employment Service Labour market programs Co-ordination of research policy Research grants and fellowships	*Anglo-Australian Telescope Agreement Act 1970* *Australian National University Act 1946* *Community Employment Act 1983* *Defence Act 1903*, sections 40A, 61, 61A, 61B, 61C, 118A and 118B *Defence (Re-establishment) Act 1965*, Parts I and II; and Part VII except to the extent that section 59 relates to Parts III, IV, V, VA and VI *Education Research Act 1970* *Employment, Education and Training Act 1988* *Higher Education Funding Act 1988*

First Column	*Second Column*	*Third Column*
Name of Department	*Principal Matters dealt with*	*Enactments*
The Department of Employment, Education and Training—*continued*		*Immigration (Education) Act 1971*, except to the extent administered by the Minister for Immigration, Local Government and Ethnic Affairs *Independent Schools (Loans Guarantee) Act 1969* *Maritime College Act 1978* *National Service Act 1951* *National Service Termination Act 1973* *Non-government Schools (Loans Guarantee) Act 1977* *Overseas Students Charge Act 1979* *Overseas Students Charge Collection Act 1979* *Re-establishment and Employment Act 1945*, Divisions 1, 2 and 3 (excluding section 43 and section 44 in relation to section 43) of Part II; Part III in relation to industrial and professional training (other than university, university-type and rural training); Division 1 of Part XI insofar as it extends the foregoing; Division 2 of Part XI; and Part XII insofar as it applies or may be applied in relation to the foregoing *States Grants (Advanced Education Assistance) Act 1976* *States Grants (Education Assistance—Participation and Equity) Act 1983* States Grants (Schools Assistance) Acts States Grants (Tertiary Education Assistance) Acts *Student Assistance Act 1973*
The Department of Finance	Evaluation and review of governmental programs and associated expenditure and staffing proposals Expenditure and staffing estimates Governmental financial administration and accounts, including administration of the Public Account Commonwealth superannuation schemes	Appropriation Acts *Audit Act 1901*, except to the extent administered by the the Prime Minister *Dartmouth Reservoir Agreement Act 1970* Loan Acts, except insofar as they give authority to borrow *Loan (Temporary Revenue Deficits) Act 1953*, section 3 Loan (War Service Land Settlement) Acts *New South Wales Grant (Chrysotile Corporation) Act 1978* *Papua New Guinea (Staffing Assistance) Act 1973*, insofar as it relates to superannuation and retirement benefits *Papua New Guinea (Staffing Assistance) Termination Act 1976* *Parliamentary Contributory Superannuation Act 1948* Parliamentary Retiring Allowances (Increases) Acts Salaries Adjustment Acts Salaries (Statutory Offices) Adjustment Acts *Special Employment-related Programs Act 1982* *States Grants (Hospital Operating Costs) Act 1976* Superannuation Acts *Superannuation Benefit (Interim Arrangements) Act 1988* *Superannuation (Distribution of Surplus) Act 1974* Superannuation (Pension Increases) Acts Supply Acts Surplus Revenue Acts *Territory Authorities (Financial Provisions) Act 1978* *Transferred Officers' Allowances Act 1948* *Treaty of Peace (Germany) Act 1919* *War Gratuity Act 1945* *War Gratuity Appropriation Act 1948* *Western Australia (South-West Region Water Supplies) Agreement Act 1965* *Wool Marketing (Loan) Act 1974*
The Department of Foreign Affairs and Trade	External affairs, including— relations and communications with overseas governments treaties, including trade agreements bilateral and multilateral trade policy international trade and commodity negotiations	Asian Development Fund Acts *Australia-Japan Foundation Act 1976* *Australian Centre for International Agricultural Research Act 1982* *Australian Development Assistance Agency (Repeal) Act 1977* *Charter of the United Nations Act 1945*

First Column *Name of Department*	*Second Column* *Principal Matters dealt with*	*Third Column* *Enactments*
The Department of Foreign Affairs and Trade—*continued*	diplomatic and consular missions disarmament and nuclear non-proliferation information co-ordination and services overseas	*Consular Fees Act 1955* *Consular Privileges and Immunities Act 1972* *Customs Tariff (New Zealand Preference) Agreement Act 1933* *Diplomatic and Consular Missions Act 1978* *Diplomatic Privileges and Immunities Act 1967* *Indus Basin Development Fund Agreement Act 1960* *Indus Basin Development Fund Supplemental Agreement Act 1965* *International Development Association Act 1960* International Development Association (Further Payment) Acts International Development Association (Special Constribution) Acts International Fund for Agricultural Development Acts International Labour Organisation Acts *International Organizations (Privileges and Immunities) Act 1963* *Nauru Independence Act 1967* *Papua New Guinea (Application of Laws) Act 1973* *Papua New Guinea Independence Act 1975* *Papua New Guinea (Staffing Assistance) Act 1973*, except to the extent administered by the Minister for Finance *Passports Act 1938* *Registration of Deaths Abroad Act 1984* *Security Treaty (Australia, New Zealand and the United States of America) Act 1952* *South Pacific Nuclear Free Zone Treaty Act 1986* *Trade Representatives Act 1933* *United Nations Educational, Scientific and Cultural Organization Act 1947* *United Nations Food and Agriculture Organization Act 1944* United States Naval Communications Station Agreement Acts
The Department of Immigration, Local Government and Ethnic Affairs	Migration, including refugees Citizenship Ethnic affairs Post-arrival arrangements for migrants, other than migrant child education Matters relating to local government Regional development	*Albury-Wodonga Development Act 1973* *Albury-Wodonga Development (Financial Assistance) Act 1973* *Aliens Act Repeal Act 1984* *Australian Citizenship Act 1948* *Departure Tax Collection Act 1978*, insofar as it relates to taxation imposed in respect of the departure of persons from Australia by sea *Growth Centres (Financial Assistance) Act 1973* *Immigration (Education) Act 1971*, insofar as it relates to migrant adult education *Immigration (Guardianship of Children) Act 1946* *Lands Commissions (Financial Assistance) Act 1973* *Local Government (Financial Assistance) Act 1986* *Migration Act 1958* *Tasmania Agreement (Launceston Precision Tool Annexe) Act 1980* *Temple Society Trust Fund Act 1949* *Urban and Regional Development (Financial Assistance) Act 1974*, except to the extent administered by the Minister for the Arts, Sport, the Environment, Tourism and Territories
The Department of Industrial Relations	Industrial relations, including conciliation and arbitration in relation to industrial disputes Promotion of sound industrial relations policies, practices and machinery Public Service pay and conditions Remuneration Tribunals	*Affirmative Action (Equal Employment Opportunity for Women) Act 1986* *Australian Federal Police Act 1979*, Divisions 2 and 3 of Part V (except sub-section 46 (1), paragraphs 47 (a), 49 (1) (o) and 54 (4) (b) and section 55) and section 66 in respect of powers vested in the Minister for Industrial Relations *Builders Labourers' Federation (Cancellation of Registration) Act 1986* *Builders Labourers' Federation (Cancellation of Registration—Consequential Provisions) Act 1986* *Building Industry Act 1985*

First Column *Name of Department*	*Second Column* *Principal Matters dealt with*	*Third Column* *Enactments*
The Department of Industrial Relations—*continued*		*Coal Industry Act 1946*, Part V *Commonwealth Employees Rehabilitation and Compensation Act 1988* *Conciliation and Arbitration Act 1904*, except to the extent administered by the Attorney-General *Defence Act 1903*, sections 58A to 58Y *Equal Employment Opportunity (Commonwealth Authorities) Act 1987* *Industrial Relations Act 1988*, except to the extent administered by the Attorney-General *Industrial Relations (Consequential Provisions) Act 1988* *Judicial and Statutory Officers (Remuneration and Allowances) Act 1984* *Long Service Leave (Commonwealth Employees) Act 1976* *Maternity Leave (Commonwealth Employees) Act 1973* *National Labour Consultative Council Act 1977* *National Occupational Health and Safety Commission Act 1985* *Remuneration and Allowances Alteration Act 1986* *Remuneration Tribunals Act 1973* *States Grants (Coal Mining Industry Long Service Leave) Act 1949* *Stevedoring Industry Acts (Termination) Act 1977* *Stevedoring Industry Finance Committee Act 1977* *Stevedoring Industry Levy Act 1977* *Stevedoring Industry Levy Collection Act 1977* *Trade Union Training Authority Act 1975* *Tradesmen's Rights Regulation Act 1946* United States Naval Communications Station (Civilian Employees) Acts
The Department of Industry, Technology and Commerce	Manufacturing and commerce including industries development Science and technology, including industrial research and development Export services Marketing, including export promotion, of manufactures and services Small business Building industry Duties of customs and excise Bounties on the production of goods Offsets, to the extent not dealt with by the Department of Defence Patents of inventions and designs, and trade marks Weights and measures Civil space program Commission for the Future	*Advance Australia Logo Protection Act 1984* *Anti-dumping Authority Act 1988* *Australian Industry Development Corporation Act 1970* *Australian Institute of Marine Science Act 1972* *Australian Nuclear Science and Technology Organisation Act 1987* *Australian Nuclear Science and Technology Organisation (Transitional Provisions) Act 1987* *Australian Trade Commission Act 1985* *Australian Trade Commission (Transitional Provisions and Consequential Amendments) Act 1985* *Automotive Industry Authority Act 1984* *Bass Strait Freight Adjustment Levy Collection Act 1984* *Beer Excise Act Repeal Act 1968* *Bounty (Agricultural Tractors and Equipment) Act 1985* *Bounty (Bed Sheeting) Act 1977* *Bounty (Berry Fruits) Act 1982* Bounty (Books) Acts *Bounty (Commercial Motor Vehicles) Act 1978* *Bounty (Computers) Act 1984* *Bounty (High Alloy Steel Products) Act 1983* *Bounty (Injection-moulding Equipment) Act 1979* *Bounty (Metal Working Machines and Robots) Act 1985* *Bounty (Metal-working Machine Tools) Act 1978* *Bounty (Paper) Act 1979* *Bounty (Printed Fabrics) Act 1981* *Bounty (Ship Repair) Act 1986* *Bounty (Ships) Act 1980* *Bounty (Steel Mill Products) Act 1983* *Bounty (Textile Yarns) Act 1981* *Canned Fruit Excise Act Repeal Act 1968* *Coal Excise Act 1949* *Commerce (Trade Descriptions) Act 1905* *Customs Act 1901*, except to the extent administered by the Attorney-General

First Column *Name of Department*	*Second Column* *Principal Matters dealt with*	*Third Column* *Enactments*
The Department of Industry, Technology and Commerce—*continued*		*Customs Administration Act 1985* *Customs Administration (Transitional Provisions and Consequential Amendments) Act 1985* *Customs Securities (Penalties) Act 1981* *Customs Tariff Act 1982* *Customs Tariff Act 1987* *Customs Tariff (Anti-Dumping) Act 1975* *Customs Tariff (Coal Export Duty) Act 1975* *Customs Tariff (Rate Alteration) Act 1988* *Customs Tariff (Stand-By Duty) Act 1985* *Customs Tariff (Uranium Concentrate Export Duty) Act 1980* Customs Tariff Validation Acts *Customs Undertakings (Penalties) Act 1981* *Defence (Transitional Provisions) Act 1946* and *Defence Transition (Residual Provisions) Act 1952*, in relation to the National Security (Industrial Property) Regulations and regulation 62 of the National Security (Supplementary) Regulations *Designs Act 1906* Diesel Fuel Tax Acts *Diesel Fuel Taxation (Administration) Act 1957* *Distillation Act 1901* *Excise Act 1901* *Excise Tariff Act 1921* Excise Tariff Validation Acts *Export Expansion Grants Act 1978* *Export Market Development Grants Act 1974* *Fertilisers Subsidy Act 1986* *Industrial Research and Development Incentives Act 1976* *Industry Research and Development Act 1986* *Liquefied Petroleum Gas (Grants) Act 1980* *Management and Investment Companies Act 1983* *Narcotic Drugs Act 1967*, sections 12 and 22 and sub-section 24 (2), and so much of the remaining provisions of that Act (other than sections 9, 10, 11, 13, 19 and 23 and sub-section 24 (1)) as relates to powers and functions under those sections *National Measurement Act 1960* *Nitrogenous Fertilizers Subsidy Act 1966* *Olympic Insignia Protection Act 1987* *Patents Act 1952* *Patents, Trade Marks, Designs and Copyright Act 1939* *Petroleum Retail Marketing Franchise Act 1980* *Petroleum Retail Marketing Sites Act 1980* *Phosphate Fertilizers Subsidy Act 1963* *Psychotropic Substances Act 1976* *Science and Industry Endowment Act 1926* *Science and Industry Research Act 1949* *Scout Association Act 1924* *Ship Construction Bounty Act 1975* *Snowy Mountains Engineering Corporation Act 1970* *Spirits Act 1906* *States Grants (Petroleum Products) Act 1965* *Statute Law (Miscellaneous Amendments) (No 1) Act 1982*, sections 191 and 192 *Steel Industry Authority Act 1983* *Structural Adjustments (Loan Guarantees) Act 1974* *Subsidy (Cultivation Machines and Equipment) Act 1986* *Subsidy (Grain Harvesters and Equipment) Act 1985* *Textiles, Clothing and Footwear Development Authority Act 1988* *Trade Marks Act 1955*
The Department of Primary Industries and Energy	Agricultural, pastoral, fishing, forest, mineral and energy industries, and electricity Water and other natural resources	*Agricultural and Veterinary Chemicals Act 1988* *Aluminium Industry Act 1960* *Apple and Pear Export Charge Act 1976* *Apple and Pear Export Charge Collection Act 1976*

First Column	*Second Column*	*Third Column*
Name of Department	*Principal Matters dealt with*	*Enactments*
The Department of Primary Industries and Energy—*continued*	Primary industries inspection and quarantine Primary industries and energy science and research, including geoscience Commodity marketing, including export promotion Commodity-specific international organisations and activities Administration of international commodity agreements Administration of export controls on primary industries and energy products Radioactive waste management	*Apple and Pear Export Underwriting Act 1981* *Apple and Pear Levy Act 1976* *Apple and Pear Levy Collection Act 1976* *Atomic Energy Act 1953* *Australian Apple and Pear Corporation Act 1973* *Australian Dried Fruits Corporation Act 1978* *Australian Horticultural Corporation Act 1987* *Australian Horticultural Corporation (Transitional Provisions and Consequential Amendments) Act 1987* *Australian Meat and Live-stock Corporation Act 1977* *Australian Meat and Live-stock Industry Policy Council Act 1984* *Australian Meat and Live-stock Industry Selection Committee Act 1984* *Australian Meat and Live-stock Legislation (Consequential Amendments and Transitional Provisions) Act 1985* *Australian Meat and Live-stock Research and Development Corporation Act 1985* *Australian Wine and Brandy Corporation Act 1980* *Barley Research Levy Act 1980* *Barley Research Levy Collection Act 1980* *Bass Strait Freight Adjustment Levy Act 1984* *Bass Strait Freight Adjustment Trust Fund Act 1984* *Beef Industry (Incentive Payments) Act 1977* *Biological Control Act 1984* *Blowering Water Storage Works Agreement Act 1963* *Brigalow Lands Agreement Act 1962* *Coal Industry Act 1946*, except Part V *Coal Production (War-time) Act Repeal Act 1948* *Coal Research Assistance Act 1977* *Commonwealth Functions (Statutes Review) Act 1981*, Part IV *Continental Shelf (Living Natural Resources) Act 1968* *Cotton Levy Act 1982* *Cotton Levy Collection Act 1982* *Dairy Adjustment Act 1974* *Dairy Industry Stabilization Act 1977* *Dairy Industry Stabilization Levy Act 1977* *Dairy Industry Stabilization Levy (Termination of Levy) Act 1986* *Dairy Legislation (Transitional Provisions and Consequential Amendents) Act 1986* Dairy Produce Acts Dairy Produce Levy Acts *Dairying Industry Research and Promotion Levy Act 1972* Dairying Industry Research and Promotion Levy Collection Acts *Dairying Industry Research and Promotion Levy (Termination of Levy) Act 1986* *Derby Jetty Agreement Act 1962* *Dried Fruits Export Charges Act 1924* *Dried Fruits Levy Act 1971* *Dried Fruits Levy Collection Act 1971* *Dried Sultana Production Underwriting Act 1982* *Dried Vine Fruits Equalization Act 1978* *Dried Vine Fruits Equalization Levy Act 1978* *Drought Assistance (Primary Producers) Act 1982* *Egg Industry Research (Hen Quota) Levy Act 1987* *Egg Industry Research (Hen Quota) Levy Collection Act 1987* *Export Control Act 1982* *Export Control (Miscellaneous Amendments) Act 1982* *Export Inspection Charges Collection Act 1985* *Export Inspection (Establishment Registration Charges) Act 1985*

First Column	*Second Column*	*Third Column*
Name of Department	*Principal Matters dealt with*	*Enactments*
The Department of Primary Industries and Energy—*continued*		*Export Inspection (Quantity Charge) Act 1985* *Export Inspection (Service Charge) Act 1985* *Fisheries Act 1952* *Fisheries Agreements (Payments) Act 1981* *Fisheries Levy Act 1984* *Fishing Industry Act 1956* *Fishing Industry Research Act 1969* *Fishing Industry Research and Development Act 1987* *Foreign Fishing Boats Levy Act 1981* *Forestry and Timber Bureau Act 1930* *Gladstone Power Station Agreement Act 1970* *Grain Legumes Levy Act 1985* *Grain Legumes Levy Collection Act 1985* *Grape Research Levy Act 1986* *Grape Research Levy Collection Act 1986* *Honey Export Charge Act 1973* *Honey Export Charge Collection Act 1973* *Honey Industry Act 1962* Honey Levy Acts *Honey Levy Collection Act 1962* *Honey Marketing Act 1988* *Horticultural Export Charge Act 1987* *Horticultural Export Charge Collection Act 1987* *Horticultural Levy Act 1987* *Horticultural Levy Collection Act 1987* *Horticultural Policy Council Act 1987* *Horticultural Research and Development Corporation Act 1987* *Income Equalization Deposits (Interest Adjustment) Act 1984* *International Sugar Agreement Act 1978* *Laying Chicken Levy Act 1988* *Laying Chicken Levy Collection Act 1988* *Liquid Fuel Emergency Act 1984* *Livestock Diseases Act 1978* *Live-stock Export Charge Act 1977* *Live-stock Export Charge Collection Act 1977* *Live-stock Slaughter (Export Inspection Charge) Act 1979* *Live-stock Slaughter (Export Inspection Charge) Collection Act 1979* *Live-stock Slaughter (Export Inspection Charge) Validation Act 1984* *Live-stock Slaughter Levy Act 1964* *Live-stock Slaughter Levy Collection Act 1964* *Loan (Income Equalization Deposits) Act 1976* *Meat Chicken Levy Act 1969* *Meat Chicken Levy Collection Act 1969* *Meat Export Charge Act 1984* *Meat Export Charge Collection Act 1984* *Meat Inspection Act 1983* *Meat Inspection Arrangements Act 1964* *Meat Research Act 1960* *Minerals (Submerged Lands) Act 1981* *Minerals (Submerged Lands) (Exploration Permit Fees) Act 1981* *Minerals (Submerged Lands) (Production Licence Fees) Act 1981* *Minerals (Submerged Lands) (Registration Fees) Act 1981* *Minerals (Submerged Lands) (Royalty) Act 1981* *Minerals (Submerged Lands) (Works Authority Fees) Act 1981* *Murray-Darling Basin Act 1983* *National Water Resources (Financial Assistance) Act 1978* *New South Wales Grant (Leeton Co-operative Cannery Limited) Act 1971* *Northern Prawn Fishery Voluntary Adjustment Scheme Loan Guarantee Act 1985* *Nuclear Non-Proliferation (Safeguards) Act 1987*

First Column	*Second Column*	*Third Column*
Name of Department	*Principal Matters dealt with*	*Enactments*
The Department of Primary Industries and Energy—*continued*		*Oil Companies (Stock Loss) Reimbursement Act 1986* *Oilseeds Levy Act 1977* *Oilseeds Levy Collection Act 1977* *Petroleum Excise (Prices) Act 1987* *Petroleum Revenue Act 1985* *Petroleum Search Subsidy Act 1959* *Petroleum (Submerged Lands) Act 1967* *Petroleum (Submerged Lands) (Exploration Permit Fees) Act 1967* *Petroleum (Submerged Lands) (Pipeline Licence Fees) Act 1967* *Petroleum (Submerged Lands) (Production Licence Fees) Act 1967* *Petroleum (Submerged Lands) (Registration Fees) Act 1967* *Petroleum (Submerged Lands) (Retention Lease Fees) Act 1985* *Petroleum (Submerged Lands) (Royalty) Act 1967* *Pig Industry Act 1986* *Pig Industry (Transitional Provisions) Act 1986* *Pig Slaughter Levy Act 1971* *Pig Slaughter Levy Collection Act 1971* *Pipeline Authority Act 1973* *Pipeline Construction (Dalton to Canberra) Act 1980* *Pipeline Construction (Young to Wagga Wagga) Act 1980* *Plant Variety Rights Act 1987* *Pork Promotion Act 1975* *Poultry Industry Assistance Act 1965* *Poultry Industry Levy Act 1965* *Poultry Industry Levy Collection Act 1965* *Primary Industries (Recovery of Levy Collection Expenses) Act 1988* *Quarantine Act 1908*, in relation to animal, plant and general quarantine *Quarantine (Validation of Fees) Act 1985*, in relation to animal, plant and general quarantine *Queensland Grant (Prosperine Flood Mitigation) Act 1976* *Re-establishment and Employment Act 1945*, Part III in relation to rural training; Division 1 of Part XI insofar as it extends the foregoing; and Part XII, insofar as it applies or may be applied in relation to the foregoing *Rural Industries Research Act 1985* *Rural Industries Research (Transitional Provisions and Consequential Amendments) Act 1985* *Seas and Submerged Lands Act 1973* Sewerage Agreements Acts *Snowy Mountains Hydro-electric Power Act 1949* Softwood Forestry Agreements Acts *Soil Conservation (Financial Assistance) Act 1985* *South Australia Grant (Fruit Canneries) Act 1971* *States and Northern Territory Grants (Bluetongue Virus Control) Act 1978* States and Northern Territory Grants (Rural Adjustment) Acts *States Grants (Beef Industry) Act 1975* *States Grants (Fruit Canneries) Act 1976* States Grants (Fruit-growing Reconstruction) Acts *States Grants (Rural Adjustment) Act 1976* States Grants (Rural Recontruction) Acts *States Grants (War Service Land Settlement) Act 1952* *Sugar Agreement Act 1985* *Sugar Cane Levy Act 1987* *Sugar Cane Levy Collection Act 1987* Tasmanian Native Forestry Agreement Acts *Tobacco Marketing Act 1965* *Torres Strait Fisheries Act 1984* *Triticale Industry Research Levy Act 1988*

First Column *Name of Department*	*Second Column* *Principal Matters dealt with*	*Third Column* *Enactments*
The Department of Primary Industries and Energy—*continued*		*Triticale Industry Research Levy Collection Act 1988* *Victoria Grant (Shepparton Preserving Company Limited) Act 1971* *Weipa Development Agreement Act 1965* Western Australia Agreement (Ord River Irrigation) Acts *Western Australia (Northern Development) Agreement Act 1963* *Wheat Industry Stabilization Fund (Disposal) Act 1962* *Wheat Marketing Act 1984* Wheat Tax Acts *Wheat Tax (Permit) Act 1984* *Wheat Tax (Permit) Collection Act 1984* *Wheat Tax Regulations (Validation) Act 1987* *Wine Grapes Levy Act 1979* *Wine Grapes Levy Collection Act 1979* *Wine Research Repeal Act 1986* *Wool Marketing Act 1987*
The Department of the Prime Minister and Cabinet	Co-ordination of government administration Assistance to Cabinet and its Committees Policy advice and administrative support to the Prime Minister Relations and communications with State Governments Status of women Multicultural affairs Bicentenary celebrations Government ceremonial and hospitality	*Administrative Arrangements Act 1987* *Advisory Council for Inter-government Relations Act 1976* *Audit Act 1901*, sections 3 to 9A inclusive and section 70A in respect of powers under sections 3 to 9A inclusive *Australian Bicentennial Authority Act 1980* *Australian Science and Technology Council Act 1978* *Complaints (Australian Federal Police) Act 1981*, Part III *Economic Planning Advisory Council Act 1983* *Governor-General Act 1974* *Inspector-General of Intelligence and Security Act 1986* *Merit Protection (Australian Government Employees) Act 1984* *Office of National Assessments Act 1977* *Ombudsman Act 1976* *Parliamentary Commission of Inquiry (Repeal) Act 1986* *Parliamentary Presiding Officers Act 1965* *Parliamentary Secretaries Act 1980* *Public Service Act 1922* *Royal Commissions Act 1902* *Royal Powers Act 1953* *Royal Style and Titles Act 1973*
The Department of Social Security	Income security policies and programs	*Air Accidents (Commonwealth Government Liability) Act 1963* *Defence (Re-establishment) Act 1965*, Parts V and VA, and section 59 in respect of powers and functions under Parts V and VA, in relation to payments to individuals *Defence (Transitional Provisions) Act 1946*, section 13 *Re-establishment and Employment Act 1945*, Division 3 of Part XI (and Part XII insofar as it applies in relation to that Division), in relation to payments to individuals *Seamen's Compensation Act 1911* *Social Security Act 1947*
The Department of Transport and Communications	Shipping and marine navigation Land transport (including road safety) Civil aviation and air navigation Aviation security Postal and telecommunications services Management of the electromagnetic spectrum Television and radio	*Air Navigation Act 1920* *Air Navigation (Charges) Act 1952* *Air Navigation Legislation (Validation and Interpretation) Act 1982* Airline Equipment (Loan Guarantee) Acts *Airlines Agreement Act 1981* *Airlines Equipment Act 1958* *Airlines Equipment (Loan Guarantee) Act 1981* *Airports (Business Concessions) Act 1959* *Airports (Surface Traffic) Act 1960* *ANL Act 1956* Appropriation (Urban Public Transport) Acts

First Column	*Second Column*	*Third Column*
Name of Department	*Principal Matters dealt with*	*Enactments*
The Department of Transport and Communications—*continued*		*Australian Airlines (Conversion to Public Company) Act 1988* *Australian Bicentennial Road Development Trust Fund Act 1982* *Australian Broadcasting Corporation Act 1983* *Australian Broadcasting Corporation (Transitional Provisions and Consequential Amendments) Act 1983* *Australian Centennial Roads Development Act 1988* *Australian Land Transport (Financial Assistance) Act 1985* *Australian National Airlines Act 1945* *Australian National Railways Commission Act 1983* *Australian National Railways Commission (Transitional Provisions and Consequential Amendments) Act 1983* *Aviation Fuel Revenues (Special Appropriation) Act 1988* *Bass Strait Sea Passenger Service Agreement Act 1984* *Broadcasting Act 1942* *Broadcasting (Limited Licences) Fees Act 1988* *Broadcasting (Ownership and Control) Act 1987* *Broadcasting (Retransmission Permits and Temporary Transmission Permits) Fees Act 1988* *Civil Aviation Act 1988* *Civil Aviation (Carriers' Liability) Act 1959* *Civil Aviation (Damage by Aircraft) Act 1958* *Departure Tax Act 1978* *Departure Tax Collection Act 1978*, except to the extent administered by the Minister for Immigration, Local Government and Ethnic Affairs *Explosives Act 1961* *Federal Airports Corporation Act 1986* *Independent Air Fares Committee Act 1981* *Inter-State Commission Act 1975* *Interstate Road Transport Act 1985* *Interstate Road Transport Charge Act 1985* *King Island Harbour Agreement Act 1973* *King Island Shipping Service Agreement Act 1974* *Lighthouses Act 1911* *National Railway Network (Financial Assistance) Act 1979* *National Roads Act 1974* *Navigation Act 1912* *OTC Act 1946* *Parliamentary Proceedings Broadcasting Act 1946* *Port Augusta to Whyalla Railway Act 1970* *Port Statistics Act 1977* *Postal and Telecommunications Commissions (Transitional Provisions) Act 1975* *Postal Services Act 1975* *Protection of the Sea (Civil Liability) Act 1981* *Protection of the Sea (Powers of Intervention) Act 1981* *Protection of the Sea (Prevention of Pollution from Ships) Act 1983* *Protection of the Sea (Shipping Levy) Act 1981* *Protection of the Sea (Shipping Levy Collection) Act 1981* *Qantas Airways Limited (Loan Guarantee) Act 1988* Queensland Beef Cattle Roads Agreement Acts *Radiocommunications Act 1983* *Radiocommunications (Frequency Reservation Certificate Tax) Act 1983* *Radiocommunications (Miscellaneous Provisions) Act 1982* *Radiocommunications (Receiver Licence Tax) Act 1983* *Radiocommunications Taxes Collection Act 1983* *Radiocommunications (Temporary Permit Tax) Act 1983* *Radiocommunications (Test Permit Tax) Act 1983*

First Column *Name of Department*	*Second Column* *Principal Matters dealt with*	*Third Column* *Enactments*
The Department of Transport and Communications—*continued*		*Radiocommunications (Transitional Provisions and Consequential Amendments) Act 1983* *Radiocommunications (Transmitter Licence Tax) Act 1983* *Radio Licence Fees Act 1964* *Railway Agreement (Adelaide to Crystal Brook Railway) Act 1980* Railway Agreement (Western Australia) Acts *Railway Standardization (New South Wales and Victoria) Agreement Act 1958* *Railway Standardization (South Australia) Agreement Act 1949* *Railways Agreement (South Australia) Act 1975* *Railways (Tasmania) Act 1975* Roads Acts Amendment Acts Roads Grants Acts *Satellite Communications Act 1984* *Sea-Carriage of Goods Act 1924* *Seat of Government Railway Act 1928* *Shipping Registration Act 1981* *Ships (Capital Grants) Act 1987* *States Grants (Beef Cattle Roads) Act 1968* *States Grants (Roads) Act 1977* *States Grants (Roads Interim Assistance) Act 1977* States Grants (Urban Public Transport) Acts *Submarine Cables and Pipelines Protection Act 1963* *Tarcoola to Alice Springs Railway Act 1974* *Telecommunications Act 1975* *Television Licence Fees Act 1964* *Trade Practices Act 1974*, Part X and sections 150 to 154 inclusive *Transport (Planning and Research) Act 1974* *Transport Planning and Research (Financial Assistance) Act 1977* *Urban Public Transport (Research and Planning) Act 1974*
The Department of the Treasury	Economic, fiscal and monetary policy Taxation Prices surveillance National and occupational superannuation Borrowing money on the public credit of the Commonwealth Banking Insurance Currency and legal tender Foreign exchange Foreign investment in Australia Census and statistics	*Asian Development Bank Act 1966* Asian Development Bank (Additional Subscription) Acts *Australian Bureau of Statistics Act 1975* *Banking Act 1959* *Banking (Transitional Provisions) Act 1959* *Banks (Housing Loans) Act 1974* *Banks (Shareholdings) Act 1972* *Census and Statistics Act 1905* *Child Support Act 1988* *Commonwealth Authorities (Northern Territory Pay-roll Tax) Act 1979* *Commonwealth Banks Act 1959* *Commonwealth Borrowing Levy Act 1987* *Commonwealth Borrowing Levy Collection Act 1987* *Commonwealth Functions (Statutes Review) Act 1981*, section 234 *Commonwealth Inscribed Stock Act 1911* *Co-operative Farmers and Graziers Direct Meat Supply Limited (Loan Guarantee) Act 1978* *Crimes (Taxation Offences) Act 1980* *Currency Act 1965* *Debits Tax Act 1982* *Debits Tax Administration Act 1982* *Estate Duty Act 1914* *Estate Duty Assessment Act 1914* *Estate Duty Convention (United States of America) Act 1953* Financial Agreement Acts *Financial Agreement Validation Act 1929* *Financial Agreements (Commonwealth Liability) Act 1932* *Financial Corporations Act 1974* *Foreign Takeovers Act 1975* *Fringe Benefits Tax Act 1986*

First Column	*Second Column*	*Third Column*
Name of Department	*Principal Matters dealt with*	*Enactments*
The Department of the Treasury—*continued*		*Fringe Benefits Tax (Application to the Commonwealth) Act 1986* *Fringe Benefits Tax Assessment Act 1986* *Fringe Benefits Tax (Miscellaneous Provisions) Act 1986* *Gift Duty Act 1941* *Gift Duty Assessment Act 1941* *Gift Duty Convention (United States of America) Act 1953* Health Insurance Levy Assessment Acts *Housing Loans Guarantees (Australian Capital Territory) Act 1959* *Housing Loans Guarantees (Northern Territory) Act 1959* *Housing Loans Insurance Act 1965* *Income Tax Act 1986* *Income Tax (Arrangements with the States) Act 1978* *Income Tax Assessment Act 1936* *Income Tax (Bearer Debentures) Act 1971* *Income Tax (Diverted Income) Act 1981* *Income Tax (Dividends and Interest Withholding Tax) Act 1974* *Income Tax (Drought Bonds) Act 1969* *Income Tax (Film Royalties) Act 1977* *Income Tax (Franking Deficit) Act 1987* *Income Tax (International Agreements) Act 1953* *Income Tax (Mining Withholding Tax) Act 1979* *Income Tax (Offshore Banking Units) (Withholding Tax Recoupment) Act 1988* *Income Tax (Rates) Act 1986* *Income Tax (Securities and Agreements) (Withholding Tax Recoupment) Act 1986* *Income Tax (Withholding Tax Recoupment) Act 1971* *Industries Assistance Commission Act 1973* *Insurance Act 1973* *Insurance (Agents and Brokers) Act 1984* *Insurance and Superannuation Commissioner Act 1987* *Insurance Contracts Act 1984* *Insurance (Deposits) Act 1932* *International Bank for Reconstruction and Development (Share Increase) Act 1988* *International Finance Corporation Act 1955* International Financial Institutions (Share Increase) Acts International Monetary Agreements Acts *International Monetary Agreements (Quota Increase) Act 1980* *International Monetary Fund (Quota Increase) Act 1983* *Life Insurance Act 1945* Loan Acts, to the extent to which they give authority to borrow *Loan Consolidation and Investment Reserve Act 1955* *Loan (Drought Bonds) Act 1969* *Loan (International Bank for Reconstruction and Development) Act 1962* *Loan (Temporary Revenue Deficits) Act 1953*, except section 3 *Loans (Australian Industry Development Corporation) Act 1974* Loans (Australian National Airlines Commission) Acts Loans (Qantas Airways Limited) Acts *Loans Redemption and Conversion Act 1921* *Loans Securities Act 1919* *Loans (Taxation Exemption) Act 1978* *Medicare Levy Act 1986* *Mint Employees Act 1964*

First Column	*Second Column*	*Third Column*
Name of Department	*Principal Matters dealt with*	*Enactments*
The Department of the Treasury—*continued*		*National Debt Sinking Fund Act 1966* *Northern Territory Grant (Special Assistance) Act 1983* *Northern Territory (Lessees' Loans Guarantees) Act 1954* *Occupational Superannuation Standards Act 1987* *Organisation for Economic Co-operation and Development (Financial Support Fund) Act 1976* Papua and New Guinea Loan (International Bank) Acts Papua New Guinea Loan (Asian Development Bank) Acts *Papua New Guinea Loan Guarantee Act 1973* Papua New Guinea Loan (International Bank) Acts Papua New Guinea Loans Guarantee Acts *Papua New Guinea (Transfer of Banking Business) Act 1973* *Pay-roll Tax Act 1941* *Pay-roll Tax Assessment Act 1941* *Pay-roll Tax (State Taxation of Commonwealth Authorities) Act 1971* *Pay-roll Tax (Termination of Commonwealth Tax) Act 1971* *Petroleum Resource Rent Tax Act 1987* *Petroleum Resource Rent Tax Assessment Act 1987* *Petroleum Resource Rent Tax (Interest on Underpayments) Act 1987* *Petroleum Resource Rent Tax (Miscellaneous Provisions) Act 1987* *Prices Surveillance Act 1983* Qantas Airways Limited (Loan Guarantee) Acts Queensland Grant (Special Assistance) Acts *Reserve Bank Act 1959* Sales Tax Acts Sales Tax Assessment Acts *Sales Tax (Exemptions and Classifications) Act 1935* *Sales Tax Procedure Act 1934* *Soldier Settlement Loans (Financial Agreement) Act 1935* *States Grants Act 1927* States Grants (Capital Assistance) Acts *States Grants (General Revenue) Act 1988* States (Works and Housing) Assistance Acts *Statistical Bureau (Tasmania) Act 1924* *Statistics (Arrangements with the States) Act 1956* Stevedoring Industry Charge Acts *Stevedoring Industry Charge Assessment Act 1947* *Stevedoring Industry Charge (Termination) Act 1977* *Tasmania Sinking Fund Agreement Act 1928* *Taxation Administration Act 1953* *Taxation Boards of Review (Transfer of Jurisdiction) Act 1986* *Taxation (Interest on Overpayments) Act 1983* *Taxation (Interest on Underpayments) Act 1986* *Taxation of Loans Act 1923* *Taxation (Unpaid Company Tax) Assessment Act 1982* *Taxation (Unpaid Company Tax—Promoters) Act 1982* *Taxation (Unpaid Company Tax—Vendors) Act 1982* Tobacco Charge Acts *Tobacco Charges Assessment Act 1955* *Treasury Bills Act 1914* *Trust Recoupment Tax Act 1985* *Trust Recoupment Tax Assessment Act 1985* Wool Tax Acts *Wool Tax (Administration) Act 1964*

First Column	*Second Column*	*Third Column*
Name of Department	*Principal Matters dealt with*	*Enactments*
The Department of Veterans' Affairs	Repatriation income support, compensation and health programs for veterans, members of the Defence Force and their dependants War graves Defence Service Homes	*Australian War Memorial Act 1980* *Defence Act 1903*, in relation to paragraph 124 (1) (qba) *Defence (Re-establishment) Act 1965*, Parts IV and VI and section 59 in respect of powers and functions under Parts IV and VI *Defence Service Homes Act 1918* *Papua New Guinea (Members of the Forces Benefits) Act 1957* *Re-establishment and Employment Act 1945*, Part I; section 43 and section 44 in relation to section 43; Division 4 of Part II; Part V; Division 1 of Part XI insofar as it extends the foregoing; and Part XII insofar as it applies or may be applied in relation to the foregoing *Seamen's War Pensions and Allowances Act 1940* *Veterans' Entitlements Act 1986* *Veterans' Entitlements (Transitional Provisions and Consequential Amendments) Act 1986* *War Graves Act 1980* *War Precautions Act Repeal Act 1920* *War Service Homes Agreement Act 1932* *War Service Homes (South Australia) Agreement Act 1934*

Printed by R. D. RUBIE, Commonwealth Government Printer, Canberra

Commonwealth of Australia Gazette

No. S 88, Monday, 13 March 1989

Published by the Australian Government Publishing Service, Canberra

SPECIAL

PROCLAMATION

Commonwealth of Australia
BILL HAYDEN
Governor-General

By His Excellency the Governor-General of the Commonwealth of Australia

I, WILLIAM GEORGE HAYDEN, Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council and under subsection 2 (32) of the *Statute Law (Miscellaneous Provisions) Act 1987*, hereby fix 1 April 1989 as the day on which the amendment of the *Trade Practices Act 1974* made by the first-mentioned Act shall come into operation.

(L.S.) GIVEN under my Hand and the Great Seal of Australia on 1 March 1989

By His Excellency's Command,

LIONEL BOWEN

Attorney-General

GOD SAVE THE QUEEN!

Printed by R. D. RUBIE,
Commonwealth Government Printer, Canberra

11510/89 Cat. No. 89 6021 5

Commonwealth of Australia Gazette

No. S 89, Monday, 13 March 1989

Published by the Australian Government Publishing Service, Canberra

SPECIAL

NOTIFICATION OF THE MAKING OF STATUTORY RULES

NOTICE is hereby given that the undermentioned Statutory Rules have been made. Copies of the Statutory Rules may be purchased at the Commonwealth Government Bookshop, 70 Alinga St, Canberra City Australian Capital Territory.

Act under which the Statutory Rules were made	*Description of the Statutory Rules*	*Year and number of the Statutory Rules*
Civil Aviation Act 1988	Civil Aviation Regulations (Amendment)	1989 No. 31
Commonwealth Electoral Act 1918	Electoral and Referendum Regulations (Amendment)	1989 No. 32

Printed by R. D. RUBIE,
Commonwealth Government Printer, Canberra

11511/89 Cat. No. 89 6033 3

Commonwealth of Australia Gazette

No. S 90, Tuesday, 14 March 1989

Published by the Australian Government Publishing Service Canberra

SPECIAL

NOTIFICATION OF THE MAKING OF STATUTORY RULES

NOTICE is hereby given that the undermentioned Statutory Rules have been made. Copies of the Statutory Rules may be purchased at the Commonwealth Government Bookshop, 70 Alinga St, Canberra City Australian Capital Territory.

Act under which the Statutory Rules were made	*Description of the Statutory Rules*	*Year and number of the Statutory Rules*
Superannuation Act 1976	Superannuation (Interest) Regulations (Amendment)	1989 No. 33
Australian Horticultural Corporation Act 1987	Australian Horticultural Corporation (Apple and Pear Export Control) Regulations (Amendment)	1989 No. 34

Printed by R. D. RUBIE,
Commonwealth Government Printer, Canberra

11512/89 Cat. No. 89 6039 4

Commonwealth of Australia Gazette

No. S 91, Tuesday, 14 March 1989

Published by the Australian Government Publishing Service, Canberra

SPECIAL

PROCLAMATION

Commonwealth of Australia

By His Excellency the Governor-General of the Commonwealth of Australia

BILL HAYDEN
Governor-General

I, WILLIAM GEORGE HAYDEN, Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council and under subsection 2 (3) of the *Community Services and Health Legislation Amendment Act (No. 2) 1988*, hereby fix 15 March 1989 as the day on which sections 27 and 36 of that Act commence.

(L. S.) GIVEN under my Hand and the Great Seal of Australia on 13 March 1989

By His Excellency's Command,

PETER STAPLES
Minister of State for Housing and Aged Care

GOD SAVE THE QUEEN!

Printed by R. D. RUBIE,
Commonwealth Government Printer, Canberra

11514/89 Cat. No. 89 6057 X

Commonwealth of Australia Gazette

No. S 92, Wednesday, 15 March 1989

Published by the Australian Government Publishing Service, Canberra

SPECIAL

PROCLAMATION

Commonwealth of Australia

By His Excellency the Governor-General of the Commonwealth of Australia

BILL HAYDEN

Governor-General

I, WILLIAM GEORGE HAYDEN, Companion of the Order of Australia, Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council and under subsections 2 (2) and (3) of the *OTC (Conversion into Public Company) Act 1988*, hereby fix:

(a) 16 March 1989 as the day on which subsection 8 (1) of that Act commences; and

(b) 1 April 1989 as the day on which subsections 7 (2) and 8 (2) and sections 9, 11 to 22 (inclusive) and 25 of that Act commence.

(L.S.) GIVEN under my Hand and the Great Seal of Australia on 13 March 1989

By His Excellency's Command

RALPH WILLIS

Minister of State for Transport and Communications

GOD SAVE THE QUEEN!

Printed by R. D. RUBIE,
Commonwealth Government Printer, Canberra

11515/89 Cat. No. 89 6051 9

Commonwealth of Australia Gazette

No. S 93, Wednesday, 15 March 1989

Published by the Australian Government Publishing Service Canberra

SPECIAL

Government House,
Canberra ACT 2600
6 March 1989

His Excellency the Governor-General, on recommendation of the delegate of the Chief of the Defence Force, has in accordance with Section 22 (1) of the Defence Force Service Awards Regulations cancelled the award of the Defence Force Service Medal and Reserve Force Medal where indicated to the following Royal Australian Air Force personnel:

ROYAL AUSTRALIAN AIR FORCE

Defence Force Service Medal

A410014 GRECH, Michael
(*Corporal*)

Reserve Force Medal

O51750 ELMS, Ronald Walter
(*Flight Lieutenant*)

O51609 LLOYD, Vivien Leon Colley
(*Flight Lieutenant*)

O51515 REES, Daniel
(*Flight Lieutenant*)

O54827 SMITH, Geoffrey Joseph
(*Flight Lieutenant*)

By His Excellency's Command
ROBIN RAWSON
Registrar of Awards

Government House,
Canberra ACT 2600
6 March 1989

It is hereby notified for general information that His Excellency the Governor-General has awarded the Defence Force Service Medal, the Reserve Force Decoration and the Reserve Force Medal, and Clasps where indicated, to the following Royal Australian Air Force personnel:

ROYAL AUSTRALIAN AIR FORCE

Defence Force Service Medal

A121761 BENNET, Lex Cameron
(*Warrant Officer*)

A228459 BENNISON, Peter James
(*Flight Sergeant*)

A228441 BLATCHFORD, Kevin Mark
(*Flight Sergeant*)

A123102 CROUCH, Lindsay James
(*Sergeant*)

A225378 DEMMERY, James Douglas
(*Sergeant*)

A228439 EASTON, Thomas
(*Flight Sergeant*)

A510905 ETHERTON, Dudley
(*Leading Aircraftman*)

A320636 HALLWORTH, William James
(*Corporal*)

A228458 HARLAND, Brian John
(*Corporal*)

A320650 HARRY, Wayne Roydon Victor
(*Corporal*)

A235990 HATTLEY, Joseph Plunkett
(*Sergeant*)

A320651 HELLIS, Philip Raymond
(*Flight Sergeant*)

A123571 HICKS, Cedric Thomas
(*Corporal*)

A127661 HOOF, Alan Frederick
(*Leading Aircraftman*)

A48774 HOOPER Robert William
(*Sergeant*)

048764 HORTON Timothy
(*Squadron Leader*)

A320652 HOWELL Gregory James
(*Corporal*)

A48769 HUGHES Edward Angas
(*Flight Sergeant*)

A228464 JOHNSON Warren Charles
(*Sergeant*)

A59442 KNOTT Kevin Frank
(*Sergeant*)

A325152 LINDBERG Alan John
(*Corporal*)

A228457 MESSELL Ralph Charles
(*Sergeant*)

A48770 MILLER Andrew Julian
(*Squadron Leader*)

A48771 NEMTSAS Peter Demetrius
(*Squadron Leader*)

A121540 NEWMAN Wayne Gregory
(*Corporal*)

A121744 PATTISON Bruce William
(*Sergeant*)

A110512 PEARMAN Robert John
(*Flight Sergeant*)

A48772 PEARSON Rodney James
(*Sergeant*)

A320639 PETTY Roderick
(*Sergeant*)

A228456 RAYNOR Stephen James
(*Flight Sergeant*)

A123573 REID Graeme Paul
(*Corporal*)

A59445 SANDERS Andrew Peter
(*Sergeant*)

A228460 SHAW Ross Alexander
(*Corporal*)

0228452 SMITH Trevor Gary
(*Wing Commander*)

A228462 SMITH Gregory Keith
(*Sergeant*)

A228463 SMITH Martin Leslie
(*Corporal*)

A123572 STACK Robert John
(*Sergeant*)

A123546 STEELE Gregory David
(*Warrant Officer*)

A62282 WARNE Robert William
(*Corporal*)

A228466 WHITE Allan John
(*Sergeant*)

First Clasp to the Defence Force Service Medal

A119517 ARNOLD Kevin William
(*Flight Sergeant*)

A46458 BARNARD Peter
(*Warrant Officer*)

A46456 BLAKESTON Peter
(*Warrant Officer*)

A119411 BRIGG Paul John
(*Flight Sergeant*)

11508/89 Cat. No. 89 6015 8

A222446 BROWN Robert Guy
(*Sergeant*)
A212789 BRUCE Robin Davies
(*Sergeant*)
A224129 CADDIES Allan John
(*Flight Sergeant*)
A119413 CAMPION Philip John
(*Warrant Officer*)
A225242 CHRISTIE David Michael
(*Flight Sergeant*)
046729 COAD Barry James
(*Flight Lieutenant*)
0119426 DANGERFIELD Richard Robert
(*Flight Lieutenant*)
0119381 DOBSON Edmund Christopher
(*Flight Lieutenant*)
A119365 ECCLES Donald Maxwell
(*Sergeant*)
A119192 EVERETT, Stephen Claude
(*Warrant Officer*)
A318828 FIECHTNER, Dietrich Gerhard
(*Sergeant*)
O225284 FITZGIBBON, Gerard Bernard
(*Flight Lieutenant*)
O119380 FRASER, Ian Kenneth
(*Flight Lieutenant*)
A119422 FRY, Leslie Francis Thomas
(*Sergeant*)
A46730 GIBSON, Malcolm Alexander
(*Warrant Officer*)
A59593 GILDARE, Robert Charles
(*Flight Sergeant*)
A58409 GILMORE, Ronald Joseph
(*Flight Sergeant*)
A318814 GRESHAM, Rex Streeter
(*Warrant Officer*)
A47716 GRIEVE, David William
(*Flight Sergeant*)
A119375 HAMILTON, Michael Boyd
(*Warrant Officer*)
A225260 HANSEN, Kevin Neils
(*Corporal*)
A119429 HARRISON, Brian Anthony Raymond
(*Sergeant*)
A119535 HART, Donald Leslie Charles
(*Warrant Officer*)
A119536 HAYWOOD, Neville John
(*Sergeant*)
A46731 HILL, Robert James
(*Warrant Officer*)
A225291 HOLLINGSWORTH, Robert Charles
(*Corporal*)
A119432 HOOPERT, Neil
(*Corporal*)
A119419 HOWLETT, Brian Graham
(*Flight Sergeant*)
A119384 HUSSEY, Reginald Roy
(*Flight Sergeant*)
A58413 JONES, Peter Charles
(*Sergeant*)
O46732 JOSEPHS, Brian Norman
(*Flight Lieutenant*)
A318815 KILFOYLE, Peter John
(*Flight Sergeant*)
O225267 KING, Norman Allen Richard
(*Flying Officer*)
A46724 KLOOSTERMAN, Cornelis Hermanus Dick
(*Warrant Officer*)
A119371 KOCZOROWSKI, John Ronnie
(*Corporal*)
A119433 LANE, Allan John
(*Corporal*)
A119434 LANGLEY, Phillip Maurice
(*Flight Sergeant*)
A234572 LEONARD, Kevin Francis
(*Warrant Officer*)
A119436 LIESCH, Ross William
(*Sergeant*)
O119366 LONG, Garry Noel
(*Squadron Leader*)
W225278 MACPHERSON, Beverley Dorothy
(*Sergeant*)
A47937 MCCARTHY, Wayne Thomas
(*Flight Sergeant*)
A318819 MCGOWAN, Andrew Edward
(*Flight Sergeant*)
A225259 MCKENZIE, Vivian
(*Sergeant*)
A119518 MELVIN, Errol Gillespie
(*Sergeant*)
A119377 NEALE, Kenneth Phillip
(*Sergeant*)
A318827 PAARSON, Robert Rein Jaan
(*Flight Sergeant*)
A119372 PETTY, Daniel Edward
(*Warrant Officer*)
A119386 PRICE, Geoffrey Roger
(*Sergeant*)
A317042 QUARRELL, Noel Thomas
(*Warrant Officer*)
A46745 RADOVANOVIC, Jack
(*Flight Sergeant*)
A119522 ROBSON, John Leslie
(*Warrant Officer*)
A112995 ROSENBERGER, Eric Edward
(*Flight Sergeant*)
A318825 ROSEWARNE, Edwin James
(*Warrant Officer*)
A119367 SANDERS, Bert Leonard Richard Franklin
(*Corporal*)
A46746 SEARLE, Larry John
(*Warrant Officer*)
O119441 SHIELDS, John Barry
(*Flight Lieutenant*)
A224435 SMITH, Terence Patrick
(*Sergeant*)
A125479 SNEESBY, James Henry
(*Leading Aircraftman*)
A318838 TAYLOR, Laurence Robert
(*Warrant Officer*)
O225263 THOMPSON, Phillip Mark
(*Flight Lieutenant*)
A46457 WALLINGTON, Alec
(*Flight Sergeant*)
A119996 WILLIS, Barry Dudley
(*Warrant Officer*)
A46735 WORNHAM, Allan Edward
(*Sergeant*)

Second Clasp to the Defence Force Service Medal

O61429 CHAMBERS, Graeme John
(*Flight Lieutenant*)
O211602 GUREVITCH, Richard Norman
(*Air Commodore*)
A222118 CINI, Anthony Paul
(*Warrant Officer*)
O316292 LEACH, David John
(*Group Captain*)
O316356 LEE, Geoffrey Ronald
(*Wing Commander*)
A17825 McDONALD, Keith
(*Flight Sergeant*)
A316323 PLUMRIDGE, Noel Rees
(*Sergeant*)
O56728 ROBINSON, Valrie Dene
(*Wing Commander*)
A44320 STONE, Terrance Luke
(*Warrant Officer*)
A111650 TWOMEY, Peter Damian
(*Warrant Officer*)

Reserve Force Decoration

O51750 ELMS, Ronald Walter
(*Flight Lieutenant*)

O51609 LLOYD, Vivien Leon Colley
(*Flight Lieutenant*)

O51515 REES, Daniel
(*Flight Lieutenant*)

O54827 SMITH, Geoffrey Joseph
(*Flight Lieutenant*)

Reserve Force Decoration with First and Second Clasp

O151162 COLVIN, John Llewellyn
(*Group Captain*)

First Clasp to the Reserve Force Medal

A226124 CAMPBELL, Alan Sid
(*Corporal*)

By His Excellency's Command
ROBIN RAWSON
Registrar of Awards.

Printed by R. D. RUBIE, Commonwealth Government Printer, Canberra

Commonwealth of Australia Gazette

No. S 94, Thursday 16 March 1989

Published by the Australian Government Publishing Service, Canberra

SPECIAL

COMMONWEALTH OF AUSTRALIA

Australian Industry Development Corporation Act 1970

DETERMINATION

I, JOHN NORMAN BUTTON, Minister of State for Industry, Technology and Commerce, pursuant to subsection 29C (1) of the *Australian Industry Development Corporation Act 1970*, determine:

(a) for the purposes of paragraph 29C (1) (a), that the assets of the Corporation arising under or in relation to each of the instruments specified in paragraph (c) of this determination are non-transferring assets;

(b) for the purposes of paragraph 29C (1) (b), that the liabilities of the Corporation arising under or in relation to each of the instruments specified in paragraph (c) of this determination are non-transferring liabilities; and

(c) for the purposes of paragraph 29C (1) (d), that the following instruments to which this Part applies are non-transferring instruments, namely all instruments evidencing, or coming into existence for the purpose of, or relating to:

(i) each borrowing of money, or raising of money otherwise than by borrowing, undertaken by the Corporation, or agreed to be undertaken by the Corporation, where the borrowing or raising, or the agreement to undertake the borrowing or raising, is outstanding or in existence immediately before the re-organisation day;

(ii) each accommodation, facility, program, or arrangement in existence immediately before the re-organisation day pursuant to which the Corporation may undertake a borrowing of money or raising of money otherwise than by borrowing or otherwise obtain credit or may be provided with banking services, whether or not such accommodation, facility, program or arrangement involves a person other than the Corporation being legally obliged to provide or procure the borrowing, raising, credit or services;

(iii) each interest rate exchange agreement, currency exchange agreement or interest rate and currency exchange agreement entered into by the Corporation where the agreement is in existence immediately before the re-organisation day; and

(iv) each determination in existence immediately before the re-organisation day by the Chief Executive of the Corporation pursuant to subsection 35 (2).

In this determination:

(1) words or expressions which are defined or given a special or extended meaning in the *Australian Industry Development Corporation Act 1970* shall have the same meaning as they have in that Act and, in particular, "instrument to which this Part applies" has the same meaning as in Part IVA of that Act; and

(2) "money" shall include money denominated in a currency other than Australian currency.

Dated this 9th day of March 1989

JOHN N. BUTTON

Printed by R. D. RUBIE,
Commonwealth Government Printer, Canberra

11516/89 Cat. No. 89 6063 7

Commonwealth of Australia Gazette

No. S 95, Friday, 17 March 1989

Published by the Australian Government Publishing Service, Canberra

SPECIAL

COMMONWEALTH OF AUSTRALIA

Wildlife Protection (Regulation of Exports and Imports) Act 1982

Section 11

DECLARATION OF AN APPROVED INSTITUTION

I, JOHN DERRICK OVINGTON the Designated Authority under sub-section 18(1) of the Wildlife Protection (Regulation of Exports and Imports) Act 1982, in pursuance of sub-section 11(1) of that Act, hereby declare the organization specified in Column 2 of the Schedule, in an item in the Schedule, to be an approved institution in relation to the class, or classes, of specimens specified in Column 3 of the Schedule in that item.

Dated this Sixteenth day of March 1989

J. D. Ovington

DESIGNATED AUTHORITY

SCHEDULE

Column 1 Item	Column 2 Name and Country of Approved Institution	Column 3 Approved class, or classes, of specimens
1	Foundation 41 365 Crown Street SURRY HILLS NSW 2010	Callithrix jacchus

Printed by R. D. RUBIE,
Commonwealth Government Printer, Canberra

11518/89 Cat. No. 89 6075 5

Commonwealth of Australia Gazette

No. S 96, Friday, 17 March 1989

Published by the Australian Government Publishing Service, Canberra

SPECIAL

AUSTRALIAN CUSTOMS SERVICE

INITIATION OF INVESTIGATION INTO ALLEGED DUMPING OF NON-WOVEN POLYPROPYLENE GEOTEXTILES EXPORTED FROM AUSTRIA

CUSTOMS ACT 1901 - NOTICE UNDER SUB-SECTION 269TC(4)

I, JOHN MELVILLE THOMPSON, delegate of the Comptroller-General of the Australian Customs Service (ACS) have accepted an application made under sub-section 269TB(1) of the Customs Act 1901, which alleges matters that would, if established, constitute reasonable grounds for the publication of a dumping notice for non-woven, continuous filament, spunbond, needle punched polypropylene geotextiles exported from Austria.

The goods may be classified within sub-headings 5602.10.00 (statistical code 07), 5602.29.00 (statistical code 11) or 5603.00.00 (statistical code 19) of Schedule 3 to the Customs Tariff Act 1987. The rate of duty from Austria is 15%.

Geofabrics Australasia Pty Ltd is the applicant and is the sole Australian manufacturer of the goods.

The ACS will prepare a preliminary finding on the complaint within 120 days of the publication of this notice. If the preliminary finding is that there are sufficient grounds for publication of a dumping duty notice, provisional measures (involving the taking of securities under Section 42 of the Customs Act 1901) may be imposed. The matter would then be referred to the Anti-Dumping Authority for further investigation and report to the Minister (within 120 days) on whether a dumping notice should be published.

The ACS has published Australian Customs Notice (ACN) No. 89/29 notifying initiation of the investigation and the procedures to be followed. Copies of the ACN are available from the Publications Section, Customs House, Canberra ACT 2600 or regional offices of the ACS in each capital city.

All interested parties are invited to lodge written submissions with Mr Peter Slack, Dumping Operations, Australian Customs Service, Customs House, 5 Constitution Avenue, Canberra ACT 2600 not later than 26 April 1989.

John M. Thompson
Delegate of the
Comptroller-General

15 March 1989.

Printed by R. D. RUBIE,
Commonwealth Government Printer, Canberra

11517/89 Cat. No. 89 6069 8

Commonwealth of Australia Gazette

No. S 97, Friday, 17 March 1989

Published by the Australian Government Publishing Service, Canberra

SPECIAL

NOTIFICATION OF THE MAKING OF STATUTORY RULES

NOTICE is hereby given that the undermentioned Statutory Rules have been made. Copies of the Statutory Rules may be purchased at the Commonwealth Government Bookshop, 70 Alinga Street, Canberra City, ACT.

Act under which the Statutory Rules were made	Description of the Statutory Rules	Year and number of the Statutory Rules
Commonwealth Serum Laboratories Act 1961	Commonwealth Serum Laboratories Regulations (Amendment)	1989 No. 35
Superannuation Act 1976	Superannuation (Approved Authorities) Regulations (Amendment)	1989 No. 36
Superannuation Act 1976	Superannuation (Eligible Employees) Regulations (Amendment)	1989 No. 37
Superannuation Act 1976	Superannuation (Approved Authorities) Regulations (Amendment)	1989 No. 38
Passports Act 1938	Passports Regulations (Amendment)	1989 No. 39
Extradition Act 1988	Extradition (Ireland) Regulations	1989 No. 40
Horticultural Export Charge Act 1987 and Horticultural Export Charge Collection Act 1987	Horticultural Export Charge Regulations (Amendment)	1989 No. 41
Horticultural Levy Act 1987 and Horticultural Levy Collection Act 1987	Horticultural Levy (Citrus) Regulations (Amendment)	1989 No. 42
Horticultural Levy Collection Act 1987	Horticultural Levy Collection Regulations (Amendment)	1989 No. 43
Horticultural Levy Act 1987 and Horticultural Levy Collection Act 1987	Horticultural Levy (Apple and Pear) Regulations (Amendment)	1989 No. 44
OTC Act 1946	OTC (Conversion into Public Company) Regulations	1989 No. 45

Printed by R. D. RUBIE,
Commonwealth Government Printer, Canberra

11519/89 Cat. No. 89 6081 2

Commonwealth of Australia Gazette

No. S 98, Tuesday 21 March 1989

Published by the Australian Government Publishing Service, Canberra

SPECIAL

COMMONWEALTH OF AUSTRALIA

Trade Practices Act 1974

CERTIFICATION FOR PUBLICATION OF UNSAFE GOODS NOTICE WITHOUT DELAY

I, NICK BOLKUS, Minister of State for Consumer Affairs, pursuant to section 65L(1) of the Trade Practices Act 1974, certify that a notice under section 65C(5) of the Trade Practices Act 1974 should be published in relation to goods of a kind specified below without delay, as it appears to me that such goods create an imminent risk of death, serious illness or serious injury.

Particulars of Goods:

NEROA SKINLESS SKIN CONDOMS and
HARMONY SKINLESS SKIN CONDOMS.

Dated the 16 day of MARCH 1989.

NICK BOLKUS
Minister of State for Consumer Affairs

COMMONWEALTH OF AUSTRALIA

Trade Practices Act 1974

DECLARATION OF UNSAFE GOODS

I, NICK BOLKUS, Minister of State for Consumer Affairs, pursuant to section 65C(5) of the Trade Practices Act 1974, declare goods of a kind specified below ('the goods') to be unsafe goods in that it appears to me the goods will or may cause injury to a person.

Particulars of Goods:

NEROA SKINLESS SKIN CONDOMS and
HARMONY SKINLESS SKIN CONDOMS.

Dated the 16 day of MARCH 1989.

NICK BOLKUS
Minister of State for Consumer Affairs

Printed by R. D. RUBIE,
Commonwealth Government Printer, Canberra

11521/89 Cat. No. 89 6093 0

Commonwealth of Australia Gazette

No. S 99, Wednesday, 22 March 1989

Published by the Australian Government Publishing Service, Canberra

SPECIAL

NOTIFICATION OF THE MAKING OF STATUTORY RULES

NOTICE is hereby given that the undermentioned Statutory Rules have been made. Copies of the Statutory Rules may be purchased at the Commonwealth Government Bookshop, 70 Alinga St, Canberra City ACT.

Act under which the Statutory Rules were made	Description of the Statutory Rules	Year and number of the Statutory Rules
Industrial Relations Act 1988	Rules of the Australian Industrial Relations Commission	1989 No.46

Printed by R. D. RUBIE,
Commonwealth Government Printer, Canberra

11523/89 Cat. No. 89 6105 6

Commonwealth of Australia Gazette

No. S 100, Wednesday, 22 March 1989

Published by the Australian Government Publishing Service, Canberra

SPECIAL

AUSTRALIAN CAPITAL TERRITORY

NOTIFICATION OF THE MAKING OF A REGULATION

NOTICE is hereby given that the undermentioned Regulation of the Australian Capital Territory has been made. Copies of the Regulation may be purchased at the Commonwealth Government Bookshop, 70 Alinga St, Canberra City Australian Capital Territory.

Ordinance under which the Regulation was made	*Description of Regulation*	*Number and year of Regulation*
Children's Services Ordinance 1986	Children's Services Regulations (Amendment)	1989 No. 6

AUSTRALIAN CAPITAL TERRITORY

NOTIFICATION OF THE MAKING OF ORDINANCES

NOTICE is hereby given that the undermentioned Ordinances of the Australian Capital Territory have been made. Copies of the Ordinances may be purchased at the Commonwealth Government Bookshop, 70 Alinga St, Canberra City Australian Capital Territory.

Number and year of Ordinance	*Short title*
15 of 1989	*Payroll Tax (Amendment) Ordinance 1989*
16 of 1989	*Wills (Amendment) Ordinance 1989*
17 of 1989	*Administration and Probate (Amendment) Ordinance 1989*
18 of 1989	*Family Provision (Amendment) Ordinance 1989*
19 of 1989	*Administration and Probate (Amendment) Ordinance (No. 2) 1989*

Printed by R. D. RUBIE,
Commonwealth Government Printer, Canberra

Cat. No. 89 6045 1

Commonwealth of Australia Gazette

No. S 101, Thursday, 23 March 1989

Published by the Australian Government Publishing Service, Canberra

SPECIAL

AUSTRALIAN CAPITAL TERRITORY

Administration and Probate (Amendment) Ordinance (No. 2) 1989

NOTICE OF COMMENCEMENT

Under section 2 of the *Administration and Probate (Amendment) Ordinance (No. 2) 1989* I fix 24 March 1989 as the date on which that Ordinance shall come into operation.

Dated this 14th day of March 1989.

ALLAN CLYDE HOLDING

Minister of State for the Arts and Territories

AUSTRALIAN CAPITAL TERRITORY

Birth (Equality of Status) Ordinance 1988

NOTICE OF COMMENCEMENT

Under subsection 2 (2) of the *Birth (Equality of Status) Ordinance 1988* I fix 24 March 1989 as the date for commencement of section 3 to section 22 inclusive of that Ordinance.

Dated this 14th day of March 1989.

ALLAN CLYDE HOLDING

Minister of State for the Arts and Territories

AUSTRALIAN CAPITAL TERRITORY

Family Provision (Amendment) Ordinance 1989

NOTICE OF COMMENCEMENT

Under section 2 of the *Family Provision (Amendment) Ordinance 1989* I fix 24 March 1989 as the date on which that Ordinance shall come into operation.

Dated this 14th day of March 1989.

ALLAN CLYDE HOLDING

Minister of State for the Arts and Territories

AUSTRALIAN CAPITAL TERRITORY

Registration of Births Deaths and Marriages (Amendment) Ordinance 1988

NOTICE OF COMMENCEMENT

Under section 2 of the *Registration of Births Deaths and Marriages (Amendment) Ordinance 1988* I fix 24 March 1989 as the date for commencement of that Ordinance.

Dated this 14th day of March 1989.

ALLAN CLYDE HOLDING

Minister of State for the Arts and Territories

AUSTRALIAN CAPITAL TERRITORY

Wills (Amendment) Ordinance 1989

NOTICE OF COMMENCEMENT

Under section 2 of the *Wills (Amendment) Ordinance 1989* I fix 24 March 1989 as the date on which that Ordinance shall come into operation.

Dated this 14th day of March 1989.

ALLAN CLYDE HOLDING

Minister of State for the Arts and Territories

Printed by R. D. RUBIE,
Commonwealth Government Printer, Canberra

11520/89 Cat. No. 89 6087 3